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Abstract 
This thesis details investigations into the generation and synthetic utility of α,β-unsaturated acyl 
ammonium intermediates using isothioureas as Lewis base organocatalysts to generate a range of 
heterocyclic products. 
Initial investigations focussed on the development of a Michael addition-lactonisation protocol 
utilising α,β-unsaturated acyl ammonium intermediates (generated in situ from HBTM 2.1 and 
α,β-unsaturated homoanhydrides) and a range of 1,3-dicarbonyl nucleophiles. Products could be 
isolated as lactones or as ring-opened highly functionalised esters, giving good yields and 
excellent enantioselectivity. 1,3-Diketones were shown to generate a mixture of regioisomers and 
whereas 1,3-ketoesters afforded only a single regioisomer. A crystal structure of an α,β-
unsaturated acyl ammonium intermediate was obtained that clearly demonstrated steric blocking 
of the Si- face of the alkene by the catalyst stereodirecting groups, therefore it can be postulated 
that enantiocontrol in the addition occurs by selective nucleophilic addition from the Re- face. 
α,β-Unsaturated acyl ammonium species were then shown to participate in asymmetric 
annulation processes with benzazole nucleophiles to afford highly functionalised heterocyclic 
products, with both lactone and lactam formation observed. The relationship between 
nucleophile structure and process regioselectivity was investigated and it was demonstrated that 
benzothiazole and benzimidazole nucleophiles afforded preferential N-cyclisation to give lactams 
whilst benzoxazoles exhibited O-cyclisation to form lactones. It was also possible to influence 
the regioselectivity by changing the electronic properties of the acyl group (R’). Due to the 
reactivity of this class of nucleophiles it was possible to access products with quaternary centres. 
Palladium-catalysed cross coupling reactions were also successful on 3-bromo substituted 
lactams, demonstrating the potential for further derivatising these interesting heterocyclic 
products. 
Finally, a cascade protocol was developed that employed Michael-Michael-lactonisation steps to 
give tricyclic products from enone malonate nucleophiles and α,β-unsaturated acyl ammonium 
intermediates (generated in situ by addition of HBTM 2.1 into acid chlorides). Interestingly, the 
reaction showed higher enantioselectivity at elevated temperatures (70 ˚C) and moderate 
regioselectivity (1,4- vs. 1,2-addition), which could not be improved after extensive screening. A 
range of lactones was isolated in moderate yields and enantioselectivity. 
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1. Introduction 
1.1 Asymmetric Catalysis 
The development of chemical processes that proceed enantioselectively has become 
increasingly important as our understanding of the impact of chirality upon biological 
interactions has grown. Often one enantiomer of a drug can have greater therapeutic 
action, but if the other enantiomer shows no appreciable effect on the body the drug can 
be safely administered as a racemic mixture. However there are many cases where the 
unwanted enantiomer causes harm to the body and in these cases the racemic drug is 
unsafe for consumption.1,2 
Strategies for carrying out asymmetric synthesis include the use of reagents from the chiral 
pool, such as amino acids and sugars, which are naturally formed in high enantioselectivity. 
This can be highly efficient as the stereocentre is preserved rather than created, but 
synthetic pathways are limited to available substrates.3 It is also possible to generate and 
then resolve racemic mixtures by, for example, selective crystallisation of one enantiomer 
as a chiral salt. This opens up many synthetic possibilities however 50% material loss must 
be incurred to achieve the desired enantiomer in high selectivity.4 Chiral auxilliaries were 
developed as a further strategy to form stereocentres enantioselectively. A substrate is 
functionalised with a chiral functional group, which serves to direct the desired reaction in 
good diastereoselectivity and is subsequently removed. This strategy has proved to be 
highly useful although the overall efficiency can be low due to the requirement of 
additional protection and deprotection steps and the stoichiometric nature of chiral 
auxiliaries. 5 
A further synthetic option is asymmetric catalysis, which aims to carry out reactions 
efficiently and enantioselectively using catalytic amounts of a chiral species to induce 
asymmetry. This circumvents the problems of loss of material inherent in resolving a 
racemic mixture, or the use of stoichiometric chiral auxiliaries. In nature, this is carried out 
by enzyme catalysis and many industrial processes have been developed which take 
advantage of the excellent selectivity that is achievable using biocatalysis.6 The major 
drawback of this method is high substrate specificity, which leads to reactions displaying 
either excellent reactivity and selectivity or no reactivity at all. This makes biocatalysis of 
limited value to synthetic chemists targeting new molecules or methodology. 
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Enantioselective organometallic catalysis offers diverse synthetic options, with structurally 
diverse catalysts able to be designed and optimised for a particular process. Industrially 
there is a competition between the economics of large scale catalysis versus other methods 
of enantioenrichment; the efficiency of the catalysed reaction is often outweighed by the 
high cost of the catalyst. Despite such problems, many robust enantioselective catalytic 
organometallic processes have been developed and embraced by chemical industry, 
including the multi-tonne production of herbicide Metolachlor. Whilst it was initially 
marketed as a mixture of its four stereoisomers 1a–d (Figure 1) it was found that around 
95% of the herbicidal activity came from two highly active stereoisomers (1a and 1b), 
enantiomers of one another.7 
 
Figure 1: Stereoisomers of the herbicide Metolachlor 
 
An enantioselective synthesis of 1a was developed with the key step being the 
enantioselective reduction of imine 2 (Scheme 1). After extensive metal and ligand 
screening the optimum catalyst for this process was an iridium-Xyliphos complex.8 This 
catalyst achieved very high turnover rates of >200,000 TOF (h-1), affording amine 3 in 
100% conversion and 79% ee.9 Using this preparative method the final herbicide product 
can be prepared with an approximate 90% active isomer content, and the application 
required for the same herbicidal activity in the field was reduced to 65% of the original 
dose.7 
 
Scheme 1: Enantioselective imine reduction in the synthesis of Metolachlor 
 
One of the main advantages of transition metal catalysts is high structural diversity which 
enables fine-tuning of catalytic activity by ligand alteration around different metal centres. 
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As a result, catalytic systems have been developed that can carry out multiple reaction types 
with only small structural changes. These greatly open up synthetic possibilities with 
minimum investment in new catalysts and/or ligands. However, such metal catalysts can be 
expensive to make due to the high cost of the metals and/or ligands used and they are 
often unstable to air and moisture, making them difficult to handle.10 Of further concern is 
the potential difficulty encountered in removing metals from reaction mixtures due to the 
possible toxicity of metal residues.11  
 
1.2 Lewis Base Organocatalysis 
An alternative to transition metal catalysis is organocatalysis, defined as “the acceleration of 
chemical reactions with a substoichiometric amount of an organic compound which does 
not contain a metal atom.”12 In the development of organocatalysis, chemists hoped to 
harness the power of biocatalysis without the drawbacks of substrate specificity and also 
open up reaction conditions that are not compatible with enzymes.13 Many organocatalysts 
show good moisture and air tolerance and can be cheaper to prepare than transition metal 
catalysts. One of the earliest reported organocatalytic reactions is the Hajos-Parrish 
intramolecular aldol reaction (Scheme 2). (S)-Proline (6) catalyses the cyclisation of 5 by 
acting as a Lewis base, donating a lone pair of electrons to form an enamine intermediate 7, 
thus activating the ketone moiety. An intramolecular aldol reaction follows, forming 
cyclised product 8 in 97% ee.14  
 
Scheme 2: Asymmetric intramolecular aldol reaction 
 
Whilst it is agreed that the reaction proceeds through an enamine intermediate (7) the 
transition state of the Hajos-Parrish aldol reaction remains disputed. The general concensus 
is that it proceeds through a chair-type transition state (Figure 2), however it is unclear 
whether the transition state is stabilised through N–H---O (9a) or CO2–H---O (9b)
15 
interactions, or if it is a combination of multiple interactions (9c).16 
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Figure 2: Postulated transition states for the Hajos-Parrish aldol reaction 
 
At the time, this result was considered a stand-alone example of organocatalysis and not 
part of a wider field. It was not until much later that proline-mediated enamine catalysis 
was revisited, and in 2000 List et al. demonstrated that (S)-proline was a successful catalyst 
in an intermolecular aldol process, giving product 12 in good yield and ee (Scheme 3).16 The 
reaction tolerates a wide range of substrates, but straight chain and α-acyloxy substituted 
aldehydes do not react.17 
 
Scheme 3: Asymmetric intermolecular aldol reaction 
 
To date, Lewis base organocatalysis remains the widest field within organocatalysis in terms 
of the reaction diversity it enables.18 Many different modes of activation within Lewis base 
organocatalysis have been investigated including enamine, iminium and SOMO (singly 
occupied molecular orbital) catalysis, which will be discussed in relation to MacMillan’s 
imidazolidinone catalysts (Figure 3). These can be considered to exhibit a “privileged” 
catalyst architecture as they can facilitate many reactions with high and predictable levels of 
enantioselectivity in mechanistically different ways.19 Ammonium enolate and acyl 
ammonium catalysis are also accessed using Lewis bases and will be discussed using the 
chemistry of isothiourea catalysts, which have been extensively investigated within the 
Smith group. 
 
Figure 3: Privileged catalyst architectures 
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1.2.1 Iminium ion catalysis 
MacMillan et al. first utilised imidazolidinone 15 to act as an enantioselective organocatalyst 
in the Diels-Alder reaction depicted in Scheme 4.20 Both endo and exo products (16a and 
16b) were obtained in an excellent ee of 99% and 93% respectively. The reaction works 
well with a range of dienes and dienophiles giving good enantioselectivity, but the endo:exo 
ratios were consistently poor. 
 
Scheme 4: Enantioselective organocatalytic Diels-Alder reaction 
 
The proposed mechanism is detailed in Scheme 5. Condensation of the amine catalyst (15) 
with aldehyde 13 generates an iminium species (17) that is more electrophilic than the 
aldehyde starting material. The presence of the geminal dimethyl groups in catalyst 15 
promotes formation of iminium 17 in good E/Z selectivity due to minimisation of steric 
interactions. The benzyl group efficiently blocks the Si-face of iminium 17, thus directing 
the reaction on the Re-face with high selectivity. Diels-Alder cycloaddition of 17 with diene 
14, followed by iminium hydrolysis generates products 16a/b and reforms catalyst 15 
(Scheme 5). 
 
Scheme 5: Catalytic cycle for the enantioselective organocatalytic Diels-Alder reaction 
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This imidazolidinone catalyst motif has since been used to catalyse a wide range of 
reactions that proceed via an iminium intermediate including a variety of 1,4-nucleophilic 
additions to α,β-unsaturated aldehydes.21,22 
The industrial utility of iminium catalysis has been recently demonstrated with the 
preparation of Telcagepant (24) on >250 kg scale by Merck.23,24 Telcagepant is a late-stage 
clinical candidate for the treatment of migraines,25 with a key step in its synthesis the 
asymmetric Michael addition of nitromethane to α,β-unsaturated aldehyde 19 (Scheme 6). 
In this case, the Jørgensen-Hayashi catalyst (21) was the most efficient and could be used as 
a crude solution after TMS-protection of alcohol 20. Enantioselective addition of 
nitromethane followed by imine hydrolysis (facilitated by acid co-catalysts) afforded 
aldehyde 23 in high yield and excellent enantioselectivity. This key intermediate was further 
derivatised in four steps into Telcagepant 24 in an excellent 27% overall yield and in 
>99.9% ee. 
 
Scheme 6: Industrial scale application of iminium ion catalysis 
 
1.2.2 Enamine catalysis 
Iminium intermediates (26) form enamines (27) upon β-deprotonation, giving two 
interconnected catalytic species with very different modes of activation (Scheme 7). Whilst 
in iminium ion catalysis the substrate is activated to nucleophilic attack by lowering of the 
LUMO energy relative to the parent carbonyl, enamine catalysis activates the substrate by 
raising the energy of the HOMO and thus increasing its nucleophilicity. 
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Scheme 7: Enamine generation from an iminium ion 
 
As enamine and iminium ion active species can interconvert it stands to reason that 
catalysts suitable for one mode of action should also work for the other. MacMillan’s 
imidazolidinone catalysts are also highly effective in enamine catalysis, such as the cross 
aldol reaction shown in Scheme 8. The cross-aldol reaction is promoted by dropwise 
addition of donor aldehyde 28 to a large excess of acceptor aldehyde 29. The initial 
addition product 31 reacts with a further equivalent of aldehyde 29 to form a hemiacetal 32, 
which prevents further addition and can be deprotected via in situ methanolysis to afford 
product 33 in good yield and high enantioselectivity. The imidazolidinone catalyst was 
successful in a variety of cross aldol reactions including those with α-acyloxy substitution, 
which were not tolerated in the corresponding (S)-proline-catalysed aldol process.26 
 
Scheme 8: Imidazolidinone-catalysed cross aldol reaction 
 
1.2.3 SOMO catalysis 
MacMillan then developed a third mode of catalytic activity, again connected to iminium 
and enamine intermediates. Upon single electron oxidation of enamine intermediate 27 a 
radical cation species 34 is generated, with its character somewhere between the 
nucleophilicity of enamine catalysis and the electrophilicity of iminium ion active species. 
This catalytic mode is defined as Single Occupied Molecular Orbital (SOMO) catalysis. 
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Scheme 9: Relationship of SOMO, iminium ion and enamine active species 
 
SOMO catalysis is highly successful at facilitating α-functionalisation of aldehydes, the first 
reported example being an α-allylation process (Scheme 10) that uses ceric ammonium 
nitrate (CAN) as an oxidant to generate the required SOMO intermediate.27 The reaction 
works well for a range of both aldehydes and allylsilanes, with good yields and 
enantioselectivity obtained in all cases. 
 
Scheme 10: α-Allylation of aldehydes using SOMO-catalysis 
 
The proposed mechanism for this transformation is detailed in Scheme 11. Initial enamine 
formation (39) is followed by a one-electron oxidation using CAN to generate SOMO 
intermediate 40. Radical intermediate 41 is obtained upon allyltrimethylsilane addition and 
is quenched with a further equivalent of CAN. Loss of trimethylsilane and imine hydrolysis 
affords product 38 and reforms catalyst 37. 
 
Scheme 11: Mechanism of SOMO-catalysed α-allylation 
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SOMO catalysis has subsequently been shown to be a highly versatile reaction mode, 
facilitating a wide range of other α-functionalisations including α-enolation,28 α-vinylation,29 
α-chlorination and α-epoxidation.30 
 
1.2.4 Acyl ammonium catalysis 
The isothiourea moiety is found in biologically relevent compounds including the drugs 
Levamisole 44 and Butamisole 45, used to treat parasitic worm infections in animals 
(Figure 4).31,32  
 
Figure 4: Isothioureas in medicine 
 
Birman et al. first explored their use as Lewis base catalysts whilst investigating amidines 
and related structures as catalytic acylating agents in the kinetic resolution of secondary 
alcohols with acid anhydrides (Scheme 13).33,34 The Lewis base catalyst intercepts the 
anhydride, generating a chiral acyl ammonium species 47. Alcohol (±)-45 is preferentially 
acylated by 47 rather than the less reactive anhydride, and resolution is achieved by 
acylation of only one enantiomer of the alcohol. The racemic mixture is therefore separated 
into an enantioenriched alcohol ((S)-45) and an ester ((R)-46). The parameters reported 
are the reaction conversion (the percentage of ester 46 compared with alcohol 45), and the 
s-factor, which takes into account the relative rates of acylation of the two enantiomers of 
alcohol 45 and can be calculated from the enantioselectivity of the process.35 As conversion 
into the ester increases the ee of the parent alcohol is enhanced as the fast reacting 
enantiomer is used up. However if conversion is pushed too far the ee of the ester is 
compromised as more of the slow reacting alcohol enantiomer is acylated, therefore a 
balance must be struck if high ee of both substrates is to be attained. 
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Scheme 12: Kinetic resolution of secondary alcohols [a]Other enantiomer of alcohol obtained 
 
2-Phenyl-6-trifluoromethyl-dihydroimidazo[1,2-a]pyridine (CF3-PIP, 48) was the first Lewis 
base catalyst investigated by Birman et al. for this process (Scheme 12). It gave a selectivity 
factor of 28 in the resolution of phenyl propanol which was improved by extending the π-
system in the catalyst (Cl-PIQ, 49).33,34 Isothiourea catalysts were shown to be viable 
alternatives offering excellent selectivity in the process. Again, extending the π-system from 
tetramisole (TM, 50) to benzotetramisole (BTM, 51) proved important for enhanced 
selectivity and excellent results were obtained with analogues including 
homobenzotetramisole (HBTM 52) and HBTM 2.1 53 (also known in the literature as 
HyperBTM).36-38 Other substrates that have been successfully resolved using isothiourea 
catalysis include a range of β-lactams,39 oxazolidinones,40 α-aryl acids41 and azlactones.42  
In addition to promoting intermolecular acyl transfer, isothioureas also carry out 
intramolecular carboxyl transfer processes. Smith et al. have developed an isothiourea-
catalysed Steglich rearrangement (Scheme 13) in which O- to C- acyl transfer is achieved, 
forming quaternary carbon centres in high enantioselectivity.37 HBTM 2.1 53 was the 
optimal catalyst in this system, with Gröger et al. employing BTM 51 in a similar reaction 
which afforded low enantioselectivity.43,44 The reaction is tolerant of a wide variety of 
substrates including branched alkyl groups in the first example of the asymmetric 
rearrangement of an α-alkyl branched oxazoyl carbonate. Isothiourea-catalysed O- to C- 
carboxyl transfer has also been shown to work for furanyl carbonates.45 
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Scheme 13: Asymmetric Steglich rearrangement 
 
The oxazole substrate (54) is thought to first react with the catalyst to lose its carbonate 
group forming ion pair 56. Nucleophilic attack then occurs through C(4) onto the less 
hindered Re-face of the acyl ammonium species 56, forming product 55 and regenerating 
the catalyst 53. 
 
Scheme 14: Proposed Steglich rearrangement mechanism 
 
1.2.5 Ammonium enolate catalysis 
Isothioureas have also been used to form synthetically useful ammonium enolate 
intermediates.46 Formation of C1-ammonium enolates can proceed directly from ketenes 
(Figure 5, A), however the process encounters problems due to the highly unstable nature 
of the ketene starting materials 57 and is subject to substrate limitations.47 To date, 
isothioureas have not been used in conjunction with ketenes for the formation of enolates. 
An alternative method was developed by Romo et al., employing in situ carboxylic acid 
activation using Mukaiyama’s reagent 61.48-51 Activated ester 60 then forms an acyl 
ammonium species (59) on reaction with a tertiary amine catalyst. Deprotonation of 59 
affords the desired ammonium enolate (58) in a mild procedure starting from cheap and 
bench-stable carboxylic acids. 
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Figure 5: Generation of C1-ammonium enolates  
 
Romo et al. showed that this ammonium enolate formation strategy was compatible with 
isothiourea catalysis, employing HBTM (52) to catalyse the desymmetrisation shown in 
Scheme 15.52 In this case, tosyl chloride was used to “activate” carboxylic acid 63 via 
formation of a sulfonate ester. Addition of LiCl enhanced the yield and it is thought that 
the lithium cation chelates the substrate in the proposed pre-transition state assembly 64. 
Chelation was proposed to lock the conformation and possibly activates the ketone to 
nucleophilic addition. 
 
Scheme 15: Isothiourea-catalysed β-lactam formation 
 
Smith et al. then investigated the use of isothioureas in intramolecular Michael addition-
lactonisation using pivaloyl chloride to activate carboxylic acid 66 in situ (Scheme 16).53 The 
procedure showed high substrate tolerance with good results for aliphatic substrates, and 
aromatic substrates with both electron-withdrawing and donating substituents. High dr of 
up to 99:1 was observed and 90–99% ee was achieved in all examples. 
 
Scheme 16: Intramolecular Michael addition-lactonisation 
 
Intermolecular Michael addition-lactonisation also works well, with α-keto-β,γ-unsaturated 
esters (69) affording lactone products (70) in good yields (Scheme 17). The potential for 
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derivatisation of the products using in situ methanolysis was investigated and the ring-
opened products (71) could be isolated in higher yields than the parent lactones (70).53 
 
Scheme 17: Intermolecular variant of Michael addition-lactonisation process 
 
The proposed mechanism for the transformation is detailed in Scheme 18. Acyl 
ammonium 74 is formed via nucleophilic attack of isothiourea catalyst 53 onto activated 
acid 73. Enolate 75 is generated by deprotonation of the acyl ammonium intermediate, with 
recent studies suggesting that this is the rate-determining step and is carried out by the 
pivalate anion (with Hünig’s base presumably acting as a proton shuttle).54 Michael addition 
into the Michael-acceptor component 76 forms enolate 77, which cyclises to form lactone 
78 and regenerate the catalyst. 
 
Scheme 18: Proposed mechanism for isothiourea-catalysed Michael addition-lactonisation 
 
To further understand the nature of enantiocontrol in the Michael addition-lactonisation 
process, computational studies were carried out on the reaction between phenylacetic acid 
68 and trifluoroenone 79 (Scheme 19).54,55 Computational analysis of the transition state 
(80) demonstrates that enantiocontrol arises from the position of the stereodirecting 
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groups in the enolate intermediate. In the lowest energy conformation the bulkier isopropyl 
group occupies a pseudo-equatorial position and the phenyl group a pseudo-axial position 
to avoid 1,2-strain. This blocks the Si-face of the enolate thereby generating an (S)-
stereocentre in the C–C bond forming step.  
Scheme 19: Computationally modelled transition state 
 
The catalyst conformation is further locked by an observed O→S attractive force, which 
prevents free rotation about the C(O)–N bond. The presence of oxygen to sulfur 
interactions is well documented in the literature: in a study of small molecular crystal 
structures, Stahl et al. showed that carbonyl groups display a strong preference for 1,5-
oxygen to sulfur interactions. The effect has been exploited in the design of a variety of 
biologically active molecules, which has recently been extensively reviewed by Meanwell et 
al.56 One example is the following system developed by Nagao et al. who used a non-
covalent O→S interaction to aid design of (acylamino)thiadiazoline derivatives as 
Angiotensin II receptor antagonists.57 X-ray crystallographic analysis of thiadiazole 82 
showed that its preferred conformer (82b) exhibits an oxygen to sulfur attractive force 
(Figure 6). This holds it in a 5-membered ring and reduces the bond distance to 2.65 Å, 
significantly shorter than the sum of the Van der Waals’ radii (3.32 Å).  
 
Figure 6: 1,5- O→S interaction in thiadiazoles 
 
In the context of Lewis base catalysis, Birman et al. has suggested that the O→S interaction 
may provide isothiourea catalysts with enhanced activity compared with amidine analogues 
due to stabilisation of the acylated intermediate.58 Romo et al. observed that the interaction 
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may enhance enantioselectivity by helping to lock the conformation of the acylammonium 
species (Figure 7).52 
 
Figure 7: Rotation in acylated amidines and isothioureas 
 
The nature of the O→S interaction is however not well understood. Recent computational 
studies by Romo et al. concerning the exact nature of this interaction will be discussed as 
part of mechanistic studies into the work described in this thesis (see section 2.5.2). 
Recent developments in the field of ammonium enolate isothiourea catalysis have 
demonstrated that N-sulfonylketimines (84) can be used as Michael acceptors in related 
processes to generate dihydropyridones in good diastereo- and enantioselectivity.59 Use of 
thiophenyl acetic acid 83 as the ammonium enolate precursor enables the generation of 
synthetically useful pyridines 87 via exploitation of a facile elimination of thiophenol 
followed by N- to O-sulfonyl transfer (Scheme 20).60 A range of substitution patterns can 
be achieved and the retention of an O-tosyl group in the products allowed for a variety of 
further derivatisations to be performed including palladium-catalysed cross couplings and 
SNAr substitutions. 
 
Scheme 20: Isothiourea-catalysed pyridine formation using N-sulfonyl imines as Michael acceptors 
 
1.2.6 α,β-Unsaturated acyl ammonium intermediates 
The advantage of any catalytic system can be seen in its generality. Ideally, one catalyst 
moiety will be able to activate a range of substrates in a variety of ways: this is well 
demonstrated by MacMillan’s imidazolidinone catalysts that are capable of iminium ion, 
enamine, and SOMO catalysis (sections 1.2.1-1.2.3). Thus far isothiourea catalysts have 
been used for a variety of acyl transfers (Figure 8 (i)) and ammonium enolate 
transformations (ii). Further development of this catalyst system to include the use of α,β-
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unsaturated species in an asymmetric process (iii) is of high synthetic interest within the 
Smith group. 
 
Figure 8: Isothiourea activation modes 
 
The use of α,β-unsaturated acyl ammonium species in asymmetric organocatalysis has 
however not been widely explored. To the best of our knowledge prior to the beginning of 
this project the only example of the utilisation of a catalytic α,β-unsaturated acyl 
ammonium intermediate was demonstrated by Fu et al. (Scheme 21).61 Fu’s catalyst 90, a 
planar chiral PPY derivative, facilitates a cyclisation process between α,β-unsaturated acid 
fluoride 89 and a silylindene 88 to generate diquinanes (91). The annulated products are 
formed in good diastereoselectivity, however the enantioselectivity is good to modest and 
the chemistry was not demonstrated to form any other product scaffolds. Other Lewis base 
catalysts tested (quinidine and tertiary phosphines) did not generate the desired products 
and no attempts to improve the enantioselectivity were reported. 
 
Scheme 21: Asymmetric [3+2] annulation catalysed by a planar chiral DMAP catalyst 
 
The proposed mechanism is detailed in Scheme 22. Acylation of acid fluoride 89 generates 
α,β-unsaturated acyl ammonium species 92. The released fluoride anion adds to silicon, 
forming ion pair 93. In situ silicon deprotection generates a carbanion that can add into the 
α,β-unsaturated acyl ammonium affording adduct 94. The authors then propose the release 
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of ketene intermediate 95 that can cyclise in an ene-type process to give product 91, 
however the nature of this cyclisation process is unknown. 
 
Scheme 22: Proposed mechanism for [3+2] asymmetric annulation process 
 
During the preparation of this thesis, but following our first publication in this area,62 
Romo et al. reported the synthesis of N-heterocycles via dinucleophile addition into α,β-
unsaturated acyl ammonium intermediates generated by acylation of α,β-unsaturated acid 
chlorides onto O-trimethylsilylquinine 98 (Scheme 23).63 Nucleophilic addition of amino 
esters formed 5-membered rings in good yields and enantioselectivity at –30 ˚C. It was also 
possible to generate 6-membered rings by extending the chain length of the amino ester 
starting materials. DBU was required to act as an acid scavenger, as without it the products 
were formed in <5% yield. Hünig’s base was also tested in this role however the 
conversion remained low. Using LiHMDS to deprotonate the amino ester is also crucial for 
reactivity and Romo postulates that the lithium chelates both the α,β-unsaturated acyl 
ammonium species and the nucleophile, thus lowering the energy of proposed transition 
state 100. The reaction scope was also expanded to include the use of 1,3-ketoesters as 
dinucleophiles, affording dihydropyranones in moderate to good yields, and in high 
enantioselectivity. 
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Scheme 23: N-Heterocycle formation via α,β-unsaturated acyl ammonium intermediates 
 
Romo et al. then showed that the α,β-unsaturated acyl ammonium intermediate could 
participate in cycloadditions (Scheme 24).64 An isothiourea-catalysed Diels-Alder-
lactonisation between 101 and 102 afforded a range of cyclised products in moderate to 
high yields, with excellent diastereo- and enantiocontrol. 
 
Scheme 24: Isothiourea-catalysed Diels-Alder-lactonisation 
 
Matsubara et al. recently demonstrated that chiral α,β-unsaturated acyl ammonium 
intermediates could be successfully generated using bifunctional hydrogen-bonding catalyst 
105.65 The tertiary amine group acts as a Lewis base to form the desired acyl ammonium 
intermediate, with the leaving group bound to the thiourea moiety (108). This can be 
delivered as a nucleophile with good enantiocontrol, followed by lactonisation to 
regenerate the catalyst. It was also possible to utilise external thiols in conjunction with 
bulky thioesters to further expand the utility of the methodology. 
 
Scheme 25: Isothiourea-catalysed Diels-Alder-lactonisation 
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1.2.7 α,β-Unsaturated acyl azolium intermediates 
As there was limited understanding of the chemistry of α,β-unsaturated acyl ammoniums at 
the start of this work, initial inspiration was taken from the field of N-heterocyclic carbene 
(NHC) catalysis. The chemistry of α,β-unsaturated acyl azolium species has been more 
extensively investigated therefore it provided a good starting point for our own work. 
 
Figure 9: α,β-Unsaturated acyl ammonium and azolium intermediates 
 
The first example of a conjugate addition involving an α,β-unsaturated acyl azolium was 
developed by Lupton et al. in 2009 (Scheme 26).66 In situ deprotonation of the catalyst salt 
affords a free NHC catalyst that directly adds into enol ester 109 to form an α,β-
unsaturated acyl azolium intermediate in an ion pair with the enolate leaving group (110), 
which can act as a nucleophile to generate lactone product 111. The yield was good using 
achiral catalyst 112, but attempts to use chiral catalysts in the reaction were only moderately 
successful and treating starting material 109 with 20 mol% of catalyst 113 gave product 111 
in a good yield but low ee. 
 
Scheme 26: NHC-catalysed Michael addition-lactonisation from enol esters 
 
One disadvantage of this procedure is the requirement to start with a substrate such as enol 
ester 109, which incorporates both the electrophilic and nucleophilic partners for the 
reaction. This could be synthetically limiting when using more complex reaction partners. 
Lupton therefore developed an direct method of generating α,β-unsaturated acyl azolium 
species by acylation of NHCs using acid fluorides 114 (Scheme 27, A).67,68 Alternatively, 
Zeitler has reported that NHC addition to an alkynyl aldehyde 119 followed by protonation 
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gives allenol 117 that rearranges to afford acyl azolium 116 (B).69 An alternative strategy uses 
aldehydes in the presence of stoichiometric oxidising agents (C).70-73 NHC addition into an 
α,β-unsaturated aldehyde 121 generates the Breslow intermediate (120) which is oxidised to 
form the desired α,β-Unsaturated acyl azolium intermediate 116. 
 
Scheme 27: α,β-Unsaturated acyl azolium formation via direct acylation or addition to alkynyl aldehydes 
 
Using this oxidation strategy Studer et al. showed that NHC 123 can catalyse the Michael 
addition-lactonisation between cinnamaldehyde (13) and 2,4-pentanedione (122).70 In this 
case organic oxidant 124 is used to oxidise the Breslow intermediate into an α,β-
unsaturated acyl azolium species. The reaction tolerates a variety of dicarbonyl nucleophiles 
and α,β-unsaturated aldehydes, however substitution at the α-position was not tolerated.  
 
Scheme 28: Development of NHC-catalysed Michael addition to α,β-unsaturated aldehydes 
 
Xiao et al. demonstrated that this reaction is amenable to asymmetric catalysis, generating 
lactone (R)-129 in high yield and stereoselectivity using either ynal addition or aldehyde 
addition-oxidation for acyl azolium formation (Scheme 30). 71,74 In both methods the use of 
molecular sieves was crucial for obtaining high yield and selectivity. 
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Scheme 29: Chiral variant of NHC-catalysed Michael addition-lactonisation 
 
Related work by You et al. (Scheme 30) screened other catalysts for the reaction and found 
that a combination of catalyst 131 (10 mol%) with NaBF4 (5 mol%) as an additive achieved 
the highest selectivity,72 however the role of the additive has not been investigated. 
 
Scheme 30: Enantioselective NHC-catalysed Michael addition to α,β-unsaturated carbonyl species 
 
Bode et al. carried out a similar annulation with a wide range of enol nucleophiles (Scheme 
31) to give annulated products in good yields and moderate to excellent 
enantioselectivity.75,76 Bode has also shown that vinylogous amides are suitable nucleophiles 
in this process, affording dihydropyridone products,77 while Biju recently showed that 
pyrazolones were successful nucleophiles in this process.78 
  
Scheme 31: Chiral variant of NHC-catalysed Michael addition-lactonisation 
 
The mechanism of these NHC-catalysed annulation processes is disputed. Studer et al. have 
carried out mechanistic studies which suggest that nucleophilic addition into the α,β-
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unsaturated acyl azolium intermediate proceeds via 1,4-addition to generate an enolate 
intermediate.79 However, Bode et al. have also conducted mechanistic studies that they 
believe are indicative of 1,2-addition followed by 3,3-rearrangement.80 A recent 
computational collaboration between Bode and Shoenebeck showed that the two pathways 
are similar in energy and as they both generate the same enolate intermediate they are 
difficult to distinguish experimentally.81 However the enolate intermediate is formed, it is 
then agreed that tautomerisation followed by cyclisation forms the lactone product and 
regenerates the catalyst. 
 
Scheme 32: Proposed catalytic cycle for NHC-catalysed Michael addition reaction 
 
One of the major limitations of these NHC-catalysed reactions is the inability to use β-
substituted α,β-unsaturated acyl azolium precursors. Recently, Xu et al. found that this 
could be circumvented by the use of saturated imidazolium catalysts (139).82 This NHC-
precursor scaffold is more normally found in ligands or components of ionic liquids,83 but 
here enables access to anti-dihydropyranones in moderate to good dr, good yields and 
generally high enantioselectivity. 
 
Scheme 33: Enantioselective NHC-catalysed Michael addition to α,β-unsaturated carbonyl species 
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1.3 Aims and Objectives 
Past work in the Smith group has demonstrated that ammonium enolate intermediates are 
competent Michael donors (Scheme 34, (A)). Elaboration of this methodology by reversal 
of the donor/acceptor roles via the introduction of an α,β-unsaturated moiety into the 
catalyst-bound species (B) would be of high synthetic value. In this regard, the 
incorporation of dinucleophiles in the reaction would lead to highly functionalised 
enantioenriched motifs. 
 
Scheme 34: Lewis base catalysis utilising saturated (i) and α,β-unsaturated (ii) substrates 
 
NHCs have been demonstrated to be successful in such processes, however isothioureas 
may provide a useful alternative to NHCs. The current strategies to form acyl azolium 
species require highly reactive starting materials or expensive stoichiometric oxidants. In 
contrast the acid activation methodology developed by Romo and Smith enables direct 
isothiourea activation of bench-stable, commercially available carboxylic acids. 
Furthermore, NHC-catalysis must be performed under rigourously dry conditions whereas 
isothiourea catalysis has proven to be versatile in bench solvents under open flask 
conditions, providing further procedural advantages. 
As MacMillan’s imidazolidinone catalysts have demonstrated, “privileged” catalyst 
architectures offer chemists a wide variety of modes of action, expanding the synthetic 
options open for the synthesis of a variety of product scaffolds. Through exploring the 
scope and mechanism of such modes we can continue to develop robust chemical 
processes that are attractive to both industry and academia. To this aim, the objectives of 
this work were to expand the applicability of isothioureas as Lewis base catalysts, by 
exploring the chemistry of α,β-unsaturated acyl ammonium intermediates. 
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2. 1,3-Diketones and 1,3-Ketoesters as Nucleophiles 
2.1 Project Aims 
Over the last decade isothioureas have been developed as powerful Lewis base 
organocatalysts, having been employed in a number of asymmetric transformations (Figure 
8). They were firstly explored as catalysts for acyl transfer reactions (Figure 8, (i)) including 
kinetic resolutions and C-acylations (see Section 1.2.4). Further development demonstrated 
the generation of ammonium enolate intermediates (ii) that participate in aldol and Michael 
addition-lactonisation processes (see Section 1.2.5).46 The chemistry of α,β-unsaturated acyl 
ammonium species (iii) however has been largely unexplored and had never been 
demonstrated before in isothiourea catalysis. Therefore at the outset of our research our 
aim was to use chiral isothiourea catalysts to generate α,β-unsaturated acyl ammonium 
intermediates that could be utilised in novel, enantioselective methodologies. 
 
Figure 10: Isothiourea activation modes 
 
Taking inspiration from the chemistry of α,β-unsaturated acyl azolium species (as discussed 
in Section 1.2.7) the aim of this project was to develop an enantioselective isothiourea-
catalysed Michael addition of dicarbonyl nucleophiles to α,β-unsaturated acyl ammonium 
intermediates. A hybrid catalytic cycle was proposed (Scheme 35) whereby the reaction is 
initiated by acylation of the catalyst with an activated acid to form an α,β-unsaturated acyl 
ammonium intermediate. Subsequent 1,4-addition (or 1,2-addition followed by 3,3-
rearrangement)79-81 generates an ammonium enolate and forms a new C-C bond, setting the 
stereocentre. Proton transfer followed by lactonisation forms the product and regenerates 
the catalyst. 
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Scheme 35: Proposed mechanism for isothiourea-catalysed Michael addition-lactonisation of α,β-unsaturated 
carboxylic acids 
 
Successful demonstration of this reaction would provide the first example of an α,β-
unsaturated acyl ammonium intermediate participating in a Michael addition. Inspired by 
the research of Xiao71 and You72 a model reaction was selected for examination (Scheme 
36). Xiao and You demonstrated that α,β-unsaturated acyl azoliums could be accessed via 
NHC precursors 131 and 128, cinnamaldehyde 13 and stoichiometric organic oxidant 124. 
Our aim was to evaluate commercially available, bench-stable carboxylic acids and 
isothioureas as α,β-unsaturated acyl ammonium precursors, eliminating the need for 
aldehyde synthesis and the use of expensive organic oxidants.  
 
Scheme 36: Test reaction for optimisation studies 
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Initial studies focussed on finding a suitable carboxylic acid activating agent to promote 
catalysis, followed by screening of chiral isothiourea catalysts to obtain acceptable levels of 
conversion and the best enantioselectivity in the process. This was followed by further fine 
tuning of base and solvent effects and investigation into product isolation methods to 
afford optimal reaction conditions, allowing exploration of the reaction scope and 
mechanism. 
 
2.2 Reaction Optimisation 
2.2.1 Activation agent screening 
The first step in the proposed catalytic cycle (Scheme 35) is the formation of an α,β-
unsaturated acyl ammonium species. To facilitate this first step, the carboxylic acid must be 
“activated” by introducing an effective leaving group. Previous work in the Smith group 
has demonstrated pivaloyl chloride as an effective activating agent, forming a mixed 
anhydride 146 in situ. However, in the model reaction (Scheme 37) pivaloyl chloride 
activation was ineffective and only starting material was returned. 
 
Scheme 37: Use of pivaloyl chloride as an activating agent 
 
One possible reason for the low reactivity observed was poor formation of mixed 
anhydride 146. To provide evidence of intermediate 146 methanol was used as a 
nucleophile (Scheme 38) in the synthesis of ester 147. “Unactivated” acid 143 does not 
esterify under these conditions therefore any formation of 147 must proceed through the 
mixed anhydride 146. After 3 h, analysis of the crude reaction mixture by 1H NMR showed 
conversion into ester 147 to be approximately 60%. This suggests modest formation of 
mixed anhydride 146, however since it was not possible to achieve conversion into lactone 
145 via our organocatalysis this activation method was deemed unsuitable. 
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Scheme 38: Methyl ester formation using pivaloyl chloride activation under isothiourea catalysis 
 
In order to find a more effective acid activation method, several in situ activating agents 
were investigated in the model reaction (Table 1). Consumption of the dicarbonyl was 
monitored by 1H NMR and calculated based upon the starting material to product ratio. In 
most cases unreacted starting materials were returned, however some success was obtained 
with both tosyl chloride and 4-methoxybenzoic anhydride. Increasing the quantity of 
activating agent had no effect on tosyl chloride activation, and with 4-methoxybenzoic 
anhydride a drop in conversion was observed at 2 equivalents and an increase at 1.2 
equivalents to 62% was achieved. 
 
Activating Agent Equivalents 
Dicarbonyl 
Consumption 
(%)[a] 
Yield 
(%)[b] 
Pivaloyl chloride 
 
1 
1.5 
0 
0 
- 
Mukaiyama 
reagent 
 
1 0 - 
Benzoyl chloride 
 
1 9 - 
Tosyl chloride 
 
1 
2 
30 
30 
- 
- 
4-methoxybenzoic 
anhydride 
 
1 
2 
1.2 
53 
41 
62 
42 
- 
59 
Table 1: Screening of activating agents [a]Calculated by 1H NMR, [b]Isolated yield 
 
To circumvent any problems of poor acid activation, pre-activated species were tested in 
the model reaction (Table 2). Despite the high reactivity of acid chlorides towards 
nucleophilic addition,84 no product was formed when cinnamoyl chloride was employed. 
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Use of cinnamic anhydride in the model reaction provided the desired product 145 with 
63% diketone consumption which was increased to 76% by using an excess of the 
anhydride. 
 
Activated Species Equivalents 
Dicarbonyl 
Consumption 
(%)[a] 
Yield (%)[b] 
Cinnamoyl chloride 
148 
 
1 0 - 
Cinnamic anhydride 
149 
 
1 
2 
63 
76 
8 
59 
Table 2: Comparison of pre-activation methods [a]Calculated by 1H NMR, [b]Isolated yield 
 
Cinnamic anhydride 149 was initially synthesised from cinnamic acid 143 using N,N’-
dicyclohexylcarbodiimide (DCC, 150 Scheme 39) as a coupling agent, however urea 
byproduct 152 coeluted with lactone 145 after the organocatalysis, making product 
purification difficult. Attempts to purify the anhydride by recrystallisation or trituration 
were unsuccessful so 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDCI.HCl, 151 Scheme 39) was investigated as an alternative coupling agent. The 
advantage of this reagent is that both the coupling agent and the urea byproduct 153 are 
water soluble, enabling purification by a simple water wash. The yield of anhydride 
obtained by this method was slightly reduced however it enabled isolation of 
organocatalysis product 145 in excellent purity. 
 
Scheme 39: Cinnamic anhydride synthesis 
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2.2.2 Isothiourea screening 
Using the optimal activation methods determined (A and B, Table 3), the chiral 
isothioureas (-)-tetramisole 50, (+)-benzotetramisole 51 and HBTM 2.1 53 (Table 3) were 
investigated. DHPB 144 afforded the product in the same yield for both activation 
methods, however the only chiral catalyst to give any conversion into product 145 was 
HBTM 2.1 53, with other chiral catalysts returning only unreacted starting materials. 
HBTM 2.1 53 gave excellent enantioselectivity (95% ee) in both cases, but a significantly 
higher yield was achieved using cinnamic anhydride (activation method B), hence this 
activation method was chosen for further reaction optimisation. 
 
Isothiourea Catalyst 
Activation 
Method 
Dicarbonyl 
Consumption (%)[a] 
Yield 
(%)[b] 
ee 
(%) 
- - 
A 
B 
0 
0 
- 
- 
- 
- 
DHPB 144 
 
A 
B 
62 
76 
59 
59 
- 
- 
TM 50 
 
A 
B 
0 
0 
- 
- 
- 
- 
BTM 51 
 
A 
B 
0 
0 
- 
- 
- 
- 
HBTM 2.1 53 
 
A 
B 
39 
57 
25 
57 
95 
95 
Table 3: Comparison of isothiourea catalysts [a]Calculated by 1H NMR, [b]Isolated yield 
 
2.2.3 Reaction concentration effects 
In an attempt to further increase conversion into desired product 145, the effects of 
reaction concentration were next investigated. A series of reactions using varying 
concentrations of 1,3-diphenyl-1,3-dipropanone 141 from 0.09 to 0.72 M was investigated 
(Table 4). A maximum conversion of 74% could be obtained using 1.2 equivalents of 
homoanhydride at a reaction concentration of 0.72 M, which could be further increased to 
86% with 1.4 equivalents of homoanhydride at the same dicarbonyl concentration. Higher 
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concentrations could not be achieved due to poor solubility of the reactants and mobility 
causing the reaction to proceed inefficiently. 
 
Anhydride 
Equivalents 
Dicarbonyl 
Concentration (M) 
Dicarbonyl 
Consumption 
(%)[a] 
1.2 
1.2 
1.2 
1.2 
1.4 
0.09 
0.18 
0.36 
0.72 
0.72 
53 
66 
73 
74 
84 
Table 4: Effects of diketone concentration on dicarbonyl consumption [a]Calculated by 1H NMR 
 
2.2.4 Product isolation and ring-opening 
Throughout optimisation it was found that reaction yields were poorly reproducible, with 
isolated yields ranging from 27-63%. However conversion into product 145 (monitored by 
crude 1H NMR spectra) was consistently high, therefore product isolation and stability was 
investigated via a comparison of silica gel contact time. Two lactone purifications were 
carried out in tandem, comparing the speed at which eluent was passed through the 
column (Scheme 40). The “fast” column gave the product in a 54% yield; the “slow” 
column which involved longer contact time of the product on the silica gave a reduced 
33% yield due to the apparent instability of the lactone. 
 
Scheme 40: Lactone isolation and silica column stability 
 
An alternative ring-opened product was targeted via in situ methanolysis of lactone 145 into 
ester 154. Ring-opening proceeded readily and afforded a chromatography-stable product 
((S)-154) in high yield (Scheme 41). Whilst formally the absolute configuration of the 
stereocentre during the ring-opening changes from (R) to (S), no epimerisation occurs in 
this process and both lactone and ring-opened products were obtained in 95% ee. 
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Scheme 41: Lactone isolation and methanolysis 
 
The absolute configuration of the lactone product 154 was determined by comparison of 
its specific rotation to that quoted in the literature (Figure 11).72 X-ray crystallographic 
analysis of lactone 155 by You et al. determined the configuration to be (S). By analogy, 
You reported that lactone 154 must have the same absolute configuration at the stereogenic 
centre. The 
20
D][  measured for lactone 154 isolated in our investigations matches the value 
reported by You et al., so it follows that the product generated via isothiourea catalysis also 
contains an (R)-stereocentre. 
 
Figure 11: Absolute configuration determination 
 
2.2.5 Base screening and catalyst loading 
Alternative bases were next examined to further improve conversion (Table 5). 
Triethylamine, MTBD (7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene, a hindered guanidine 
base) and K2CO3 all gave low conversion into product 154. Improved yields were obtained 
with DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) however the enantioselectivity was 
compromised. In this case the reaction works well in the absence of an isothiourea catalyst, 
so the erosion of enantioselectivity is presumably due to competing Lewis base catalysis by 
DBU. When NEt(iPr2) was employed, lower catalyst loadings were tolerated but a modest 
drop in reaction conversion was observed. In contrast using PS-BEMP (2-tert-butylimino-
2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine on polystyrene, loading of 
~2.2 mmolg-1) afforded 154 in increased yields and tolerated catalyst loadings as low as 5 
mol% without any drop in yield. Further reductions to 1 mol% were successful but resulted 
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in reduced yield even at extended reaction times. Therefore further investigations were 
carried out using PS-BEMP as the base with 5 mol% isothiourea catalyst loading.  
 
Base Catalyst loading (mol%) 
Yield 
(%) 
ee 
(%) 
NEt3 20 17[a] - 
MTBD 
 
20 0[a] - 
K2CO3 20 10[a] - 
NEt(iPr2) 
20 
10 
5 
77[b] 
70[b] 
62[a] 
95 
95 
- 
DBU 
 
20 
0 
86[b] 
75[a] 
73 
- 
PS-BEMP 
 
20 
10 
5 
2.5 
1 
85[b] 
82[b] 
85[b] 
69[b] 
62[b] 
95 
95 
94 
93 
93 
Table 5: Base and catalyst loading optimisation [a]Diketone consumption calculated from crude NMR 
[b]Isolated yield 
 
2.2.7 Optimised reaction conditions 
The optimised reaction conditions are summarised in Scheme 42. The use of an excess of 
homoanhydride as a pre-activated carboxylic acid was crucial for both high yield and 
enantioselectivity. High concentration is important for increasing the reaction conversion, 
and a concentration of 0.72 M diketone is a good compromise between starting material 
consumption and mobility of the reaction mixture. Of the bases investigated, PS-BEMP 
was optimal as it allowed low catalyst loadings to be employed. Finally, in situ methanolysis 
generates highly functionalised esters that are more stable to column chromatography and 
improves product isolation. With the optimised reaction conditions established, a survey of 
the scope of the reaction was next investigated. 
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Scheme 42: Finalised reaction conditions 
 
2.3 Reaction Scope: Symmetrical Diketones 
2.3.1 Anhydride synthesis and scope 
To probe the substrate scope and limitations of this reaction, a wide range of 
homoanhydrides was prepared according to the previously described EDCI coupling 
procedure (Scheme 43). A variety of β-aryl and β-alkyl α,β-unsaturated anhydrides were 
synthesised in order to explore steric and electronic effects in the Michael addition-
lactonisation process, as well as the incorporation of heterocyclic substituents. The majority 
of anhydrides were accessed easily in CH2Cl2, however it was necessary to synthesise 
heterocyclic substrates 163 and 164 in THF to prevent the formation of polymeric material. 
The anhydrides were found to be stable in the freezer over the course of several months. 
 
Scheme 43: Anhydride synthesis via EDCI coupling [a]THF used as solvent 
 
The range of homoanhydrides was then investigated under the optimised reaction 
conditions to examine the substrate scope of the Michael addition-lactonisation. 
Anhydrides with substituted aromatic groups were tolerated well (Scheme 44), with 
electron-withdrawing groups (165 and 166) giving high yields and good enantioselectivity. 
Electron-donating groups gave significantly lower conversion, with 4-methoxy substitution 
affording product 167 in a moderate 44% yield. This is possibly due to reduced 
electrophilicity in the electron rich α,β-unsaturated acyl ammonium intermediate. 
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Increasing the catalyst loading from 5 to 10 mol% led to an improvement in the yield, 
however a slight drop in enantioselectivity was observed. Substitution in the 2- (170) or 3- 
(168 and 169) position round the β-aryl ring was also tolerated, with little effect on the 
enantioselectivity of the process. 
 
Scheme 44: Aryl anhydrides in the Michael addition-lactonisation reaction ([a]10 mol% catalyst) 
 
Pleasingly, the substrate scope was extended to include β-heterocyclic substituents (171 and 
172, Scheme 45). The furanyl example gave a slightly lower yield, possibly due to the ring 
being slightly more electron-rich. Linear alkyl groups were also successful in the reaction, 
but β-branched alkyl anhydrides did not react under the reaction conditions. Alkyl 
substitution also resulted in lower ee than seen for aromatic substrates. Enantioselectivity 
could be increased by reducing the reaction temperature from 0 to –78 C however a 
significant drop in yield was incurred in both cases. You et al. found that methyl 
substitution afforded only a 10% yield in their NHC-catalysed Michael addition-
lactonisation process,72 so the use of isothioureas provides a significant advantage for these 
substrates. 
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Scheme 45: Heterocyclic and alkyl anhydrides in the Michael addition-lactonisation reaction 
[a]carried out at –78 C 
 
2.3.2 Diketone scope 
We then turned our attention to alternative symmetrical dicarbonyl nucleophiles. First, a 
range of commercially available alkyl diketones was investigated (Scheme 46).i Dimethyl 
substitution afforded product 176 in reasonable yield but low enantioselectivity, possibly 
due to reduced steric bulk leading to poor facial discrimination in the transition state. 
Branched (and hence more sterically demanding) alkyls were investigated, however they 
were not successful in the reaction and this is proposed to be due to hindrance of the 
nucleophilic addition. Isopropyl substitution afforded product 177 in a low yield 
contaminated with an unknown product. Further purification was unsuccessful and it 
proved impossible to obtain a pure sample for full characterisation. tert-Butyl substituted 
diketone displayed no reactivity and formation of product 178 was not observed. 
 
Scheme 46: Alkyl diketones in the Michael addition-lactonisation reactioni 
 
To further investigate the scope of the reaction with regards to symmetrical diketones, a 
range of aryl diketones was prepared via LiHMDS deprotonation of aryl ketones and 
                                                 
i Carried out by Dr Carmen Simal 
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addition to aryl acid chlorides (Scheme 47). This procedure afforded symmetrical diketones 
179-183 in modest yields.ii 
 
Scheme 47: Synthesis of symmetrical dicarbonyl speciesii 
 
These aryl diketones were subsequently examined in the Michael addition-lactonisation 
reaction (Scheme 48). Electron-poor diketones gave higher yields, possibly due to increased 
acidity of the α-protons increasing the enolate concentration present. Equally this could 
explain the reduced enantioselectivity for electron poor nucleophiles due to enhanced 
background reaction rate. Use of diketone donors with electron-poor homoanhydrides 
improved both the yield and enantioselectivity, with 186 being obtained in 54% yield and 
96% ee whilst 185 was obtained in a lower 40% yield and 90% ee. 
 
Scheme 48: Symmetrical aryl diketones as nucleophilesii 
 
To probe the scope of the isothiourea-catalysed reaction further, our attention turned to 
cyclic diketone 189 reported by Bode to be ineffective in the corresponding NHC-catalysed 
                                                 
ii Carried out by Dr Charlene Fallan 
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process.76 Significantly, cyclic diketone 189 was successful in the isothiourea-catalysed 
process, however a short reoptimisation of solvent was required to increase the 
enantioselectivity. In CH2Cl2, the reactivity was good but the ee modest. Changing to THF 
increased the ee but led to a drop in enantioselectivity, however a 10:1 mixture of 
THF:CH2Cl2 afforded lactone 111 in good yield and enantioselectivity.
iii This result further 
demonstrated the utility of our process in examples where NHC-catalysts are unsuccessful. 
 
Solvent Yield (%) ee (%) 
CH2Cl2 82 74 
THF 39 87 
THF:CH2Cl2 (10:1) 80 86iii 
Table 6: Solvent effects observed for cyclic diketone annulation 
 
2.4 Use of Non-Symmetrical Dicarbonyl Nucleophiles 
2.4.1 Diketones 
To further expand the scope, non-symmetrical diketones were examined. Initial 
investigations using 1-phenylbutane-1,3-dione 190 resulted in a 69:31 mixture of 
regioisomers 191a and 191b that were difficult to separate by chromatography (Scheme 
49).iv  
 
Scheme 49: Regioselectivity using 1-phenylbutane-1,3-dioneiv 
 
Ring-opening of regioisomeric lactones 191a and 191b with methanol affords ester 192 in a 
1:1 mixture of diastereomers that could not be separated (Scheme 50),iv therefore ring-
                                                 
iii Carried out by Dr Charlene Fallan 
iv Carried out by Dr Carmen Simal 
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opening to improve product isolation was not suitable for products generated from non-
symmetrical nucleophiles. 
 
Scheme 50 : Ring-opening of regioisomeric pairsv 
 
2.4.2 Ketoesters 
Ethyl benzoylacetate 193 was explored as a nucleophile in the optimised process, resulting 
in lactone 194 as a single regioisomer. Isolation of 194 proved difficult due to instability on 
silica gel. A number of chromatography conditions (quantity of silica, column eluents) were 
investigated and CH2Cl2 was identified as the optimum eluent with a short silica contact 
time. 
 
Scheme 51: Ethyl benzoylacetate as dicarbonyl nucleophile 
 
The high regio- and enantioselectivity obtained with ethyl benzoylacetate 193 led to 
examination of reaction scope using this nucleophile (Figure 12). Introduction of the ester 
functionality into the dicarbonyl increases the pKa of the α-protons,85 leading to lower 
consumption of starting material compared with 1,3-diphenyl-1,3-dipropanone 141 in all 
examples. Despite isolation problems, a range of lactones were successfully isolated in 
moderate yields and good enantioselectivity. Methyl substitution gave lower 
enantioselectivity with product 201 isolated in 65% ee. Heterocycles worked well, with 
thienyl 199 and furanyl 200 examples being isolated in good yield and high ee. Electron-
withdrawing aryl substitution was highly successful in the process, however electron-
donating groups were not tolerated. Several attempts were made to obtain the 4-methoxy 
substituted lactone however a combination of very low conversion and lactone hydrolysis 
meant isolation was unsuccessful. 
                                                 
v Carried out by Dr Carmen Simal 
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Figure 12: Scope of the reaction using ethyl benzoylacetatevi,vii 
 
2.5 Mechanistic Investigations 
2.5.1 Postulated mechanism 
Inspired by related Lewis base-catalysed Michael-addition lactonisations, the catalytic cycle 
shown in Scheme 52 is proposed. The reaction is initiated by acylation of the catalyst with 
the homoanhydride to form an α,β-unsaturated acyl ammonium intermediate. Two 
mechanistic pathways have then been suggested by the groups of Bode76,81 and Studer79 for 
related NHC-catalysed processes proceeding via α,β-unsaturated acyl azolium intermediates 
(as discussed in Chapter 1, Section 1.2.7). If we assume that isothioureas behave similarly to 
NHCs in Lewis base catalysis, we can propose that the reaction could proceed via 1,2-
addition of the nucleophile into the α,β-unsaturated acyl ammonium intermediate followed 
by [3,3]-rearrangement to afford an ammonium enolate intermediate (as favoured by 
Bode). Alternatively, the same enolate could be formed directly via Michael addition of the 
nucleophile into the α,β-unsaturated intermediate (as suggested by Studer). Since 
experimental and computational studies in the NHC literature have proved to be 
inconclusive, with the energies of the two pathways being very similar, it is undetermined 
which pathway is most likely for our isothiourea-catalysed process. From the ammonium 
                                                 
vi Carried out by Dr Carmen Simal 
vii Carried out by Dr Charlene Fallan 
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enolate, the product is formed via proton transfer and subsequent lactonisation; the 
product can then be ring-opened in situ with methanol to form highly functionalised esters. 
 
Scheme 52: Proposed catalytic cycle for the isothiourea-catalysed annulation process 
 
In order to support this proposed mechanism, some control experiments were 
performed.viii It was possible to isolate α,β-unsaturated acyl ammonium 202 as a chloride 
salt by reacting cinnamoyl chloride with stoichiometric HBTM 2.1 at room temperature in 
CH2Cl2. The intermediate was formed as a precipitate that was isolated by filtration in a 
77% yield. Intermediate 202 was then successfully employed as a precatalyst in the process 
(Scheme 53), which is consistent with the reaction proceeding via an α,β-unsaturated acyl 
ammonium intermediate. 
 
Scheme 53: Isolation and reaction of an acyl ammonium intermediateviii 
 
Our attention then turned to work by Lupton et al. that demonstrated that α,β-unsaturated 
enol esters could be employed as nucleophile precursors in an NHC-catalysed conjugate 
addition (Scheme 54, A).66 Initial addition of NHC 113 to ester 109 generates an ion pair 
                                                 
viii Carried out by Dr Charlene Fallan 
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(110) comprised of an α,β-unsaturated acyl azolium electrophile and an enolate nucleophile. 
Product 111 was then formed in good yield but low ee. It is possible that in our process the 
nucleophile 141 could intercept the homoanhydride before the catalyst, however enol ester 
203 did not rearrange under isothiourea catalysis,ix which is consistent with our proposal 
that the homoanhydride directly acylates HBTM 2.1 in the mechanism. 
 
Scheme 54: Rearrangement of α,β-unsaturated esters under Lewis Base catalysisix 
 
2.5.2 Proposed stereochemical model 
To generate the observed (R)-lactone, the stereodetermining step in the mechanism must 
proceed via nucleophilic addition to the Si-face of the ketone or the Re-face of the olefin of 
the α,β-unsaturated acyl ammonium ion in order to impart an (R)-stereocentre in the 
product (Scheme 55). 
 
Scheme 55: Stereocentres induced during nucleophilic addition and lactonisation 
 
In order to analyse how the transition state induces preferential 1,2- or 1,4-addition to the 
back face as drawn, it is important to consider the conformation of the acyl ammonium 
species. Firstly it is assumed that the C-C(O) σ-bond adopts an s-cis conformation in order 
                                                 
ix Carried out by Charlene Fallan 
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to minimise steric interactions between the substituents on the olefin and the 
tetrahydropyrimidine portion of the isothiourea ring (Figure 13).  
 
Figure 13: Postulated non-bonding oxygen - sulfur interaction 
 
It is also thought that an oxygen to sulfur interaction exists, stabilising the species and 
holding it in the syn-conformation shown in Figure 13. A study by Stahl et al., using small 
molecule crystal structures to determine conformational preferences, observed that many 
species show a strong preference for 1,5-oxygen to sulfur interactions.86 The nature of the 
interaction is not well understood but has been suggested to be an nO→σ*C-S orbital 
interaction.46,57 It could also simply be an electrostatic interaction between the oxygen and 
sulfur atoms overcoming lone pair repulsion, but no evidence for this has yet been 
reported. Recently, Romo in collaboration with Tantillo carried out computational 
investigations into an isothiourea-catalysed Diels-Alder reaction also proceeding via an α,β-
unsaturated acyl ammonium intermediate (Scheme 56).64 Experimental results showed that 
a single diastereomer of the product was obtained (103) in excellent enantioselectivity. 
Computational calculations then showed that there was a large energy preference (>5 
kcalmol-1) for diene approach from the Re-face due to steric blocking by the (-)-BTM 
catalyst on the Si-face (204), thus affording excellent stereocontrol in the process. 
 
Scheme 56: Isothiourea-catalysed Diels-Alder-lactonisation, with diene approach from the less hindered Si-face 
 
They also carried out natural bond orbital (NBO) analysis of the α,β-unsaturated acyl 
ammonium species to probe the orbital interactions responsible for the observed 
conformation. While an oxygen to sulfur n→σ* interaction did contribute to the stability of 
the system, this effect was negated by the destabilising energy of lone pair repulsion 
between oxygen and sulfur (Figure 14). However when the dihedral angle is 180o 
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unfavourable ns→σC-H interactions arise, which increase the energy of this conformation 
and leads to the observed syn-conformational lock. 
 
Figure 14: Significant NBO calculations for syn- and anti-conformations 
 
Whatever the true nature of the O→S interaction, it enhances enantioselectivity in 
isothiourea-catalysed processes by locking the conformation of the acylated intermediate.52 
This allows facial selectivity to arise from the positioning of the stereodirecting groups on 
the isothiourea catalyst. Isolated α,β-unsaturated intermediate 202 was analysed by X-ray 
crystallography (Figure 15), and the conformation of the catalyst in the solid state is 
thought to closely resemble the conformational preference in solution phase. 
  
Figure 15: X-ray crystal structure of α,β-unsaturated acyl ammonium intermediate 202x 
 
As seen in Figure 15 the 6-membered tetrahydropyrimidine ring adopts a pseudo half-chair 
conformation in order to reduce 1,2-interactions.87-89 The isopropyl group sits in an 
                                                 
x Crystal obtained by Dr Charlene Fallan and analysed by Prof. Alexandra Slawin 
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equatorial position, locking the ring with the phenyl group sitting axially. The vertical 
positioning of the phenyl ring blocks the Si-face of the acylated catalyst, hence the 
nucleophilic addition occurs from the Re-face and installs an (R) stereocentre that is 
retained in the lactone product. 
 
2.5.3 Effect of E/Z anhydride configuration 
In order to investigate the effect of double bond geometry on the reaction a sample of cis-
cinnamic acid was synthesised. Alkyne 205 was selectively reduced using Lindlar’s catalyst 
to give a reaction mixture containing 90% cis-alkene 206, 6% alkyne 205, and small 
quantities of the alkane 207 and trans-alkene 208. The reaction required two cycles to 
achieve improved conversion into alkene 206, giving material clean enough to take through 
to the next step without further purification. 
 
Scheme 57: Selective reduction of ethyl phenylpropiolate using Lindlar catalyst 
 
cis-Ester 206 was then hydrolysed using lithium hydroxide, affording cis-cinnamic acid 209 
in 89% yield (cis-geometry confirmed by matching 1H NMR data to the literature).90 cis-
Anyhydride 210 was generated using an EDCI coupling in a 56% yield, affording the 
product in an overall yield of 50% over 3 steps. 
 
Scheme 58: Reduction and anhydride coupling of cis-ethyl cinnamate 
 
Subjecting the cis-anhydride 210 to the optimised addition-lactonisation reaction conditions 
afforded the ring-opened product 154 in 41% yield (Scheme 59). HPLC analysis revealed 
that the use of the (Z,Z) ahydride favoured formation of the opposite (R)-enantiomer with 
low enantioselectivity. 
 2. 1,3-Diketones and 1,3-Ketoesters as Nucleophiles  
 
45 
 
Scheme 59: Use of cis-cinnamic anhydride in the Michael addition-lactonisation reaction 
 
A switch in enantioselectivity might be expected with a change of olefin geometry, however 
the reason for low enantioselectivity is not fully understood. If we assume that the s-cis 
conformation is retained in the (Z)-α,β-unsaturated acyl ammonium intermediate, we must 
consider the conformation that the phenyl group adopts (Figure 16). In the case of the (E)-
intermediate it adopts a planar conformation, therefore facial selectivity is dictated only by 
the position of the catalyst stereodirecting groups. Whilst no crystal structure has been 
obtained for the (Z)-intermediate, it can be reasoned that the close proximity of the 
carbonyl group would prevent the phenyl group lying in the plane of the α,β-unsaturated 
system. This would provide further steric hindrance to nucleophilic addition and reduce the 
catalyst’s influence over facial selectivity. This therefore demonstrates the importance of 
(E,E)-geometry of the anhydride to obtain good enantioselectivity in the Michael addition-
lactonisation process. 
 
Figure 16: Conformations of α,β-unsaturated acyl ammonium species with E- and Z-configurations 
 
2.6 Conclusions 
A novel Michael addition-lactonisation process has been developed, demonstrating the first 
use of an α,β-unsaturated acyl ammonium intermediate in isothiourea organocatalysis. 
Screening of dinucleophiles demonstrated that 1,3-diphenyl-1,3-dipropanone afforded 
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comparible yields in our process to those reported by the groups of You72 and Xiaou71 
Advantages of the isothiourea-catalysed system include the use of bench-stable, easily 
accessible starting materials. Increased enantioselectivity for electron-donating aryl groups 
is also obtained, alongside significantly better yields for alkyl substrates compared with 
NHC catalysis. The scope of the reaction has also been expanded with the first reports of 
electron-withdrawing aryl substituents and heterocycles in the reaction.  
A variety of aryldiketones were successful in the reaction and the first successful use of 
electron-poor and heteroarene containing diketones was demonstrated. Ethyl 
benzoylacetate had also not been previously employed as a nucleophile in Michael addition-
lactonisations with α,β-unsaturated carbonyl species and was successful using a range of 
anhydrides with a selection of lactones being isolated in moderate to good yields and high 
enantioselectivity. 
α,β-Unsaturated acyl ammonium intermediate 202 was isolated by addition of HBTM 2.1 
to cinnamoyl chloride. The acyl ammonium species was then successfully used as a 
precatalyst in the process which is consistent with the postulated mechanism. It was also 
possible to analyse the isolated α,β-unsaturated acyl ammonium salt by X-ray 
crystallography. Assuming that the shape of the intermediate is similar in solid and solution 
phases, the configuration of the intermediate is consistent with our predicted 
stereochemical model. 
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3. Benzazoles as Nucleophiles 
3.1 Introduction 
3.1.1 Benzazoles in medicinal chemistry 
The synthesis of benzazole-containing compounds is of high synthetic interest, primarily 
due to their biological activity. A search of PubChem,91 a database of molecules and their 
biological activities run by the National Centre for Biotechnology Information (a subsidiary 
of the National Institute of Health) in the USA, revealed 4,055 biologically active 
compounds containing a benzoxazole moiety (211), 10,323 containing benzothiazole (212) 
and 20,709 containing benzimidazole (213).xi 
 
Figure 17: Structues of benzazoles 
  
The medicinal uses of benzazoles have been the subject of several recent reviews92-95 which 
highlight the hugely diverse range of bioactivities displayed by these compounds. 
Benzothiazole, benzimidazole and benzoxazole-containing compounds are effective in a 
range of therapeutic treatments and have displayed impressive anti-bacterial, anti-fungal, 
anti-parasitic and anti-cancer properties. Due to their wide-ranging modes of action they 
are of great interest to medicinal chemists. This in turn makes them attractive targets for 
the development of, and incorporation into, new chemical methodologies. 
 
3.1.2 Benzazoles in conjugate addition processes 
A potentially versatile way of installing benzazoles is by conjugate addition of acyl 
benzazoles to Michael acceptors. Acyl benzazole nucleophiles have recently been shown by 
Lam et al. to be competent nucleophiles in a nickel-catalysed enantioselective Michael 
addition to nitroalkenes.96 The products were achieved in high yields, moderate to excellent 
dr and good enantioselectivity (Scheme 60). 
                                                 
xi Search methodology: Structure search → substructure → input the relevent heterocycle 
→ filters: bioactivity: active 
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Scheme 60: 1,4 (371a)-addition of benzazole nucleophiles to nitroalkenes 
 
Building upon work from Liso et al. that found that acyl benzazole can add to allyl 
malonates,97 Pittman Jr. et al. reported that acyl benzothiazole and benzoxazole 
nucleophiles undergo 1,4-addition to α,β-alkynyl ester 219 (Scheme 61), generating 
intermediate diesters 220 which readily underwent in situ intramolecular cyclisation and 
double bond isomerisation to generate novel lactams 221 and 222 in good yields. 98 
 
Scheme 61: Addition of 2-phenacyl benzazoles to α,β-unsaturated alkynyl ester 
 
To date, conjugate additions of acyl benzazoles remains an underexplored reaction. 
Development of new conjugate additions with this class of nucleophile is therefore of 
interest to install benzazole groups in novel, efficient and potentially enantioselective 
methodologies. This could, in turn, allow access to new molecular architectures for 
medicinal chemistry. 
 
3.1.3 Project aims 
With the aim to expand the scope of our isothiourea-catalysed Michael addition-cyclisation 
methodology beyond the use of 1,3-dicarbonyl nucleophiles (Chapter 2), we decided to 
investigate the nucleophilic addition of acyl benzazoles to α,β-unsaturated acyl ammonium 
intermediates. The two processes reported by Lam and Pittman Jr. provide good precedent 
for benzazoles to act as competent Michael donors, suggesting that they may participate in 
isothiourea-catalysed Michael addition processes. 
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A potential complication of the targeted Michael addition-cyclisation is the regioselectivity 
of the cyclisation step (Scheme 62). We propose that 1,4-addition of nucleophile 223 to 
α,β-unsaturated acyl ammonium intermediate 224 would generate intermediate 225, which 
may promote catalyst turnover through both N- and O-cyclisation affording lactam 226a or 
lactone 226b. Both products are interesting and novel heterocycle-containing molecular 
classes, and we aimed to develop reaction conditions to promote selective formation of 
either of the heterocyclic cores. To investigate the postulated regiodivergence we proposed 
to synthesise a variety of benzazole nucleophiles, changing both the electronic properties 
of the acyl and heterocyclic moieties, then use them in conjunction with α,β-unsaturated 
acyl ammonium intermediates to form a range of heterocyclic products in good 
enantioselectivity. 
 
Scheme 62: Potential regiodivergence in the Michael addition-cyclisation process 
 
3.2 2-Phenacylbenzothiazole: Initial Screening and Scope 
3.2.1 Regioisomer formation and identification 
2-Phenacylbenzothiazole (227) was employed in a model reaction (Scheme 63) utilising 
related conditions to those developed for 1,3-dicarbonyl nucleophiles (as discussed in 
Chapter 2). Homoanhydride 149 (1.4 equivalents) was dissolved in CH2Cl2 at 0 ˚C, then 
nucleophile 227, base and catalyst (HBTM 2.1, 5 mol%) were added and the flask stirred at 
0 ˚C to room temperature overnight. It was possible to use NEt(iPr)2 as base instead of the 
more expensive PS-BEMP without losing reactivity at low catalyst loadings. Two 
regioisomers (228a and 228b) were identified, which were distinguishable in the crude 1H 
NMR spectrum. The regioisomeric ratio was measured by 1H NMR as 88:12, and the 
isomers were readily separated by column chromatography although only a small quantity 
of the minor isomer was isolated. 
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Scheme 63: Regioisomeric annulation products 
  
The identity of the two isomers was determined by 13C {1H} NMR spectroscopy (Figure 
18). Whilst the lactone and lactam 13C signals have similar chemical shifts (166.6 and 167.9 
ppm), a characteristic ketone signal (191.2 ppm) could be confidently assigned in the 
spectrum of the major isomer (228a). This signal is absent in the spectrum of the minor 
isomer 228b therefore it was reasoned that lactamisation must be the major cyclisation 
pathway. 
 
Figure 18: 13C {1H} NMR evidence for regioisomer structure 
 
Further evidence for the structure of 228a was gained by X-ray crystallographic analysis 
(Figure 19), which clearly shows the novel tricyclic heterocycle structure. It is interesting to 
note that the observed O→S distance in the crystal structure is 2.574 Å, significantly 
shorter than the Van der Waals’ radii (4.144 Å). This is consistent with our previous 
observations of an attractive O→S interaction in the acyl ammonium intermediate, and 
provides further evidence of its ubiquity where oxygen and sulfur exist in a 1,5-relationship. 
 
Figure 19: X-ray crystallographic evidence for major regioisomer structure 
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During sample preparation an enantioenriched sample of the major isomer 228a separated 
into racemic crystals and enantiopure non-crystalline material. The crystals obtained 
provide good evidence of the formation of N-cyclised lactam 228a but as it was not 
possible to access suitable crystals of enantiopure material we were unable to prove the 
absolute stereochemistry. The absolute configuration of the products has therefore been 
assumed to be analogous to previous work (Section 2.2.5). 
 
3.2.2 Isothiourea screening 
Initial reaction screening using isothiourea HBTM 2.1 53 afforded N-cyclised product 228a 
in moderate enantioselectivity (64% ee). Alternative isothiourea catalysts were tested to see 
if increased selectivity could be achieved (Table 7), however both tetramisole (TM 50) and 
benzotetramisole (BTM 51) displayed poor conversion, lower regioselectivity and reduced 
enantioselectivity. This is consistent with results obtained with dicarbonyl nucleophiles 
(Section 2.2.2). 
 
Catalyst 
Regioisomeric 
ratio 
(228a:228b) 
Yield (%)[a] ee (%)[a] 
DHPB 144 92 : 8 82 - 
HBTM 2.1 53 92 : 8 75 64 
TM 50 78 : 22 - 40[b] 
BTM 51 88 : 12 - 45[b] 
Table 7: Catalyst screening [a]major regioisomer 228a, [b]samples obtained by preparative TLC 
 
3.2.3 Solvent and temperature effects 
A solvent screen was then carried out, and showed that the reaction did not require 
anhydrous solvents and proceeded well in all bench solvents tested including acetone and 
THF (Table 8). Chlorinated solvents afforded the lowest ee although the reason for this is 
unknown. Test reactions indicated that no significant background reaction was taking 
place, suggesting that an alternative solvation effect is responsible. A maximum ee of 84% 
was achieved in THF with a small drop in regioselectivity from 92:8 (CH2Cl2) to 89:11 
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(THF). The rr could not be improved by reaction dilution or cooling the reaction to -78 ˚C 
therefore bench grade THF/0 ˚C were chosen as the optimum reaction conditions. 
 
Solvent 
Regioisomeric ratio 
(228a:228b) 
Yield (%) 
(0 ˚C) [a] 
ee (%) 
(0 ˚C)[a] 
ee (%) 
(-78 ˚C)[a] 
CH2Cl2 92 : 8 75 64 66[b] 
THF 89 : 11 87 84 84[b] 
Acetone 85 : 15 - 82[b] 81[b] 
Toluene 89 : 11 - 82[b] 81[b] 
EtOAc 88 : 12 - 81[b] 82[b] 
Et2O 93 : 7 - 81[b] 80[b] 
1,4-dioxane 88 : 12 - 77[b] - 
MeCN 90 : 10 - 73[b] - 
CHCl3 95 : 5 - 53[b] - 
Table 8: Solvent and temperature screening [a]major regioisomer 228a, [b]sample obtained via preparative TLC 
 
3.2.4 Recrystallisation 
The racemic form of the major regioisomer (228a) was significantly more crystalline than 
the enantiopure form, and we were able to exploit this effect to enhance the product ee 
(Table 9). After product isolation the ee of 228a was 83%. Upon recrystallisation from 
ethyl acetate the racemic form crystallised preferentially, giving a solid on filtration with 5% 
ee. Concentrating the liquors gave 228a as a solid with 97% ee. The increased crystallinity 
of the racemic material is further demonstrated by a significant difference in the melting 
points of the two samples, the racemic sample melting at 192-194 ˚C and the enantiopure 
at 168-171 ˚C.  
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Sample Yield (%) ee (%) mp (˚C) 
228a 
No recrystallisation 78 83 - 
Recrystallisation solid 8 5 192-194 
Recrystallisation filtrate 67 96 168-171 
228b No recrystallisation 12 90 178 (dec) 
Table 9: Enhancement of ee by recrystallisation 
 
3.2.5 Anhydride scope 
Following the determination of the optimum reaction conditions the scope of the reaction 
with respect to 2-phenacylbenzothiazole was investigated. We wanted to investigate both 
steric and electronic effects by testing a variety of aryl and alkyl α,β-unsaturated anhydrides. 
A wide range of cheap, commercially available carboxylic acids are available as anhydride 
precursors, but to further widen the scope a number of non-commercially available acids 
were synthesised via a Knoevenagel condensation between malonic acid 229 and aryl 
aldehydes, affording acids 230-233 in good yields without the need for chromatographic 
purification (Scheme 64). 
 
Scheme 64: Acid synthesis via Knoevenagel condensation 
 
When mesitaldehyde (234) was subjected to the same reaction conditions however, the 
only product formed was non-decarboxylated product 235 (Table 10) with a conversion of 
89% as measured by 1H NMR. Increasing the temperature (to facilitate decarboxylation) 
saw low conversion (10%) to decarboxylated acid 236, suggesting that the reaction 
conditions favour starting materials at elevated temperature. 
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Reaction 
Temperature 
Aldehyde 
234[a] 
Diacid 
235[a] 
Mono acid 
236[a] 
85 ˚C 11 89 - 
120 ˚C 90 - 10 
Table 10: Koevenagel condensation of mesitaldehyde [a]Compound ratio determined by 1H NMR 
 
An alternative synthetic route to 236 from Aitken et al. was employed,99 condensing 
mesitaldehyde 234 with ethyl acetate in a sodium metal mediated aldol reaction (Scheme 4) 
that afforded mesitylcinnamic acid 236 in a moderate 52% yield over the two steps. 
 
Scheme 65: Sodium mediated synthesis of mesitylcinnamic acid 
 
With these acids in hand, the corresponding homoanhydrides were prepared via EDCI 
coupling. The scope of the reaction was then investigated under the previously optimised 
conditions (Scheme 67). The products were isolated by column chromatography, and in 
most cases the regioisomers were readily separated. In the cases of 4-CF3 substitution 
(238a/238b) and 2- or 3-Br substitution (240a/240b, 241a/241b) the regioisomers 
coeluted and could not be separated. For these examples the crude rr (determined by 1H 
NMR) and the regioisomeric mixture obtained after purification do not necessarily match 
due to the minor O-cyclised isomer being more sensitive to silica chromatography. In all of 
these cases, the regioisomeric mixture could be fully separated by chiral HPLC so ee values 
could be calculated for each regioisomer.  
 3. Benzazoles as Nucleophiles  
 
55 
 
Scheme 66: Reaction scope with 2-phenacyl benzothiazole [a]regioisomeric ratios calculated from crude 1H NMR 
spectrum [b]Product recrystallised from ethyl acetate, ee enhanced from 83 to 97% 
 
Use of an electron withdrawing group led to a slight reduction in the regioselectivity but 
regioisomers 238a/238b were obtained in good yield and enantioselectivity. 4-methoxy 
substitution was also tolerated and gave 239a/239b in moderate yields. 2-Bromocinnamic 
anhydride led to a moderate yield, possibly due to reduced reactivity of the sterically bulky 
Michael-acceptor. Unusually, 2-bromo minor isomer 240b was formed in significantly 
lower ee (31%) than the corresponding major regioisomer 240a, and the reason for this is 
not currently understood (for further discussion see Sections 3.4.2-3.4.5). Mesitylcinnamic 
anhydride was inactive in the process and it is thought that double ortho-substitution 
provides too much steric blocking for nucleophilic addition to take place. Pleasingly, 3-
bromo-substitution gave good yields and enantioselectivity for both regioisomers 
241a/241b.  
The reaction scope was extended to incorporate heterocyclic substituents (Scheme 67), 
which were successful however 3-furyl and thiophenyl substitution gave reduced yields of 
243a/243b and 244a/244b in comparison to aryl substituents. In these cases, the crude 1H 
NMR spectra were complex and it is thought that poor yields are due to both reduced 
reactivity and increased byproduct formation leading to problematic purification. Alkyl 
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substitution was well tolerated and did not lead to a drop in enantioselectivity (which was 
observed in reactions with 1,3-diketone nucleophiles, see Chapter 2). Ester substitution 
products 246a/246b were successfully formed however were isolated in low ee. 
 
Scheme 67: Reaction scope with 2-phenacyl benzothiazole [a]regioisomeric ratios calculated from crude 1H NMR 
spectrum [b]1.05 equivalents of homoanhydride used 
 
3.3 Exploring Regioselectivity Effects 
3.3.1 Influencing regioselectivity 
To probe the nature of regioselectivity in the Michael addition-cyclisation process a range 
of alternative nucleophiles were targeted. The first aim was to change the electronic 
properties of the acyl group to investigate the relationship between nucleophile structure 
and regioselectivity. It was reasoned that conjugated ester and amide groups may disfavour 
O-cyclisation to give single regioisomers similar to the observations made with diketone 
and ketoester nucleophiles (Figure 20). Conversely, it was hoped that an electron poor acyl 
group may increase the proportion of O-cyclisation. 
 
Figure 20: Regioselectivity for benzothiazole and dicarbonyl nucleophiles 
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We were also interested in the effects of changing the heterocycle from benzothiazole to 
benzoxazole and benzimidazole (Figure 21). In the case of benzothiazole we propose that 
O-cyclisation is disfavoured due to the presence of an O→S interaction between the 
heterocycle and the acyl group which must be broken to allow O-cyclisation. In contrast, 
benzoxazole and benzimidazole nucleophiles do not form O→S interactions which could 
significantly change the relative energies of the cyclisation pathways and thus alter the 
regioselectivity of the process. 
 
Figure 21: Regioselectivity for benzothiazole and dicarbonyl nucleophiles 
 
3.3.2 Nucleophile synthesis 
Initial work towards the synthesis of 2-phenacylbenzothiazole (227) concentrated on a 
reported Claisen condensation between 2-methylbenzothiazole (247) and ethyl benzoate 
(248) using n-butyl lithium as the base.100 The reaction was carefully repeated a number of 
times, however the reaction was capricious: it failed approximately half the time and the 
reason for this is unknown. It is thought that the deprotonation step was successful each 
time since a marked colour change from pale yellow to dark brown was observed. When 
successful, the yield of the reaction ranged between 22 and 60%, and when unsuccessful 
only starting material was returned. The use of 2-methylbenzimidazole in this condensation 
afforded 249 in a moderate 36% yield, but methylbenzoxazole did not produce the desired 
product 250, with predominantly starting material returned. 
 
Scheme 68 : Synthesis of nucleophiles via Claisen condensation 
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Lozinskii et al. reported that nucleophilic addition of dimethylbenzimidazole 251 into 
benzoyl chloride 252 was successful, using triethylamine as a mild base (Scheme 69).101 The 
reaction initially forms a double addition ester 253, which must be subsequently hydrolysed 
to afford the desired acylbenzazole 249. 
 
Scheme 69: Synthesis of nucleophiles via an ester formation-hydrolysis strategy 
 
Using this strategy, 2-phenacyl benzimidazole 254, benzothiazole 227 and benzoxazole 250 
were synthesised in moderate yields (Figure 22). Benzoxazole 250 was formed by room 
temperature hydrolysis in MeOH/KOH due to product instability at higher temperatures. 
In contrast it was necessary to carry out the hydrolysis into 255 in a 1:1 mixture of n-
butanol and DMF at reflux overnight due to low ester solubility. 
 
Figure 22: Benzazole yields for the ester formation-hydrolysis strategy 
 
An alternative strategy was to switch the nucleophile/electrophile roles of the heterocycle 
and acyl partner in a simple NaHMDS mediated coupling reported to achieve a wide range 
of products in good yields.102 This route generated amide and ester substituted 
benzothiazoles 256 and 257 in very good yields (Scheme 70). Attempts to use this method 
to install electron withdrawing aryl groups have however been unsuccessful, with 4-
fluoroacetophenone returning only unreacted starting materials and 4-nitroacetophenone 
decomposing upon addition of NaHMDS. Problems of double nucleophilic addition were 
encountered in the addition to 2-chlorobenzoxazole. Alongside the desired amide 258 a 
large quantity of 259 was formed leading to very difficult chromatographic separation. To 
reduce the formation of the double addition product reagent addition order, reaction 
temperature, and dilution were investigated. The best way to minimise double addition was 
through slow dropwise addition of the chlorinated heterocycle at -78 ˚C. This improved the 
ratio of single to double addition products from 0.8 : 1 to 2.5 : 1, which enabled some 
separation by chromatography leading to a 258 in a moderate yield of 34%. 
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Scheme 70: Synthesis of nucleophiles via an NaHMDS coupling strategy [a]Dropwise addition of 
chlorobenzoxazole at -78 ˚C to reduce formation of 259 
 
In summary, a range of benzothiazole nucleophiles incorporating a range of electron 
donating and withdrawing acyl groups, as well as benzoxazole and benzimidazole-
containing nucleophiles, has been successfully synthesised (Table 11). 
 
X R Product Method Yield (%) 
S Ph 227 B 51 
S PhNO2 255 A 78 
S NMe2 256 B 99 
S OtBu 257 B 88 
O Ph 250 A 67 
O NMe2 258 B 34 
NH Ph 254 A 65 
NMe Ph 249 A 55 
Table 11: Summary of synthetic methods used to generate benzazole nucleophiles 
 
3.3.3 Nucleophile effects on annulation regioselectivity 
With a range of benzazole nucleophiles in hand, tests were carried out to determine their 
reactivity and regioselectivity in annulation processes with cinnamic anhydride using the 
previously optimised conditions. Firstly we investigated the effects of changing the acyl 
group on the benzothiazole-containing nucleophile (Scheme 71). Azaarylamide 256 and 
azaarylester 257 afforded N-cyclised products 260 and 261 regioselectively and in good 
yields, which is consistent with our observations using ketoester nucleophiles. We believe 
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that conjugated acyl groups disfavour the formation of the lactonisation intermediate (as 
conjugation must be broken), thus reducing O-cyclisation. It is also possible that the 
increased donor capabilities of the ester and amide groups could increase the strength of 
the O→S interaction in the precyclisation intermediate, further stabilising the lactamisation 
intermediate and potentially enhancing the regioselectivity. In comparison, 4-
nitrophenacylbenzothiazole 255 led to the formation of 262a/262b with a greater 
proportion of O-cyclisation (75:25 rr) compared with the parent phenyl substituted 
nucleophile (88:12 rr). The electron withdrawing acyl group could lower the energy of the 
lactonisation intermediate by providing additional charge stabilisation, thus increasing the 
proportion of O-cyclisation. 
 
Scheme 71: Effects of the acyl group on annulation regioselectivity 
 
We then investigated the effects of changing the heterocycle moiety. Interestingly 2-
phenacylbenzoxazole 250 gave a complete switch in regioselectivity compared with 
benzothiazole, with almost exclusively O-cyclised product 263 observed. It was not possible 
to force benzoxazole N-cyclisation by the use of benzoxazole-amide nucleophile 258 (only 
starting materials were returned).  
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Scheme 72: Effects of the heterocycle on annulation regioselectivity 
 
Initial investigations into benzimidazole reactivity showed that 2-phenacylbenzimidazole 
254 showed good activity, forming a 1:1 mixture of two products that could not be 
separated by chromatography. Mass spectrometry analysis of the mixture identified a single 
product mass which suggests a mixture of regioisomers or tautomers. 1H NMR analysis 
(Figure 23) shows two spin systems: spin system A can be attributed to product 265c, a 
tautomeric form of N-cyclised product 265b. Spin system B is likely to be either 265a or 
265b, however it has not been possible to confidently assign spin system B as the NMR 
spectra could not be sufficiently separated for conclusive analysis. 
 
Scheme 73: Potential products from the benzimidazole nucleophile 
 
Figure 23: Identification of products by 1H NMR 
Spin system A (265c) 
Spin system B (265a or 265b) 
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To simplify the NMR spectra for further analysis the reaction was repeated with crotonic 
anhydride (Scheme 74). In this case 266 was isolated as an 80:20 mixture of regioisomers 
(which could be confidently assigned by 1H and 13C NMR), with N-cyclised isomer 266 
formed in 4:1 dr. The major diastereomer was confirmed by NOE analysis. Due to the 
complex mixture it was not possible to measure the enantioselectivity of the process due to 
poor separation of the 6 peaks in the chiral HPLC spectrum. 
 
Scheme 74: Crotonic anhydride and benzimidazole nucleophile [a]ee not able to be determined due to coelution 
of peaks in all chiral HPLC conditions tested 
 
Attempts to use protected benzimidazoles in this reaction proved unsucessful (Scheme 75) 
and this is possibly because the resulting lactams 267/268 cannot tautomerise to the 
preferred product configuration (cf. tautomer 266). 
 
Scheme 75: Attempted use of protected benzimidazole nucleophiles 
 
3.3.4 Reaction scope: benzamide 
The scope of the reaction utilising azaarylamide 256 was further investigated, since 
selection of this nucleophile in the annulation process allows for regioselective formation 
of N-cyclised products (Scheme 76). Unlike the phenacylbenzothiazole series (Scheme 67) 
recrystallisation was not required to enhance the ee as all products were formed in excellent 
enantioselectivity. Furthermore no O-cyclisation was observed in any of the reaction 
mixtures. Electron-withdrawing substitution was successful and afforded 269 in good yield 
and high ee, whilst 4-methoxy substitution (270) led to a moderate drop in yield due to 
lower reactivity of electron rich Michael acceptors. 2- and 3-bromo substitution was well 
tolerated with a lower yield observed for 2-substitution, possibly due to increased steric 
hindrance. 2-Furyl substituted 273 was accessed in a good yield but the introduction of 3-
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furyl and 3-thiophenyl groups led to reduced yields of 274 and 275. As observed in the 
phenacyl benzothiazole series this is thought to be due to a combination of lower reactivity 
and difficult purification. Methyl substitution was successful in the reaction, giving a small 
drop in enantioselectivity. Pleasingly, product 277 containing an ester moiety was obtained 
in good yield and high ee.  
 
Scheme 76: Reaction scope with azaaryl amide, anhydride screening 
 
3.3.5 Reaction scope: benzoxazole 
To further investigate the scope of this reaction, 2-phenacylbenzoxazole was explored as a 
nucleophile under the optimised conditions (Scheme 77). Use of this heterocycle affords O-
cyclisation in excellent selectivity, with only a small amount of the N-cyclised product 
visible in the crude 1H NMR spectrum (typically ≤ 3%); in each case the minor regioisomer 
was not isolated by column chromatography. The use of an electron withdrawing aryl 
group on the homoanhydride gave reduced yields, whereas 4-methoxy substitution gave 
279 in good yield. This is the reverse of the trend observed for N-cyclisation. 2-Bromo 
substitution was not tolerated and returned starting materials, this is possibly due to steric 
hindrance being too high for addition of benzoxazole nucleophile 250. 3-Bromo 
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substitution however worked well in the process and 280 was isolated in good yield and 
excellent enantioselectivity. As has been observed with other nucleophiles 2-furyl 
substitution was well tolerated however 3-furyl and thiophenyl groups give reduced yield. 
Lactone 282 was isolated in a particularly low yield and this is thought to be partly a 
problem in the isolation of the product. Use of fumarate anhydride demonstrated reduced 
enantio- and regioselectivity with 285a/285b isolated as an inseparable mixture of 
regioisomers in modest ee. This is the only example where significant amounts of N-
cyclisation was observed for the benzoxazole series. 
 
Scheme 77: Reaction scope with 2-phenacyl benzoxazole, anhydride screening [a]regioisomeric ratios 
calculated from crude 1H NMR spectrum 
 
3.4 Mechanistic understanding of regioselectivity 
3.4.1 Proposed mechanism 
The proposed mechanism (Scheme 78) is modelled closely on the mechanism discussed in 
Chapter 2. We believe that pre-cyclisation intermediates 288a and/or 288b (conformers of 
one another) are generated via nucleophilic addition into α,β-unsaturated acyl ammonium 
species 286 followed by proton transfer. It is thought that the regioselectivity of the 
process is related to the relative energies of the lactamisation and lactonisation pathways.  
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Scheme 78: Intermediates in regiodivergence mechanism 
 
In the benzothiazole case, an oxygen to sulfur interaction was observed in the X-ray crystal 
structures for both the α,β-unsaturated acyl ammonium intermediate 202 and the N-
cyclised product 228a, with reduced atom distances compared with the Van der Waals’ 
radii (Scheme 79). We therefore propose that a similar interaction is present in 
intermediates 289 and 290a. This could provide additional stabilisation to N-cyclisation 
intermediate 290a compared to O-cyclisation intermediate 290b for benzothiazole-
containing nucleophiles. 
 
Scheme 79: O→S interactions in the proposed mechanism 
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3.4.2 Computational studies 
To probe these proposals computational studies have been carried out examining the 
nature of the two cyclisation pathways in collaboration with the Cheong group at Oregon 
State University.xii In the determination of the intermediates along the cyclisation pathways 
conformational searches were carried out manually and exhaustively,103 with calculations 
implemented in Gaussian09.104 It was found that the O→S interactions postulated in 
Scheme 79 are observed and provide a significant 4-5 kcalmol-1 stabilisation energy; it is 
proposed that these interactions are maintained throughout the cyclisation pathways. The 
pre-cyclisation intermediate for O-cyclisation (Figure 24) shows a 2.0 kcalmol-1 preference 
for nucleophilic addition anti- to the stereodirecting groups. This suggests that the 
stereodirecting groups provide efficient steric blocking for both Michael addition and 
lactonisation steps in this case. 
 
Figure 24: anti- conformation of O-cyclisation (benzothiazole)xiii 
 
Surprisingly in the N-cyclisation pathway the expected nucleophilic attack anti- to the 
catalyst stereodirecting groups is higher in energy than syn-addition (1.5 kcalmol-1 
difference, Figure 25). The calculated syn-lactamisation intermediate appears to be 
additionally stabilised by a π-stacking interaction between the benzothiazole ring and the 
phenyl substituent on the catalyst. Interestingly anti-lactamisation is 0.4 kcalmol-1 higher in 
energer than anti-lactonisation. This suggests that there may be other stabilising interactions 
at play in the O-cyclisation mechanism. 
                                                 
xii All computional work carried out by Daniel Walden 
xiii Diagrams provided by Daniel Walden 
anti-lactonisation 
ΔG‡ = 10.7 (ΔΔG‡ = 0.0) 
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Figure 25: anti- and syn- conformations of N-cyclisation (benzothiazole)xiv  
 
The partial reaction coordinate was also calculated (Figure 26) and showed that 
lactonisation proceeds via a stepwise mechanism, with formation of a tetrahedral 
intermediate prior to catalyst release. For the lactamisation pathway however no tetrahedral 
intermediate could be located and it is therefore thought that it proceeds via a concerted 
asynchronous transition state.  
 
Figure 26: Partial reaction coordinate (benzothiazole)xiv  
 
The N-cyclised product was calculated to be both the kinetic and thermodynamic product. 
Not only is the cyclisation pathway lower in energy than the corresponding lactonisation 
mechanism, but the final lactam product is additionally stabilised both by an O→S 
interaction and a non-classical hydrogen bond between the lactam carbonyl group and the 
adjacent aryl ring. Pleasingly, the interatomic distances predicted computationally closely 
match those measured in the lactam crystal structure (Figure 27). 
                                                 
xiv Diagrams provided by Daniel Walden 
anti-lactamisation 
ΔG‡ = 11.1 (ΔΔG‡ = 0.4) 
syn-lactamisation 
ΔG‡ = 9.6 (ΔΔG‡ = 0.0) 
ΔG 
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Figure 27: Conformation of N-cyclised lactam and stabilising interactions displayed in A: computed structure 
and B: X-ray structure of 228axv 
 
Using all the computed parameters it was possible to calculate a predicted rr for the 
process of 87:13. This directly matches the experimental results (88:12 rr, Scheme 80). 
 
Scheme 80: Comparison of experimental and computed regioisomeric ratios (benzothiazole)xv 
 
The calculations were repeated for the same annulation process with 2-phenacyl 
benzoxazole as the nucleophile. It was hoped that this would give insight into the reasons 
for the complete switch in regioselectivity using this heterocycle. Experimentally, almost 
exclusive O-cyclisation is observed for this nucleophile. The lowest energy pre-cyclisation 
intermediate found was an anti-lactonisation intermediate (Figure 28), which is consistent 
with our experimental results. The transition state conformation closely resembles that of 
O-cyclisation using the benzothiazole nucleophile (Figure 24) but it is 3.6 kcalmol-1 lower in 
energy. 
 
Figure 28: anti- conformation of O-cyclisation (benzothiazole)xv 
                                                 
xv Diagrams provided by Daniel Walden 
O—S = 2.574 Å 
 
O—H = 2.314 Å 
 
anti-lactonisation 
ΔG‡ = 7.1 (ΔΔG‡ = 0.0) 
 3. Benzazoles as Nucleophiles  
 
69 
In the benzoxazole case, N-cyclisation syn- to the stereodirecting groups proved 
significantly higher in energy than anti-addition (Figure 29). Nucleophilic attack anti- to the 
stereodirecting groups appears to place the heterocyclic ring in a flat conformation 
orthogonal to the carbonyl group. This is in contrast to the benzothiazole case which had a 
more flattened angle of attack, and is 0.8 kcalmol-1 higher in energy despite additional 
stabilisation from an O→S interaction (Figure 25). 
  
Figure 29: anti- and syn- conformations of N-cyclisation (benzoxazole)xvi 
 
Calculation of the partial reaction coordinate for benzoxazole cyclisation showed that both 
lactonisation and lactamisation proceed via stepwise mechanisms, with tetrahedral 
intermediates identified for each pathway. The lactam is both the kinetic and 
thermodynamic product, with the O-cyclisation pathway lower in energy than N-cyclisation 
for all identified intermediates. 
 
Figure 30: Partial reaction coordinate (benzoxazole)xvi 
 
From these calculated transition state energies the computed rr for the benzoxazole 
annulation process is close to 99:1, which is consistent with the experimental results 
(Scheme 81). 
                                                 
xvi Diagrams provided by Daniel Walden 
anti-lactamisation 
ΔG‡ = 10.3 (ΔΔG‡ = 3.2) 
syn-lactamisation 
ΔG‡ = 13.1 (ΔΔG‡ = 7.0) 
ΔG 
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Scheme 81: Comparison of experimental and computed regioisomeric ratios (benzoxazole) 
 
3.4.2 Link between regioisomerism and enantioselectivity 
During the investigation into the reaction scope, several unusual results were observed: 
regioisomeric pairs 262a/262b and 240a/240b were obtained in significantly different ee 
(Scheme 82). This was unexpected because it is thought that the two regioisomers are 
generated from common intermediate 295 in which the stereocentre configuration has 
already been set.  
 
Scheme 82: Different ee for regioisomeric pairs [a]ee measured from mixture of regioisomers 
 
To investigate this effect, mechanistic studies were carried out using 4-nitro substituted 
regioisomers 262a/262b as they were separable by chromatography. It was hoped that 
useful information about the link between enantioselectivity and regioselectivity might be 
gained by carrying out ring-opening of products 262a/b followed by recyclisation of acid 
292 to see if any change in enantioselectivity occurs (Figure 31 (a)). A crossover experiment 
in the presence of an external nucleophile should also give information about any 
reversibility in the process (Figure 31 (b)). 
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Figure 31: Targeted mechanistic studies 
 
Racemic acid (±)-292 was synthesised via gram-scale organocatalytic formation of the two 
regioisomers 262a and 262b using (±)-HBTM 2.1 as the catalyst, followed by in situ 
methanolysis to form methyl ester 293. The addition of DMAP was essential to ring open 
the N-cyclised regioisomer whereas the O-cyclised isomer ring-opened more readily. Ester 
hydrolysis under basic conditions led to decomposition, but heating ester 293 in 
concentrated HCl afforded acid (±)-292 in a 70% yield over three steps on gram-scale 
(Scheme 83). Enantioenriched acid was synthesised in the same way in an 83% overall 
yield. The acid could not be separated by chiral HPLC but the enantioenriched ester 293 
was found to have an 83:17 er. For these investigations er rather than ee is reported in 
order to give a clearer picture of any change in the enantiomeric ratios during recyclisation. 
 
Scheme 83: Ring opening and ester hydrolysis [a]calculated by 1H NMR, [b]determined by chiral HPLC analysis, 
[c]er could not be determined by chiral HPLC 
 
3.4.3 Direct recyclisation 
Racemic acid 292 was recyclised via in situ activation by pivaloyl chloride followed by 
deprotonation with NEt(iPr)2 and cyclisation with a variety of isothiourea catalysts (Table 
12). The regioisomeric ratio was measured by 1H NMR analysis and the ee of the major 
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isomer measured by chiral HPLC after isolation by chromatography. The ee of the minor 
isomers could not be measured due to significant product degradation. With no catalyst 
present the major N-cyclised product 262a is formed racemically with a higher N- to O-
cyclisation ratio than in the catalysed reaction. In the presence of (2S,3R)-HBTM 2.1 
however we were excited to observe that non-zero ee could be achieved by cyclising 
racemic acid (±)-292 under asymmetric catalysis. Cyclisation resulted in 42% ee for major 
regioisomer 262a with a greater proportion of O-cyclisation (Table 13).  
 
Starting material 
configuration 
Catalyst 
rr[b] 
(262a:262b) 
er (262a) 
2:1 dr, 50:50 er[a] – 96:4 51:49 
2:1 dr, 50:50 er[a] (2S,3R)-HBTM 2.1 85:15 71:29 
Table 12: Recyclisation of racemic ring-opened acid [a]Measured for methyl ester 293, [b]calculated from the 
crude 1H NMR 
 
The recyclisation process was repeated using an enantioenriched acid (Table 13). When 
cyclisation occurred in the absence of any catalyst it again generated 262a racemically. 
Enantiopure (2S,3R)-HBTM 2.1 formed N-cyclised product 262a in 90:10 er, and 
interestingly the same er was obtained using both (±)-HBTM 2.1 and achiral isothiourea 
DHPB. 
 
Starting material 
configuration 
Catalyst 
rr[b] 
(262a:262b) 
er (262a) 
2:1 dr, 83:17er[a] – 71:29 49:51 
2:1 dr, 83:17er[a] (2S,3R)-HBTM 2.1 80:20 90:10 
2:1 dr, 83:17er[a] (±)-HBTM 2.1 75:25 91:9 
2:1 dr, 83:17er[a] DHPB 79:21 90:10 
Table 13: Recyclisation of enantioenriched ring-opened acid [a]Measured for methyl ester 293, [b]calculated from 
the crude 1H NMR 
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Based upon the recyclisation of enantioenriched acid (3S)-292, we have proposed a 
mechanism for the observed results (Scheme 84). In the non-catalysed case racemisation 
could be achieved by a slow rate of cyclisation combined with a relatively fast rate of retro-
Michael addition. This leads to erosion of the er before cyclisation takes place, giving the 
cyclised products in reduced er. Since a variety of Lewis base catalyst (racemic, asymmetric 
and achiral) gave the same result of retention of er from starting material to cyclised 
product, we can postulate that the cyclisation rate is now fast with all catalysts tested. The 
retro-Michael is now relatively slow, and so does not have an opportunity to erode the er 
prior to cyclisation. 
 
Scheme 84: Relationship between the rates of retro-Michael addition and cyclisation, and the effects upon the 
product er 
 
3.4.2 Recyclisation in the presence of an external nucleophile 
A crossover experiment was carried out where racemic acid 292 was cyclised in the 
presence of external nucleophile 227 and (2S,3R)-HBTM 2.1 (53) (Scheme 85). This was 
undertaken to conclusively demonstrate whether the cyclisation exhibits reversibility. The 
only source of a cinnamic acid precursor is acid (±)-292 therefore any formation of 
crossover products 228a/228b must arise from reaction reversibility. We were interested in 
both the ratio and the er of the four potential products (which are distinguishable by 1H 
NMR spectroscopy). 
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Scheme 85: Recyclisation in the presence of an external nucleophile to show reversibility 
 
Analysis of the crude reaction mixture showed the presence of all four products (as labelled 
in Figure 32) suggesting that the reaction has a degree of reversibility. Assuming that all of 
acid 292 cyclised, the mixture of products contained a total of 12% crossover products 
228a and 228b. It was possible to isolate 228a and 262a, the N-cyclised regioisomers for 
both nucleophiles and calculate the er for both species. Crossover lactam 228a was isolated 
in high er because the addition of the crossover nucleophile takes place under 
predominantly asymmetric catalytic control. 262a was isolated in low but non-racemic er, 
which is consistent with prior observations. 
 
Figure 32: Product identification in the crude NMR spectrum 
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3.4.5 Mechanistic implications of recyclisation investigations 
This study has shown that recyclisation of a racemic acid under asymmetric catalysis leads 
to regioisomers of enhanced ee. It has also shown that the reaction is somewhat reversible 
and that cyclisation of the enantioenriched acid under asymmetric, racemic and achiral 
catalysis afforded products with the same enhanced ee. During these recyclisation 
experiments we directly accessed diastereomeric intermediates cis- and trans-294 (Scheme 
86, with cis- and trans- referring to the relative configuration of the newly formed C-C bond 
to the catalyst stereodirecting groups) which are also accessed via nucleophilic addition of 
255 to α,β-unsaturated acyl ammonium 202 followed by proton transfer. 
Crossover experiments have shown that the nucleophilic addition is somewhat reversible 
(k1/k1
-1 and k2/k2
-1) therefore the ratio of intermediates cis-294 to trans-294 could change 
over time. Resubmission of the lactam and lactone products to the reaction conditions 
however did not lead to a change in the ee, suggesting that reversibility is not the sole cause 
of ee differences between the generated regioisomers. Also to consider is the possibility 
that the two diastereomeric intermediates cis- and trans-294 could cyclise at different rates: if 
kN ≠ k’N or kO ≠ k’O then different ratios of the four products would be obtained, giving a 
different er values for the major and minor regioisomers. Unfortunately due to the 
complex nature of the cyclisation mechanism it is not possible to say with certainty what 
the root causes are of the regioisomeric differences in ee. 
 
Scheme 86: Reversibility and cyclisation rates affording N- and O-cyclised products 
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3.5 Accessing Quaternary Centres 
3.5.1 Anhydride synthesis 
It was hoped that the strong reactivity of benzazole nucleophiles might enable an 
annulation process with trisubstituted anhydrides to access interesting heterocyclic 
molecules bearing quaternary centres. 3-Methylbut-2-enoic acid was commercially available 
and in order to extend our investigation further a range of non-commercially available acids 
were targeted. A Horner-Wadsworth-Emmons reaction with phosphonate 295 followed by 
ester hydrolysis generated acids 296 and 297 in moderate yields but unfortunately 
trifluoromethylated acid 298 could not be formed under a variety of Horner-Wadsworth-
Emmons or Wittig protocols tested.105 
 
Scheme 87: Synthesis of trisubstituted anhydrides 
 
An alternative procedure to form 298 was employed from Tarrant and Taylor,106 which 
initially afforded β-hydroxy acid 300 upon condensation of 1,1,1-trifluoroacetone (299) 
with malonic acid (229) (Scheme 88). To dehydrate this intermediate it was necessary to 
heat hydroxyacid 300 in 50% aqueous sulfuric acid for 14 hours at 200 ˚C in distillation 
apparatus. As the unsaturated acid formed it was distilled across into a collecting flask, 
giving 298 as a colourless oil after aqueous extraction in 31% yield. 
 
Scheme 88: Condensation of trifluoroacetone with malonic acid 
 
Whilst the (E)- and (Z)- isomers of 298 were readily identifiable by 1H and 19F NMR the 
configuration of the major isomer could not be confirmed by standard NOESY spectra 
due to long-range CH→CH3 coupling, which gave positive results for both isomers in the 
mixture. A heteronuclear-NOESY experiment was therefore carried out (HOESY, Figure 
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33). After irradiating a specific 19F frequency a 1H spectrum was immediately run. 
Enhancement of a 1H peak after 19F irradiation indicates that the proton and fluorine are 
close in space. After irradiation of the CF3 group of the major isomer (δF -71.45 ppm) a 
1H 
signal enhancement was observed for the α-proton of the major isomer only. This NOE 
result therefore indicates that the major isomer has the (E)-configuration. 
 
Figure 33: HOESY of trifluoromethylated acid 298 
 
Geranic and neric acids ((Z)-303 and (E)-303) were also targeted because as (E/Z)-
isomers of one another they could give information about the effects of (E/Z)-geometry 
on the isothiourea-catalysed annulation process. Initially it was hoped that geraniol ((Z)-
301) and nerol ((E)-301) could be oxidised into the corresponding carboxylic acids using a 
Jones oxidation, however this resulted in (E/Z)-isomerisation. Instead, a two-step method 
was employed (Scheme 89) with manganese dioxide giving aldehydes (Z)-302 and (E)-302 
in good yields followed by Pinnick oxidation to afford the carboxylic acids (Z)-303 and 
(E)-303. The (E/Z)-ratio was unchanged throughout the two step procedure. 
 
Scheme 89: Two-step oxidations of geraniol (Z)-301 and nerol (E)-301 [a]Measured by 1H NMR analysis, 
[b]Measured by GC analysis 
 
α-1H minor α-1H major 
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3.5.2 Anhydride scope 
An initial test reaction between 3-methylbut-2-enoic anhydride (304) and 2-
phenacylbenzothiazole 227 afforded achiral N-cyclised product 305 in good yield, with no 
observed O-cyclisation in the crude 1H NMR (Scheme 90). This is the first time that a 
quaternary centre has been accessed using our isothiourea-catalysed Michael addition-
cyclisation protocol. 
 
Scheme 90: Annulation process utilising dimethyl substituted anhydride 
 
Unfortunately when a range of other anhydrides were tested no reactivity was observed 
(Scheme 91). Further screening with alternative benzazole nucleophiles was met with 
failure, and it is not understood why the process shows such a high degree of specificity. 
 
Scheme 91: Unsuccessful trisubstituted anhydrides in annulation process 
 
The use of trifluoromethylated anhydride 309 however successfully generated cyclised 
product 310 bearing a chiral, quarternary trifluoromethylated centre. Interestingly this is the 
only case yet investigated where a significant amount of 1,2-addition product was also 
observed. The 1,4- and 1,2-addition products (310 and 311) were isolated in a 7:3 mixture 
after column chromatography which could be subsequently separated by trituration with 
Et2O to give 1,2-addition product 311 as a solid and 1,4-addition product 310 as a yellow oil 
upon concentration of the trituration liquors. Pleasingly, whilst 310 was isolated in a 
modest yield (28%) it was formed in excellent ee (96%). 
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Scheme 9: Annulation processed utilising trisubstituted anhydrides 
 
3.6 Product Derivatisations 
In order to demonstrate the synthetic utility of the annulation products obtained by this 
isothiourea-catalysed methodology, derivatisation of brominated lactam 272 and lactone 
280 was investigated. These compounds were successfully synthesised regioselectively on a 
gram-scale in excellent enantioselectivity using the previously optimised conditions (Figure 
34). The 3-bromo substitution was thought to be a useful synthetic handle for palladium-
catalysed coupling reactions, making them relevant to pharmaceutical screening protocols. 
 
Figure 34: Gram-scale synthesis of derivatisation substrates 
 
3.6.1 Suzuki couplings 
The first coupling reaction investigated was a Suzuki coupling employing methoxyboronic 
acid 312 with palladium acetate as a catalyst (conditions from Martinez et al.).107 Initially, 
tri(o-tolyl)phosphine was used as the ligand (Table 14) however this afforded product 313 
in only 44% yield. Switching to dppf increased the yield to 70% and it is thought that the 
increased bulk of the ligand improves the efficiency of reductive elimination.108 
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Ligand Yield (%) ee (%) 
P(o-tolyl)3 44 99 
1,1'-Bis(diphenylphosphino)ferrocene (dppf) 70 99 
Table 14: Ligand effects on Suzuki coupling with methoxyboronic acid 
 
The same conditions were employed using lactone 280, however whilst the expected 
product peaks were observable in the crude 1H NMR it was not possible to isolate any of 
coupled product 314 after chromatography. Trituration and recrystallisation were tested as 
purification methods however both were unsuccessful. Lactone instability to 
chromatography is a problem for many of the products synthesised via our methodology, 
and the very electron rich nature of the aromatic substituent in 280 appears to enhance 
lactone instability and render it impossible to isolate. 
 
Scheme 92: Suzuki coupling of 280 with methoxyboronic acid 
 
3.6.2 Heck reactions 
A Heck reaction was then attempted between lactam 272 and methyl acrylate 315, using 
conditions from Baccanari et al.109 Heating at 100 ˚C overnight in a sealed tube using 
acetonitrile as the solvent afforded product 316 in a 43% yield, with the rest of the mass 
returned as starting material. In order to increase reaction conversion the process was 
repeated in DMF and heated at 125 ˚C. This increased the yield to 89% (alongside 11% 
unreacted starting material). The enantioselectivity of 316 could not be measured via chiral 
HPLC due to poor visualisation of the enantiomers. Despite many attempts, it was not 
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possible to obtain a reliable HPLC spectrum showing the desired peaks. It is assumed 
however that the Heck reaction is unlikely to have changed the enantioselectivity since the 
Suzuki coupling resulted in no erosion of enantioselectivity at high temperatures. 
 
Solvent Temperature Yield (%) 
Acetonitrile 100 ˚C 43 
DMF 125 ˚C 89 
Table 15: Solvent/temperature effects on Heck reaction with methyl acrylate 
 
In the case of lactone 280 (Table 16) similar problems were encountered when heating the 
reaction at 100 ˚C in acetonitrile, with 66% starting material returned plus 33% of the 
desired coupled product 317a. When the reaction was repeated at 125 ˚C, N-cyclised 
regioisomer 317b was unexpectedly isolated in 11% yield. This suggests that the elevated 
temperature leads to process reversibility and allows access to the higher energy N-
cyclisation pathway. Again, the products did not behave as expected on chiral HPLC and 
so no enantioselectivity has been measured. 
 
Solvent Temperature rr O-cyclised 317a N-cyclised 317b 
Acetonitrile 100 ˚C 100:0 33% - 
DMF 125 ˚C 65:35 41% 11% 
Table 16: Solvent/temperature effects on Heck reaction with methacrylate and unexpected regioisomerisation 
 
 3. Benzazoles as Nucleophiles  
 
82 
3.7 Conclusions 
Nucleophiles containing benzazole heterocycles have been shown to be useful and 
interesting reagents in a Michael addition-cyclisation procedure proceeding via an α,β-
unsaturated acyl ammonium intermediate. A wide range of examples has been synthesised 
showing good reactivity with a range of alkyl, aryl and heterocyclic α,β-unsaturated 
homoanhydrides. These nucleophiles could cyclise both through the carbonyl moiety and 
through the N-heterocycle, and it was possible to selectively form one regioisomer through 
judicious choice of nucleophile. Furthermore, it was possible to generate quaternary centres 
in high enantioselectivity. 
The cyclisation mechanism was investigated and it is thought that regioselectivity relies on 
the relative energies of cyclisation pathways. Computational work showed that for 
benzothiazole substrates the pre-lactamisation intermediate was especially stabilised by 
retention of O→S interactions and by π-π stacking between the benzothiazole ring and the 
catalyst stereodirecting group. For benzoxazole species however, N- and O-cyclisation both 
proceed anti- to the stereodirecting groups with O-cyclisation calculated as being lower in 
energy. It is thought that relative cyclisation rates and reaction reversibility might be 
responsible for some of the regioisomeric pairs displaying different ee. 
It was then shown that 3-bromosubstituted annulation products could be derivatised using 
pharmaceutically relevant palladium-catalysed coupling reactions. This was very successful 
for an N-cyclised product, but showed limited suitability for the O-cyclised lactone tested 
due to lactone instability. Given the medicinal interest in benzazole containing 
compounds,92-95 it is hoped that in the future it may be possible to submit our novel 
benzazole-containing compounds to biological testing, to ascertain if they have any useful 
bioactivity. 
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4. Cascades from α,β-Unsaturated Acyl Ammonium 
Intermediates 
4.1 Lewis Base Catalysed Cascade Processes 
Cascade reactions proceed via a sequence of chemical processes that generate several 
intermediates, each one more thermodynamically stable than the last, until a product is 
achieved that is stable to the reaction conditions.110 The use of cascades in natural product 
synthesis has long been considered a “gold standard” in the field, as complex product 
architectures can be elegantly and efficiently achieved. This in turn has driven the 
development of increasingly efficient and therefore economical synthetic methods for the 
production of target molecules for the pharmaceutical and fine chemicals industries.111 
Historically, the development of organocatalysis was driven by a desire to mimic the 
chemistry of enzyme catalysis using small molecules,13 and since many complex 
biosyntheses are facilitated by enzyme-catalysed cascade processes112 the development of 
cascade-promoting organocatalysis is of great interest to the synthetic community.113 Lewis 
base catalysis is a versatile way of achieving cascade reactions, with most published work 
exploiting the interconnected nature of enamine and iminium intermediates. This field has 
been recently been reviewed by Song and Wang,114 and representative examples of iminium 
and enamine initiated cascades will be shown here to demonstrate how chemical 
complexity is built from simple principles. 
 
4.1.1 Iminium-initiated cascades 
Nucleophilic addition reactions into an α,β-unsaturated iminium intermediate (323) can 
take advantage of the nucleophilicity of the resultant enamine (324) to carry out a second 
chemical process. This was first demonstrated by MacMillan et al. in an efficient γ-arylation, 
β-chlorination process (Scheme 93).115 The use of low temperature and EtOAc as solvent 
was important to achieve high stereoselectivity. A variety of aryl nucleophiles could be 
installed in this way, including furans, thiophenes and indoles. 
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Scheme 93: Intermediates in iminium-enamine catalysis 
 
Using this cascade design it is also possible to form cyclic substrates by reacting an imine 
intermediate with a tethered nucleophile-electrophile system. This has been exploited by 
Brenner-Moyer et al. in the formation of fused bicyclic products (328) from cyclic 
unsaturated β-dicarbonyl substrates 326 (Scheme 94).116,117 The reaction is believed to 
proceed via initial 1,4-addition of the malonate moiety into an iminium intermediate. The 
resultant enamine 327 undergoes a second 1,4-addition to afford ring closure, followed by 
hydrolysis to afford the products in high diastereo- and enantioselectivity.  
 
Scheme 94: Iminium-enamine cascade formation of cyclohexenes 
 
MacMillan et al. demonstrated that iminium-iminium cascades were also viable catalytic 
pathways in the synthesis of complex molecular architectures (Scheme 95).113 Tetracycle 
332 was formed in excellent enantioselectivity from the addition of vinylindole 329 to 
propargyl aldehyde 330. The mechanism is thought to proceed via an initial [4+2] 
cycloaddition. The cascade can then afford two processes: ring closure via amine addition 
to the α,β-unsaturated iminium moiety and methylselenide elimination. The authors 
propose that methylselenide elimination occurs first, however this leads to a dicationic 
intermediate that has not been directly observed. 
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Scheme 95: Iminium-iminium cascade in natural product synthesis 
 
The authors were especially interested in the generation of scaffold 332 because it is a 
common architecture present in several natural product families including Strychnos, 
Aspidosperma and Kopsia. Excitingly, it was possible to further elaborate organocascade 
product 333 (synthesised in both enantiomeric forms) to form six indole alkaloids 334-339 
(Figure 35). The alkaloids were made using short synthetic sequences, many shorter than 
had been previously achieved, highlighting the utility of organocascade processes in the 
efficient formation of complex architectures. 
 
Figure 35: Synthesis of natural products from a tetracyclic advanced intermediate 
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4.1.2 Enamine-initiated cascades 
Many reported enamine-initiated cascades have been designed to proceed via enamine-
iminium-enamine protocols, as first demonstrated by Enders et al. in a 3-component 
cascade, forming four contiguous stereocentres (Scheme 96).118 Enamine-catalysed 
Michael-addition to nitroalkene 341 is followed by iminium-catalysed Michael addition to 
α,β-unsaturated aldehyde 13. Finally, ring closure affords aldol product 342 which 
undergoes hydrolysis and elimination to give cyclohexene 343 in moderate yield but with 
excellent stereocontrol. 
 
Scheme 96: 3-component enamine-iminium-enamine cascade 
 
Recent work by Melchiorre et al. has shown that oxindoles such as 345 can act in a similar 
Michael-Michael-Aldol process to give spirooxindoles 346 in high diastereo- and 
enantioselectivity (Scheme 97, A).119 This work was then developed further to accomplish 
the formation of six contiguous stereocentres in a reaction that imparts impressive 
molecular complexity from relatively simple starting materials (Scheme 97, B).120 Both A 
and B undergo an enamine-catalysed [1,4]-addition as before, but only A can proceed via a 
second [1,4]-addition due to the presence of a blocking group at the β-position of the α,β-
unsaturated aldehyde in system B. Instead, [1,6]-addition occurs in this case to give a 
dienamine intermediate that can carry out ring closure. Unlike in reaction A, the 
cyclohexane formed is not amenable to the elimination of water so is isolated as alcohol 
348 with all six newly-formed stereocentres retained. Pleasingly, this procedure was also 
amenable to the formation of spirocyclic benzofuranones. 
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Scheme 97: Formation of spirocyclic oxindoles via organocascade catalysis 
 
4.1.3 Cascades using α,β-unsaturated acyl ammonium/azolium intermediates 
Recent work has demonstrated that α,β-unsaturated acyl ammonium and azolium species 
can be used as intermediates in cascade reactions. The first example was reported by Studer 
et al. who treated an external nucleophile with a tethered dielectrophile in the presence of 
an NHC catalyst in a Michael-Michael-lactonisation (MML) process (Scheme 98).121 An α,β-
unsaturated acyl azolium intermediate is generated in situ by oxidation of the Breslow 
intermediate (see Section 1.2.7 for more details). Diketone addition to the α,β-unsaturated 
acyl azolium species then affords enolate 350, which can undergo an intramolecular 
Michael addition followed by lactonisation to form tricyclic product 351/352 and 
regenerate the catalyst. Alkyl diketones afforded higher diastereoselectivity than aryl 
diketones, but excellent enantioselectivity was observed for all examples. 
 
Scheme 98: NHC-catalysed Michael-Michael-lactonisation organocascade via addition of an external 
nucleophile 
 
An alternative to this tethering strategy (Figure 36, A) is to react a simple α,β-unsaturated 
acyl species with a tethered nucleophile-electrophile (Figure 36, B). This gives access to 
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different product architectures and enables the use of commercially available α,β-
unsaturated acyl ammonium/azolium precursors. 
 
Figure 36: Organocascade strategies using α,β-unsaturated acyl ammonium/azolium intermediates 
 
Romo et al. were the first to use this tethering method in a Michael-Aldol-lactonisation 
(MAL) process (Scheme 99).122 Commercially available α,β-unsaturated acid chlorides were 
employed in this transformation to generate complex cyclopentanes 355 in good yields and 
high diastereo- and enantioselectivity. The dicarbonyl portion of the nucleophile 353 acts 
as a Michael donor to generate intermediate 354, which is set up to do an Aldol reaction 
followed by lactonisation to give the products. The reaction requires a lithiated base 
(LiHMDS or t-butyllithium) and the authors postulate that the lithium is required to chelate 
enolate 354 in order to facilitate the cyclisation process. Initial Michael addition anti to the 
stereodirecting groups on the isothiourea catalyst gives good stereocontrol, with the 
proposed cyclisation transition state (354) alleviating 1,3-allylic strain between R3 and the 
enolate. This gives a high level of stereocontrol over the cyclisation step and the reaction 
affords a single diastereomer in all examples. 
 
Scheme 99: Isothiourea-catalysed Michael-Aldol-lactonisation organocascade via acid chlorides 
 
Studer et al. then showed that this MAL cascade was amenable to NHC catalysis, with 
isolation of either cyclopentanes (357) or cyclopentenes (358) depending on the substrate 
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used.123 The two reactions proceed via the same mechanism but CO2 is eliminated more 
readily in aryl-substituted examples thus none of the cyclopentane was observed, only the 
eliminated cyclopentene product in these cases. LiCl was used as an additive to speed up 
the reaction and also to enhance enantioselectivity. 
 
Scheme 100: Oxidative NHC-catalysed Michael-Aldol-lactonisation organocascade via α,β-unsaturated 
aldehydes 
 
This elimination of CO2 was also observed by Biju et al. who investigated an MAL reaction 
between α-bromoenal 359 and the same ketoester 356 under NHC-redox catalysis.124 The 
authors only investigated the use of aryl ketones in the MAL process therefore only 
cyclopentenes 358 were isolated. Compared with Studer’s work the yield of 358 is slightly 
lower however the enantioselectivity is enhanced even in the absence of the LiCl additive, 
using the same NHC catalyst (128). 
 
Scheme 101: NHC-catalysed Michael-Aldol-lactonisation organocascade via α-bromoenals 
 
Hui et al. have recently used α-bromoenals in a Michael-Mannich-lactamisation cascade, 
affording complex tricyclic products 362 in good yields and excellent diastereo- and 
enantioselectivity.125 The malonate portion of the nucleophile-electrophile substrate 360 
initiates a Michael addition into an α,β-unsaturated acyl azolium species, affording enolate 
361 that undergoes ring closure via an intramolecular Mannich reaction. Lactamisation from 
the pendant amine then releases the catalyst and generates the product. 
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Scheme 102: Michael-Mannich-lactamisation organocascade via α-bromoenals 
 
4.2 Project Aims 
The utility of the α,β-unsaturated acyl ammonium intermediate is still relatively 
underexplored and we hoped to further investigate the chemistry that these intermediates 
can undergo. Combining the chemistry developed within this thesis and the MAL 
chemistry initiated by Romo et al. 122 we aimed to access an isothiourea-catalysed MML 
cascade (Scheme 103) utilising tethered Michael donor-acceptor substrates and α,β-
unsaturated acyl ammonium intermediates. 
 
Scheme 103: Isothiourea-catalysed Michael-Aldol-Lactonisation process 
 
A tethered nucleophile-electrophile would initiate the cascade by adding into the α,β-
unsaturated acyl ammonium intermediate, forming an enolate that can undergo an 
intramolecular Michael addition to form a 5-membered ring. Finally, lactonisation would 
form a 5,6-bicyclic product and regenerate the catalyst (Scheme 104). 
 
Scheme 104: Proposed MML reaction between a tethered nucleophile-electrophile and an α,β-unsaturated acyl 
ammonium intermediate 
 
A related process has been demonstrated by Li et al. who used NHC catalysis to generate 
spirocyclic products 365 via an MML cascade in moderate dr (Scheme 105).126 
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Unfortunately in this process they were unable to achieve any enantioselectivity, with a 
wide range of chiral NHC catalysts trialled affording 0% ee. This process was therefore 
thought to be a good challenge for isothiourea catalysis, to investigate whether it is possible 
to achieve enantioselectivity in a novel MML cascade reaction. 
 
Scheme 105: NHC-catalysed Michael-Michael-Lactonisation process 
 
In Li’s process the second (intramolecular) Michael-addition is thought to be highly 
diastereoselective, therefore the low diastereoselectivity must arise from poor facial control 
over the initial nucleophilic addition (Figure 37). The use of a symmetrical nucleophile 
would remove this complication and therefore dicarbonyl nucleophile-electrophiles were 
targeted for our isothiourea-catalysed process. 
 
Figure 37: Facial selectivity in the nucleophilic addition of non-symmetrical oxindole nucleophiles and 
symmetrical dicarbonyl nucleophiles 
 
Symmetrical dicarbonyl nucleophiles containing an enone Michael acceptor such as 366 
have been demonstrated in a Lewis base-catalysed Michael-Michael cascade in work by 
Wang et al. (Scheme 106). The enone-malonate acts as a Michael donor in the absence of 
base, forming enamine 368 that can undergo a second Michael addition followed by 
hydrolysis to give cyclopentane products 369 containing 3 contiguous stereocentres. The 
process works well for electron poor and electron rich aryl enals 367, giving high yields and 
excellent diastereo- and enantioselectivity at moderate catalyst loading (10 mol%). This 
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gave us confidence that enone-malonates would be suitable for testing in an isothiourea-
catalysed MML cascade. 
 
Scheme 106: Lewis base-catalysed Michael-Michael-Lactonisation process 
 
4.3 Reaction Optimisation 
4.3.1 Initial results 
Initial screening of the MML reaction utilised reaction conditions similar to those reported 
by Romo et al. for their MAL cascade.122 Enone-malonate 370 (synthesised via cross-
metathesis between 2-allyl diethylmalonate and methylvinyl ketone) was chosen as the 
model nucleophile-electrophile component and cinnamoyl chloride 148 was used as the 
α,β-unsaturated acyl ammonium precursor. Enone-malonate 370 was first deprotonated by 
addition of LiHMDS, followed by addition of Hünig’s base and isothiourea catalyst 
(HBTM 2.1). The acid chloride was added last as a solution in CH2Cl2 and the reaction 
stirred overnight. Two products were observed in the crude 1H NMR spectrum which were 
separable by chromatography and identified as 1,2-addition product 371b and 1,4-addition 
cascade product 371a (Scheme 107). Moderate regioselectivity (76:24 371a:b) and poor 
enantioselectivity (38% ee, 371a) was achieved, however we were pleased to generate the 
desired product. 
 
Scheme 107: Initial results 
 
The two products can be formed via the mechanisms proposed in Scheme 108. In the 1,2-
addition pathway, deprotonated enone-malonate 372 can add to either the acid chloride 148 
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or the α,β-unsaturated acyl ammonium intermediate 202 to afford the undesired 1,2-
addition product 371b. Alternatively, 1,4-addition of the enone-malonate can afford enolate 
intermediate 373 that is set up to carry out an intramolecular 1,4-addition followed by 
lactonisation to afford the cascade product 371b. 
 
Scheme 108: Proposed 1,2 (371b)- and 1,4 (371a)-addition mechanisms 
 
4.3.2 Determination of product configuration 
MML product 371a was obtained as a single diastereomer and to determine the 
configuration a 1H NOE analysis was carried out. A suitable 1H NMR solvent had to be 
determined as in CDCl3 the bridgehead protons signals (B and D, Figure 38) overlap. The 
spectrum is further complicated by the presence of diastereotopic ethyl ester groups, one 
of which splits again into a diastereotopic pair giving three complex signals which obscure 
the protons of interest. After screening several deuterated solvents it was found that 
deuterated benzene afforded full separation of the bridgehead signals B and D, with partial 
overlap between F and the ester groups. This was sufficient signal separation to carry out 
NOE analysis. Proton assignments were made for both the CDCl3 and C6D6 spectra by 2D 
NMR analysis including COSY and HSQC. 
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Figure 38: 1H NMR assignments of 371a in CDCl3 and C6D6 
 
Irradiation of protons B and D showed signal enhancement for one another, along with the 
ortho-protons on the phenyl ring (Figure 39). Proton E also showed an NOE interaction 
with the phenyl ring but no NOEs were observed between proton E and either B or D. 
This suggests that protons B and D, which do exhibit NOEs, are cis- to one another 
whereas proton E is on the opposite face. 
 
Figure 39: NOE interactions exhibited by 371a 
 
To date it has not been possible to obtain an absolute configuration for the 1,4-addition 
product 371a. It is an oil and therefore cannot be analysed by X-ray crystallography, and 
suitable derivatisations to known compouds have not been identified. Based upon our 
understanding of Michael addition into α,β-unsaturated acyl ammoniums, we believe that 
the initial intermolecular Michael addition proceeds from the Re-face at the β-carbon, 
generating enolate 375 (Scheme 109). The subsequent intramolecular Michael addition also 
occurs from the Re-face to minimise steric interactions with the stereodirecting groups of 
the catalyst. We believe that the syn-ring junction is formed due to lithium chelation of the 
enolate and enone oxygen atoms. This is consistent with the Heathcock model which states 
that a closed transition state (where Li+ can transfer from one enolate to another) is 
A’ A B,D 
CO
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CH
2
CH
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E C 
A’ E C 
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371a, 1H NMR, CDCl3, 500 MHz 
371a, 1H NMR, C6D6, 300 MHz 
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favoured compared to an open transition state (where enolate and enone groups are in an 
anti-conformation and metal transfer does not occur).127 Whilst transition state 375b also 
conforms to the Heathcock model a steric clash can be envisaged between the enone 
moiety and the catalyst. We therefore believe that the intramolecular Michael addition 
proceeds via intermediate 375a, leading to asyn-ring junction. Based upon the assumption 
that initial Michael addition installis an (R)-stereocentre at C(7), we therefore believe that 
the final product obtained has a (4aS, 7R, 7aR) configuration. 
 
Scheme 109: Stereochemical outcomes of proposed transition states 
 
4.3.3 Aims and procedures for reaction screening 
1,4-Addition product 371a was obtained in poor yield and this was thought to be due in 
part to lactone instability to chromatography. To ensure result reproducibility, it was 
decided to compare ratios of 1,2- and 1,4-addition products from the crude 1H NMR 
spectra throughout the screening process (A, Figure 40). This was carried out by 
comparison of the integration of C(7)H (B, Figure 40) to either an olefinic proton or the 
CH2 signal of the 1,2-addition product (C, Figure 40). This choice depended on which 
areas of the crude 1H NMR spectra were cleanest, but as demonstrated in A the same 
results are obtained using either method. Samples of 371a for chiral HPLC analysis were 
prepared by preparative TLC to increase throughput. 
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Figure 40: Regioisomeric ratios obtained from crude 1H NMR spectra 
 
The two main problems to be addressed during optimisation were the regioselectivity 
(76:24 1,4-:1,2-addition) and enantioselectivity of the process (36% ee). In order to gain 
more information about the two problems the reaction was repeated at 0% and 100% 
catalyst loading (Table 17). With no catalyst present (0 mol%), 1,2-addition product 371a 
was generated in good regioselectivity (65:10) suggesting that the background reaction 
accounts for the poor regioselectivity of the process but only has minimal impact on the 
enantioselectivity of 371a. At 100 mol% catalyst loading the reaction proceeded to form 
only 1,4-addition product 371a in low 45% ee, suggesting that the isothiourea-catalysed 
addition process promotes excellent regioselectivity but is not very enantioselective. 
  
C 1,2-addition product 371b 
B 1,4-addition product 371a 
A crude reaction mixture 
∫ 0.76 ∫ 0.24 ∫ 0.49    
 4. Cascades from α,β-Unsaturated Acyl Ammoniums  
 
97 
 
Catalyst 
loading (mol%) 
SM 
(370) 
1,2 
(371b) 
1,4 
(371a) 
ee (%) 
20  24 76 38% 
0 25 65 10 - 
100   100 45% 
Table 17: Initial MML screening 
 
4.3.4 Base screening 
Firstly, alternative bases were screened to see if this had an effect on the regio- or 
enantioselectivity of the MML process (Table 18). Using LiHMDS with cinnamic 
anhydride as the electrophile afforded an improved 1,2-:1,4-addition ratio, however the 
enantioselectivity was reduced to 18% and unexpectedly the opposite enantiomer was 
formed in excess. The use of NaHMDS afforded only 1,2-product 74 with cinnamoyl 
chloride and returned only starting material with cinnamic anhydride, while PS-BEMP 
afforded no conversion into product with either electrophile. The reason for the base-
specificity of the MML process is not understood, but matches the observations of Romo 
et al. during the optimisation of their MAL process.122 The optimisation was therefore 
continued using LiHMDS/cinnamoyl chloride. 
 
 
  
Base 
SM 
(370) 
1,2 
(371b) 
1,4 
(371a) 
ee 
(%) 
SM 
(370) 
1,2 
(371b) 
1,4 
(371a) 
ee 
(%) 
LiHMDS  24 76 38% 21 14 65 
18% 
(ent) 
NaHMDS    -    - 
PS-
BEMP 
   -    - 
Table 18: Base and electrophile screening 
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4.3.5 Solvent mixtures 
In Romo’s MAL procedure a mixture of CH2Cl2:THF is employed to give optimum 
enantioselectivity. An investigation into the relationship between solvent mixture 
composition and selectivity was carried out (Table 19). We started at a 30:70 mixture of 
CH2Cl2/THF in line with Romo’s observations, but found that increasing the proportion 
of CH2Cl2 in the reaction solvent afforded worse regio- and enantioselectivity. In contrast 
the selectivity was increased at higher THF content, with the best enantioselectivity 
obtained at 89-100% THF content and the best regioselectivity of 74:14 afforded in 100% 
THF. We therefore removed CH2Cl2 from the reaction mixture, and proceeded with THF 
as the reaction solvent. 
 
CH2Cl2 (%) THF (%) 
SM 
(370) 
1,2 
(371b) 
1,4 
(371a) 
ee (%) 
95 5 - 75 25 [a] 
80 20 - 41 59 8% 
60 40 - 32 68 15% 
40 60 - 37 63 25% 
30 70 - 24 76 38% 
20 80 - 40 60 40% 
11 89 - 42 58 49% 
0 100 12 14 74 49% 
Table 19: Probing CH2Cl2:THF solvent mixtures 
[a]ee not determined, complex 1H NMR and HPLC spectrum 
 
4.3.6 Catalyst screening 
Alternative isothiourea catalysts were then tested in the reaction. BTM 51 afforded higher 
enantioselectivity (58% ee), however the amount of 1,4-addition was significantly decreased 
with both BTM 51 and TM 50. Enhancement of the 1,2-addition reaction is due to 
increased background reaction, which could occur if the α,β-unsaturated acyl ammonium 
intermediates with other isothioureas are less reactive, or if the intermediate is at a lower 
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concentration in solution. As HBTM 2.1 afforded significantly better regio- and 
enantioselectivity we continued with HBTM 2.1 53 as the isothiourea catalyst. 
 
Catalyst 
SM 
(370) 
1,2 
(371b) 
1,4 
(371a) 
ee 
(%) 
 
HBTM 2.1 53 
12 14 74 49% 
 
BTM 50 
13 59 29 58% 
 
TM 51 
15 70 15 
45% 
(ent) 
Table 20: Isothiourea screening 
 
4.3.7 Base additives 
The MAL procedure developed by Romo et al. uses a second base (NEt(iPr)2) as an acid 
scavenger. An investigation into the use of alternative base additives in our MML process 
was carried out (Table 21). With no additional base, the ratio of 1,2-:1,4-addition is reduced 
to 50:50 compared with the use of NEt(iPr)2 (14:74) and the ee is lower (20%). Use of two 
equivalents of LiHMDS gave a messy reaction mixture with no discernable product peaks 
in the crude 1H NMR spectrum, as did DBU. Lower ee was observed with NEt3, PS-
BEMP and Cs2CO3 (21-43% ee). K2CO3 and K2HPO4 gave very similar enantioselectivity 
to NEt(iPr)2, however the 1,2-:1,4-addition ratio was reduced (57 and 60% 1,4-addition 
product content compared with 74% for NEt(iPr)2) therefore we continued with NEt(
iPr)2 
as the base additive. 
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Base 
Additive 
SM 
(370) 
1,2 
(371b) 
1,4 
(371a) 
ee 
(%) 
- - 50 50 20% 
NEt(iPr)2 12 14 74 49% 
LiHMDS mess 
DBU mess 
NEt3 10 32 58 21 
PS-BEMP 21 18 61 42 
Cs2CO3 15 21 64 43 
K2CO3 14 26 60 48 
K2HPO4 12 31 57 53 
Table 21: Base additive screening 
 
4.3.8 Temperature screening 
The next parameter to be investigated was reaction temperature. Unexpectedly, at lower 
temperature the enantioselectivity was significantly reduced, with 1,4-addition product 
obtained in only 2% ee at -78 ˚C. This was unexpected, as low temperatures (and thus 
more rigid transition states) are more usually associated with enantioselective catalysis. 
Increasing the temperature to 20 ˚C increased the ee to 60%, which could be further 
improved by heating the reaction. At 70 ˚C 371a was obtained in 76% ee, so we decided to 
continue with this reaction temperature. 
  
 4. Cascades from α,β-Unsaturated Acyl Ammoniums  
 
101 
 
Temperature 
(oC) 
SM 
(370) 
1,2 
(371b) 
1,4 
(371a) 
ee 
(%) 
-78 18 53 35 2% 
-20 8 35 57 20% 
0 11 33 56 51% 
20 9 27 64 60% 
40 15 27 57 70% 
50 24 22 53 70% 
70 15 20 46 76% 
Table 22: Reaction temperature screening 
 
We have previously observed that the background reaction affords 1,2-addition 
regioselectively, so does not significantly impact the enantioselectivity of the 1,4-addition 
process. Changes in ee upon changing the temperature are therefore not simply due to 
altering the relative rates of both 1,2- and 1,4-addition reactions. It also cannot be related 
to changes in acyl ammonium concentration as the 1,4-addition product is only generated 
via this intermediate, so the selectivity should be independent of concentration. We do not 
currently understand the nature of this trend, and hope to be able to clarify the reasons 
through modelling in future work. 
At the higher temperatures starting material degradation was observed, so to get a better 
picture of the material recovery the screening proceeded using an internal standard (1,4-
dinitrobenzene) to give 1H NMR yields of each species at the end of the reaction (Table 
23). Repeating the reaction at 70 ˚C in THF (with fresh LiHMDS to ensure good starting 
material conversion) gave 1,4-addition product 371a in 51% 1H NMR yield and 71% ee. 
The enantioselectivity could be further improved by heating the solvent above its boiling 
point in a sealed tube, however this gave worse material recovery due to increased 
degradation at the very high temperatures. Using dioxane as solvent/co-solvent also 
increased the ee, with more degradation observed giving lower 1H NMR yields of the 
 4. Cascades from α,β-Unsaturated Acyl Ammoniums  
 
102 
desired product 371a (35-36%). A compromise was therefore sought, and 70 oC in THF 
was chosen as the optimal combination. 
 
Solvent 
Temperature 
(oC) 
SM 
(370)[a] 
1,2 
(371b)[a] 
1,4 
(371a)[a] 
ee 
(%) 
THF 
70 <5 23 51 71 
100[b] 24 13 15 82 
120[b] 22 21 13 80 
Dioxane 70 <5 13 35 80 
THF/dioxane 
(1:1) 
70 9 19 36 80 
Table 23: High temperature screening [a]1H NMR yield using 1,4-dinitrobenzene as internal standard [b]Reaction 
carried out in a sealed tube 
 
Slow electrophile addition was investigated, but while the ratio of 1,2-:1,4-addition was 
improved, greater starting material degradation was observed over the longer reaction time 
and the overall yield of the 1,4-MML product 371a was reduced. Diluting the reaction led 
to enhanced reaction times and greater starting material degradation, with no change in the 
ratio of regioisomers. 
 
4.3.9 Effect of electrophiles 
The use of alternative electrophiles to cinnamoyl chloride was next investigated in order to 
determine whether they afforded different ratios of 1,2-:1,4-addition. Of the electrophiles 
tested only homoanhydride 149 afforded any product, but unfortunately, the 1,2-:1,4- ratio 
was reduced and the enantioselectivity significantly lower using this activation method. All 
other activated acids tested afforded no product formation, but considerable degradation 
of the diester starting material was observed. Imidazole amide 378, recently demonstrated 
in our lab to be suitable for the generation of ammonium enolate intermediates in Michael 
addition-lactonisation processes,xvii also returned only starting material. α-Substituted acid 
                                                 
xvii Carried out by Claire Young, unpublished results 
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chlorides 379 and 380 were hoped to reduce the rate of 1,2-addition by steric blocking at 
the α-position, however they demonstrated no reactivity. 
 
Electrophile 
SM 
(370)[a] 
1,2 
(371b)[a] 
1,4 
(371a)[a] 
ee 
(%) 
 
149 
22 23 32 40% 
 
376 
28 - - - 
 
377 
40 - - - 
 
378 
[a] - - - 
 
379 
[a] - - - 
 
380 
[a] - - - 
Table 24: Electrophile screening [a]1H NMR yield using 1,4-dinitrobenzene as internal standard 
 
Also tested was the effect of acid chloride equivalents on the reaction (Table 25). At 
increased equivalents of acid chloride the amount of 1,2-addition remained almost constant 
(17-22% 1H NMR yield), but the amount of 1,4-addition product fell from 34% to 17% at 
three equivalents of 148. At a higher reaction temperature of 120 ˚C increased 
enantioselectivity was achieved, with 371a formed in 86% ee using 2 or 3 equivalents of 
acid chloride 148 but at reduced 1H NMR yields (27-28%). Lower total material recovery at 
higher acid chloride equivalents and higher temperatures suggests that byproduct formation 
and degradation pathways are more significant. At lower equivalents of cinnamoyl chloride, 
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the starting material conversion was significantly reduced (results not shown), so we 
maintained 1.4 equivalents of 148 at 70 ˚C as the optimum conditions. 
 
Temperature 
Acid 
chloride 
(equiv) 
SM 
(370)[a] 
1,2 
(371b)[a] 
1,4 
(371a)[a] 
ee 
(%) 
70 ˚C 
1.4 20 18 34 76 
2 17 22 25 79 
3 18 19 17 81 
120 ˚C 
1.4 12 17 22 82 
2 10 18 27 86 
3 16 20 28 86 
Table 25: Acid chloride equivalents [a]1H NMR yield using 1,4-dinitrobenzene as internal standard 
 
4.3.10 Catalyst loading 
Next to be investigated was the effect of the catalyst loading on the selectivity of the 
reaction. Unsurprisingly, at lower catalyst loading the rate of 1,4-addition is slower 
therefore more 1,2-addition is observed. Whilst it was hoped that higher catalyst loading 
would result in the reverse effect, no appreciable increase in the ratio of 1,2-:1,4- products 
was observed even at very high catalyst loadings of 50 mol%, therefore the catalyst loading 
remained at 20 mol%. 
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Catalyst loading 
(mol%) 
SM 
(370)[a] 
1,2 
(371b)[a] 
1,4 
(371a)a[] 
5 14 34 23 
20 <5 23 51 
30 15 17 40 
50 10 13 37 
Table 26: Catalyst Loading [a]1H NMR yield using 1,4-dinitrobenzene as internal standard 
 
4.3.11 Non-lithiated bases 
The role of Li+ in the MML process is not fully understood, but it is thought to be essential 
for chelating the transition state of the intramolecular Michael addition step (375, Scheme 
110). In the absence of Li+, 1,2-addition is favoured because the transition state (381) does 
not rely on chelation to preorganise the proposed transition state assembly. 
 
Scheme 110: The role of Li+ in the MML process 
 
The role of the base additive (NEt(iPr)2) remains mysterious: without it, the catalyst appears 
to not turn over with the 1H NMR yield of the 1,4-MML product approximately matching 
the catalyst loading (20 mol% gave 371a in 24% 1H NMR yield, Table 27). The remainder 
of the starting material is either returned unchanged or can go on to form the 1,2-addition 
product. Turnover is achieved by addition of an organic base such as NEt(iPr)2, or an 
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inorganic base. Cs2CO3 was retested at 70 ˚C due to its success at 0 ˚C, giving comparible 
results to NEt(iPr)2 (42%, 76% ee). 
Also tested were a range of non-lithiated bases, using LiCl as an additive to provide the 
required Li+ ions for chelation. NEt(iPr)2 afforded only 12% 371a, with very poor starting 
material conversion (61% remaining) suggesting that deprotonation is inefficient. KHMDS 
and NaHMDS afforded worse conversion to 371a (31% and 19% 1H NMR yields 
respectively) and strong organic base PS-BEMP also afforded poor regioselectivity. The ees 
for these reactions were not determined due to the reduced conversions. 
 
1st Base 
(1 equiv) 
2nd Base 
(1.4 equiv) 
Additive 
(1 equiv) 
SM 
(370)[a] 
1,2 (371b)[a] 1,4 (371a)[a] ee (%) 
LiHMDS 
- - 29 18 24 82 
NEt(iPr)2 - <5 23 51 71 
Cs2CO3 - 12 20 42 76 
NEt(iPr)2 
NEt(iPr)2 LiCl 
61 14 12 - 
KHMDS 31 20 31 - 
NaHMDS 21 17 19 - 
PS-BEMP 23 25 34 - 
Table 27: Base screening [a]1H NMR yield using 1,4-dinitrobenzene as internal standard 
 
4.3.12 Affecting lithium aggregation states 
Lithium is well known to form a range of coordinated species when solvated, with different 
coordination numbers achieved when different ligands are applied.128,129 The aggregation 
state, and thus the chelation ability, of Li+ is therefore strongly affected by solvation and 
the ratio of ligands present in the system. In our MML process there are a large number of 
competing ligands including THF, NEt(iPr)2 and a range of enolate intermediates therefore 
gaining insight into the specific Li-aggregation in this system is too complex for simple 
analysis. We can however potentially affect the Li-aggregation by changing the ratio of 
LiHMDS to NEt(iPr)2 in the system (Table 28). Interestingly, changing the ratio of 
LiHMDS to NEt(iPr)2 from 1:0.3 to 1:3 made no appreciable difference to the ratios of 
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products obtained (39-41% 371a, 72-74% ee). Catalytic NEt(iPr)2 (0.3 equivalents) was 
sufficient to fulfil its role in the system, but the minimum cut-off was not further 
investigated since no improvement in selectivity was observed. Catalytic LiHMDS was also 
tested in the reaction although this resulted in very poor conversion into both 1,2- and 1,4-
products 371b and 371a (6% and 18% respectively). 
 
LiHMDS 
(equiv) 
NEt(iPr)2 
(equiv) 
SM 
(370)[a] 
1,2 (371b)[a] 1,4 (371a)[a] ee (%) 
1 
0 29 18 24 82 
0.3 12 17 40 74 
1 14 18 39 74 
3 16 19 41 72 
0.3 1 64 6 18 80 
Table 28: Effect of changing the ratio of LiHMDS to NEt(iPr)2 
[a]1H NMR yield using 1,4-dinitrobenzene as internal 
standard 
 
The coordinating ability of the solvent was then investigated (Table 29). LiHMDS was 
added as a solution in toluene to remove competing ligation from THF. Using this 
LiHMDS solution, conversion into product was reduced even when using THF as the main 
reaction solvent. Because conversions were so low these reactions were not analysed by 
chiral HPLC so the product ee has not been recorded. If toluene was used as the reaction 
solvent, no conversion into any products was observed and this solvent effect is possibly 
hampering reactivity in the other reactions even when very small quantities of toluene are 
used. None of the reactions showed any improvement in 1,2-:1,4-selectivity, therefore no 
change was made to the reaction solvent used. 
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Solvent 
SM 
(370)[a] 
1,2 
(371b)[a] 
1,4 
(371a)[a] 
THF 9 14 14 
MeCN 4 22 6 
DCE <5 9 5 
DMF 19 7 12 
EtOAc 9 19 14 
Toluene  - - 
Table 29: Solvent screening [a]1H NMR yield using 1,4-dinitrobenzene as internal standard 
 
4.3.13 Optimised Reaction Conditions 
After a thorough screening process, it appears that the most important factor in controlling 
the enantioselectivity of the process is the reaction temperature, with elevated temperatures 
significantly enhancing the ee of the proucts. A compromise of 70 ˚C in THF was chosen 
as at higher temperatures greater product degradation was observed. A second base 
(NEt(iPr)2) is used to aid catalyst turnover, and HBTM 2.1 was the best catalyst in this 
system. It is possible that other avenues of investigation may further improve the 
regioselectivity of the process, but until now a 7:3 ratio of 1,4-:1,2- addition is the highest 
achieved, giving 1,4-addition product 371a as a single diastereomer in 71% ee. 
 
Scheme 111: Optimised Conditions 
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4.4 Reaction Scope 
4.4.1 Enone-malonate synthesis via cross-metathesis 
In order to investigate the scope of the MML process with respect to the nucleophile-
electrophile reactant, an optimisation of the starting material synthesis was carried out. It 
was not possible to generate the enone-malonate starting materials via ozonolysis/Wittig 
procedures due to the unstable nature of intermediate aldehydes, leading to no formation 
of the desired products. Grubbs II-catalysed cross metathesis between allylester 382 and 
methyl vinyl ketone 383 afforded the desired product 370, but the conversion was low so a 
range of alternative catalysts developed by the Nolan group130 were tested to try and 
improve the efficiency of the reaction.xviii These catalysts have been shown to be highly 
effective in cross-metathesis processes however in our reaction M20 385 and M31 387 gave 
poor conversion to product 370 (12-27%, Scheme 112). M23 386 and M2 388 afforded 
higher conversions of 41% and 56% respectively on a 0.5 mmol scale. However when the 
M2-catalysed reaction was scaled up to 15 mmol the conversion dropped to 39%. No 
competing homocoupling of allyl ester 382 was observed and the reaction did not tolerate 
lower catalyst loadings. Increased and decreased equivalents of methyl vinyl ketone 383 
were also investigated however no improvement to the conversion was achieved. 
 
Scheme 112: Screening of metathesis catalysts [a]15 mmol scale [b]0.5 mmol scale 
 
In order to investigate the scope of the MML process we hoped to synthesis a range of 
enone-dicarbonyl starting materials, varying both the steric and electronic properties to 
ascertain their effects on the cascade process. The cross-metathesis reaction enabled access 
to a range of enone-malonates in moderate yields (19-23%, Scheme 113), with the 
                                                 
xviii Catalysts M2, M20, M23 and M31 were kindly donated by Prof S. P. Nolan and are 
commercially available from Umicore 
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incorporation of sterically small (methyl) and large (iso-propyl) substitutents, as well as 
dibenzyl malonate. 2-Allyl-1,3-diketones were also investigated however product 392 could 
not be isolated as it showed a high tendency to perform intramolecular 1,4-addition, giving 
392 and rearranged product 393 as a mixture upon purification. 
 
Scheme 113: Cross metathesis between allyl 1,3-dicarbonyls and methyl vinyl ketone 
 
Attempts to couple allyl malonates with phenyl vinyl ketone was unfortunately 
unsuccessful, with starting materials returned unreacted under the cross-metathesis 
conditions. To date therefore we have not been able to prepare a wider variety of enone-
dicarbonyl starting materials for use in the MML cascade, but it is hoped that the scope 
could be improved in future work by investigation of alternative synthetic pathways. 
 
4.4.2 Cascade scope 
A preliminary investigation into the scope of the reaction has been carried out using the 
enone-malonates synthesised via cross metathesis (Scheme 114). Annulation with 
cinnamoyl chloride afforded bicyclic products 371a and 394-398a in moderate 
regioselectivity (61:39 to 77:23). Upon repetition of the reaction with diethyl enone-
malonate on a larger scale we observed increases in both the yield of 371a (32% to 41%) 
and its ee (71% to 82%) compared with the results obtained during reaction screening, with 
no change in the regioisomeric ratio (68:32). 
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It was generally possible to separate the major 1,4-cascade products from the side products 
by chromatography (generated via 1,2-addition), however the 1,2-products coeluted with 
the enone-malonate starting materials. In most cases the starting material was fully 
converted during the reaction time however the use of bulky isopropyl substituted enone-
malonate gave a slower reaction, which afforded 1,4-product 396a, 1,2-product 396b and 
starting material 389 in a 51:22:16 crude mixture. Upon purification, this afforded 396a in a 
moderate 44% yield and 396b in 36% as a 7:3 mixture with the starting material. Extending 
the reaction time increased degradation products and did not increase the yields of either 
1,4- or 1,2-addition products. 
Use of a methyl ester group led to increased 1,4-:1,2-addition ratio (77:23 394a:b) and gave 
an increased yield of 1,4-addition product 394a (63%) with no significant drop in ee (71%). 
This was pleasing because previous results with methyl substituted 1,3-diketones afforded 
annulation products in decreased ee (Section 2.3.2). Benzyl substitution was well tolerated, 
with the results for 395a/395b closely matching those of other linear alkyl malonates.  
We then investigated the use of alkyl substituted Michael acceptors by using commercially 
available crotonoyl chloride (R2 = Me) as the α,β-unsaturated acyl ammonium precursor. 
Dimethylmalonate 1,4-addition product 397a was isolated in 56% yield, which closely 
matches the results obtained with cinnamoyl chloride (394a, 63%). This was also observed 
for dibenzylmalonate substituted products 398a/398b which were obtained in identical 
regioisomeric ratios (77:23) and yields (398b, 54%) compared with the phenyl-substituted 
product 395a/398b. Excitingly, the methyl substituted products 397a and 398a were 
isolated in much higher 90% ee compared with phenyl cubstituted products 394a/395a 
(70-72% ee). In future work, the scope of this reaction will be extended to further explore 
the relationship between steric/electronic effects and enantioselectivity. From the 
preliminary results seen here, we can be confident that the process is robust for a variety of 
substituents, and especially high enantioselectivity can be obtained for alkyl examples. 
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Scheme 114: Reaction scope [a]Isolated as a mixture of 1,2 (371b)-addition product 396b and starting material 
389 (7:3, inseparable by chromatography) 
 
4.5 Conclusions 
As part of our efforts to explore the chemistry of α,β-unsaturated acyl ammonium 
intermediates we have successfully demonstrated the first Lewis base-catalysed Michael-
Michael-lactonisation process, utilising enone-malonates as Michael donor-acceptor species 
alongside α,β-unsaturated acyl ammonium intermediates generated in situ from addition of 
HBTM 2.1 into α,β-unsaturated acid chlorides. Pleasingly, the cyclised products were 
formed as single diastereomers, suggesting that stereocontrol is excellent for both inter- 
and intramolecular Michael additions. 
Interestingly, enhanced enantioselectivity at elevated temperatures was observed and we 
were able to carry out an enantioselective organocatalytic cascade process at high 
temperatures of 70 ˚C in THF. We also demonstrated the importance of Li+ ions for 
efficient conjugate addition, which is proposed to be due to important chelation 
interactions in the intramolecular Michael addition transition state. HBTM 2.1 afforded 
both the best regio- and enantioselectivity in this system, with other isothioureas tested 
(BTM and TM) giving poor regioselectivity due to enhanced background reactions. 
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The reaction scope has demonstrated that a range of enone-malonates successfully 
participates in the cascade reaction, affording 1,4-addition products in moderate 
regioselectivity, yields and enantioselectivity. Increased steric bulk reduces starting material 
conversion, but regio- and enantioselectivity remained unchanged. “Small” alkyl groups 
demonstrated increased regioselectivity, but again the enantioselectivity was similar across 
the range. 
In future work, we aim to expand the scope of the reaction to include a wider range of 
enone-malonates and to further investigate the effects of changing the sterics and 
electronics of the α,β-unsaturated acid chloride component. In order to expand the scope, 
we also hope to improve the starting material synthesis. The cross-metathesis is low 
yielding and has shown high substrate specificity, which limits the synthetic possibilities of 
the reaction. Alternative strategies such as Tsuji-Trost coupling of malonates to allyl 
acetates could be investigated, which if successful could provide a reliable method to 
generate the starting materials in increased yields. 
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5. Conclusions 
At the outset of this work, the chemistry of α,β-unsaturated acyl ammonium intermediates 
was underexplored, with only one process reported by Fu et al. exploiting Lewis base 
catalysis to afford diquinane products in low ee (Section 1.2.6). We set out to further 
explore the potential of these catalytic intermediates in a range of 1,4-additions, in order to 
broaden the applicability of a potentially important catalytic intermediate. 
We have successfully developed Michael addition-cyclisation processes employing a wide 
range of nucleophiles including 1,3-diketones, 1,3-ketoesters and 2-acylbenzazoles, 
accessing novel heterocyclic products in excellent ee. The origin of the enantioselectivity in 
our Michael addition-cyclisation process was explored by examination of the crystal 
structure of the α,β-unsaturated acyl ammonium intermediate, and insight into the relative 
energies of N- and O- cyclisation pathways for annulation of cinnamic anhydride with 2-
phenacyl benzothiazole and benzoxazole was gained by computational work (carried out in 
collaboration with the Paul Ha Yeon Cheong). Given the precedent for biological activity 
demonstrated by benzazole containing compounds, we hope that future work will enable 
evaluation of the bioactivity of the heterocycles we have accessed. 
We then went on to demonstrate that α,β-unsaturated acyl ammonium intermediates can 
participate in complex chemical cascades. A Michael-Michael-lactonisation process was 
developed, which showed an interesting relationship between enantioselectivity and 
temperature. The reactions were performed at 70 ˚C for optimum enantioselectivity, and to 
the best of our knowledge this is the first organocatalytic reaction to require such elevated 
temperatures to improve ee. In a preliminary reaction scope a range of enone-malonates 
were employed in the cascade process giving access to tricyclic lactone products in 
moderate yields and good enantioselectivities. 
Since we embarked upon this research the field of α,β-unsaturated acyl ammonium catalysis 
has grown rapidly, with work by Romo and Matsubara successfully utilising this 
intermediate in a diverse range of Michael additions to access novel products. As the field 
of organocatalysis continues to grow, the ability to exploit a wide range of catalytic 
intermediate is crucial for accessing different product architectures. As part of this growth, 
the development of α,β-unsaturated acyl ammonium intermediates in catalysis provides an 
important expansion of the chemistry that we can access, and thus the products we can 
obtain. 
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6. Experimental 
6.1 General Information 
Reactions involving moisture sensitive reagents were carried out under a nitrogen 
atmosphere using standard vacuum line techniques in addition to dry solvents. All 
glassware used was flame dried and cooled under vacuum. 
For moisture sensitive reactions, solvents (THF, CH2Cl2, toluene, hexane and Et2O) were 
obtained anhydrous and purified by an alumina column (Mbraun SPS-800). Petrol is 
defined as petroleum ether 40-60 °C. All other solvents and commercial reagents were used 
as supplied without further purification unless stated otherwise. 
Room temperature (rt) refers to 20-25 °C. Temperatures of 0 °C and -78 °C were obtained 
using ice/water and CO2(s)/acetone baths respectively. Temperatures of 0 °C to -50 °C for 
overnight reactions were obtained using an immersion cooler (HAAKE EK 90). Reflux 
conditions were obtained using a DrySyn heating mantle equipped with a contact 
thermometer. In vacuo refers to the use of a Büchi Rotavapor R-2000 rotary evaporator with 
a Vacubrand CVC2 vacuum controller or a Heidolph Laborota 4001 rotary evaporator with 
a vacuum controller.  
Analytical thin layer chromatography was performed on pre-coated aluminium plates 
(Kieselgel 60 F254 silica). TLC visualisation was carried out with ultraviolet light (254 nm), 
followed by staining with a 1% aqueous KMnO4 solution. Flash column chromatography 
was performed on Kieselgel 60 silica in the solvent system stated. 
1H, 13C and 19F nuclear magnetic resonance (NMR) spectra were acquired on either a 
Bruker Avance 300 (300 MHz, 1H, 75 MHz 13C{1H}, 282 MHz 19F{1H}), Bruker Avance 
II 400 (400 MHz, 1H, 100 MHz 13C{1H}, 376 MHz 19F{1H}) or a Bruker Avance II 400 
(500 MHz, 1H, 125 MHz 13C{1H}, 470 MHz 19F{1H}) spectrometer at ambient 
temperature in the deuterated solvent stated. All chemical shifts are quoted in parts per 
million (ppm) relative to the residual solvent as the internal standard. All coupling 
constants, J, are quoted in Hz. Multiplicities are indicated by: s (singlet), d (doublet), t 
(triplet), q (quartet), sept (septet), ABq (AB quartet), oct (octet), m (multiplet), dd (doublet 
of doublets), ddd (doublet of doublet of doublets, dt (doublet of triplets), dq (doublet of 
quartets) and td (triplet of doublets). The abbreviation Ar is used to denote aromatic, Ph to 
denote phenyl, Bn to denote benzyl, br to denote broad and app to denote apparent. NMR 
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peak assignments were confirmed using 2D 1H correlated spectroscopy (COSY), 2D 1H 
nuclear Overhauser effect spectroscopy (NOESY), 2D 1H−13C heteronuclear multiple-
bond correlation spectroscopy (HMBC), and 2D 1H−13C heteronuclear single quantum 
coherence (HSQC) where necessary. 
Infrared spectra (max/cm-1) were recorded on a Shimadzu IRAffinity-1 using a Pike 
attenuated total reflectance (ATR) accessory. Only the characteristic peaks are quoted.  
Melting points were recorded on an Electrothermal 9100 melting point apparatus and are 
uncorrected. Dec refers to decomposition. 
HPLC analyses were obtained on two separate machines; a Gilson HPLC consisting of a 
Gilson 305 pump, Gilson 306 pump, Gilson 811C dynamic mixer, Gilson 805 manometric 
module, Gilson 401C dilutor, Gilson 213XL sample injector and sample detection was 
performed with a Gilson 118 UV/vis detector while the temperature was assumed to be 23 
°C; a Shimadzu HPLC consisting of a DGU-20A5 degasser, LC-20AT liquid 
chromatograph, SIL-20AHT autosampler, CMB-20A communications bus module, SPD-
M20A diode array detector and a CTO-20A column oven which allowed the temperature 
to be set from 25-40 °C. Separation was achieved using DAICEL CHIRALCEL OD-H 
and OJ-H columns or DAICEL CHIRALPAK AD-H, AS-H, IA, IB, IC and ID columns. 
All chiral HPLC traces were compared to the authentic racemic trace prepared in 
analogous fashion. 
Mass spectrometry (m/z) data were acquired by electrospray ionisation (ESI), chemical 
ionisation (CI), electron impact (EI), atmospheric solids analysis probe (ASAP), 
atmospheric pressure chemical ionization (APCI) or nanospray ionisation (NSI) either at 
the University of St Andrews or the EPSRC National Mass Spectrometry Service Centre, 
Swansea. At the University of St Andrews, low and high resolution ESI MS were carried 
out on a Micromass LCT spectrometer. At the EPSRC National Mass Spectrometry 
Service Centre, low resolution NSI MS was carried out on a Micromass Quattro II 
spectrometer and high resolution NSI MS on a Thermofisher LTQ Orbitrap XL 
spectrometer. 
Optical rotations were measured on a Perkin Elmer Precisely/Model-341 polarimeter or 
Optical Activity AA-1000 polarimeter, operating at the sodium D line with a 100 mm path 
cell at rt. 
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6.2 α,β-Unsaturated Acids 
General Procedure A: Knoevenagel Condensation 
 
To a solution of the corresponding aldehyde (1 equiv) in pyridine (1.5 M), was added 
malonic acid (1.2 equiv) and piperidine (0.12 equiv) at room temperature. The reaction 
mixture was heated at 85 ˚C for 18 h. After cooling to room temperature the solution was 
acidified using 6 M HCl affording the carboxylic acid as a precipitate which was isolated by 
filtration. The acid was purified by column chromatography or recrystallisation as required. 
 (E)-2-Bromocinnamic acid (230) 
 
The title compound was prepared according to General Procedure A from 2-
bromobenzaldehyde (3.49 mL, 30.0 mmol), malonic acid (3.75 g, 36.0 mmol and piperidine 
(0.35 mL, 3.60 mmol) in pyridine (20 mL) to give the carboxylic acid 230 as a white solid 
which was washed with hexane; no further purification needed (6.78 g, 99%); mp 217–219 
˚C {Lit.131 217.5–218.5 °C}; δH (300 MHz, DMSO-d6) 6.57 (1H, d, J 15.9, ArCH=CH), 
7.32 – 7.39 (1H, m, J 7.6, 1.8, ArC(5)H), 7.40 – 7.47 (1H, m, ArC(4)H), 7.71 (1H, dd, J 7.9, 
1.4, ArC(3)H), 7.84 (1H, d, J 15.9, ArCH=CH), 7.90 (1H, dd, J 7.8, 1.8ArC(6)H), 12.64 
(1H, br, s, COOH). Data in agreement with the literature.131  
 (E)-3-Bromocinnamic acid (231) 
 
The title compound was prepared according to General Procedure A from 3-
bromobenzaldehyde (3.49 mL, 30.0 mmol), malonic acid (3.75 g, 36.0 mmol) and 
piperidine (0.35 mL, 3.60 mmol) in pyridine (20 mL) to give the carboxylic acid 231 as a white 
solid which was washed with hexane; no further purification needed (6.45 g, 95%); mp 
176–178 ˚C {Lit.132 175–176.3 °C}; δH (300 MHz, DMSO-d6) 6.61 (1H, d, J 16.0, 
ArCH=CH), 7.37 (1H, t, J 7.9, C(5)H), 7.56 (1H, d, J 16.1, ArCH=CH), 7.57 – 7.62 (1H, 
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m, C(4)H), 7.71 (1H, dt, J 7.8, 1.3, ArC(6)H), 7.94 (1H, t, J 1.8, ArC(2)H), 12.52 (1H, s, 
COOH). Data in agreement with the literature.132  
 (2E)-3-(Thiophen-3-yl)prop-2-enoic acid (232) 
 
The title compound was prepared according to General Procedure A from thiophene-3-
carbaldehyde (2.59 mL, 30.0 mmol), malonic acid (3.75 g, 36.0 mmol) and piperidine (0.35 
mL, 3.60 mmol) in pyridine (20 mL) to give the carboxylic acid 232 as an off-white solid, no 
further purification needed (4.33 g, 94%); mp 148–150 ˚C {Lit.133 151 ˚C}; δH (300 MHz, 
CDCl3) 6.27 (1H, d, J 15.9, ArCH=CH), 7.32 (1H, ddd, J 5.1, 1.4, 0.4, ArC(4)H), 7.36 (1H, 
ddd, J 5.1, 2.9, 0.6, ArC(5)H), 7.56 (1H, dd, J 2.9, 1.3, ArC(2)H), 7.78 (1H, d, J 15.9, 
ArCH=CH). Data in agreement with the literature.133,134 
 (2E)-3-(Furan-3-yl)prop-2-enoic acid (233) 
 
The title compound was prepared according to General Procedure A from furan-3-
carbaldehyde (2.59 mL, 30.0 mmol), malonic acid (3.75 g, 36.0 mmol) and piperidine (0.35 
mL, 3.60 mmol) in pyridine (20 mL) to give the carboxylic acid which was recrystallised from 
EtOAc/hexane to give 233 as a brown solid (2.51 g, 61%); mp 151–152 ˚C {Lit.135 152.5–
154}; δH (500 MHz, d4-MeOD) 6.20 (1H, d, J 15.8, ArCH=CH), 6.75 (1H, d, J 1.9, 
ArC(4)H), 7.52 – 7.56 (1H, m, ArC(5)H), 7.59 (1H, d, J 15.8, ArCH=CH), 7.80 – 7.85 (1H, 
m, ArC(2)H). Data in agreement with the literature.135,136 
 (E)-2,4,6-Trimethylcinnamic acid (236) 
 
Procedure from Aitken et al.99 Mesitaldehyde (1.48 mL, 10.0 mmol) was added dropwise to 
a suspension of sodium metal (230 mg, 10.0 mmol) in ethyl acetate (20 mL) at 0 ˚C and the 
flask stirred for 3 h at 0 ˚C. Acetic acid was then added dropwise until a persistent yellow 
colour appeared, followed by water (20 mL). The flask was stirred for 20 min at room 
temperature then the organic layer separated, washed with saturated NaHCO3 solution (20 
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mL × 2), dried over MgSO4, filtered and concentrated in vacuo to afford the crude ethyl 
ester which was added to a 2 M solution of NaOH in water (20 mL) and heated at reflux for 
3 h. After cooling to room temperature the reaction mixture was acidified using 
concentrated HCl. The precipitate was isolated by filtration and washed with hexane to 
give 236 as a pale brown solid (0.99 g, 52%); mp 176–178 ˚C {Lit.137 178–179 ˚C}; δH (300 
MHz, CDCl3) 2.29 (3H, s, ArC(4)CH3), 2.36 (6H, s, 2 × ArC(2)CH3), 6.10 (1H, d, J 16.3, 
ArCH=CH), 6.91 (2H, s, 2 × ArC(3)H), 7.98 (1H, d, J 16.3, ArCH=CH). Data in 
agreement with the literature.137,138 
 (2E)-4,4,4-Trifluoro-3-methylbut-2-enoic acid (298) 
 
Procedure from Tarrant and Taylor.106 Malonic acid (12.5 g, 120 mmol) and piperidine 
(1.19 mL, 12.0 mmol) were added to pyridine (50 mL) and cooled to 0 ˚C. 1,1,1-
Trifluoromethylketone (8.96 mL, 100 mmol) was added to the flask by syringe addition 
directly into the pyridine solution to minimise loss through ketone volatility. After 1 h 
stirring at 0 ˚C the flask was then warmed to room temperature and stirred for 16 h. The 
flask was then heated to 90 ˚C for 24 h, followed by 130 ˚C for 4 h. The flask was cooled 
to room temperature and acidified using a 6 M solution of hydrochloric acid. The aqueous 
layer was washed with ethyl acetate (50 mL × 3) and the combined organic layers dried 
over MgSO4, filtered and concentrated in vacuo to afford the β-hydroxy acid which was used 
without further purification. The hydroxy acid was added to a solution of concentrated 
sulfuric acid (50 mL) in water (50 mL) at room temperature. The flask was attached to 
distillation apparatus and heated slowly to 200 ˚C under atmospheric pressure, with a 
mixture of water and crude α,β-unsaturated acid collected in the receiver flask. After 
heating for 16 h at 200 ˚C the mixture in the receiver flask was washed with CH2Cl2 (50 mL 
× 3), and the combined organic layers dried over MgSO4, filtered and concentrated in vacuo 
to afford the crude acid which was purified by vacuum distillation (<1 mbar) at 70 ˚C to 
afford acid 298 as a colourless oil (4.18 g, 31%, E:Z 89:11 confirmed by 1H→19F NOE); bp 
158–163 ˚C {Lit.106 160–166 ˚C}; δH (500 MHz, CDCl3) 1.67 (3H, d, J 1.1, (Z)-CH3), 2.28 
(3H, d, J 1.7, (E)-CH3), 6.36 (1H, h, J 1.5, (E)-CH), 6.52 – 6.55 (1H, m, (Z)-CH), 12.08 (1H, 
s, CO2H); δF (471 MHz, CDCl3) -82.95 (Z), -71.45 (E). Data in agreement with the 
literature.106,139 
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 (2E)-3,7-Dimethylocta-2,6-dienoic acid (E-303) 
 
Geraniol (4.38 mL, 25.0 mmol) and activated manganese dioxide (10.88 g, 125 mmol) were 
added to CH2Cl2 (25 mL) and stirred at room temperature for 18 h, after which more 
manganese dioxide (3.90 g, 45.0 mmol) was added and the flask stirred for a further 24 h. 
The reaction mixture was filtered through celite and concentrated in vacuo to afford the 
aldehyde as a colourless oil (2.83 g, 75%, E:Z = 97:3 by 1H NMR) which was used without 
further purification. To a mixture of t-butanol (100 mL) and 2-methyl-2-butene (2 M in 
THF, 45 mL, 90.0 mmol) was added the crude aldehyde (2.28 g, 15.0 mmol). A solution of 
sodium chlorite (2.72 g, 30.0 mmol) and sodium dihydrogen phosphate dihydrate (9.36 g, 
60.0 mmol) in water (100 mL) was added to the aldehyde solution and the flask stirred at 
room temperature for 72 h. The mixture was extracted with ethyl acetate (100 mL × 3) and 
the combined organic layers dried over MgSO4, filtered and concentrated in vacuo. The 
crude acid was purified by column chromatography (10% EtOAc/petrol) to afford acid E-
303 as a colourless oil (1.61 g, 64%, E/Z 97:3 by GC); GC analysis: Column: Agilent DB-5 
(30 m, 0.25 mm ID, 0.5 μm film), Method: (Injector 250 °C, FID 325 °C, linear velocity 40 
cm/s (He), oven ramps (Initial 100 °C (2 min hold) → 220 °C (20 °C/min, 5 min hold)), tR 
(E-isomer) 6.69 min, tR (Z-isomer): 6.89 min); δH (300 MHz, CDCl3) 1.61 (3H, d, J 1.4, 
C(7)(CH3)(CH3)), 1.69 (3H, d, J 1.4, C(7)(CH3)(CH3)), 2.16 – 2.19 (7H, m, C(3)CH3, 2 × 
CH2), 5.02 – 5.11 (1H, m C(6)H), 5.69 (1H, q, J 1.2, C(2)H). Data in agreement with the 
literature.140 
 (2Z)-3,7-Dimethylocta-2,6-dienoic acid (Z-303) 
 
Nerol (4.38 mL, 25.0 mmol) and activated manganese dioxide (10.88 g, 125 mmol) were 
added to CH2Cl2 (25 mL) and stirred at room temperature for 18 h, after which more 
manganese dioxide (3.90 g, 45.0 mmol) was added and the flask stirred for a further 24 h. 
The reaction mixture was filtered through celite and concentrated in vacuo to afford the 
aldehyde as a colourless oil (3.28 g, 86%, E:Z = 9:91 by 1H NMR) which was used without 
further purification. To a mixture of t-butanol (100 mL) and 2-methyl-2-butene solution (2 
 6. Experimental  
 
121 
M in THF, 45 mL, 90.0 mmol) was added the crude aldehyde (2.28 g, 15.0 mmol). A 
solution of sodium chlorite (2.72 g, 30.0 mmol) and sodium dihydrogen phosphate 
dihydrate (9.36 g, 60.0 mmol) dissolved in water (100 mL) was added to the aldehyde 
solution and the flask stirred at room temperature for 72 h. The mixture was extracted with 
ethyl acetate (100 mL × 3) and the combined organic layers dried over MgSO4, filtered and 
concentrated in vacuo. The crude acid was purified by column chromatography (10% 
EtOAc/petrol) to afford acid Z-303 as a colourless oil (1.58 g, 63%, E/Z 10:90 by GC); 
GC analysis: Column: Agilent DB-5 (30 m, 0.25 mm ID, 0.5 μm film), Method: (Injector 
250 °C, FID 325 °C, linear velocity 40 cm/s (He), oven ramps (Initial 100 °C (2 min hold) 
→ 220 °C (20 °C/min, 5 min hold)), tR (E-isomer) 6.69 min, tR (Z-isomer): 6.89 min; δH 
(300 MHz, CDCl3) 1.61 (3H, d, J 1.4, C(7)(CH3)(CH3)), 1.69 (3H, d, J 1.3, C(7)(CH3)(CH3)), 
1.93 (3H, d, J 1.4, C(3)CH3), 2.10 – 2.23 (2H, m, CH2), 2.58 – 2.71 (2H, m, CH2), 5.08 – 
5.20 (1H, m, C(6)H), 5.68 (1H, q, J 1.2, 0.8, C(2)H). Data in agreement with the 
literature.141 
2-Cyclohexylideneacetic acid (296) 
 
Modified procedure from Peters and Tiseni.142 Triethylphosphonoacetate (13.9 mL, 70.0 
mmol) was added dropwise to a suspension of sodium hydride (60% in mineral oil, 2.80 g, 
70.0 mmol) in dry THF (70 mL) under nitrogen at 0 ˚C. The flask was stirred at 0 ˚C for 30 
min then warmed to room temperature over 30 min. A solution of cyclohexanone (7.0 mL, 
70.0 mmol) in dry THF (50 mL) was then added dropwise and the flask stirred at room 
temperature for 18 h. The reaction was quenched by careful addition of water at 0 ˚C then 
the mixture extracted with Et2O (3 × 100 mL). The combined organic phase was washed 
with brine, dried over anhydrous MgSO4 and concentrated in vacuo to afford the crude ester 
which was used without further purification. The crude oil was dissolved in methanol (150 
mL) followed by addition of sodium hydroxide (11.8 g, 210.0 mmol) and water (50 mL). 
The flask was stirred at room temperature for 48 h then quenched by acidification with 6 M 
HCl. The mixture was concentrated in vacuo then extracted with CH2Cl2 (3 × 100 mL). The 
combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in 
vacuo to afford the crude acid. Purification by recrystallisation from ethanol/water afforded 
acid 296 as a white solid (4.56 g, 47%); mp 89–91 C {Lit.143 89–90 °C}; δH (300 MHz, 
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CDCl3) 1.50 – 1.79 (6H, m, cyclohexylC(3)H2, cyclohexylC(4)H2, cyclohexylC(5)H2), 2.13 – 
2.35 (2H, m, cyclohexylC(2/6)H2), 2.72 – 2.94 (2H, m, cyclohexylC(2/6)H2), 5.57 – 5.72 
(1H, m, C-CH), 11.76 (1H, s, OH). Data in agreement with the literature.143,144  
 (2E)-3-Phenylbut-2-enoic acid (297) 
 
Modified procedure from Peters and Tiseni.142 Triethylphosphonoacetate (19.8 mL, 100 
mmol) was added dropwise to a suspension of sodium hydride (60% in mineral oil, 4.00 g, 
100 mmol) in dry THF (100 mL) under nitrogen at 0 ˚C. The flask was stirred at 0 ˚C for 
30 min then warmed to room temperature over 30 min. A solution of acetophenone (11.7 
mL, 100 mmol) in dry THF (50 mL) was then added dropwise and the flask stirred at room 
temperature for 18 h. The reaction was quenched by careful addition of water at 0 ˚C then 
the mixture extracted with Et2O (3 × 100 mL). The combined organic phase was washed 
with brine, dried over anhydrous MgSO4 and concentrated in vacuo to afford the crude ester 
which was used without further purification. The crude oil was dissolved in methanol (150 
mL) followed by addition of sodium hydroxide (16.8 g, 300.0 mmol) and water (50 mL). 
The flask was stirred at room temperature for 48 h then quenched by acidification with 6 M 
HCl. The mixture was concentrated in vacuo then extracted with CH2Cl2 (3 × 100 mL). The 
combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in 
vacuo to afford the crude acid. Purification by recrystallisation from ethanol/water afforded 
acid 297 as a white solid (5.71 g, 35%); mp 93–94 C {Lit.141  91–92 °C}; δH (300 MHz, 
CDCl3) 2.62 (3H, d, J 1.3, CH3), 6.19 (1H, q, J 1.3, C=CH), 7.37 – 7.43 (3H, m, 2 × 
PhC(3)H, PhC(4)H), 7.44 – 7.57 (2H, m, 2 × PhC(2)H). Data in agreement with the 
literature.141  
 (Z)-Ethyl cinnamate (206) 
 
Ethyl phenylpropiolate (1.0 mL, 6.00 mmol) was dissolved in a mixture of hexane and 1-
hexene (7:2 v/v, 12 mL) under N2 at rt, followed by addition of quinoline (1.1 mL, 9.00 
mmol) and palladium on calcium carbonate (Lindlar’s catalyst, 360 mg). The flask was 
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connected to a hydrogen-filled balloon (1 atm) and stirred at rt. The progress of the 
reaction was monitored by TLC (CH2Cl2). The starting alkyne was consumed after 1 h and 
the reaction was stopped by displacement of the hydrogen atmosphere with nitrogen. The 
resulting mixture was filtered through a Celite pad, and the filtrate was washed with 10% 
acetic acid (4 × 50 mL), water (3 × 50 mL), and saturated NaHCO3 (4 × 50 mL), then 
dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by column 
chromatography to give the ester 206 as a clear oil (458 mg, 43%); δH (300 MHz, CDCl3) 
1.25 (3H, t, J 7.2, CH3), 4.17 (2H, q, J 7.2, OCH2), 5.95 (1H, d, 12.6, PhCH=CH), 6.95 (1H, 
d, 12.6, PhCH=CH), 7.32-7.39 (3H, m, ArH), 7.56-7.60 (2H, m, ArH). Data in agreement 
with the literature.145 
(Z)-Cinnamic acid (209) 
 
To a solution of cis-ethyl cinnamate (458 mg, 2.60 mmol) in THF (37 mL), was added a 
solution of LiOH.H2O (327 mg, 7.80 mmol) in H2O (12 mL) at rt. The resulting reaction 
mixture was heated at 60 C for 16 h then cooled to room temperature and acidified with 8 
M HCl. The aqueous phase was extracted with Et2O (3 × 50 mL) and the combined 
organic layers were dried over MgSO4 and concentrated in vacuo to give the acid 209 as a 
pale yellow solid (327 mg, 85%); mp 64-68 °C {Lit.11 66-68 °C}; δH (400 MHz, CDCl3) 5.97 
(1H, d, J 12.8, PhCH=CH), 7.07 (1H, d, J 12.8, PhCH=CH), 7.34-7.39 (3H, m, ArH), 7.58-
7.62 (2H, m, ArH). Data in agreement with the literature.90 
 
6.3 a,b-Unsaturated Anyhydrides 
General Procedure B: Anhydride Synthesis 
 
To a solution of carboxylic acid (1.4 equiv) in CH2Cl2
 or THF as specified (0.8 M) was 
added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.HCl (EDCI.HCl) (1.0 equiv) and 
the solution stirred for 1-2 h at room temperature. The solution was diluted with CH2Cl2 
(50 mL) and then washed sequentially with water (2 × 50 mL) and saturated aqueous 
NaHCO3 solution (50 mL). The organic layer was dried over anhydrous MgSO4, filtered, 
and concentrated in vacuo to afford the homoanhydride. 
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(E)-Cinnamic anhydride (149) 
 
The title compound was prepared according to General Procedure B from (E)-cinnamic acid 
(741 mg, 5.00 mmol) and EDCI.HCl (959 mg, 5.00 mmol) in CH2Cl2 (6 mL) to give the 
homoanhydride 149 as a white solid (448 mg, 64%); mp 118-120 C {Lit.1 130 °C}; δH (400 
MHz, CDCl3) 6.54 (2H, d, J 16.0, ArCH=CH), 7.40–7.47 (6H, m, ArH), 7.54–7.63 (4H, m, 
ArH), 7.86 (2H, d, J 16.0, ArCH=CH). Data in agreement with the literature.146,2 
(E)-3-(4-(Trifluoromethyl)phenyl)acrylic anhydride (155) 
 
The title compound was prepared according to General Procedure B from 4-
trifluoromethylcinnamic acid (1080 mg, 5.00 mmol) and EDCI.HCl (959 mg, 5.00 mmol) 
in CH2Cl2 (10 mL) to give the homoanhydride 155 as a white solid (425 mg, 41%); mp 127-
128 C; max (film)/cm-1 1757, 1705 (C=O), 1631 (C=C), 1321 (CF3); δH (300 MHz, CDCl3) 
6.61 (2H, d, J 16.0, CH=CHCO), 7.69 (8H, s, ArH), 7.88 (2H, d, J 16.0, CH=CHCO); δC 
(75 MHz, DMSO) 119.7 (2×CH=CHCO), 123.9 (q, 1JCF 270.8, 2×CF3), 125.9 (q, 
3JCF 3.7, 
4×ArC(3)), 129.6 (4×ArC(2)), 130.8 (q, 2JCF 32.0, 2×ArC(4)), 137.5 (2×ArC(1)), 146.7 
(2×CH=CHCO), 162.2 (2×CO); δF (282 MHz, CDCl3) 63.5; m/z (ES+) 437 ([M+Na]+, 
20%), 301 ([M-6F]+, 100%); HRMS (ES+) C20H12F6O3Na
+ ([M+Na]+) requires 437.0585, 
found 437.0588 (0.8 ppm). 
(E)-3-(4-Fluorophenyl)acrylic anhydride (156) 
 
The title compound was prepared according to General Procedure B from (E)-3-(4-
fluorophenyl)acrylic acid (166 mg, 1.00 mmol) and EDCI.HCl (96 mg, 0.50 mmol) in 
CH2Cl2 (4 mL) to give the homoanhydride 156 as a white solid (207 mg, 66%); mp 86-90 °C; 
max (film)/cm-1 1755, 1699 (C=O), 1595, 1508; δH (300 MHz, CDCl3) 6.44 (2H, d, J 16.2, 
ArCH=CH), 7.07-7.16 (4H, m, ArH), 7.54-7.61 (4H, m, ArH), 7.81 (2H, d, J 16.2, 
ArCH=CH); δC (75 MHz, CDCl3) 116.3 (d, 
2JCF 22.1, 4×ArC(3)), 116.4 (d, 
6JCF 2.2, 
 6. Experimental  
 
125 
2×CH=CHCO), 129.9 (d, 4JCF 3.3, 2×ArC(1)), 130.6 (d, 
3JCF 8.7, 4×ArC(2)), 147.3 
(2×CH=CHCO), 162.3 (2×CO), 164.4 (d, 1JCF 253.2, 2×ArC(4)); δF (300 MHz, CDCl3) 
108.1; m/z (FTMA+) 149 ([M-C9H6FO2]+, 100%), 315 ([M+H]+, 25%); HRMS (FTMS+) 
C18H13F2O3 ([M+H]
+) requires 315.0827, found 315.0831 (+1.2 ppm).  
(E)-3-(4-Methoxyphenyl)acrylic 3-(4-methoxyphenyl)propanoic anhydride (157) 
 
The title compound was prepared according to General Procedure B from 4-methoxycinnamic 
acid (891 mg, 5.00 mmol) and EDCI.HCl (959 mg, 5.00 mmol) in THF (20 mL) to give the 
homoanydride 157 as a white solid (442 mg, 52%); mp 116-119 °C {Lit.2 104-105 °C}; δH (400 
MHz, CDCl3) 3.86 (6H, s, ArOCH3), 6.39 (2H, d, J 15.8, ArCH=CH), 6.91-6.96 (4H, m, 
ArH), 7.50-7.57 (4H, m, ArH), 7.80 (2H, d, J 15.8, ArCH=CH). Data in agreement with the 
literature.147 
(E)-3-(Furan-2-yl)acrylic anhydride (163) 
 
The title compound was prepared according to General Procedure B from furylacrylic acid 
(690 mg, 5.00 mmol) and EDCI.HCl (959 mg, 5.00 mmol) in THF (10 mL) to give the 
homoanhydride 163 as a brown solid (485 mg, 75%); mp 68-71 C; max (film)/cm-1 3142 (C-
H), 3123 (C-H), 2965 (C-H), 2936 (C-H), 2909 (C-H), 2856 (C-H), 2818 (C-H), 1772 
(C=O), 1695 (C=O), 1624 (furan), 1555 (furan), 1474 (furan), 1226 (C-O); δH (300 MHz, 
CDCl3) 6.39 (2H, d, J 15.5, CH=CHCO), 6.53 (2H, dd, J 3.5, 1.8, furanylC(4)H), 6.75 (2H, 
d, J 3.5, furanylC(3)H), 7.55 (2H, d, J 1.7, furanylC(5)H), 7.58 (2H, d, J 15.5, CH=CHCO); 
δC (75 MHz, CDCl3) 112.9 (2×furanylC(4)), 114.3 (2×furanylC(3)), 117.1 (2×CH=CHCO), 
134.3 (2×CH=CHCO), 146.0 (2×furanylC(5)), 150.6 (2×furanylC(2)), 162.7 (2×C=O); m/z 
(NSI+) 297 ([M+K]+, 100%), 281 ([M+Na]+, 20%); HRMS (NSI+) C14H10O5Na
+ ([M+Na]+) 
requires 281.0420, found 281.0424 (+1.3 ppm). 
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(E)-3-(Thiophen-2-yl)acrylic anhydride (164) 
 
The title compound was prepared according to General Procedure B from thienylacrylic acid 
(770 mg, 5.00 mmol) and EDCI.HCl (959 mg, 5.00 mmol) in THF (10 mL) to give the 
homoanhydride 164 as a brown solid (522 mg, 72%); mp 86-88 C; max (film)/cm-1 2972 (C-
H), 1728 (C=O); 3069 (C-H), 3026 (C-H), 2966 (C-H), 1761 (C=O), 1694 (C=C), 1616 
(C=C), 1413 (C-O), 1236 (C-S-C); δH (300 MHz, CDCl3) 6.30 (2H, d, J 15.7, CH=CHCO), 
7.10 (2H, dd, J 5.0, 3.7, thienylC(4)H), 7.31-7.38 (2H, d, J 3.7, thienylC(3)H), 7.48 (2H, d, J 
5.0, 1.0, thienylC(5)H), 7.94 (2H, dt, J 15.7, 0.8, CH=CHCO); δC (75 MHz, CDCl3) 115.3 
(2×CH=CHCO), 128.6 (2×thienylC(4)), 130.3 (2×thienylC(5)), 132.7 (2×thienylC(3)), 
139.1 (2×thienylC(2)), 141.0 (2×CH=CHCO), 162.4 (2×C=O); m/z (ES+) 313 ([M+Na]+, 
100%); HRMS (ES+) C14H10O3NaS2
+ ([M+Na]+) requires 312.9961, found 312.9969 (2.6 
ppm). 
(E)-3-(3-Methylphenyl)acrylic anhydride (158) 
 
The title compound was prepared according to General Procedure B from 3-methylcinnamic 
acid (810 mg, 5.00 mmol) and EDCI.HCl (576 mg, 3.00 mmol) in CH2Cl2 (10 mL) to give 
the homoanhydride 158 as a white solid (582 mg, 76%); mp 61-64 C; max (film)/cm-1 2918 
(C-H), 1755 (C=O), 1697 (C=O), 1697 (C=C); δH (400 MHz, CDCl3) 2.39 (6H, s, CH3), 
6.52 (2H, d, J 15.9, CH=CHCO), 7.16-7.42 (8H, m, ArH), 7.83 (2H, d, J 15.9, 
CH=CHCO); δC (75 MHz, CDCl3) 21.5 (2×CH3), 116.4 (2×CH=CHCO), 126.0 
(2×ArC(6)H), 129.1 (2×ArC(2)H), 129.3 (2×ArC(4)H), 132.3 (2×ArC(5)H), 133.8 
(2×ArC(1)), 138.9 (2×ArC(3)), 149.0 (2×CH=CHCO), 162.7 (2×CO); m/z (ES+) 329 
([M+Na]+, 100%); HRMS (ES+) C20H18O3Na
+ ([M+Na]+) requires 329.1156, found 
329.1154 (+0.7 ppm). 
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(E)-3-(3-Chlorophenyl)acrylic anhydride (159) 
 
The title compound was prepared according to General Procedure B from 3-chlorocinnamic 
acid (732 mg, 4.00 mmol) and EDCI.HCl (461 mg, 2.40 mmol) in CH2Cl2 (20 mL) to give 
the homoanydride 159 as a white solid (389 mg, 56%); mp 96-99 C; max (film)/cm-1 3082 (C-
H), 1759 (C=O), 1632 (C=C), 1095 (C-Cl); δH (400 MHz, CDCl3) 6.52 (2H, d, J 15.9, 
CH=CHCO), 7.33-7.49 (6H, m, ArH), 7.57 (2H, t, J 1.7, ArH), 7.78 (2H, d, J 15.9, 
CH=CHCO); δC (100 MHz, CDCl3) 118.2 (2×CH=CHCO), 126.9 (2×ArCH), 128.4 
(2×ArCH), 130.5 (2×ArCH), 131.3 (2×ArCH), 135.3 (2×ArC), 135.6 (2×ArC), 147.2 
(2×CH=CHCO), 162.0 (2×C=O); m/z (ES+) 369 ([M+Na]+, 10%); HRMS (ES+) 
C18H12Cl
35
2O3Na
+ ([M+Na]+) requires 369.0065, found 369.0061 (+0.9 ppm). 
(E)-3-(2-Chlorophenyl)acrylic anhydride (S1) 
 
The title compound was prepared according to General Procedure B from 2-chlorocinnamic 
acid (913 mg, 5.00 mmol) and EDCI.HCl (576 mg, 3.0 mmol) in CH2Cl2 (20 mL) to give 
the homoanhydride S1 as a white solid (417 mg, 48%); mp 139-139 C; max (film)/cm-1 3082 
(C-H), 1759 (C=O), 1632 (C=C), 1078 (C-Cl); δH (400 MHz, CDCl3) 6.54 (2H, d, J 16.0, 
CH=CHCO), 7.30-7.40 (4H, m, ArH), 7.44-7.47 (2H, m, ArC(5)H), 7.68 (2H, dd, J 7.6, 1.7, 
ArC(6)H), 8.29 (2H, d, J 16.0, CH=CHCO); δC (100 MHz, CDCl3) 119.4 (2×CH=CHCO), 
127.4 (2×ArCH), 128.1 (2×ArCH), 130.5 (2×ArCH), 132.1 (2×ArCH), 132.2 (2×ArCCl), 
135.6 (2×ArC), 144.4 (2×CH=CHCO), 161.9 (2×CO); m/z (ES+) 369 ([M+Na]+, 50%); 
HRMS (ES+) C18H12Cl
35
2O3Na
+ ([M+Na]+) requires 369.0054, found 369.0061 (1.9 ppm). 
(E)-But-2-enoic anhydride (160) 
 
The title compound was prepared according to General Procedure B from crotonic acid (258 
mg, 3.00 mmol) and EDCI.HCl (576 mg, 3.00 mmol) in CH2Cl2 (6 mL) to give the 
homoanhydride 160 as a colourless oil (136 mg, 59%); δH (400 MHz, CDCl3) 1.95 (6H, dd, J 
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7.0, 1.7, CH3), 5.91 (2H, dq, J 15.5, 1.7, CH3CH=CH), 7.14 (2H, dq, J 15.5, 7.0, 
CH3CH=CH). Data in agreement with the literature.
148 
(E)-Hex-2-enoic anhydride (161) 
 
The title compound was prepared according to General Procedure B from trans-2-hexenoic 
acid (342 mg, 3.00 mmol) and EDCI.HCl (576 mg, 3.00 mmol) in CH2Cl2 (6 mL) to give 
the homoanhydride 161 as a colourless oil (171 mg, 54%); max (film)/cm-1 2962 (C-H), 2934 
(C-H), 2874 (C-H), 1780 (C=O), 1722 (C=O), 1645 (C=C); δH (300 MHz, CDCl3) 0.88 
(6H, t, J 7.4, CH3), 1.45 (4H, h, J 7.4, C(5)H2), 2.17 (4H, qd, J 7.2, 1.6, C(4)H2), 5.81 (2H, 
dt, J 15.6, 1.6, CH=CHCO), 7.06 (2H, dt, J 15.6, 7.0, CH=CHCO); δC (75 MHz, CDCl3) 
13.6 (2×CH3), 21.1 (2×C(5)H2), 34.5 (2×C(4)H2), 120.6 (2×CH=CHCO), 154.0 
(2×CH=CHCO), 162.1 (2×CO); m/z (NSI+) 228 ([M+NH4]
+, 100%); HRMS (NSI+) 
C12H22NO3
+ ([M+NH4]
+) requires 228.1594, found 228.1596 (+0.8 ppm). 
(E)-2-Bromocinnamic anhydride (S2) 
 
The title compound was prepared according to General Procedure B from (E)-2-
bromocinnamic acid (225 mg, 5.00 mmol) and EDCI.HCl (576 mg, 3.00 mmol) in CH2Cl2 
(10 mL) to give the homoanhydride S2 as a white solid (394 mg, 36%); mp 135–138 °C; max 
(film)/cm-1 2970 (C-H), 1759 (C=O), 1701 (C=O), 1624 (C=C); δH (500 MHz, CDCl3) 6.49 
(2H, d, J 15.9, ArCH=CH), 7.29 (2H, td, J 7.7, 1.7, ArC(3)H), 7.35 – 7.40 (2H, m, 
ArC(5)H), 7.66 (4H, ddd, J 9.1, 8.0, 1.5, ArC(4)H, ArC(6)H), 8.26 (2H, d, J 15.9, 
ArCH=CH); δC (126 MHz, CDCl3) 119.4 (2 × ArCH=CH), 125.9 (2 × ArC(1)Br), 127.9 (2 
× ArC(5)H), 128.1 (2 × ArC(3)H), 132.2 (2 × ArC(4)H), 133.7 (2 × ArC(6)H), 133.7 (2 × 
ArC(2)), 146.8 (2 × ArCH=CH), 161.7 (2 × CO); m/z (APCI+) 211 ([M–C9H6BrO2]
+, 
100%), 437 ([M+H]+, 60%), 454 ([M+NH4]
+, 80%); HRMS (APCI+) C18H13Br
79
2O3 
([M+H]+) requires 434.9226, found 434.9221 (–1.1 ppm). 
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(E)-3-Bromocinnamic anhydride (S3) 
 
The title compound was prepared according to General Procedure B from (E)-3-
bromocinnamic acid (7.95 g, 35.0 mmol) and EDCI.HCl (4.03 g, 21.0 mmol) in CH2Cl2 (50 
mL) to give the homoanhydride S3 as a white solid (4.75 g, 62%); mp 126–128 °C; max 
(film)/cm-1 3078 (C-H), 1755 (C=O), 1627 (C=C); δH (500 MHz, CDCl3) 6.51 (2H, d, J 
15.9, ArCH=CH), 7.31 (2H, t, J 7.9, ArC(5)H), 7.50 (2H, dt, J 7.8, 1.3 ArC(6)H), 7.57 (2H, 
ddd, J 8.0, 2.0, 1.0, ArC(4)H), 7.73 (2H, t, J 1.8, ArC(2)H), 7.77 (2H, d, J 15.9, ArCH=CH); 
δC (75 MHz, CDCl3) 118.2 (2 × ArCH=CH), 123.4 (2 × ArC(1)Br), 127.3 (2 × ArC(4)H), 
130.7 (2 × ArC(5)H), 131.3 (2 × ArC(6)H), 134.2 (2 × ArC(2)H), 135.8 (2 × ArC(2)), 147.1 
(2 × ArCH=CH), 162.0 (2 × CO); m/z (APCI+) 211 ([M–C9H6BrO2]
+, 100%), 437 
([M+H]+, 6055%), 454 ([M+NH4]
+, 75%); HRMS (APCI+) C18H13Br
79
2O3 ([M+H]
+) 
requires 434.9226, found 434.9223 (–0.7 ppm). 
 (2E)-3-(Furan-3-yl)prop-2-enoic anhydride (S4) 
 
The title compound was prepared according to General Procedure B from (2E)-3-(furan-3-
yl)prop-2-enoic acid (1.38 g, 10.0 mmol) and EDCI.HCl (1.15 g, 6.00 mmol) in THF (10 
mL) to give the homoanhydride S4 as a brown solid (0.87 g, 67%); mp 109–110 °C; max 
(film)/cm-1 3125 (C-H), 1775 (C=O), 1632 (C=C); δH (500 MHz, CDCl3) 6.22 (2H, d, J 
15.7, ArCH=CH), 6.63 (2H, d, J 2.0, ArC(4)H), 7.47 (2H, d, J 1.8, ArC(5)H), 7.73 (2H, s, 
ArC(2)H), 7.74 (2H, d, J 15.7, ArCH=CH); δC (75 MHz, CDCl3) 107.5 (2 × furylC(4)H), 
116.6 (2 × ArCH=CH), 122.6 (2 × furylC(3)), 138.7 (2 × furylC(2)H), 145.0 (2 × 
furylC(5)H), 145.9 (2 × ArCH=CH), 162.6 (2 × CO); m/z (APCI+) 121 ([M–C7H5O3]
+, 
100%), 259 ([M+H]+, 35%), 276 ([M+NH4]
+, 30%); HRMS (APCI+) C14H11O5 ([M+H]
+) 
requires 259.0601, found 259.0596 (–1.9 ppm). 
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 (2E)-3-(Thiophen-3-yl)prop-2-enoic anhydride (S5) 
 
The title compound was prepared according to General Procedure Bfrom (2E)-3-(thiophen-3-
yl)prop-2-enoic acid (1.54 g, 10.0 mmol) and EDCI.HCl (1.15 g, 6.00 mmol) in THF (10 
mL) to give the homoanhydride S5 as a brown solid (1.16 g, 80%); mp 102–105 °C; max 
(film)/cm-1 3097 (C-H), 1771 (C=O), 1620 (C=C); δH (500 MHz, CDCl3) 6.33 (2H, d, J 
15.8, ArCH=CH), 7.34 (2H, dd, J 5.1, 1.3, ArC(4)H), 7.38 (2H, dd, J 5.2, 2.9, ArC(5)H), 
7.61 (2H, dd, J 3.0, 1.3, ArC(2)H), 7.82 (2H, d, J 15.8, ArCH=CH); δC (126 MHz, CDCl3) 
116.4 (2 × ArCH=CH), 125.3 (2 × thiopheneC(5)H), 127.6 (2 × thiopheneC(4)H), 130.2 (2 
× thiopheneC(2)H), 137.1 (2 × thiopheneC(3)), 142.0 (2 × ArCH=CH), 162.9 (2 × CO); 
m/z (APCI+) 137 ([M–C7H5O2S]
+, 100%), 291 ([M+H]+, 30%), 308 ([M+NH4]
+, 55%); 
HRMS (APCI+) C14H11O3S2 ([M+H]
+) requires 291.0144, found 291.0140 (–1.4 ppm). 
 (E)-2,4,6-Trimethylcinnamic anhydride (S6) 
 
The title compound was prepared according to General Procedure B from (E)-2,4,6-
trimethylcinnamic acid (2.85 g, 15.0 mmol) and EDCI.HCl (1.73 g, 9.00 mmol) in CH2Cl2 
(20 mL) to give the homoanhydride S6 as a pale brown solid (1.34 g, 49%); mp 131–133 °C; 
max (film)/cm-1 2859 (C-H), 1757 (C=O), 1605 (C=C); δH (300 MHz, CDCl3) 2.30 (6H, s, 
ArC(4)CH3), 2.38 (12H, s, ArC(2,6)CH3), 6.18 (2H, d, J 16.3, ArCH=CH), 6.88 – 6.95 (4H, 
m, ArC(3,5)H), 8.06 (2H, d, J 16.3, ArCH=CH); δC (126 MHz, CDCl3) 21.2 (2 × 
ArC(4)CH3), 21.4 (4 × ArC(2)CH3), 121.5 (2 × ArCH=CH), 129.6 (4 × ArC(3)H), 130.2 (2 
× ArC(1)), 137.5 (4 × ArC(2)CH3), 139.5 (2 × ArC(4)CH3), 147.3 (2 × ArCH=CH), 162.7 
(2 × CO); m/z (APCI+) 173 ([M–C12H13O2]
+, 100%), 363 ([M+H]+, 5%), 380 ([M+NH4]
+, 
20%); HRMS (APCI+) C24H27O3 ([M+H]
+) requires 363.1955, found 363.1951 (–1.0 ppm). 
 (E)-4,4,4-Trifluoro-3-methylbut-2-enoic anhydride (309) 
 
The title compound was prepared according to General Procedure B from (E)-4,4,4-trifluoro-
3-methylbut-2-enoic acid (2.31 g, 15.0 mmol) and EDCI.HCl (1.73 g, 9.00 mmol) in 
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CH2Cl2 (25 mL) to give the homoanhydride 309 as a pale yellow oil
xix (1.33g, 60%); max 
(film)/cm-1 2642 (C-H), 1707 (C=O), 1292 (C-F); δH (500 MHz, CDCl3) 2.32 (3H, d, J 1.6, 
2 × CH3), 6.33 (1H, dt, J 3.0, 1.6, 2 × C=CH); δC (126 MHz, CDCl3) 13.1 (2 × CH3), 
119.63 (q, 3JCF 5.8, 2 × C=CH), 122.67 (q, 
1JCF 274.8, 2 × CF3), 147.78 (q, 
2JCF 31.0, 2 × 
C=CH), 159.40 (2 × CO); δF (471 MHz, CDCl3) -71.63; m/z (APCI
+) 137 ([M–C5H4F3O2]
+, 
75%), 221 (unknown degradation peak, 100%), 291 ([M+H]+, 75%); HRMS (APCI+) 
C10H9F6O3 ([M+H]
+) requires 291.0450 found 291.0445 (–1.9 ppm). 
 (E)-2-Methylbut-2-enoic anhydride (S7) 
 
The title compound was prepared according to General Procedure B from (E)-2-methylbut-2-
enoic acid (500 mg, 5.00 mmol) and EDCI.HCl (576 mg, 3.00 mmol) in CH2Cl2 (10 mL) to 
give the homoanhydride S7 as a pale yellow oil (205 mg, 45%); δH (500 MHz, CDCl3) 1.84 
(3H, dd, J 7.2, 1.3, C(3)CH3), 1.86 (3H, d, J 1.3, C(2)CH3), 6.97 (1H, dddd, J 8.5, 7.1, 5.7, 
1.4, C(3)H). Data in agreement with the literature.149 
2-Cyclohexylideneacetic anhydride (307) 
 
The title compound was prepared according to General Procedure B from 2-
cyclohexylideneacetic acid (1.40 g, 10.0 mmol) and EDCI.HCl (1.15 g, 6.00 mmol) in 
CH2Cl2 (20 mL) to give the homoanhydride 307 as a colourless oil (0.59 g, 45%); max (film) 
/cm-1 2926 (C-H), 2855 (C-H), 1776 (C=O), 1676 (C-O), 1630 (C=C); δH (400 MHz, 
CDCl3) 1.48 – 1.73 (12H, m, 6 × CH2), 2.20 – 2.28 (4H, m, 4 × CH2C=CH), 2.77 – 2.88 
(4H, m, 4 × CH2C=CH), 5.53 – 5.74 (2H, m, 2 × C=CH); δC (101 MHz, CDCl3) 26.2 (2 × 
CH2), 27.3 (2 × CH2), 28.4 (2 × CH2), 30.4 (2 × CH2), 38.3 (2 × CH2C=CH), 112.3 (2 × 
CH2C=CH), 162.2 (2 × C=CH), 169.7 (2 × C=O); m/z (APCI
+) 123 ([M–C8H11O2]
+, 
100%), 263 ([M+H]+, 40%), 280 ([M+NH4]
+, 45%); HRMS (APCI+) C16H23O3 ([M+H]
+) 
requires 263.1642, found 263.1637 (–1.8 ppm). 
  
                                                 
xix xix The product was approximately 80% pure and used without further purification 
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 (2E)-3-Phenylbut-2-enoic anhydride (306) 
 
The title compound was prepared according to General Procedure B from (2E)-3-phenylbut-
2-enoic acid (3.24 g, 20.0 mmol) and EDCI.HCl (2.30 g, 12.0 mmol) in CH2Cl2 (50 mL) to 
give the homoanhydride 306 as a pale yellow oil (1.77 g, 58%); max (film) /cm-1 2922 (C-H), 
2852 (C-H), 1771 (C=O), 1709 (C-O), 1609 (C=C); δH (500 MHz, CDCl3) 2.66 (6H, d, J 
1.3, CH3), 6.19 (2H, d, J 1.3, C=CH), 7.38 – 7.44 (6H, m, PhC(2)H, PhC(4)H), 7.49 – 7.53 
(4H, m, PhC(3)H); δC (126 MHz, CDCl3) 18.8 (2 × CH3), 115.9 (2 × C=CH), 126.6 (4 × 
ArC(2)H), 128.8 (4 × ArC(3)H), 129.9 (2 × ArC(4)H), 141.7 (2 × ArC(1)), 161.4 (2 × CO), 
162.3 (2 × C=CH); m/z (APCI+) 145 ([M–C10H9O2]
+, 80%), 307 ([M+H]+, 5%), 324 
([M+NH4]
+, 10%), 318 (unknown product, 100%); HRMS (APCI+) C20H19O3 ([M+H]
+) 
requires 307.1329, found 307.1326 (–0.9 ppm). 
3-Methylbut-2-enoic anhydride (304) 
 
The title compound was prepared according to General Procedure B from 3-methylbut-2-
enoic acid (2.00 g, 20.0 mmol) and EDCI.HCl (2.30 g, 12.0 mmol) in CH2Cl2 (50 mL) to 
give the homoanhydride 304 as a colourless oil (0.71 g, 39%); δH (500 MHz, CDCl3) 1.93 (3H, 
d, J 1.5, CH3), 2.19 (3H, d, J 1.5, CH3), 5.68 (1H, h, J 1.4, C=CH). Data in agreement with 
the literature.150 
(E)-4-Ethoxy-4-oxobut-2-enoic anhydride (S8) 
 
The title compound was prepared according to General Procedure B from (E)-4-ethoxy-4-
oxobut-2-enoic acid (1.44 g, 10.0 mmol) and EDCI.HCl (1.15 g, 6.00 mmol) in CH2Cl2 (20 
mL) to give the homoanhydride S8 as a brown oil (795 mg, 59%); max (film) /cm-1 2986 (C-
H), 1798 (C=O), 1721 (C=O); δH (500 MHz, CDCl3) 1.33 (6H, t, J 7.2, CH3), 4.29 (4H, q, J 
7.2, CH2CH3), 6.87 (2H, d, J 15.7, CO2EtCH=CH), 6.98 (2H, d, J 15.8, CO2EtCH=CH); δC 
(75 MHz, CDCl3) 14.2 (2 × CH3), 62.0 (2 × CH2), 131.4 (2 × EtO2C-CH=CH), 137.5 (2 × 
EtO2C-CH=CH), 159.7 (2 × =CHCO), 164 (2 × CO2Et); m/z (APCI
+) 127 ([M–C6H7O4]
+, 
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35%), 271 ([M+H]+, 5%), 288 ([M+NH4]
+, 100%); HRMS (APCI+) C12H18NO7 
([M+NH4]
+) requires 288.1078, found 288.1074 (–1.3 ppm). 
 (E)-3,7-Dimethylocta-2,6-dienoic anhydride (E,E)-308 
 
The title compound was prepared according to General Procedure B from (2E)-3,7-
dimethylocta-2,6-dienoic acid (840 mg, 5.00 mmol) and EDCI.HCl (576 mg, 3.00 mmol) in 
CH2Cl2 (10 mL) to give the homoanhydride (E,E)-308 as a colourless oilxx (492 mg, 62%); 
max (film) /cm-1 2968 (C-H), 2916 (C-H), 2857 (C-H), 2359 (C-H), 2342 (C-H), 1778 
(C=O), 1716 (C-O), 1634 (C=C); δH (400 MHz, CDCl3) 1.61 (6H, d, J 1.4, C(7)CH3(CH3)), 
1.69 (6H, d, J 1.5, C(7)CH3(CH3)), 2.14 – 2.25 (14H, m, C(3)CH3, C(4)H2, C(5)H2), 5.03 – 
5.10 (2H, m, C(6)H), 5.67 – 5.72 (2H, m, C(2)H); δC (101 MHz, CDCl3) 17.8 (2 × CH3), 
19.6 (2 × CH3), 25.1 (2 × CH3), 26.0 (2 × CH2), 41.3 (2 × CH2), 114.9 (2 × C(2)H), 122.7 
(2 × C(6)H), 132.9 (2 × C(7)), 162.2 (2 × C(1)O), 166.1 (2 × C(3)); m/z (APCI+) 151 ([M–
C10H15O2]
+, 75%), 336 ([M+NH4]
+, 30%); HRMS (APCI+) C20H34NO3 ([M+NH4]
+) requires 
336.2533, found 336.2528 (–1.5 ppm). 
(Z)-3,7-Dimethylocta-2,6-dienoic anhydride (R,R)-308 
 
The title compound was prepared according to General Procedure B from (2Z)-3,7-
dimethylocta-2,6-dienoic acid (840 mg, 5.00 mmol) and EDCI.HCl (576 mg, 3.00 mmol) in 
CH2Cl2 (20 mL) to give the homoanhydride (R,R)-308 as a colourless oilxxi (490 mg, 62%); 
max (film) /cm-1 2970 (C-H), 2914 (C-H), 2859 (C-H), 2359 (C-H), 2342 (C-H), 1776 
(C=O), 1717 (C-O), 1632 (C=C); δH (400 MHz, CDCl3) 1.62 (6H, d, J 1.5, C(7)CH3(CH3)), 
1.68 (6H, d, J 1.5, C(7)CH3(CH3)), 1.95 (6H, d, J 1.4, C(3)CH3), 2.13 – 2.23 (4H, m, CH2), 
2.61 – 2.71 (4H, m, CH2), 5.10 – 5.17 (2H, m, C(6)H), 5.65 – 5.70 (2H, m, C(2)H); δC (101 
MHz, CDCl3) 17.7 (2 × CH3), 25.9 (2 × CH3), 26.7 (2 × CH2), 34.1 (2 × CH2), 43.7 (2 × 
CH2), 115.4 (2 × C(2)H), 123.4 (2 × C(6)H), 132.6 (2 × C(7)), 161.6 (2 × C(1)O), 166.6 (2 
                                                 
xx The product was approximately 80% pure and used without further purification 
xxi The product was approximately 90% pure and used without further purification. 
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× C(3)); m/z (APCI+) 151 ([M–C10H15O2]
+, 100%), 336 ([M+NH4]
+, 10%); HRMS (APCI+) 
C20H34NO3 ([M+NH4]
+) requires 336.2533, found 336.2526 (–2.4 ppm). 
 (Z)-Cinnamic anhydride (210) 
 
The title compound was prepared according to General Procedure B from (Z)-cinnamic acid 
(318 mg, 2.15 mmol) and EDCI.HCl (206 mg, 1.07 mmol) in CH2Cl2 (10 mL) to give the 
homoanhydride 210 as a white gumxxii (169 mg, 56%); max (film)/cm-1 2963 (C-H) , 1778 
(C=O), 1717 (C=O), 1616 (C=C), 1020 (C-O); δH (400 MHz, CDCl3) 5.85 (2H, d, J 12.5, 
ArCH=CH), 7.11 (2H, d, J 12.5, ArCH=CH), 7.32-7.42 (6H, m, ArH), 7.56-7.71 (4H, m, 
ArH); δC (100 MHz, CDCl3) 117.8 (2×ArCH=CH), 126.3 (4×ArCH), 130.0 (2×ArCH), 
130.2 (4×ArCH), 134.2 (2×ArC), 147.9 (2×ArCH=CH), 161.4 (2×CO); m/z (ES+) 301 
([M+Na]+, 100%); HRMS (ES+) C18H14O3Na
+ ([M+Na]+) requires 301.0841, found 
301.0840 (0.3 ppm). 
E)-4-Methylpent-2-enoic anhydride (162) 
 
The title compound was prepared according to General Procedure B from 4-methyl-pentenoic 
acid (570 mg, 5.00 mmol) and EDC.HCl (959 mg, 5.00 mmol) in CH2Cl2 (10 mL) to give 
the homoanyhdride 162 as a colourless oil (194 mg, 37%); δH (400 MHz, CDCl3) 1.09 (12H, d, 
J 6.8, CH(CH3)2), 2.51 (2H, dpd, J 13.4, 6.8, 1.5, CH(CH3)2), 5.83 (2H, dd, J 15.7, 1.5, 
CH=CHCO), 7.11 (2H, dd, J 15.7, 6.6, CH=CHCO); δC (101 MHz, CDCl3) 21.13 
(CH(CH3)2), 31.47 (CH(CH3)2), 118.01 (CH=CHCO), 160.21 (CH=CHCO), 162.61 
(CHC(O)O). Data in agreement with the literature.151 
 
6.4 Nucleophiles 
General Procedure C: Diketone Synthesis 
 
                                                 
xxii The product was approximately 90% pure and used without further purification. 
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To a solution of arylketone (1.0 equiv) in THF (10 mL) at 78 °C was added LiHMDS (1.0 
M in THF, 1.5 equiv) over 15 min and the resulting mixture stirred at 78 °C for 1 h. Acid 
chloride (1.2 equiv) was added dropwise as a solution in THF (2 mL) at 78 °C over 5 min 
and the solution warmed to room temperature over 1 h and stirred for a further 17 h. The 
reaction was quenched with 10% citric acid (20 mL) and extracted with EtOAc (2 × 100 
mL). The combined organics were washed with H2O (20 mL), dried over anhydrous 
MgSO4, filtered and concentrated in vacuo. Purification of the residue by chromatography 
gave the diketone. 
1,3-bis(Furan-2-yl)propane-1,3-dione (179) 
 
The title compound was prepared according to General Procedure C from 2-acetylfuran (550 
mg, 5.00 mmol), furoyl chloride (590 μL, 6.00 mmol) and LiHMDS (1.0 M in THF, 7.50 
mL, 7.50 mmol) and purified by chromatography (20% Et2O/petrol) to afford diketone 179 
as a pale-yellow solid (443 mg, 43% yield); mp 73-74 °C {Lit. 74-75 °C}; (400 MHz, 
CDCl3) 6.59 (2H, dd, J 3.5, 1.7, Ar(4)H), 6.62 (1H, s, =CH), 7.21 (2H, dd, J 3.5, 0.8, 
Ar(3)H), 7.62 (2H, dd, J 1.7, 0.8, Ar(5)H). Data in agreement with the literature.152 
Compound synthesised by Dr Charlene Fallan. 
1,3-bis(4-Bromophenyl)propane-1,3-dione (181) 
 
The title compound was prepared according to General Procedure C from 4-
bromoacetophenone (995 mg, 5.00 mmol), 4-bromobenzoyl chloride (1.31 g, 6.00 mmol) 
and LiHMDS (1 M in THF, 7.50 mL, 7.50 mmol) and purified by chromatography (20% 
Et2O/petrol) to afford the diketone 181 as a pale-yellow powder (550 mg, 29% yield); mp 
185-186 °C {Lit. 185-186 °C};(400 MHz, CDCl3) 6.79 (1H, s, =CH), 7.64 (4H, d, J 8.7, 
Ar(3)H), 7.85 (4H, d, J 8.7, Ar(2)H). Data in agreement with the literature.153 Compound 
synthesised by Dr Charlene Fallan. 
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1,3-bis(4-Methylphenyl)propane-1,3-dione (180) 
 
The title compound was prepared according to General Procedure C from 4-
methylacetophenone (671 mg, 5.00 mmol), 4-toluoyl chloride (928 mg, 6.00 mmol) and 
LiHMDS (1 M in THF, 7.50 mL, 7.50 mmol) and purified by chromatography (20% 
Et2O/petrol) to afford diketone 180 as a pale-yellow solid (499 mg, 40% yield); mp 125-126 
°C {Lit. 127-127.4 °C};(400 MHz, CDCl3) 2.44 (6H, s, 2 × ArCH3), 6.83 (1H, s, =CH), 
7.30 (4H, d, J 8.0, Ar(3)H), 7.90 (4H, dd, J 8.2, Ar(2)H). Data in agreement with the 
literature.154 Compound synthesised by Dr Charlene Fallan. 
1,3-bis(4-Trifluoromethylphenyl)propane-1,3-dione (182) 
 
The title compound was prepared according to General Procedure C from 4-
trifluoromethylacetophenone (640 mg, 5.00 mmol), 4-trifluoromethylbenzoyl chloride (1.25 
g, 6.00 mmol) and LiHMDS (1.0 M in THF, 7.50 mL, 7.50 mmol) and purified by 
chromatography (20% Et2O/petrol) to afford diketone 182 as a yellow solid (207 mg, 12% 
yield); mp 125-126 °C(400 MHz, CDCl3) 6.89 (1H, s, =CH), 6.83 (1H, s, =CH), 7.78 
(4H, d, J 8.2, Ar(3)H), 8.11 (4H, d, J 8.1, Ar(2)H). Data in agreement with the literature.155 
Compound synthesised by Dr Charlene Fallan. 
General Procedure D: Benzazole Synthesis with NaHMDS 
 
To a degassed solution of chlorobenzazole (1 equiv) and carbonyl nucleophile (3 equiv) in 
dry toluene (xx mL) was added NaHMDS (3.0 eq, xx M solution in toluene or THF) 
dropwise at 0 oC, and the solution stirred for 5 h at 0 oC followed by room temperature for 
16 h. Excess NaHMDS was quenched by dropwise addition of saturated aqueous NH4Cl 
(50 mL) at 0 oC. The organic layer was separated, then the aqueous layer extracted with 
EtOAc (2 × xx mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The residue was as specified to afford the product.  
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2-Phenacylbenzothiazole (227) 
 
The title compound was prepared according to General Procedure D from 2-
chlorobenzothiazole (2.62 mL, 20.0 mmol) and acetophenone (6.99 mL, 60.0 mmol) in dry, 
degassed toluene (60 mL), with NaHMDS (30 mL, 2 M in THF, 12.0 mmol) and purified by 
trituration with cold hexane to give the azaarylketone 227 as a yellow-brown solid (4.76 g, 
94%); mp 115–117 °C {Lit.9  113–114 °C}; δH (400 MHz, CDCl3) 4.85 (2H, s, keto-CH-
2COAr), 6.38 (1H, s, enol-CHCOHAr), 7.31 (1H, t, J 7.6, enol-benzothiazoleC(6)H), 7.39 
(1H, t, J 7.5, enol-benzothiazoleC(6)H), 7.42 – 7.52 (6H, m, ArH), 7.51 (1H, t, J 7.7, enol-
benzothiazoleC(5)H), 7.62 (1H, t, J 7.4, keto-benzothiazoleC(5)H), 7.79 (1H, d, J 7.9, enol-
benzothiazoleC(4)H), 7.82 (1H, d, J 8.2, enol-benzothiazoleC(7)H)), 7.88 (3H, m, keto-
benzothiazoleC(4)H, enol-phenacylC(2’)H), 8.02 (1H, d, J 8.0, keto-benzothiazoleC(7)H), 
8.10 (2H, d, J 7.5 keto-phenacylC(2’)H). Data in agreement with the literature.156 
2-(1,3-Benzothiazol-2-yl)-N,N-dimethylacetamide (256) 
 
The title compound was prepared according to General Procedure D from 2-
chlorobenzothiazole (521 μL, 4.00 mmol) and N,N-dimethylacetamide (1.12 mL, 12.0 
mmol) in dry, degassed toluene (15 mL), with NaHMDS (6 mL, 2 M in THF, 12.0 mmol) to 
give the azaarylamide 256 after aqueous work up as a white solid, no further purification 
required (875 mg, 99%); mp 98–100 C {Lit.96  92–93 °C}; δH (300 MHz, CDCl3) 2.88 (3H, 
s, NCH3CH3), 2.98 (3H, s, NCH3CH3), 4.11 (2H, s, CH2CO), 7.24 (1H, ddd, J 8.4, 7.3, 1.2, 
benzothiazoleC(6)H), 7.34 (1H, ddd, J 8.1, 7.2, 1.2, benzothiazoleC(5)H), 7.74 (1H, ddd, J 
7.9, 1.3, 0.6, benzothiazoleC(4)H), 7.88 (1H, ddd, J 8.2, 1.1, 0.6, benzothiazoleC(7)H). Data 
in agreement with the literature.96 
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tert-Butyl 2-(1,3-benzothiazol-2-yl)acetate (257) 
 
The title compound was prepared according to General Procedure D from 2-
chlorobenzothiazole (521 μL, 4.00 mmol) and tert-butylacetate (1.61 mL, 12.0 mmol) in dry, 
degassed toluene (15 mL), with NaHMDS (20 mL, 0.6 M in toluene, 12.0 mmol) and 
purified by chromatography (10% hexane/CH2Cl2) to give the azarylacetate 257 as an off-
white solid (876 mg, 88%); mp 69–72 C {Lit.102  (oil)}; δH (300 MHz, CDCl3) 1.50 (9H, s, 
C(CH3)3), 4.10 (2H, s, CH2CO), 7.38 (1H, ddd, J 7.8, 7.5, 1.2, benzothiazoleC(6)H), 7.47 
(1H, ddd, J 7.8, 7.5, 1.5, benzothiazoleC(5)H), 7.87 (1H, ddd, J 8.0, 1.2, 0.6, 
benzothiazoleC(4)H), 8.00 (1H, ddd, J 8.0, 1.2, 0.6, benzothiazoleC(7)H). Spectroscopic 
data in agreement with the literature.102 
2-(1,3-Benzoxazol-2-yl)-N,N-dimethylacetamide (258) 
 
A degassed solution of N,N-dimethylacetamide (5.56 mL, 60.0 mmol) in dry toluene (150 
mL) was cooled to –78 oC. To this flask a solution of 2-chlorobenzoxazole (4.18 mL, 20.0 
mmol) in dry toluene (20 mL) was added via syringe pump over 5 h at –78 oC (slow 
addition required to minimise double nucleophile addition). The flask was warmed to room 
temperature for 20 mins then quenched by addition of saturated aqueous NH4Cl (150 mL). 
The organic layer was separated, then the aqueous layer was extracted with EtOAc (2 × 
100 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated 
in vacuo. The crude was purified by column chromatography (10% EtOAc/CH2Cl2→5% 
MeOH/CH2Cl2) to give the the azaarylamide 258 as an off-white solid (1.39 g, 34%); mp 
136–137 °C; max (film)/cm
-1 2938 (C-H), 1645 (C=O), 1614 (benzoxazole), 1271 
(benzoxazole), 1258 (benzoxazole); δH (500 MHz, CDCl3) 3.00 (3H, s, CH3), 3.12 (3H, s, 
CH3), 4.06 (2H, s, CH2), 7.27 – 7.35 (2H, m, benzoxazoleC(5)H, benzoxazoleC(6)H), 7.49 
– 7.54 (1H, m, benzoxazoleC(7)H), 7.66 – 7.72 (1H, m, benzoxazoleC(4)H); δC (126 MHz, 
CDCl3) 35.0 (CH2) 35.7 (CH3), 37.8 (CH3), 110.6 (benzoxazoleC(7)H), 119.8 
(benzoxazoleC(4)H), 124.3 (benzoxazoleC(6)H), 124.9 (benzoxazoleC(5)H), 141.1 
(benzoxazoleC(4a)), 151.1 (benzoxazoleC(7a)), 160.8 (benzoxazoleC(2)), 166.1 (C=O); m/z 
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(NSI+) 205 ([M+H]+, 100%), 227 ([M+Na]+, 15%); HRMS (NSI+) C11H13N2O2 ([M+H]
+) 
requires 205.0972, found 205.0970 (–0.8 ppm). 
General Procedure E: Benzazole Synthesis via Diesters 
 
To a solution of methylbenzazole (1 equiv) and acyl chloride (2.5 equiv) in HPLC grade 
acetonitrile stored over molecular sieves (0.6-2.5 M) was added NEt3 (2.5 equiv) and the 
solution stirred for 18 h at reflux. On cooling, the double addition ester was isolated by 
filtration and used immediately without purification. The ester was hydrolysed as specified 
and the product could be isolated by filtration or aqueous work up. 
2-(1,3-Benzothiazol-2-yl)-1-(4-nitrophenyl)ethanone (255) 
 
The title compound was prepared according to General Procedure E from 2-
methylbenzothiazole (1.27 mL, 10.0 mmol), 4-nitrobenzoyl chloride (4.08 g, 22.0 mmol)) 
and NEt3 (3.05 mL, 22.0 mmol) in HPLC grade acetonitrile (10 mL) to give the ester as a 
yellow solid which was used immediately. Heating the ester at reflux in a mixture of DMF 
(15 mL) and 1-butanol (15 mL) for 16 h gave the azaarylketone 255 after filtration as an 
orange solid (2.32 g, 78%); mp 212–214 °C (dec); max (film)/cm-1 3080 (C-H), 2827 (C-H), 
1610 (C=O), 1572 (C=C, aromatic), 1518 (NO2), 1456 (C=C, heteroaromatic), 1340 (NO2), 
1110 (C-N); δH (300 MHz, DMSO-d6) 6.86 (1H, s, enol-CH=COH), 7.22 (1H, dt, J 7.9, 4.4, 
benzothiazoleC(6)H), 7.41 (1H, d, J 3.6, benzothiazoleC(4)H), 7.41–7.56 (1H, m, 
benzothiazoleC(5)H), 7.84 (1H, d, J 7.8, benzothiazoleC(7)H), 8.11 (2H, d, J 8.7, 
(C6H4NO2)C(2)H), 8.31 (2H, d, J 8.7, (C6H4NO2)C(3)H); δC (75 MHz, DMSO) 87.7 (enol-
CH=COH), 112.0 (benzothiazoleC(4)H), 122.6 (benzothiazoleC(6)H), 122.8 
(benzothiazoleC(7)H), 123.8 (2 × (C6H4NO2)C(3)H) 126.3 (benzothiazoleC(7a)), 127.0 
(benzothiazoleC(5)H), 127.9 (2 × (C6H4NO2)C(2)H), 138.7 (benzothiazoleC(4a)), 144.8 
(C6H4NO2)C(4)), 148.4 (C6H4NO2)C(1)), 163.6 (benzothiazoleC(2)), 179.8 (enol-CH=COH); 
m/z (NSI+) 299 ([M+H]+, 100%); HRMS (NSI+) C15H11O3N2S ([M+H]
+) requires 299.0485, 
found 299.0484 (–0.3 ppm). 
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2-Phenacylbenzoxazole (250) 
 
The title compound was prepared according to General Procedure E from 2-
methylbenzoxazole (4.76 mL, 40.0 mmol), benzoyl chloride (20.4 mL, 120 mmol) and NEt3 
(19.96 mL, 144 mmol) in HPLC grade acetonitrile (200 mL). The actonitrile was removed 
in vacuo then the crude dissolved in CH2Cl2 (100 mL). The organic layer was washed with 
saturated aqueous NaHCO3 solution, dried over MgSO4, filtered, and concentrated in vacuo 
to reveal the ester as a brown oil that was used without further purification. The crude ester 
was dissolved in methanol (100 mL), solid KOH (5.6 g, 100.0 mmol) was added 
portionwise and the flask was stirred at room temperature for 20 h. The methanol was 
removed in vacuo then the residue dissolved in CH2Cl2 and acidified using 2 M HCl. The 
aqueous layer was separated and the organic layer washed with saturated aqueous NaHCO3, 
dried over MgSO4, filtered and concentrated in vacuo. The crude was purified by column 
chromatography (5% EtOAc/petrol ether) followed by recrystallisation from ethanol to 
give the the azaarylketone 250 as an off-white solid (6.24 g, 67%); mp 90–92 C {Lit.157 87–
89 °C}; δH (300 MHz, CDCl3) 4.66 (2H, s, keto- CH2-CO), 6.22 (1H, s, enol-CH=COH), 
7.27 – 7.39 (4H, m, br, ArH), 7.41 – 7.56 (7H, m, br, ArH), 7.62 (2H, s, br, ArH), 7.72 (1H, 
s, br, ArH), 7.89 (2H, s, br, ArH), 8.01 – 8.09 (2H, m, br, PhC(2)H). Data in agreement 
with the literature.157  
2-Phenacylbenzimidazole (254) 
 
The title compound was prepared according to General Procedure E from 2-
methylbenzimidazole (6.61 g, 50.0 mmol), benzoyl chloride (19.2 mL, 165 mmol)) and 
NEt3 (22.9 mL, 165 mmol) in HPLC grade acetonitrile (20 mL) to give the ester as a yellow 
solid which was used immediately. Heating the ester at reflux in isopropylalcohol (50 mL) 
for 3 h gave the azaarylketone 254 after filtration as a yellow solid as a 1:4 mixture of 
enamino:keto tautomers (6.54 g, 55%); mp 176–178 C {Lit.101  178–179 °C}; δH (300 
MHz, DMSO-d6) 4.69 (2H, s, keto-CH2CO), 6.11 (1H, s, enamino-CHCO), 7.12 – 7.21 (4H, 
m, benzimidazoleC(5)H and benzimidazoleC(6)H), 7.38 – 7.60 (9H, m, ArH), 7.62 – 7.72 
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(1H, m, keto-phenylC(4)H), 7.83 – 7.92 (2H, m, 2 × enamino-phenylC(2)H), 8.04 – 8.13 (2H, 
m, 2 × keto-phenylC(2)H), 12.31 (1H, s, NH). Data in agreement with the literature.101 
1-Methyl-2-phenacylbenzimidazole (249) 
 
The title compound was prepared according to General Procedure E from 1,2-
dimethylbenzimidazole (1.46 g, 10.0 mmol), benzoyl chloride (2.55 mL, 22.0 mmol) and 
NEt3 (3.05 mL, 22.0 mmol) in HPLC grade acetonitrile (10 mL) to give the ester as a yellow 
solid which was used immediately. Heating the ester at reflux with KOH (0.62g, 11.0 
mmol) and ethanol (10 mL) gave the azaarylketone 249 after filtration as an off-white solid 
(1.63 g, 65%); mp 138–140 C {Lit.101  134–134.5 °C}; δH (300 MHz, DMSO-d6) 3.72 (3H, 
s, keto-NCH3), 3.77 (3H, s, enamino-NCH3), 4.86 (2H, s, keto-CH2-CO), 6.30 (1H, s, enamino- 
=CH-CO), 7.13 – 7.29 (2H, m, benzimidazoleC(5)H, benzimidazoleC(6)H), 7.41 – 7.53 
(4H, m, PhC(3)H, PhC(4)H, benzimidazoleC(7)H), 7.53 – 7.63 (3H, m, PhC(3)H, 
benzimidazoleC(4)H), 7.61 – 7.75 (1H, m, PhC(4)H), 7.93 – 8.07 (2H, m, PhC(2)H), 8.11 
(2H, d, J 7.3, PhC(2)H). Data in agreement with the literature.101  
tert-butyl 2-(2-oxo-2-phenylethyl)-1,3-benzodiazole-1-carboxylate (S9) 
 
To a solution of 2-phenacylbenzimidazole (4.73 g, 20.0 mmol) in dry CH2Cl2 (10 mL) was 
added NEt3 (2.91 mL, 21.0 mmol) and DMAP (366 mg, 3.00 mmol) followed by Boc-
anhydride (4.58 g, 21.0 mmol). The flask was stirred at room temperature for 18 h then the 
CH2Cl2 solution was washed with water (15 mL) followed by saturated aqueous NH4Cl, 
dried over MgSO4 and concentrated in vacuo. The crude material was purified by column 
chromatography (CH2Cl2→5% EtOAc/CH2Cl2 →10% EtOAc/CH2Cl2) to give the 
azaarylketone S9 as a pale green solid (3.14 g, 47%); mp 126–128 °C; max (film)/cm
-1 2980 
(C-H), 1743 (C=O, Boc), 1694 (C=O, ketone); δH (500 MHz, CDCl3) 1.60 (9H, s, 
C(CH3)3), 1.78 (9H, s, C(CH3)3), 4.99 (2H, s, keto-CH2CO), 7.15 (1H, s, enol-CHCOH), 7.22 
– 7.40 (4H, m, 2 × benzimidazoleC(5)H, 2 × benzimidazoleC(6)H), 7.44 – 7.48 (3H, m, 2 
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× keto-phenylC(3)H, keto-phenylC(4)H), 7.51 – 7.56 (3H, m, 2 × enol-phenylC(3)H, 
benzimidazoleC(7)H), 7.61 – 7.66 (1H, m, enol-phenylC(4)H), 7.73 – 7.78 (1H, m, 
benzimidazoleC(7)H), 7.93 – 7.99 (4H, m, 2 × keto-phenylC(2)H, 2 × 
benzimidazoleC(4)H), 8.04 – 8.08 (2H, m, 2 × enol-phenylC(2)H); δC (126 MHz, CDCl3) 
28.0 (C(CH3)3), 28.3 (C(CH3)3), 42.5 (keto-CH2CO), 84.5 (enol-CHCOH), 85.8 (C(CH3)3), 
85.9 (C(CH3)3), 115.1 (benzimidazoleC(4)H), 115.1 (benzimidazoleC(4)H), 115.8 
(benzimidazoleC(7)H), 119.8 (benzimidazoleC(7)H), 123.6 (benzimidazoleC(6)H), 124.2 
(benzimidazoleC(5)H), 124.7 (benzimidazoleC(6)H), 124.9 (benzimidazoleC(5)H), 126.2 (2 
× keto-phenylC(2)H), 128.2 (2 × enol-phenylC(2)H), 128.5 (2 × keto-phenylC(3)H), 128.9 (2 
× enol-phenylC(3)H), 130.3 (keto-phenylC(4)H), 130.5 (benzimidazoleC(7a)), 133.3 
(benzimidazoleC(7a)), 133.6 (enol-phenylC(4)H), 136.4 (keto-phenylC(1)), 136.7 (enol-
benzimidazoleC(2)), 138.0 (benzimidazoleC(4a)), 142.3 (benzimidazoleC(4a)), 148.9 
(CO2C(CH3)3), 149.0 (CO2C(CH3)3), 150.1 (keto-benzimidazoleC(2)), 154.9 (enol-phenylC(1)), 
171.7 (enol-CHCOH), 194.4 (keto-CH2CO); m/z (NSI
+) 337 ([M+H]+, 100%), 237 ([M–
C5H8O2]
+, 45%); HRMS (NSI+) C20H21N2O3 ([M+H]
+) requires 337.1547, found 337.1547 
(+0.1 ppm).  
 
6.5 Michael Addition-Lactonisation Products 
General Procedure F: Lactone formation 
 
To a solution of the corresponding homoanhydride (1.4 equiv) in dry CH2Cl2 (0.72 M) 
under argon, was added dicarbonyl (1.0 equiv), isothiourea (HBTM 2.1, 0.05 equiv) and 
polymer-bound 2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-
diazaphosphorine (PS-BEMP) (1.1 equiv) at 0 °C. The reaction mixture was stirred and 
gradually warmed to room temperature over 5 h. The solvent was removed in vacuo and 
the residue was purified by column chromatography on silica gel (CH2Cl2) to afford the 
lactone products. 
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(R)-B-benzoyl-4,6-diphenyl-3,4-dihydro-2H-pyran-2-one (145) 
 
The title compound was prepared according to modified General Procedure F from (E)-
cinnamic anhydride (100 mg, 0.36 mmol), 1,3-diphenyl-1,3-propanedione (40 mg, 0.18 
mmol), HBTM 2.1 (11.1 mg, 0.036 mmol) and EtN(iPr)2 (78 μL, 0.45 mmol) in CH2Cl2 
(0.25 mL) and purified by chromatography (CH2Cl2) to afford the lactone 145 as a white 
solid (30 mg, 49%); mp 120-125 °C; 
22
D][  –7.6 (c 0.5 in CHCl3); {Lit.9 
22
D][  6.5 (c 1.0 in 
CHCl3) 95% ee}; chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 
1.0 mL min-1, 254 nm, 20 °C), tR major: 14.7 min, tR minor: 32.4 min, 95% ee; δH (300 
MHz, CDCl3) 3.04 (1H, dd, J 15.9, 2.5, C(3)H2), 3.19 (1H, dd, J 15.9, 7.7, C(3)H2), 4.55 (1H, 
dd, J 7.7, 2.5, C(4)H), 7.02-7.29 (11H, m, ArH), 7.32-7.38 (2H, m, ArH), 7.44-7.51 (2H, m, 
ArH). Data in agreement with the literature.72 
(R)-5-Benzoyl-6-methyl-4-phenyl-3,4-dihydro-2H-pyran-2-one, (R)-5-Acetyl-4,6-
diphenyl-3,4-dihydro-2H-pyran-2-one (191a, 191b) 
 
The title compound was prepared according to General Procedure F from (E)-cinnamic 
anhydride (70 mg, 0.25 mmol), 1-phenylbutane-1,3-dione (29 mg, 0.18 mmol), HBTM 2.1 
(2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 mg, 0.20 mmol) in CH2Cl2 
(0.25 mL). Chromatographic purification of the residue (CH2Cl2) gave 191a as a white solid 
(15 mg, 29% in 96:4 rr), 191b as a white solid (2 mg, 4% in 3:96 rr) and a mixture of 191a 
and 191b (29 mg, 55% in 34:66 rr). Compounds synthesised by Dr Carmen Simal. 
191a: mp 80-84 °C; 
22
D][  19.6 (c 1.0 in CHCl3); {Lit.
10 
22
D][  26.7 (c 1.0 in CHCl3) 96% 
ee}; chiral HPLC analysis, ChiralPak OD-H (15% i-PrOH:hexane, flow rate 1.0 mL min-1, 
254 nm, 20 °C), tR major: 15.4 min, tR minor: 18.9 min, 70% ee; δH (300 MHz, CDCl3) 1.91 
(3H, d, J 0.9, CH3), 2.95 (1H, dd, J 15.9, 3.6, CH2), 3.08 (1H, dd, J 15.9, 7.5, CH2), 4.32-4.36 
(1H, m, CH), 7.14-7.65 (10H, m, ArH).  
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Representative data for 191b: 
22
D][  94.0 (c 0.15 in CHCl3); chiral HPLC analysis, 
ChiralPak AS-H (15% i-PrOH:hexane, flow rate 1.0 mL min-1, 254 nm, 30 °C), tR major: 
21.4 min, tR minor: 30.7 min, 61% ee; δH (500 MHz, CDCl3) 1.80 (3H, s, CH3), 2.94 (1H, 
dd, J 16.0, 2.0, CH2), 3.06 (1H, dd, J 16.0, 7.8, CH2), 4.48-4.50 (1H, m, CH), 7.21-7.34 (6H, 
m, ArH), 7.46-7.55 (4H, m, ArH). Data in agreement with the literature.10 
 (R)-Ethyl 2-oxo-4,6-diphenyl-3,4-dihydro-2H-pyran-5-carboxylate (194) 
 
The title compound was prepared according to General Procedure F from (E)-cinnamic 
anhydride (70 mg, 0.25 mmol), ethyl 3-oxo-3-phenylpropanoate (31 μL, 0.18 mmol), 
HBTM 2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 mg, 0.20 mmol) 
in CH2Cl2 (0.25 mL) and purified by chromatography (CH2Cl2) to afford the lactone 194 as a 
yellow gum (35 mg, 60%); 
22
D][  67.0 (c 1.0 in CHCl3); {Lit.
9 
22
D][  70.0 (c 1.0 in CHCl3) 
92% ee}; chiral HPLC analysis, ChiralPak AD-H (3% i-PrOH:hexane, flow rate 1.0 mL 
min-1, 254 nm, 20 °C), tR major: 17.3 min, tR minor: 26.1 min, 94% ee; δH (400 MHz, 
CDCl3) 0.90 (3H, t, J 7.2, CH3), 2.95 (1H, dd, J 15.8, 2.4, C(3)H2), 2.98 (1H, dd, J 15.8, 7.6, 
C(3)H2), 3.89-4.01 (2H, m, OCH2), 4.43 (1H, dd, J 7.6, 2.4, C(4)H), 7.26-7.54 (10H, m, 
ArH). Data in agreement with the literature.72  
(R)-Ethyl 2-oxo-6-phenyl-4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyran-5-
carboxylate (195) 
 
The title compound was prepared according to General Procedure F from (E)-3-(4-
(trifluoromethyl)phenyl)acrylic anhydride (104 mg, 0.25 mmol), ethyl 3-oxo-3-
phenylpropanoate (31 μL, 0.18 mmol), HBTM 2.1 (2.8 mg, 0.009 mmol) and PS-BEMP 
(2.2 mmol/g loading) (90 mg, 0.20 mmol) in CH2Cl2 (0.25 mL) and purified by 
chromatography (CH2Cl2) to afford the lactone 195 as a white gum (43 mg, 61%); 
22
D][  
56.6 (c 1.0 in CHCl3); chiral HPLC analysis, ChiralPak AD-H (15% i-PrOH:hexane, flow 
rate 1.0 mL min-1, 254 nm, 20 °C), tR major: 8.0 min, tR minor: 11.0 min, 94% ee; max 
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(film)/cm-1 1782 (C=O), 1694 (C=O), 1323 (C-F); δH (400 MHz, CDCl3) 0.88 (3H, t, J 7.2, 
CH3), 2.94 (1H, dd, J 16.0, 2.4, C(3)H2), 3.15 (1H, dd, J 16.0, 7.6, C(3)H2), 3.89-4.00 (2H, 
m, OCH2), 4.47 (1H, dd, J 7.6, 2.4, C(4)H), 7.38-7.53 (7H, m, ArH), 7.61 (2H, d, J 8.0, 
ArH); δC (75 MHz, CDCl3) 13.6 (CH3), 36.1 (C(3)H2), 38.8 (C(4)H), 61.3 (OCH2), 111.0 
(C(5)), 124.1 (q, 1JCF 270.1, CF3), 126.4 (q, 
3JCF 3.8, 2×C(4)ArC(3)), 127.4 (2×ArCH), 128.2 
(2×ArCH), 128.8 (2×ArCH), 130.3 (q, 2JCF 32.3, C(4)ArC(4)), 130.5 (ArCH), 133.0 
(PhC(1)), 144.2 (CF3PhC(1)), 159.4 (C(6)), 165.5 (CO), 166.2 (CO); δF (300 MHz, CDCl3) 
63.1; m/z (NSI+) 423 ([M+CH3OH+H]+, 100%), 391 ([M+H]+, 30%); HRMS (NSI+) 
C21H18F3O4 ([M+H]
+) requires 391.1152, found 391.1155 (+0.8 ppm). Compound 
synthesised by Dr Carmen Simal. 
(R)-Ethyl 4-(4-fluorophenyl)-2-oxo-6-phenyl-3,4-dihydro-2H-pyran-5-carboxylate 
(196) 
 
The title compound was prepared according to General Procedure F from (E)-3-(4-
fluorophenyl)acrylic anhydride (314 mg, 1.0 mmol), ethyl 3-oxo-3-phenylpropanoate (124 
μL, 0.72 mmol), HBTM 2.1 (11.1 mg, 0.036 mmol) and PS-BEMP (2.2 mmol/g loading) 
(360 mg, 0.80 mmol) in CH2Cl2 (1.0 mL) and purified by chromatography (CH2Cl2) to 
afford the lactone 196 as a pale yellow oil (171 mg, 70%); 
22
D][  26.1 (c 1.0 in CH2Cl2); 
chiral HPLC analysis, ChiralPak AD-H (10% i-PrOH:hexane, flow rate 1.0 mL min-1, 220 
nm, 30 °C), tR major: 9.4 min, tR minor: 13.1 min, 89% ee; max (film)/cm-1 2926 (C-H), 
1784 (C=O), 1705 (C=O), 1508 (C=C), 1224 (C-F); δH (300 MHz, CDCl3) 0.91 (3H, t, J 
7.1, CH3), 2.94 (1H, dd, J 15.8, 2.4, C(3)H2), 3.13 (1H, dd, J 15.8, 7.6, C(3)H2), 3.97 (2H, qd, 
J 7.1, 2.2, OCH2), 4.43 (1H, dd, J 7.6, 2.4, C(4)H), 6.99-7.12 (2H, m, FPhC(3,5)H), 7.22-
7.28 (2H, m, FPhC(2,6)H), 7.38-7.58 (5H, m, PhH); δC (75 MHz, CDCl3) 13.6 (CH3), 36.5 
(C(3)H2), 38.3 (C(4)H), 61.2 (OCH2), 111.7 (C(5)), 116.2 (d, 
2JC-F 21.6, 2×C(4)ArC(3)H), 
128.2 (2×ArCH), 128.5 (d, 3JC-F 8.2, 2×C(4)ArC(2)H), 128.8 (2×ArCH), 130.4 (ArCH), 
133.1 (PhC(1)), 135.8 (d, 4JCF 3.3, C(4)ArC(1)), 158.8 (C(6)), 162.4 (d, 
1JC-F 246.5, CF), 165.9 
(CO), 166.4 (CO); δF (282 MHz, CDCl3) 115.1; m/z (APCI+) 341 ([M+H]+, 100%); 
HRMS (APCI+) C20H18FO4
 ([M+H]+) requires 341.1184 found 341.1179 (1.4 ppm). 
Compound synthesised by Dr Charlene Fallan. 
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(R)-Ethyl 4-(3-chlorophenyl)-2-oxo-6-phenyl-3,4-dihydro-2H-pyran-5-carboxylate 
(197) 
 
The title compound was prepared according to General Procedure F from (E)-3-
chlorophenyl)acrylic anhydride (347 mg, 1.0 mmol), ethyl 3-oxo-3-phenylpropanoate (124 
μL, 0.72 mmol), HBTM 2.1 (11.1 mg, 0.036 mmol) and PS-BEMP (2.2 mmol/g loading) 
(360 mg, 0.80 mmol) in CH2Cl2 (1.0 mL) and purified by chromatography (CH2Cl2) to 
afford the lactone 197 as a pale yellow oil (121 mg, 47%); 
22
D][  2.1 (c 0.38 in CH2Cl2); 
chiral HPLC analysis, ChiralPak AD-H (5% i-PrOH:hexane, flow rate 0.5 mL min-1, 220 
nm, 30 °C), tR major: 25.5 min, tR minor: 39.1 min, 92% ee; max (film)/cm-1 2980 (C-H), 
1732 (C=O), 1708 (C=O), 1597 (C=C), 1066 (C-Cl); δH (400 MHz, CDCl3) 0.92 (3H, t, J 
7.1, CH3), 2.96 (1H, dd, J 15.9, 2.4, C(3)H2), 3.14 (1H, dd, J 15.9, 7.7, C(3)H2), 3.98 (2H, qd, 
J 7.1, 2.0, OCH2), 4.41 (1H, dd, J 7.7, 2.4, C(4)H), 7.17 (1H, dt, J 6.6, 1.9, ArH), 7.25-7.30 
(3H, m, ArH), 7.42-7.55 (5H, m, ArH); δC (75 MHz, CDCl3) 13.6 (CH3), 36.2 (C(4)H), 38.7 
(C(3)H2), 61.3 (OCH2), 111.1 (C(5)H), 125.0 (ArCH), 127.3 (ArCH), 128.2 (2×ArCH), 
128.3 (ArCH),128.8 (2×ArCH), 130.4 (ArCH), 130.7 (ArCH), 133.0 (PhC(1)), 135.1 
(C(4)ArC(3)), 142.1 (C(4)ArC(1)), 159.3 (C(6)H), 165.7 (CO), 166.3 (CO); m/z (APCI+) 357 
([M+H]+, 90%); HRMS (NSI+) C20H18Cl
35O4 ([M+H]
+) requires 357.0888, found 357.0888 
(0.0 ppm). 
(S)-Ethyl 4-(2-chlorophenyl)-2-oxo-6-phenyl-3,4-dihydro-2H-pyran-5-carboxylate 
(198) 
 
The title compound was prepared according to General Procedure F from (E)-3-
chlorophenyl)acrylic anhydride (89 mg, 0.25 mmol), ethyl 3-oxo-3-phenylpropanoate (31 
μL, 0.18 mmol), HBTM 2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 
mg, 0.20 mmol) in CH2Cl2 (0.25 mL) and purified by chromatography (CH2Cl2) to afford 
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the lactone 198 as a pale yellow oil (29 mg, 46%); 
22
D][  25.0 (c 1.3 in CHCl3); chiral HPLC 
analysis, ChiralPak AD-H (15% i-PrOH:hexane, flow rate 1.0 mL min-1, 220 nm, 30 °C), tR 
major: 6.3 min, tR minor: 7.4 min, 96% ee; max (film)/cm-1 2980 (C-H), 1728 (C=O), 1687 
(C=O), 1597 (C=C), 1037 (C-Cl); δH (400 MHz, CDCl3) 0.90 (3H, t, J 7.1, CH3), 2.99 (1H, 
dd, J 15.9, 2.4, C(3)H2), 3.09 (1H, dd, J 16.0, 7.7, C(3)H2), 3.94 (2H, qd, J 7.1, 2.7, OCH2), 
4.92 (1H, dd, J 7.7, 2.4, C(4)H), 7.21-7.29 (3H, m ArH), 7.39-7.52 (4H, m, ArH), 7.50-7.61 
(2H, m, ArH); δC (75 MHz, CDCl3) 13.6 (CH3), 34.7 (C(3)H2), 35.9 (C(4)H), 61.2 (OCH2), 
110.6 (C(5)), 127.4 (ArCH), 127.7 (ArCH), 128.2 (2×ArCH), 128.8 (2×ArCH), 129.3 
(ArCH), 130.5 (ArCH), 130.5 (ArCH), 132.9 (PhC(1)), 133.5 (C(4)ArC(2)), 136.6 
(C(4)ArC(1)), 160.0 (C(6)), 165.7 (CO), 166.0 (CO); m/z (APCI+) 357 ([M+H]+, 65%), 375 
([M+NH4]
+,50%); HRMS (APCI+) C20H18Cl
35O4 ([M+H]
+) requires 357.0888, found 
357.0885 (0.9 ppm). 
(S)-Ethyl 4-(furan-2-yl)-2-oxo-6-phenyl-3,4-dihydro-2H-pyran-5-carboxylate (200) 
 
The title compound was prepared according to General Procedure F from (E)-3-(furan-2-
yl)acrylic anhydride (258 mg, 1.0 mmol), ethyl 3-oxo-3-phenylpropanoate (124 μL, 0.72 
mmol), HBTM 2.1 (11.1 mg, 0.036 mmol) and PS-BEMP (2.2 mmol/g loading) (360 mg, 
0.80 mmol) in CH2Cl2 (1.0 mL) and purified by chromatography (CH2Cl2) to afford the 
lactone 200 as a yellow oil (146 mg, 65%); 
22
D][  6.19 (c 1.0 in CH2Cl2); chiral HPLC 
analysis, ChiralPak AD-H (5% i-PrOH:hexane, flow rate 0.5 mL min-1, 220 nm, 30 °C), tR 
major: 24.8 min, tR minor: 29.2 min, 92% ee; max (film)/cm-1 2982 (C-H), 2928 (C-H), 1728 
(C=O), 1684 (C=O), 1014 (C-OC); δH (500 MHz, CDCl3) 0.96 (3H, t, J 7.1, CH2CH3), 2.99 
(1H, dd, J 16.0, 7.2, C(3)H2), 3.12 (1H, dd, J 16.0, 1.6, C(3)H2), 3.98-4.05 (2H, m, OCH2), 
4.49 (1H, d, J 6.2, C(4)H), 6.18 (1H, d, J 3.0, furanylC(3)H), 6.29 (1H, s, furanylC(4)H), 
7.35 (1H, s, furanylC(5)H), 7.37-7.48 (5H, m, PhH); δC (75 MHz, CDCl3) 13.6 (CH3), 32.7 
(C(4)H), 33.3 (C(3)H2), 61.2 (OCH2), 106.5 (furanylC(3)H), 109.5 (C(5)H), 110.5 
(furanylC(4)H), 128.0 (2×ArCH), 128.7 (2×ArCH), 130.3 (ArCH), 133.1 (PhC(1)), 142.8 
(furanylC(5)H), 152.4 (furanylC(2)H), 159.4 (C(6)H), 165.9 (CO), 166.1 (CO); m/z (APCI+) 
345 ([M+MeOH+H]+, 100%), 313 ([M+H]+, 25%); HRMS (APCI+) C18H17O5 ([M+H]
+) 
requires 313.1071, found 313.1068 (0.8 ppm). 
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(S)-Ethyl -2-oxo-6-phenyl-4-(thiophen-2-yl)-3,4-dihydro-2H-pyran-5-carboxylate 
(199) 
 
The title compound was prepared according to General Procedure F from (E)-3-(thiophen-2-
yl)acrylic anhydride (110.4 mg, 0.38 mmol), ethyl 3-oxo-3-phenylpropanoate (52 μL, 0.27 
mmol), HBTM 2.1 (4.31 mg, 0.014 mmol) and PS-BEMP (2.0 mmol/g loading) (136.0 mg, 
0.30 mmol) in CH2Cl2 (0.38 mL) and purified by chromatography (CH2Cl2) to afford the 
lactone 199 as a yellow oil (33.3 mg, 38%); 
22
D][  -9.94 (c 0.8 in CH2Cl2); chiral HPLC 
analysis, ChiralPak AD-H (5% i-PrOH:hexane, flow rate 0.5 mL min-1, 220 nm, 20 ˚C), tR 
major: 25.1 min, tR minor: 29.5 min, 94% ee; max (film) /cm-1 2980 (C-H), 2905 (C-H), 
1782 (C=O), 1699 (C=O); δH (400 MHz, CDCl3) 0.96 (3H, t, J 7.1, CH3), 2.99 (1H, dd, J 
16.0, 7.2, C(3)HH), 3.12 (1H, dd, J 16.0, 2.1, C(3)HH), 4.02 (2H, qd, J 7.1, 1.2, OCH2), 4.49 
(1H, dd, J 7.2, 1.5,C(4)H), 6.18 (1H, dt, J 3.2, 0.8, thienylC(3)H), 6.29 (1H, dd, J 3.2, 1.9, 
thienylC(4)H), 7.35 (1H, dd, J 1.9, 0.8, thienylC(5)H), 7.36-7.53 (5H, m, PhH); δC (126 
MHz, CDCl3) 13.6 (CH3), 34.0 (C(4)H), 36.5 (C(3)H2), 61.2 (OCH2), 111.9 (C(5)), 124.5 
(thienylC(5)H), 125.0 (thienylC(3)H), 127.2 (thienylC(4)H), 128.0 (CHAr), 128.7 (CHAr), 
130.2 (CHAr), 133.0 ((PhC(1)), 143.0 (thienylC(2)), 159.1 (C(6)), 165.7 (CO), 166.0 (CO); 
m/z (NSI+) 329 ([M+H]+, 30%), 351 ([M+Na]+, 80%); HRMS (NSI+) C18H17O4S ([M+H]
+) 
requires 329.0842, found 329.0844 (+0.6 ppm). 
(R)-Ethyl 6-methyl-2-oxo-4-phenyl-3,4-dihydro-2H-pyran-5-carboxylate (S10) 
 
The title compound was prepared according to General Procedure F from (E)-cinnamic 
anhydride (280 mg, 1.00 mmol), ethyl acetoacetate (94 μL, 0.72 mmol), HBTM 2.1 (2.8 mg, 
0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (360 mg, 0.20 mmol) in CH2Cl2 (1.0 mL) 
and purified by chromatography (CH2Cl2) to afford the lactone S10 as a white solid (135 mg, 
72%); mp 79-80 °C {Lit9 83-84 °C} chiral HPLC analysis, ChiralPak OD-H (15% i-
PrOH:hexane, flow rate 1.0 mL min-1, 254 nm, 30 °C), tR minor: 6.2 min, tR minor: 10.5 
min, 70% ee; 
20
D][  101.5 (c 1.0 in CH3Cl), {Lit
9 
20
D][  130.6 (c 1.0 in CH3Cl); 91% ee}; 
 6. Experimental  
 
149 
δH (300 MHz, CDCl3) 1.20 (3H, t, J 7.1, CO2CH2CH3), 2.48 (3H, d, J 1.0, C(6)CH3), 2.83 
(1H, dd, J 15.9, 2.4, C(3)H2), 2.96 (1H, dd, J 15.9, 7.5, C(3)H2), 4.14 (2H, q, J 7.1, OCH2), 
4.26-4.28 (1H, m, C(4)H), 7.13-7.16 (2H, m, ArH), 7.22-7.34 (3H, m, ArH). Data in 
agreement with the literature.9 
(S)-Ethyl 4-methyl-2-oxo-6-phenyl-3,4-dihydro-2H-pyran-5-carboxylate (201) 
 
The title compound was prepared according to General Procedure F from (E)-but-2-enoic 
anhydride (39 mg, 0.25 mmol), ethyl 3-oxo-3-phenylpropanoate (31 μL, 0.18 mmol), 
HBTM 2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 mg, 0.20 mmol) 
in CH2Cl2 (0.25 mL) and purified by chromatography (CH2Cl2) to afford the lactone 201 as a 
colourless oil (21 mg, 45%); 
22
D][  +4.67 (c 0.5 in CH2Cl2); chiral HPLC analysis, ChiralPak 
OD-H (2.5% i-PrOH:hexane, flow rate 0.5 mL min-1, 220 nm, 30 °C), tR minor: 21.1 min, 
tR major: 23.5 min, 65% ee; max (film)/cm-1 2978 (C-H), 2938 (C-H), 1728 (C=O), 1705 
(C=O), 1690 (C=O); δH (500 MHz, CDCl3) 0.98 (3H, t, J 7.1, CH2CH3), 1.24 (3H, d, J 7.1, 
C(4)CH3), 2.65 (1H, dd, J 15.8, 2.1, C(3)H2), 2.83 (1H, dd, J 15.8, 6.7, C(3)H2), 3.20 (1H, tt, 
J 6.9, 3.6, C(4)H), 4.03 (2H, q, J 7.1, OCH2), 7.38 (5H, dt, J 14.2, 7.4, PhH); δC (100 MHz, 
CDCl3) 13.7 (CH2CH3), 19.3 (C(4)(CH3)), 28.4 (C(4)H), 35.7 (C(3)H2), 61.0 (OCH2), 114.1 
(ArCH), 128.0 (2×ArCH), 128.6 (2×ArCH), 130.0 (ArCH), 133.3 (PhC(1)), 157.5(C(6)), 
166.8 (CO), 167.0 (CO); m/z (NSI+) 261 ([M+H]+, 60%); HRMS (NSI+) C15H17O4 
([M+H]+) requires 261.1121, found 261.1125 (+1.4 ppm). 
(R)-4-Phenyl-3,4,7,8-tetrahydro-2H-chromene-2,5(6H)-dione (111) 
 
The title compounds were prepared according to General Procedure E using 1,3-
cyclohexanedione (80 mg, 0.72 mmol), anhydride 3 (278 mg, 1.00 mmol), HBTM 2.1 (22 
mg, 10 mol %) and EtN(iPr)2 (138 μL, 0.80 mmol) in THF:DCM (10:1, 2 mL) and purified 
by chromatography (CH2Cl2) to afford the title lactone 111 as a yellow solid (139 mg, 80%); 
mp 112-113 °C; [α]D
20 118.2 (c 1.0, CHCl3); HPLC analysis, ChiralPak AD-H (5% i-
PrOH:hexane, flow rate 1.0 mL min-1, 220 nm, 30 °C), tR major: 14.9 min, tR minor: 22.5, 
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82% ee; νmax (film) 2953 (C-H), 1784 (C=O), 1705 (C=O); δH (400 MHz, CDCl3) 2.06-2.18 
(2H, m, CH2), 2.45-2.48 (2H, m, CH2), 2.61-2.75 (2H, m, CH2), 2.90-2.99 (2H, m, C(3)H), 
4.32 (1H, t, J 5.0, C(4)H), 7.14-7.17 (2H, m, 2×ArH), 7.20-7.25 (1H, m, ArH), 7.28-7.32 
(2H, m, 2×ArH); δC (100 MHz, CDCl3) 20.5 (C(7)H2), 27.2 (C(8)H2), 33.7 (C(4)H), 36.2 
(C(3)H2), 36.6 (C(6)H2), 117.1 (C=CO), 126.4 (2×C(4)ArC(2)H), 127.4 (C(4)ArC(4)H), 
128.9 (2×C(4)ArC(3)H), 140.4 (C(4)ArC(1)), 165.8 (C(10)), 167.3 (C(2)O)), 196.2 (C(5)O); 
m/z (NSI+) 243 ([M+H]+, 60%); HRMS (NSI+) C15H15O3 ([M+H]
+) requires 243.1016, 
found 243.1018 (+0.9 ppm). Compound synthesised by Dr Charlene Fallan. 
 
General Procedure G: Ring-Opened Products 
 
To a solution of the corresponding homoanhydride (1.4 equiv) in dry CH2Cl2 (0.72 M) under 
argon, was added isothiourea (HBTM 2.1, 0.05 equiv) and polymer-bound 2-tert-
butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine (PS-BEMP) (1.1 
equiv) at 0 °C followed by addition of the corresponding diketone (1.0 equiv). The reaction 
mixture was stirred at 0 °C and gradually warmed to room temperature over 5 h. The 
reaction was quenched with MeOH (2 mL) and stirred at room temperature for 16 h. The 
solvent was removed in vacuo and the residue was purified by column chromatography on 
silica gel (CH2Cl2→2%EtOAc/ CH2Cl2) to afford the ester 6-22. 
(3S)-Methyl 4-benzoyl-5-oxo-3,5-diphenylpentanoate (154) 
 
The title compound was prepared according to General Procedure G from (E)-cinnamic 
anhydride (70 mg, 0.25 mmol), 1,3-diphenyl-1,3-propanedione (40 mg, 0.18 mmol), HBTM 
2.1 (2.8 mg, 0.009 mmol), PS-BEMP (2.2 mmol/g loading, 90 mg, 0.20 mmol) and purified 
by chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to afford the ester 154 as a white solid 
(53 mg, 83%); mp 104-107 °C; 
22
D][  +9.6 (c 0.25 in CHCl3); chiral HPLC analysis, 
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ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 220 nm, 30 °C), tR major: 
11.8 min, tR minor: 17.0 min, 96% ee; max (film)/cm-1 2367 (C-H), 1742 (C=O), 1690 
(C=O), 1653 (C=O), 1489 (CH3-O); δH (400 MHz, CDCl3) 2.77-2.93 (2H, m, C(2)H2), 3.50 
(3H, s, OCH3), 4.40 (1H, td, J 9.5, 4.9, C(3)H), 5.84 (1H, d, J 9.5, C(4)H), 7.04-7.19 (3H, m, 
ArH), 7.21-7.33 (4H, m, ArH), 7.37-7.48 (3H, m, ArH), 7.54 (1H, t, J 7.4, ArH), 7.75 (2H, 
dd, J 8.3, 1.3, ArH), 7.98 (2H, dd, J 8.5, 1.1, ArH); δC (100 MHz, CDCl3) 38.2 (C(2)), 42.8 
(C(3)), 51.7 (OCH3), 62.4 (C(4)), 127.2 (ArC(4)H), 128.5 (2×ArCH), 128.6 (2×ArCH), 
128.7 (2×ArCH), 128.7 (2×ArCH), 129.0 (4×ArCH), 133.4 (ArCH), 133.8 (ArCH), 136.7 
(ArC), 136.9 (ArC), 140.4 (ArC), 172.1 (C(1)), 194.5 (CO), 194.8 (CO); m/z (NSI+) 387 
([M+H]+, 100%), 404 ([M+NH4]
+, 35%); HRMS (NSI+) C25H23O4 ([M+H]
+) requires 
387.1591, found 387.1596 (+1.3 ppm).  
(3S)-Methyl 4-benzoyl-3-(4-trifluoromethylphenyl)-5-oxo-5-phenylpentanoate (165) 
 
The title compound was prepared according to General Procedure G from (E)-4-
trifluoromethyl cinnamic anhydride (103 mg, 0.25 mmol), 1,3-diphenyl-1,3-propanedione 
(40 mg, 0.18 mmol), HBTM 2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading, 
90 mg, 0.20 mmol) and purified by chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to 
afford the ester 165 as a white solid (64 mg, 79%); mp 142-145 °C; 
22
D][  2.5 (c 1.0 in 
CHCl3); chiral HPLC analysis, ChiralPak AD-H, (20% i-PrOH:hexane, flow rate 1.0 mL 
min-1, 254 nm, 20 °C), tR major: 12.7 min, tR minor: 22.1 min, 97% ee; max (film)/cm-1 2972 
(C-H), 2853 (C-H), 2322 (C-H), 1734 (C=O), 1684 (C=O), 1325 (CF3); δH (400 MHz, 
CDCl3) 2.76-2.99 (2H, m, C(2)H), 3.51 (3H, s, OCH3), 4.46 (1H, td, J 9.5, 4.7, C(3)H), 5.84 
(1H, d, J 9.5, C(4)H), 7.27-7.51 (9H, m, ArH), 7.52-7.62 (1H, m, ArH), 7.66-7.80 (2H, m, 
ArH), 7.95-8.03 (2H, m, ArH); δC (75 MHz, CDCl3) 37.9 (C(2)), 42.5 (C(3)), 51.8 (OCH3), 
61.8 (C(4)), 124.1 (q, 1JCF 270.2, CF3), 125.5 (q, 
3JCF 3.7, C(3)ArC(3)), 128.6 (2×ArCH), 
128.8 (2×ArCH), 129.0 (2×ArCH), 129.0 (2×ArCH), 129.1 (2×ArCH), 129.4 (q, 2JCF 32.3, 
C(3)ArC(4)), 133.7 (ArC(4)H), 134.1 (ArC(4)H), 136.5 (ArC), 136.6 (ArC), 144.7 (ArC), 
171.8 (C(1)), 194.2 (CO), 194.5 (CO); δF (282 MHz, CDCl3) 63.14; m/z (NSI+) 472 
([M+NH4]
+, 100%), 455 ([M+H]+, 90%); HRMS (NSI+) C26H22F3O4 ([M+H]
+) requires 
455.1465, found 455.1467 (+0.5 ppm).  
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(3S)-Methyl 4-benzoyl-3-(4-fluorophenyl)-5-oxo-5-phenylpentanoate (166) 
 
The title compound was prepared according to General Procedure G from (E)-3-(4-
fluorophenyl)acrylic anhydride (79 mg, 0.25 mmol), 1,3-diphenylpropane-1,3-dione (40 mg, 
0.18 mmol), HBTM 2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 mg, 
0.20 mmol) in CH2Cl2 (0.25 mL) and purified by chromatography 
(CH2Cl2→2%EtOAc/CH2Cl2) to afford the ester 166 as a white solid (60 mg, 82%); mp 92-
96 °C; 
22
D][  +20.2 (c 1.0 in CHCl3); chiral HPLC analysis, ChiralPak IA (20% i-
PrOH:hexane, flow rate 1.0 mL min-1, 254 nm, 30 °C), tR major: 10.0 min, tR minor: 14.3 
min, 95% ee; max (film)/cm-1 2951 (C-H), 1734 (C=O), 1694 (C=O), 1260 (C-F); δH (400 
MHz, CDCl3) 2.78 (1H, dd, J 15.6, 9.6, C(2)H), 2.87 (1H, dd, J 15.6, 9.6, C(2)H), 3.51 (3H, 
s, OCH3), 4.39 (1H, ddd, J 9.6, 9.6, 4.6, C(3)H), 5.79 (1H, d, J 9.6, C(4)H), 6.81-6.87 (2H, 
m, ArH), 7.19-7.24 (2H, m, ArH), 7.30-7.34 (2H, m, ArH), 7.41-7.58 (4H, m, ArH), 7.74-
7.76 (2H, m, ArH), 7.98-8.00 (2H, m, ArH); δC (100 MHz, CDCl3) 38.4 (C(2)), 42.1 (C(3)), 
51.8 (OCH3), 62.5 (C(4)), 115.4 (d, 
2JCF 21.4, C(3)ArC(3)H), 128.7 (2×ArCH), 128.8 
(2×ArCH), 129.0 (2×ArCH), 129.1 (2×ArCH), 130.2 (d, 3JCF 8.1, C(3)ArC(2)H), 133.5 
(ArC(4)H), 134.0 (ArC(4)H), 136.1 (ArC), 136.6 (ArC), 136.8 (ArC), 161.8 (d, 1JCF 240.3, 
CF), 172.0 (C(1)), 194.4 (CO), 194.6 (CO); δF (300 MHz, CDCl3) 115.9; m/z (NSI+) 405 
([M+H]+, 100%), 422 ([M+NH4]
+, 45%); HRMS (NSI+) C25H22FO4 ([M+H]
+) requires 
405.1497, found 405.1496 (0.2 ppm). 
(3S)-Methyl 4-benzoyl-3-(4-methoxyphenyl)-5-oxo-5-phenylpentanoate (167) 
 
The title compound was prepared according to General Procedure G from (E)-3-(4-
methoxyphenyl)acrylic anhydride (85 mg, 0.25 mmol), 1,3-diphenylpropane-1,3-dione (40 
mg, 0.18 mmol), HBTM 2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 
mg, 0.20 mmol) in CH2Cl2 (0.25 mL) and purified by chromatography 
(CH2Cl2→2%EtOAc/CH2Cl2) to afford the ester 167 as a pale yellow solid (33 mg, 44%); 
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mp 110-114 °C; 
22
D][  +18.1 (c 1.0 in CHCl3); chiral HPLC analysis, ChiralPak AD-H 
(15% i-PrOH:hexane, flow rate 1.0 mL min-1, 254 nm, 20 °C), tR major: 26.7 min, tR minor: 
44.7 min, 94% ee; 
The reaction was repeated using a modified General Procedure D with increased catalyst 
loading from (E)-3-(4-methoxyphenyl)acrylic anhydride (85 mg, 0.25 mmol), 1,3-
diphenylpropane-1,3-dione (40 mg, 0.18 mmol), HBTM 2.1 (5.6 mg, 0.018 mmol) and PS-
BEMP (2.2 mmol/g loading) (90 mg, 0.20 mmol) in CH2Cl2 (0.25 mL) and purified by 
chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to afford the ester 167 as a pale yellow solid 
(42 mg, 56%); mp 110-114 °C; 
22
D][  +8.2 (c 1.0 in CHCl3); chiral HPLC analysis, 
ChiralPak AD-H (15% i-PrOH:hexane, flow rate 1.0 mL min-1, 254 nm, 20 °C), tR major: 
26.7 min, tR minor: 44.7 min, 88% ee; max (film)/cm-1 1732 (C=O), 1690 (C=O), 1252 (C-
O), 1159 (C-O); δH (300 MHz, CDCl) 2.78 (1H, dd, J 15.6, 9.6, C(2)H), 2.86 (1H, dd, J 
15.6, 5.1, C(2)H), 3.50 (3H, s, CO2CH3), 3.70 (3H, s, ArOCH3), 4.36 (1H, ddd, J 9.6, 9.6, 
4.8, C(3)H), 5.80 (1H, d, J 9.6, C(4)H), 6.66-6.71 (2H, m, ArH), 7.13-7.18 (2H, m, ArH), 
7.28-7.57 (6H, m, ArH), 7.74-7.78 (2H, m, ArH), 7.98-8.00 (2H, m, ArH); δC (75 MHz, 
CDCl3) 38.5 (C(2)), 42.1 (C(3)), 51.7 (CO2CH3), 55.2 (OCH3), 62.7 (C(4)), 113.9 
(2×C(4)ArC(3)H), 128.7 (2×C(4)ArC(2)H), 128.7 (2×ArCH), 129.0 (4×ArCH), 129.5 
(2×ArCH), 132.3 (ArC), 133.3 (ArCH), 133.8 (ArCH), 136.8 (ArC), 136.9 (ArC), 158.5 
(ArC), 172.2 (C(1)), 194.6 (CO), 194.9 (CO); m/z (NSI+) 417 ([M+H]+, 85%), 434 
([M+NH4]
+,100%); HRMS (NSI+) C26H25O5 ([M+H]
+) requires 417.1697, found 417.1699 
(+0.6 ppm).  
(3S)-Methyl 4-benzoyl-3-(furan-2-yl)-5-oxo-5-phenylpentanoate (171) 
 
The title compound was prepared according to General Procedure G from (E)-furylacrylic 
anhydride (65 mg, 0.25 mmol), 1,3-diphenyl-1,3-propanedione (40 mg, 0.18 mmol), HBTM 
2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 mg, 0.20 mmol) in 
CH2Cl2 (0.25 mL) and purified by chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to afford 
the ester 171 as a dark yellow solid (46 mg, 69%); mp 74-77 °C; 
22
D][  +30.6 (c 0.5 in 
CHCl3); chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1.0 mL 
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min-1, 254 nm, 20 °C), tR major: 15.0 min, tR minor: 17.1 min, 96% ee; max (film)/cm-1 1738 
(C=O), 1697 (C=O), 1655(C=O), 1593 (furan), 1578 (furan), 1508 (furan), 1445 (C-O); δH 
(400 MHz, CDCl3) 2.78-2.94 (2H, m, C(2)H2), 3.60 (3H, s, OCH3), 4.46 (1H, td, J 8.9, 4.5, 
C(3)H), 5.97-6.09 (3H, m, furanyl(H)), 7.13-7.19 (1H, m, C(4)H2), 7.33-7.43 (4H, m, ArH), 
7.45-7.56 (2H, m, ArH), 7.87 (4H, ddd, J 17.5, 8.4, 1.1, ArH); δC (100 MHz, CDCl3) 35.9 
(C(2)H2), 36.3 (C(3)H), 51.9 (OCH3), 58.7 (C(4)H), 107.8 (furanylC(4)H), 110.5 
(furanylC(3)H), 128.7 (2×ArCH), 128.7 (2×ArCH), 128.8 (2×ArCH), 129.0 (2×ArCH), 
133.5 (ArC(4)H), 133.8 (ArC(4)H), 136.2 (ArC(1)), 136.6 (ArC(1)), 141.6 (furanylC(5)H), 
153.2 (furanylC(2)), 172.1 (C(1)), 194.4 (CO), 194.7 (CO); m/z (NSI+) 377 ([M+H]+, 100%), 
394 ([M+NH4]
+, 45%); HRMS (NSI+) C23H21O5 ([M+H]
+) requires 377.1384, found 
377.1387 (+0.9 ppm). 
(3S)-Methyl 4-benzoyl-5-oxo-5-phenyl-3-(thiophen-2-yl)pentanoate (172) 
 
The title compound was prepared according to General Procedure G from (E)-thienyl acrylic 
anhydride (73 mg, 0.25 mmol), 1,3-diphenyl-1,3-propanedione (40 mg, 0.18 mmol), HBTM 
2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 mg, 0.20 mmol) in 
CH2Cl2 (0.25 mL). and purified by chromatography (CH2Cl2→ 2%EtOAc/CH2Cl2) to 
afford the ester 172 as a dark yellow solid (51 mg, 86%); mp 91-94 °C; 
22
D][  +29.5 (c 0.4 in 
CHCl3); chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1.0 mL 
min-1, 254 nm, 20 °C), tR major: 16.1 min, tR minor: 22.9 min, 94% ee; max (film)/cm-1 1736 
(C=O), 1686 (C=O), 1655 (C=O), 1593 (C-C), 1578 (C-C), 1445 (C-O), 1263 (C-S); δH 
(400 MHz, CDCl3) 2.80-2.99 (2H, m, C(2)H2), 3.58 (3H, s, OCH3), 4.70 (1H, td, J 8.9, 4.5, 
C(3)H), 5.99 (1H, d, J 9.0, C(4)H), 6.74 (1H, dd, J 5.1, 3.5, thienylC(4)H), 6.80-6.85 (1H, m, 
thienylC(3)H), 7.03 (1H, dd, J 5.1, 0.9, thienylC(5)H), 7.30-7.58 (6H, m, ArH), 7.80-7.86 
(2H, m, ArH), 7.94-8.00 (2H, m, ArH); δC (100 MHz, CDCl3) 38.2 (C(3)H), 39.0 (C(2)H), 
51.9 (OCH3), 62.0 (C(4)H), 124.4 (thienylC(5)H), 126.5 (thienylC(3)H), 126.8 
(thienylC(4)H), 128.8 (4×ArCH), 129.0 (2×ArCH), 129.0 (2×ArCH), 133.5 (ArC(4)H), 
133.9 (ArC(4)H), 136.6 (ArC), 136.7 (ArC), 143.5 (thienylC(2)), 172.1 (C(1)), 194.4 (CO), 
194.5 (CO); m/z (NSI+) 393 ([M+H]+, 55%); HRMS (NSI+) C23H21O4S ([M+H]
+) requires 
393.1155, found 393.1157 (+0.5 ppm). 
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(3S)-Methyl 4-benzoyl-3-(3-chlorophenyl)-5-oxo-5-phenylpentanoate (169) 
 
The title compound was prepared according to General Procedure G from (E)-3-(3-
chlorophenyl)acrylic anhydride (87 mg, 0.25 mmol), 1,3-diphenylpropane-1,3-dione (40 mg, 
0.18 mmol), HBTM 2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 mg, 
0.20 mmol) in CH2Cl2 (0.25 mL) and purified by chromatography 
(CH2Cl2→2%EtOAc/CH2Cl2) gave the ester 169 as a pale yellow solid (51 mg, 67%); mp 
124-126 °C; 
22
D][  +18.1 (c 1.0 in CHCl3); chiral HPLC analysis, ChiralPak AD-H (20% i-
PrOH:hexane, flow rate 1.0 mL min-1, 220 nm, 30 °C), tR major: 10.3 min, tR minor: 13.2 
min, 96% ee; max (film)/cm-1 2361 (C-H), 1738 (C=O), 1684 (C=O), 1261 (C-O); δH (400 
MHz, CDCl3) 2.74-2.95 (2H, m, C(2)H2), 3.52 (3H, s, OCH3), 4.36 (1H, td, J 9.5, 4.6, 
C(3)H), 5.82 (1H, d, J 9.5, C(4)H), 7.01-7.17 (3H, m, ArH), 7.24 (1H, d, J 1.8, ArH), 7.29-
7.38 (2H, m, ArH), 7.38-7.51 (3H, m, ArH), 7.55 (1H, tt, J 6.9, 1.2, ArH), 7.77 (2H, dd, J 
8.4, 1.2, ArH), 7.98 (2H, dd, J 8.4, 1.2, ArH); δC (100 MHz, CDCl3) 38.0 (C(2)), 42.4 (C(3)), 
51.8 (OCH3), 61.8 (C(4)), 127.0 (C(3)ArC(6)H), 127.5 (C(3)ArC(2)H), 128.6 (ArC(1)H), 
128.7 (2×ArCH), 128.8 (2×ArCH), 128.9 (2×ArCH), 129.1 (2×ArCH), 129.8 
(C(3)ArC(5)H), 133.6 (PhC(4)H), 134.0 (PhC(4)H), 134.3 (C(3)ArC(3)Cl), 136.5 (PhC(1)), 
136.7 (PhC(1)), 142.6 (C(3)ArC(1)), 171.8 (C(1)), 194.2 (CO), 194.5 (CO); m/z (NSI+) 421 
([M+H]+, 100%); HRMS (NSI+) C25H21Cl
35O4 ([M+H]
+) requires 421.1202, found 421.1201 
(+0.2 ppm). 
(3S)-Methyl 4-benzoyl-3-(2-chlorophenyl)-5-oxo-5-phenylpentanoate (170) 
 
The title compound was prepared according to General Procedure G from (E)-3-(2-
chlorophenyl)acrylic anhydride (87 mg, 0.25 mmol), 1,3-diphenylpropane-1,3-dione (40 mg, 
0.18 mmol), HBTM 2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 mg, 
0.20 mmol) in CH2Cl2 (0.25 mL) and purified by chromatography (CH2Cl2→2% 
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EtOAc/CH2Cl2) gave the ester 170 as a yellow solid (53 mg, 69%); mp 93-96 °C; 
22
D][  
46.8 (c 1.3 in CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (10% i-PrOH:hexane, flow 
rate 1.0 mL min-1, 254 nm, 30 °C), tR major: 10.8 min, tR minor: 14.1 min, 93% ee; max 
(film)/cm-1 2924 (C-H), 2361 (C-H), 1734 (C=O), 1686 (C=O), 1651 (C=O), 1258 (C-O); 
δH (400 MHz, CDCl3) 2.90-3.09 (2H, m, C(2)H2), 3.50 (3H, s, OCH3), 4.79 (1H, q, J 7.8, 
C(3)H), 6.08 (1H, d, J 7.8, C(4)H), 7.04 (2H, pd, J 7.3, 1.8, ArH), 7.22-7.31 (2H, m, ArH), 
7.36 (4H, dt, J 13.4, 7.7, PhH), 7.43-7.58 (2H, m, PhH), 7.79-7.93 (4H, m, PhH); δC (100 
MHz, CDCl3) 35.8 (C(2)), 39.1 (C(3)), 51.7 (OCH3), 59.1 (C(4)), 126.9 (C(3)ArC(5)H), 128.4 
(ArCH), 128.7 (2×ArCH), 128.8 (2×ArCH), 128.9 (2×ArCH), 128.9 (2×ArCH), 130.2 
(ArCH), 133.4 (PhC(4)H), 133.8 (PhC(4)H), 134.0 (CCl), 136.4 (PhC(1)), 136.9 (PhC(1)), 
137.8 (C(3)ArC(1)), 172.1 (C(1)), 194.4 (CO), 195.1 (CO); m/z (NSI+) 421 ([M+H]+, 100%); 
HRMS (NSI+) C25H21Cl
35O4 ([M+H]
+) requires 421.1203, found 421.1201 (+0.4 ppm). 
(3S)-Methyl 4-benzoyl-3-methyl-5-oxo-5-phenylpentanoate (173) 
 
The title compound was prepared according to a General Procedure G from (E)-crotonic 
anhydride (39 mg, 0.25 mmol), 1,3-diphenyl-1,3-propanedione (40 mg, 0.18 mmol), HBTM 
2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 mg, 0.20 mmol) in 
CH2Cl2 (0.25 mL) and purified by chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to afford 
the ester 173 as a colourless oil (39 mg, 67%); 
22
D][  +31.8 (c 1.25 in CH2Cl2); chiral HPLC 
analysis, ChiralPak AD-H (5% i-PrOH:hexane, flow rate 0.5 mL min-1, 220 nm, 30 °C), tR 
major: 35.0 min, tR minor: 38.7 min, 70% ee; compound data as below. 
The reaction was repeated using a modified General Procedure D at a lower temperature from 
(E)-crotonic anhydride (39 mg, 0.25 mmol), 1,3-diphenyl-1,3-propanedione (40 mg, 0.18 
mmol), HBTM 2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 mg, 0.20 
mmol) in CH2Cl2 (0.25 mL), the reaction was carried out at 78 C and purified by 
chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to afford the ester 15 as a colourless oil (24 
mg, 41%); 
22
D][  +32.7 (c 0.9 in CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (5% i-
PrOH:hexane, flow rate 0.5 mL min-1, 220 nm, 30 °C), tR major: 35.0 min, tR minor: 38.7 
min, 85% ee; max (film)/cm-1 2974 (C-H), 2953 (C-H), 2924 (C-H), 1724 (C=O), 1686 
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(C=O), 1670 (C=O), 1593 (O-CH3); δH (300 MHz, CDCl3) 1.09 (3H, d, J 7.0, CH(CH3)), 
2.38-2.68 (2H, m, C(2)H2), 3.00-3.20 (1H, m, C(3)H), 3.65 (3H, s, OCH3), 5.66 (1H, d, J 
8.0, C(4)H), 7.37-7.62 (6H, m, ArH), 7.95-8.06 (4H, m, ArH); δC (100 MHz, CDCl3) 17.8 
(CH(CH3)), 31.5 (C(3)), 38.6 (C(2)), 51.7 (OCH3), 60.0 (C(4)), 128.8 (2×ArCH), 128.8 
(2×ArCH), 129.0 (2×ArCH), 129.0 (2×ArCH), 133.7 (2×ArC), 136.6 (ArC), 137.0 (ArC), 
173.2 (C(1)), 195.6 (CO), 195.8 (CO); m/z (NSI+) 325 ([M+H]+, 100%), 342 ([M+NH4]
+, 
35%); HRMS (NSI+) C20H21O4 ([M+H]
+) requires 325.1434, found 325.1440 (+1.7 ppm). 
(3S)-Methyl 3-(1,3-dioxo-1,3-diphenylpropan-2-yl)hexanoate (174) 
 
The title compound was prepared according to General Procedure G from (E)-hexenoic 
anhydride (53 mg, 0.25 mmol), 1,3-diphenyl-1,3-propanedione (40 mg, 0.18 mmol), HBTM 
2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 mg, 0.20 mmol) in 
CH2Cl2 (0.25 mL) and purified by chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to afford 
the ester 174 as a colourless oil (36 mg, 57%); 
22
D][  0.2 (c 1.0 in CHCl3); chiral HPLC 
analysis, ChiralPak AD-H (5% i-PrOH:hexane, flow rate 0.5 mL min-1, 220 nm, 30 °C), tR 
major: 29.5 min, tR minor: 32.8 min, 80% ee; compound data as below. 
The reaction was repeated using a modified General Procedure D at a lower temperature from 
(E)-hexenoic anhydride (53 mg, 0.25 mmol), 1,3-diphenyl-1,3-propanedione (40 mg, 0.18 
mmol), HBTM 2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 mg, 0.20 
mmol) in CH2Cl2 (0.25 mL) at 78 C and purified by chromatography 
(CH2Cl2→2%EtOAc/CH2Cl2) to afford the ester 174 as a colourless oil (22 mg, 35%); 
22
D][  +45.8 (c 0.5 in CHCl3); chiral HPLC analysis, ChiralPak AD-H (5% i-PrOH:hexane, 
flow rate 0.5 mL min-1, 220 nm, 30 °C), tR major: 29.5 min, tR minor: 32.8 min, 93% ee; max 
(film)/cm-1 2957 (C-H), 2932 (C-H), 2872 (C-H), 1730 (C=O), 1694 (C=O), 1668 (C=O), 
1595 (O-CH3); δH (400 MHz, CDCl3) 0.81 (3H, t, J 7.1, C(6)H3), 1.16-1.31 (1H, m, C(4)H2), 
1.33-1.45 (2H, m, C(5)H2), 1.49-1.63 (1H, m, C(4)H2), 2.47-2.72 (2H, m, C(2)H2), 2.84-3.00 
(1H, m, C(3)H), 3.62 (3H, s, OCH3), 5.87 (1H, d, J 7.2, CH(COPh)2), 7.35-7.63 (6H, m, 
ArH), 8.00 (4H, dt, J 8.6, 1.4, ArH); δC (100 MHz, CDCl3) 14.1 (C(6)), 20.8 (C(5)), 33.5 
(C(4)), 35.2 (C(2)3), 36.3 (C(3))CH), 51.6 (OCH3), 58.4 (CH(COPh)2), 128.8 (2×ArCH), 
128.8 (2×ArCH), 129.0 (2×ArCH), 129.0 (2×ArCH), 133.6 (ArCH), 133.6 (ArCH), 136.8 
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(ArC), 137.0 (ArC), 173.7 (C(1)), 195.9 (CO), 196.2 (CO); m/z (NSI+) 353 ([M+H]+, 100%); 
HRMS (NSI+) C22H25O4 ([M+H]
+) requires 353.1747, found 353.1753 (+1.6 ppm). 
(3S)-Methyl 4-acetyl-5-oxo-3-phenylhexanoate (176) 
 
The title compound was prepared according to General Procedure G from (E)-cinnamic 
anhydride (70 mg, 0.25 mmol), pentane-2,4-dione (19 μL, 0.18 mmol), HBTM 2.1 (2.8 mg, 
0.009 mmol) and PS-BEMP (2.2 mmol/g loading) (90 mg, 0.20 mmol) in CH2Cl2 (0.25 mL) 
and purified by chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to afford the ester 176 as a 
white solid (30 mg, 64%); mp 68-72 °C; 
22
D][  +57.3 (c 1.0 in CHCl3); chiral HPLC 
analysis, ChiralPak OJ-H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 254 nm, 30 °C), tR 
major: 20.9 min, tR minor: 34.2 min, 37% ee; max (film)/cm-1 1722, 1686, 1356, 1146; δH 
(400 MHz, CDCl3) 1.85 (3H, d, J 0.4, CH3), 2.27 (3H, d, J 0.4, CH3), 2.58 (2H, dd, J 7.2, 6.6, 
C(2)H2), 3.52 (3H, s, OCH3), 3.97 (1H, ddd, J 11.6, 7.2, 6.6, C(3)H), 4.26 (1H, d, J 11.6, 
C(4)H), 7.18-7.24 (3H, m, ArH), 7.26-7.31 (2H, m, ArH); δC (100 MHz, CDCl3) 29.7 (CH3), 
30.0 (CH3), 39.3 (C(2)), 41.7 (C(3)), 51.8 (OCH3), 74.2 (C(4)), 127.6 (C(3)ArC(4)H), 128.1 
(2×ArCH), 129.0 (2×ArCH), 139.9 (C(3)ArC(1)), 171.6 (C(1)), 202.8 (CO), 203.0 (CO); 
m/z (NSI+) 263 ([M+H]+, 100%); HRMS (NSI+) C15H19O4 ([M+H]
+) requires 263.1278, 
found 263.1270 (3.0 ppm). Compound synthesised by Dr Carmen Simal. 
(3S)-Methyl-5-(4-methylphenyl)-4-[(4-methylphenyl)carbonyl]-5-oxo-3-[4-
(trifluoromethyl)phenyl]pentanoate (186) 
 
The title compound was prepared according to General Procedure G from (E)-3-(4-
(Trifluoromethyl)phenyl)acrylic anhydride (104 mg, 0.25 mmol), 1,3-bis(4-
Methylphenyl)propane-1,3-dione (45 mg, 0.18 mmol), HBTM 2.1 (2.8 mg, 0.009 mmol) 
and PS-BEMP (2.2 mmol/g loading) (90 mg, 0.20 mmol) in CH2Cl2 (0.25 mL) and purified 
by chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to afford the ester 186 as an off-white 
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solid (47 mg, 54%); mp 120-123 °C; 
22
D][  23.2 (c 1.1 in CHCl3); chiral HPLC analysis, 
ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 220 nm, 30 °C), tR major: 
14.1 min, tR minor: 20.1 min, 97% ee; max (film)/cm-1 2954 (C-H), 1730 (C=O), 1686 
(C=O), 1605 (C=C), 1110 (C-F); δH (500 MHz, CDCl3) 2.32 (3H, s, PhCH3), 2.38 (3H, s, 
PhCH3), 2.74-2.96 (2H, m, C(2)H2), 3.50 (3H, s, OCH3), 4.45 (1H, td, J 9.6, 4.4, C(3)H), 
5.77 (1H, d, J 9.6, C(4)H), 7.11 (2H, d, J 8.0, tolylC(2)H), 7.22 (2H, d, J 8.0, tolylC(2)H), 
7.40 (4H, q, J 8.3, C(3)ArH), 7.67 (2H, d, J 8.1, tolylC(3)H), 7.90 (2H, d, J 8.1, tolylC(3)H); 
δC (125 MHz, CDCl3) 21.7 (ArCH3), 21.8 (ArCH3), 37.9 (C(2)H2), 42.5 (C(3)H), 51.8 
(OCH3), 61.8 (C(4)H), 124.1 (q, 
1JCF 272.0, CF3), 125.4 (q, 
3JCF 3.6, 2×C(3)ArC(3)), 128.8 
(2×ArCH), 129.0 (2×ArCH), 129.1 (2×ArCH), 129.5 (2×ArCH), 129.8 (2×ArCH), 134.0 
(C(5)ArC(1)), 134.2 (C(5)ArC(1)), 144.7 (C(3)ArC(1)), 145.0 (C(5)ArC(4)), 145.1 
(C(5)ArC(4)), 171.8 (OCH3), 193.7 (CO), 194.1 (CO); δF (282 MHz, CDCl3) 63.10; m/z 
(NSI+) 483 ([M+H]+, 100%), 500 ([M+NH4]
+, 30%); HRMS (NSI+) C28H26F3O4 ([M+H
+]) 
requires 483.1778, found 483.1775 (+0.8 ppm). 
(3S)-Methyl-5-(furan-2-yl)-4-[(furan-2-yl)carbonyl]-5-oxo-3-[4-
(trifluoromethyl)phenyl]pentanoate (188) 
 
The title compound was prepared according to General Procedure G from (E)-3-(4-
(Trifluoromethyl)phenyl)acrylic anhydride (104 mg, 0.25 mmol), 1,3-bis(furan-2-yl)propane-
1,3-dione (37 mg, 0.18 mmol), HBTM 2.1 (2.8 mg, 0.009 mmol) and PS-BEMP (2.2 
mmol/g loading) (90 mg, 0.20 mmol) in CH2Cl2 (0.25 mL) and purified by chromatography 
(CH2Cl2→2%EtOAc/CH2Cl2) gave 188 as a yellow solid (71 mg, 91%); mp 151-154 °C; 
22
D][  10.8 (c 1.0 in CH2Cl); chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, 
flow rate 1.0 mL min-1, 254 nm, 30 °C), tR major: 12.7 min, tR minor: 21.4 min, 94% ee; max 
(film)/cm-1 2974 (C-H), 2926 (C-H), 1734 (C=O), 1670 (C=O), 1458 (furan), 1113 (C-F); 
δH (500 MHz, CDCl3) 2.81 (2H, qd, J 15.9, 7.2, C(2)H2), 3.49 (3H, s, OCH3), 4.40 (1H, td, J 
10.0, 4.5, C(3)H), 5.50 (1H, d, J 10.3, C(4)H), 6.43 (1H, dd, J 3.5, 1.5, furanyl(4)H), 6.55 
(1H, dd, J 3.5, 1.5, furanyl(4)H), 7.12 (1H, d, J 3.5, furanyl(3)H), 7.34-7.46 (5H, m, 4×ArH 
and furanyl(3)H), 7.50 (1H, s, furanyl(5)H), 7.59 (1H, s, furanyl(4)H); δC (125 MHz, CDCl3) 
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38.1 (C(2)H2), 41.6 (OCH3), 51.8 (C(3)H), 61.6 (C(4)H), 113.0 (furanylC(4)H), 113.1 
(furanylC(4)H), 119.1 (furanylC(3)H), 119.6 (furanylC(3)H), 124.1 (q, 1JCF 272.0, CF3). 125.4 
(d, 3JCF 3.6, 2×C(3)ArC(3)H), 128.8 (2×C(3)ArC(2)H), 129.4 (q, 
2JCF 32.4, ArC(4)CF3), 144.3 
(ArC(1)), 147.2 (furanylC(5)H), 147.7 (furanylC(5)H), 151.9 (furanylC(2)), 152.2 
(furanylC(2)), 171.4 (C(1)), 181.8 (CO), 181.8 (CO); δF (282 MHz, CDCl3) 63.12; m/z 
(NSI+) 435 ([M+H]+, 100%), 452 ([M+NH4]
+, 70%); HRMS (NSI+) C22H18F3O6 ([M+H]
+) 
requires 435.1050, found 435.1052 (+0.5 ppm). 
(3S)-Methyl 4-benzoyl-3-(3-methylphenyl)-5-oxo-5-phenylpentanoate (168) 
 
The title compound was prepared according to General Procedure G from (E)-3-(3-
methylphenyl)acrylic anhydride (76 mg, 0.25 mmol), 1,3-diphenyl-1,3-propanedione (40 
mg, 0.18 mmol), and purified by chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to afford 
the ester 168 as an off-white solid (56 mg, 75%); mp 110-112 °C; 
22
D][  +19.8 (c 0.8 in 
CHCl3); chiral HPLC analysis, Chiralcel AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min
-
1, 254 nm, 30 °C) tR major: 9.9 min, tR minor: 13.3 min, 91% ee; max (film)/cm-1 1728 
(C=O, ester), 1688 (C=O), 1668 (C=O) 1257 (CH3-O); (400 MHz, CDCl3) 2.20 (3H, s, 
ArCH3), 2.81 (1H, dd, J 15.7, 9.3, C(2)H), 2.89 (1H, dd, J 15.7, 5.0, C(2)H), 3.51 (3H, s, 
CO2CH3), 4.36 (1H, td, J 9.3, 5.0, C(3)H), 5.83 (1H, d, J 9.4, C(4)H), 6.94-6.82 (1H, m, 
(C3)Ar(2)H,), 7.03 (3H, dd, J 4.9, 3.8, (C3)Ar(4,5,6)H), 7.37-7.29 (2H, m, ArH), 7.49-7.37 
(3H, m, ArH), 7.55 (1H, tt, J 7.4, 2.8, ArH), 7.84-7.71 (2H, m, ArH), 8.04-7.93 (2H, m, 
ArH); C(100 MHz, CDCl3) 21.3 (C(3)ArCH3(3)), 38.0 (C(2)), 42.5 (C(3)), 51.5 (CO2CH3), 
62.1 (C(4)), 125.3 (C(3)-ArC(6)), 127.8 (C(3)-ArC(2)), 128.3 (C(3)-ArC), 128.4 (C(5)-ArC), 
128.5 (C(5)-ArCH), 128.8 (C(5)-ArC), 129.2 (C(3)-ArC), 133.1 (C(5)-ArC(4)), 133.6 (C(5)-
ArC(4)), 136.6 (C(5)-ArC(1)), 136.8 (C(5)-ArC(1)), 137.9 (C(3)-ArC(3)), 140.1 (C(3)-
ArC(1)), 172.04 (C(1)), 194.4 (C(5)), 194.8 (C(5)); m/z (ESI+) 401 ([M+H]+, 100%); 
HRMS (ESI+) C26H25O4 ([M+H]
+), found 401.1750, requires 401.1747 (+0.7 ppm). 
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(3S)-Methyl-5-(4-bromophenyl)-4-[(4-bromophenyl)carbonyl]-5-oxo-3-
phenylpentanoate (183) 
 
The title compound was prepared according to General Procedure G from (E)-cinnamic 
anhydride (70 mg, 0.25 mmol) and 1,3-bis(4-bromophenyl)propane-1,3-dione (78 mg, 0.18 
mmol) and purified by chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to afford the ester 
183 as a white solid (50 mg, 52%); mp 172-173 °C; 
22
D][  +9.2 (c 0.9 in CHCl3); chiral 
HPLC analysis; Chiralcel AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 254 nm, 30 
°C) tR major: 13.8 min, tR minor: 18.3 min, 66% ee; max (film) 1734 (C=O, ester), 1701 
(C=O), 1664 (C=O), 1259 (CH3-O); (400 MHz, CDCl3) 2.80 (1H, dd, J 15.7, 9.0, 
C(2)H), 2.87 (1H, dd, J 15.7, 4.8, C(2)H), 3.52 (3H, s, CO2CH3), 4.37 (1H, td, J 9.3, 4.8, 
C(3)HPh), 5.74 (1H, d, J 9.7, C(4)H), 7.28-6.82 (5H, m, 5 × Ar(3)H,), 7.46 (2H, d, J 8.6, 
Ar(4,2)H), 7.58 (4H, dd, J 9.4, 8.6, Ar(4,2)H), 7.84 (2H, d, J 8.6 Hz, ArH); C(100 MHz, 
CDCl3) 38.0 (C(2)), 42.6 (C(3)), 51.7 (CO2CH3), 62.5 (C(4)), 127.3, 128.3, 128.6, 128.8 
(C(5)-ArC), 129.3 (C(5)-ArC), 130.0 (C(5)-ArCH), 130.3 (C(5)-ArCH), 131.9 (C(5)-ArCH), 
132.2 (C(5)-ArCH), 135.1 (C(5)-ArC), 135.2 (C(5)-ArC), 139.8 (C(3)-ArC(1)), 171.9 (C(1)), 
193.3 (C(5)), 193.5 (C(5)); HRMS (ESI+) C25H21Br792O4 ([M+H]+), found 542.9800, 
requires 542.9801 (0.5 ppm). Compound synthesised by Dr Charlene Fallan. 
(3S) Methyl-5-oxo-3-phenyl-5-[4-(trifluoromethyl)phenyl]-4-{[4-
(trifluoromethyl)phenyl]carbonyl}pentanoate (184) 
 
The title compound was prepared according to General Procedure G from 1,3-bis(4-
trifluoromethylphenyl)propane-1,3-dione (76 mg, 0.18 mmol) and (E)-cinnamic anhydride 
(70 mg, 0.25 mmol) and purified by chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to 
afford the ester 184 as a white solid (62 mg, 67%); mp 121-122 °C; 
22
D][  +63.2 (c 1.55 in 
CHCl3); chiral HPLC analysis; Chiralcel AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min
-
1, 254 nm, 30 °C) tR major: 10.0 min, tR minor: 13.5 min, 81% ee; max (film) 1734 (C=O, 
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ester), 1705 (C=O), 1668 (C=O); (400 MHz, CDCl3) 2.80 (1H, dd, J 15.7, 9.0, C(2)H), 
2.87 (1H, dd, J 15.7, 4.8, C(2)H), 3.52 (3H, s, CO2CH3), 4.37 (1H, td, J 9.3, 4.8, C(3)H), 
5.74 (1H, d, J 9.7, C(4)H), 7.28-6.82 (5H, m, 5 × Ar(3)H,), 7.46 (2H, d, J 8.6, Ar(4,2)H), 
7.58 (4H, dd, J 9.4, 8.6, Ar(4,2)H), 7.84 (2H, d, J 8.6 Hz, ArH); C(100 MHz, CDCl3) 37.9 
(C(2)), 42.6 (C(3), 51.7 (CO2CH3), 62.8 (C(4)), 123.3 (q, JC-F 273.0 Hz, 2 × C(5)-ArCF3), 
125.7 (q, JC-F 3.3 Hz, C(5)-Ar(3)CH), 126.0 (q, JC-F 3.4 Hz, C(5)-Ar(3)CH), 127.5 (C(3)-
Ar(4)C), 128.3 (C(3)-Ar(2)C), 128.6 (C(3)Ar(3)C), 128.7 (C(5)Ar(2)C), 129.1 (C(5)Ar(2)C), 
134.9 (q, JC-F 32.9 Hz, C(5)-ArC(4)), 135.2 (q, JC-F 32.8 Hz, C(5)-ArC(4)), 139.1 (C(5)-
ArC(1)), 139.5 (C(5)-ArC(1)), 171.9 (C(1)), 193.6 (C(5)), 193.7 (C(5)); F(376 MHz, CDCl3) 
63.8 (CF3); m/z pending. Compound synthesised by Dr Charlene Fallan. 
(3S)-Methyl-5-(4-methylphenyl)-4-[(4-methylphenyl)carbonyl]-5-oxo-3-
phenylpentanoate (185) 
 
The title compound was prepared according to General Procedure G from 1,3-bis(4-
methylphenyl)propane-1,3-dione (55 mg, 0.18 mmol) and (E)-cinnamic anhydride (70 mg, 
0.25 mmol) and purified by chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to afford the 
ester 185 as an off-white solid (30 mg, 40%); mp 142-143 °C; 
22
D][  -3.6 (c 0.65 in CHCl3); 
chiral HPLC analysis; Chiralcel AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 254 
nm, 30 °C) tR major: 16.9 min, tR minor: 23.6 min, 90% ee; max (film) 2970 (C−H), 1736 
(C=O, ester), 1693 (C=O), 1654 (C=O); (400 MHz, CDCl3) 2.32 (3H, s, ArCH3), 2.38 
(3H, s, ArCH3), 2.83 (1H, dd, J 15.7, 9.6, C(2)H), 2.88 (1H, dd, J 15.7, 4.7, C(2)H), 3.49 
(3H, s, CO2CH3), 4.40 (1H, td, J 9.6, 4.7, C(3)H), 5.77 (1H, d, J 9.6, C(4)H), 7.35-7.03 (9H, 
m, 5 × Ar(3)H, and 4 × C(5)-Ar(3)H), 7.68 (2H, d, J 8.3, C(5)-Ar(2)H), 7.90 (2H, d, J 8.3, 
C(5)-Ar(2)H); C(100 MHz, CDCl3) 21.6 (ArCH3), 21.6 (ArCH3), 38.2 (C(2)), 42.6 (C(3)), 
51.5 (CO2CH3), 62.1 (C(4)), 127.0 (C(3)-ArC(4)), 128.3 (C(3)-ArC(2,3)), 128.7 (C(5)-
ArC(3)), 129.0 (C(5)-ArC(2)), 129.0 (C(5)-ArC(3)), 129.2 (C(5)-ArC(2)), 129.5 (C(5)-
ArC(2)), 134.1 (C(5)-ArC(1)), 134.3 (C(5)-ArC(1)), 140.5 (C(3)-ArC(1)), 144.1 (C(5)-
ArC(4)), 144.7 (C(5)-ArC(4)), 172.0 (C(1)), 193.8 (C(5)), 194.3 (C(5)); m/z (ESI+) 302 
([M+H]+, 100%); HRMS (ESI+) C27H27O4 ([M+H]
+), found 415.1906, requires 415.1904 
(0.5 ppm). Compound synthesised by Dr Charlene Fallan. 
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(3S)-Methyl-5-(furan-2-yl)-4-[(furan-2-yl)carbonyl]-5-oxo-3-phenylpentanoate (187) 
 
The title compound was prepared according to General Procedure G from 1,3-bis(Furan-2-
yl)propane-1,3-dione (37 mg, 0.18 mmol) and (E)-cinnamic anhydride (70 mg, 0.25 mmol) 
and purified by chromatography (CH2Cl2→2%EtOAc/CH2Cl2) to afford the ester 187 as a 
pale yellow solid (61 mg, 93%); mp 131-133 °C; 
22
D][  +21.1 (c 1.65 in CHCl3); chiral 
HPLC analysis; Chiralcel AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 254 nm, 30 
°C) tR major: 14.1 min, tR minor: 21.1 min, 90% ee; max (film) 1732 (C=O, ester), 1674 
(C=O), 1645 (C=O); (400 MHz, CDCl3) 2.86-2.82 (2H, m, C(2)H), 3.49 (3H, s, 
CO2CH3), 4.38 (1H, td, J 9.8, 4.7, C(3)H), 5.50 (1H, dd, J 10.4, 0.9, C(4)H), 6.42 (1H, ddd, J 
3.7, 1.7, 0.9 Hz, furanyl(4)H), 6.54 (1H, ddd, 3.7, 1.7, 1.0, furanyl(4)H), 7.20-7.07 (4H, m, 
C(3)Ar(2,3)H), 7.27-7.25 (2H, m, C(3)Ar(4)H and furanyl(3)H), 7.37 (1H, dt, J 3.6, 0.9, 
furanyl(3)H), 7.50-7.49 (1H, m, furanyl(5)H), 7.60-7.59 (1H, m, furanyl(5)H); C(100 MHz, 
CDCl3) 38.4 (C(2)), 41.8 (C(3)), 51.5 (CO2CH3), 62.0 (C(4)), 112.7 (C(5)-furanyl(4)C), 112.8 
(C(5)-furanyl(4)C), 118.7 (C(5)- furanyl(3)C), 119.3 (C(5)- furanyl(3)C), 127.1 (C(3)-
Ar(4)H), 128.2 (C(3)-Ar(2)CH), 128.3 (C(3)-Ar(3)CH), 139.8 (C(3)-ArC(1)), 146.8 (C(5)- 
furanyl(5)), 147.4 (C(5)- furanylC(5)), 151.9 (C(5)- furanylC(2)), 152.1 (C(5)- furanylC(2)), 
171.6 (C(1)), 181.9 (C(5)), 182.0 (C(5)); m/z (ESI+) 367 ([M+H]+, 100%); HRMS (ESI+) 
C21H19O6 ([M+H]
+), found 367.1175, requires 367.1176 (0.3 ppm). Compound 
synthesised by Dr Charlene Fallan. 
General Procedure H: Lactams and Lactones From Benzazoles 
 
To a solution of the corresponding homoanhydride (1.4 equiv) in bench grade THF (0.72 
M), was added benzazole (1.0 equiv), isothiourea (HBTM 2.1, 0.05 equiv) and EtN(iPr)2 
(1.1 equiv) at 0 °C. The reaction mixture was stirred and gradually warmed to room 
temperature over 5 h. The solution was diluted with EtOAc and washed sequentially with 
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0.1 M HCl and saturated NaHCO3 solution, dried over anhydrous MgSO4, filtered and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel to 
afford the product(s). 
(11R)-10-Benzoyl-11-phenyl-8-thia-1-azatricyclo[7.4.0.02,7]trideca-2,4,6,9-tetraen-13-
one (228a) and (4R)-5-(1,3-benzothiazol-2-yl)-4,6-diphenyl-3,4-dihydro-2H-pyran-2-
one (228b) 
 
The title compounds were prepared according to General Procedure H from (E)-cinnamic 
anhydride (700 mg, 2.50 mmol) and 2-phenacyl benzothiazole (455 mg, 1.80 mmol), 
EtN(iPr)2 (0.35 mL, 2.00 mmol) and HBTM 2.1 (5.5 mg, 1 mol %) in THF (5 mL) and 
purified by chromatography on silica gel (10:2 CH2Cl2/hexane) to afford 228a as a yellow 
solid (595 mg, 86%) and 228b as a yellow solid (63 mg, 9%). The major isomer was 
suspended in Et2O then recrystallised from EtOAc: crystals were obtained (68 mg, 10% 
overall yield, 4% ee) plus liquors which were concentrated in vacuo to give a yellow solid.  
228a (major): (472 mg, 68% yield); mp 168-171 °C; 
20
D][  148.5 (c 1.0 in CHCl3); chiral 
HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 
°C), tR minor: 13.2 min, tR major: 22.5 min, 97% ee; max (film)/cm-1 3024 (C-H), 2984 (C-
H), 2913 (C-H), 1722 (C=O), 1597 (C=C), 1574 (C=C), 1477 (C-N), 1360 (C-S), 1269 (C-
O); δH (500 MHz, CDCl3) 3.05 (1H, dd, J 15.9, 2.2, C(12)H2), 3.29 (1H, dd, J 15.9, 6.9, 
C(12)H2), 4.38 (1H, dd, J 6.9, 2.2, C(11)H), 7.11 (2H, d, J 7.2, 2×C(11)PhC(2)H), 7.21-7.44 
(10H, m, ArH), 7.62 (1H, s, C(6)H), 8.47 (1H, d, J 7.8, C(3)H); δC (126 MHz, CDCl3) 38.6 
(C(11)H), 41.4 (C(12)H2), 107.7 (C(10)), 117.5 (C(3)H), 122.0 (C(6)H), 125.9 (C(5)H), 126.8 
(2×C(11)PhC(2)H), 127.0 (2×C(10)COPhC(3)H, C(4)H), 127.6 (C(11)PhC(4)H), 127.8 
(C(7)), 128.1 (2×C(10)COPhC(2)H), 129.3 (2×C(11)PhC(3)H), 130.3 (C(10)COPhC(4)H), 
136.0 (C(2)), 139.4 (C(10)COPhC(1)), 140.8 (C(11)PhC(1)), 156.2 (C(9)), 167.9 (C(13)O), 
191.2 (C(10)CO); m/z (NSI+) 384 ([M+H]+, 60%); HRMS (NSI+) C24H18O2NS ([M+H]
+) 
requires 384.1053, found 384.1052 (0.2 ppm). 
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228b (minor): (63 mg, 9%); mp 192194 °C; 
20
D][  18.4 (c 1.0 in CHCl3); chiral HPLC 
analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR 
major: 7.7 min, tR minor: 10.8 min, 86% ee; max (film)/cm-1 2974 (C-H), 2372 (C-H), 1775 
(C=O), 1647 (C=N), 1491 (C=C), 1435 (C=C), 1339 (C-S), 1271 (C-O); δH (300 MHz, 
CDCl3) 3.08 (1H, dd, J 15.8, 1.6, C(3)H2), 3.32 (1H, dd, J 15.8, 7.6, C(3)H2), 5.03 (1H, dd, J 
7.6, 1.6, C(4)H), 7.23-7.36 (6H, m, ArH), 7.38-7.52 (3H, m, ArH), 7.55-7.63 (4H, m, ArH), 
7.93 (1H, d, J 7.8, HetArH); δC (75 MHz, CDCl3) 36.9 (C(3)H2), 41.3 (C(4)H), 115.1 (C(5)), 
121.3 (C(5)HetArCH), 123.1 (C(5)HetArCH), 125.5 (C(5)HetArCH), 126.1 
(C(5)HetArCH), 127.0 (2×C(4)PhC(2)H), 127.8 (C(4)PhC(4)H), 128.9 (2×C(6)PhC(3)H), 
129.3 (2×C(4)PhC(3)H), 130.1 (2×C(6)PhC(2)H), 130.8 (C(6)PhC(4)H), 131.9 
(C(6)PhC(1)), 135.7 (C(5)HetArC), 139.6 (C(4)PhC(1)), 152.4 (C(5)HetArC), 154.4 (C(6)), 
164.2 (C(5)HetArC=N), 166.6 (C(2)O); m/z (NSI+) 384 ([M+H]+, 60%); HRMS (NSI+) 
C24H18O2NS ([M+H]
+) requires 384.1053, found 384.1052 (0.2 ppm). 
(11R)-10-Benzoyl-11-(3-methylphenyl)-8-thia-1-azatricyclo[7.4.0.02,7]trideca-
2(7),3,5,9-tetraen-13-one (S11a) and (R)-5-(benzo[d]thiazol-2-yl)-6-phenyl-4-m-tolyl-
3,4-dihydro-2H-pyran-2-one (S11b) 
 
The title compounds were prepared according to General Procedure H from (E)-3-(3-
Methylphenyl)acrylic anhydride (771 mg, 2.52 mmol) and 2-phenacyl benzothiazole (607 
mg, 2.40 mmol), EtN(iPr)2 (0.46 mL, 2.64 mmol) and HBTM 2.1 (7 mg, 1 mol %) in THF 
(4 mL) and purified by chromatography (20% hexane/CH2Cl2) to afford the title 
compounds S11a and S11b as yellow solids.  
S11a (major): (732 mg, 77%); mp 159-161 °C; [α]D
20 101.0 (c 1.0, CHCl3); chiral HPLC 
analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR 
minor: 10.8 min, tR major: 16.4 min, 86% ee; νmax (film) 1714(C=O), 1604 (C=O), 1481; δH 
(400 MHz, CDCl3) 2.28 (3H, s, ArCH3), 3.05 (1H, dd, J 15.9, 2.4, C(12)H2), 3.27 (1H, dd, J 
15.9, 6.9, C(12)H2), 4.31 (1H, dd, J 6.9, 2.4, C(11)H), 6.89 (2H, d, J 9.3, ArH), 7.06 (1H, d, J 
7.5, ArH), 7.17 (1H, t, J 7.5, ArH), 7.28 (2H, s, ArH), 7.29 (2H, s, ArH), 7.32-7.42 (3H, m, 
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ArH), 7.61-7.64 (1H, m, ArH), 8.45-8.49 (1H, m, ArH); δC (100 MHz, CDCl3) 21.5 
(C(11)ArCH3), 38.4 (C(11)H), 41.3 (C(12)H2), 107.7 (C10), 117.5 (C(6)ArCH), 121.9 
(C(5)ArCH), 123.7 (C(11)ArC(6)H), 125.8 (C(4)H), 126.9 (C(11)ArC(4)H), 127.0 
(2×C(10)ArC(2)H), 127.4 (C(3)H), 127.8 (C(7)), 128.0 (2×C(10)ArC(3)H), 128.3 
(C(11)ArC(5)H), 129.1 (C(11)ArC(2)H), 130.2 (C(10)ArC(4)H), 136.0 (C(11)Ar(3)C), 138.9 
(C(10)ArC(1)), 139.3 (C(2)ArC), 140.7 (C(11)ArC(1)), 156.1 (C(9)), 167.9 (C(13)=O), 191.2 
(C(10)=O). 
S11b (minor): (39 mg, 4%); mp 146-147 °C; [α]D
20 9.7 (c 0.75, CHCl3); HPLC analysis, 
ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR minor: 
6.9 min, tR major: 9.7 min, 85% ee; νmax (film) 2982 (C-H), 1772 (C=O), 1504; δH (400 
MHz, CDCl3) 2.31 (3H, s, C(4)ArCH3), 3.07 (1H, dd, J 15.7, 0.7, C(3)H2), 3.31 (1H, dd, J 
15.7, 7.6, C(3)H2), 4.97 (1H, dd, J 7.7, 1.7, C(4)H), 7.04 (1H, d, J 7.8, C(4)ArC(4)H), 7.11-
7.13 (1H, m, C(4)ArC(6)H), 7.16-7.22 (1H, m, C(4)ArC(2)H), 7.25-7.32 (2H, m, 
2×C(5)HetArCH), 7.37-7.46 (3H, m, C(6)ArC(3,4)H), 7.48-7.53 (1H, m, C(4)ArC(5)H), 
7.56-7.60 (2H, m, 2×C(6)ArC(2)H), 7.62 (1H, d, J 8.0, C(5)HetArCH), 7.93 (1H, d, J 8.2, 
C(5)HetArCH); δC (100 MHz, CDCl3) 21.5 (ArCH3), 36.9 (C(3)H2), 41.2 (C(4)H), 115.0 
(C(6)), 121.2 (C(5)HetArCH), 123.0 (C(5)HetArCH), 123.8 (C(5)HetArCH), 125.3 
(C(4)ArC(6)H), 125.9 (C(5)HetArCH), 127.7 (C(4)ArC(4)H), 128.5 (C(6)ArC(4)H), 128.8 
(2×C(6)ArC(2)H), 129.0 (C(4)ArC(5)H), 129.9 (2×C(6)ArC(3)H), 130.7 (C(4)ArC(2)H, 
131.9 (C(6)ArC(1)), 135.7 (C(5)HetArC), 138.8 (C(4)ArC(3)), 139.4 (C(4)ArC(1)), 152.4 
(C(5)), 154.1 (C(5)HetArC), 164.1 (C(5)HetArC=N), 166.6 (C(2)). 
(11S)-10-Benzoyl-11-(furan-2-yl)-8-thia-1-azatricyclo[7.4.0.02,7]trideca-2,4,6,9-tetraen-
13-one (242a) and (4S)-5-(1,3-benzothiazol-2-yl)-4-(furan-2-yl)-6-phenyl-3,4-dihydro-
2H-pyran-2-one (242b) 
 
The title compounds were prepared according to General Procedure H from (E)-3-(Furan-2-
yl)acrylic anhydride (430 mg, 1.67 mmol) and 2-phenacyl benzothiazole (421 mg, 1.67 
mmol), EtN(iPr)2 (319 μL, 1.8 mmol) and HBTM 2.1 (5 mg, 1 mol %) in THF (3 mL) and 
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purified by chromatography (20% hexanes/CH2Cl2) to afford the title compounds 38a as a 
yellow solid and 38b as a yellow solid.  
38a (major): (446 mg, 72%); mp 127-128 °C; [α]D
20 30.3 (c 1.0, CHCl3); HPLC analysis, 
ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR minor: 
15.0 min, tR major: 20.3 min, 80% ee; max (film)/cm-1 3142 (C-H), 3136 (C-H), 2363 (C-H), 
1732 (C=O), 1626 (C=C), 1605 (C=C), 1474 (C-N), 1362 (C-S), 1275 (C-O); δH (400 MHz, 
CDCl3) 3.16 (1H, dd, J 16.1, 6.0, CH2), 3.24 (1H, dd, J 16.1 2.6, CH2), 4.43 (1H, ddd, J 6.1, 
2.6, 1.0, C(11)H), 5.95 (1H, m, furanylC(x)H), 6.24 (1H, dd, J 3.3, 1.9, furanylC(4)H), 7.29-
7.51 (8H, m, ArH), 7.54-7.61 (1H, m, ArH), 8.46-8.53 (1H, m, ArH); δC (100 MHz, CDCl3) 
32.9 (C(11)H), 37.9 (C12)H2), 105.6 (C(10)), 106.8 (furanylC(3)H), 110.3 (furanylC(4)H), 
117.6 (ArCH,), 121.9 (ArCH), 125.8 (ArCH), 126.9 (2×ArCH), 127.0 (ArCH), 127.5 (C(7)), 
128.2 (2×ArCH), 130.4 (ArCH), 136.0 (C(10)ArC(1)), 139.3 (C(2)), 142.7 (furanylC(5)H), 
153.5 (furanylC(1)), 156.6 (C(9)), 167.7 (C(13)=O), 190.8 (C(10)C=O). 
38b (minor): (60 mg, 10%) mp 122-125 °C; 
22
D][  6.2 (c 1.0 in CH2Cl2); chiral HPLC 
analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR 
minor: 7.6 min, tR major: 15.0 min, 80% ee; max (film)/cm-1 3117 (C-H), 3063 (C-H), 2924 
(C-H), 1782 (C=O), 1649 (C=N), 1597 (C=C), 1344 (C-S), 1277 (C-O); δH (300 MHz, 
CDCl3) 3.20 (1H, dd, J 15.9, 6.7, C(3)H2), 3.26 (1H, dd, J 15.9, 1.9, C(3)H2), 5.14 (1H, dd, J 
6.8, 2.0, C(4)H), 6.18 (1H, d, J 3.3, furanyl(3)H), 6.24 (1H, dd, J 3.3, 1.8, furanyl(4)H), 7.31 
(1H, t, J 7.6, ArH), 7.34 (1H, d, J 1.8, furanyl(5)H), 7.44 (3H, td, J 7.3, 1.5, ArH), 7.49-7.57 
(3H, m, ArH), 7.61-7.68 (1H, m, ArH), 7.98 (1H, d, J 8.2, ArH); δC (75 MHz, CDCl3) 33.9 
(C(3)), 35.1 (C(4)), 106.9 (furanylC(3)H), 110.4 (furanylC(4)H), 113.3 (C(5)), 121.3 
(C(5)HetArC(7)H), 123.1 (C(5)HetArC(4)H), 125.6 (C(5)HetArC(6)H), 126.2 
(C(5)HetArC(5)H), 129.0 (2×C(6)PhC(3)H), 130.1 (2×C(6)PhC(2)H), 131.0 
(C(6)PhC(4)H), 131.8 (C(6)PhC(1)), 135.7 (C(5)HetArC(7a)), 142.8 (furanylC(5)H), 152.2 
(furanylC(2)), 152.4 (C(5)HetArC(3a)), 154.8 (C(6)), 164.0 (C(5)HetArC=N), 166.4 (C(2)O). 
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(11S)-10-Benzoyl-11-propyl-8-thia-1-azatricyclo[7.4.0.02,7]trideca-2,4,6,9-tetraen-13-
one (S12a) and (4S)-5-(1,3-benzothiazol-2-yl)-6-phenyl-4-propyl-3,4-dihydro-2H-
pyran-2-one (S12b) 
 
The title compounds were prepared according to General Procedure H from (E)-Hex-2-enoic 
anhydride (314 mg, 1.00 mmol) and 2-phenacyl benzothiazole (182 mg, 0.72 mmol), 
EtN(iPr)2 (138 μL, 0.79 mmol) and HBTM 2.1 (2 mg, 1 mol %) in THF (2 mL) and 
purified by chromatography on silica gel (10:2 CH2Cl2/hexane) to afford S12a as a yellow 
solid and S12b as a yellow solid.  
S12a (major): (502 mg, 79%); mp 143-145 °C; 
20
D][   (c 1.0 in CHCl3); chiral HPLC 
analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR 
minor: 10.3 min, tR major: 16.0 min, 88% ee; max (film)/cm-1 2957 (C-H), 2930 (C-H), 2870 
(C-H), 1717 (C=O), 1599 (C=C), 1574 (C=C), 1474 (C-N), 1368 (C-S), 1275 (C-O); δH 
(400 MHz, CDCl3) 0.55 (3H, t, J 7.3, CH3), 1.04 (2H, dq, J 15.3, 7.9, 7.0, CH2CH3), 1.30 
(2H, q, J 7.9, CH2CH2CH3), 2.77 (1H, dd, J 16.2, 2.1, C(12)H2), 2.96 (1H, dd, J 16.2, 6.3, 
C(12)H2), 3.13 (1H, qd, J 7.0, 2.1, C(11)H), 7.17-7.23 (1H, m, C(5)H), 7.23-7.29 (1H, m, 
C(4)H), 7.33-7.38 (3H, m, C(10)COPhC(3)H, C(10)COPhC(4)H), 7.39-7.42 (2H, m, 
C(10)COPhC(2)H), 7.44 (1H, dd, J 7.5, 1.1, C(6)H), 8.39- 8.47 (1H, m, C(3)H); δC (126 
MHz, CDCl3) 13.6 (CH3), 19.6 (CH2CH2CH3), 32.3 (C(11)H), 35.8(CH2CH2CH3), 37.7, 
(C(12)H2) 109.8 (C(10)), 117.6 (C(3)H), 121.9 (C(6)H), 125.8 (C(5)H), 127.0 (C(4)H), 127.2 
(2×C(10)COPhC(3)H), 127.7 (C(7)), 128.4 (2×C(10)COPhC(2)H), 130.1 
(C(10)COPhC(4)H), 136.2 (C(2)), 140.1 (C(10)COPhC(1)), 154.4 (C(9)), 169.1 (C(13)O), 
191.8 (C(10)CO); m/z (NSI+) 372 ([M+Na]+, 100%), 350 ([M+H]+, 30%); HRMS (NSI+) 
C21H20O2NS ([M+H]
+) requires 350.1209, found 350.1204 ( ppm). 
S12b (minor): (47 mg, 7%); mp 192-194 °C; 
20
D][  1.3 (c 1.0 in CHCl3); chiral HPLC 
analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR 
minor: 4.9 min, tR major: 7.0 min, 92% ee; max (film)/cm-1 2953 (C-H), 2926 (C-H), 2870 
(C-H), 1770 (C=O), 1651 (C=N), 1491 (C=C), 1354 (C-S), 1273 (C-O); δH (500 MHz, 
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CDCl3) 0.90 (3H, t, J 7.2, CH3), 1.32 (1H, dq, J 18.8, 6.1, CH2CH2CH3), 1.40-1.58 (2H, m, 
CH2CH2CH3), 1.61-1.71 (1H, m, CH2CH2CH3), 2.85-3.00 (2H, m, C(3)H2), 3.70-3.77 (1H, 
m, C(4)H), 7.32 (1H, t, J 7.5, C(5)HetArCH), 7.34-7.36 (2H, m, ArH), 7.37-7.49 (4H, m, 
ArH), 7.66 (1H, d, J 8.0, C(5)HetArCH), 7.98 (1H, d, J 8.2, (C(5)HetArCH); δC (126 MHz, 
CDCl3) 14.1 (CH3), 19.9 (CH2CH2CH3), 33.5 (CH2CH2CH3), 35.2 (C(4)H), 35.5 (C(3)H2), 
117.2 (C(5)), 121.4 (C(5)HetArC(7)H), 123.0 (C(5)HetArC(4)H), 125.5 (C(5)HetArC(6)H), 
126.2 (C(5)HetArC(5)H), 128.9 (2×C(6)PhC(3)H), 130.1 (2×C(6)PhC(2)H), 130.6 
(C(6)PhC(4)H), 132.1 (C(6)PhC(1)), 134.7 (C(5)HetArC), 152.5 (C(5)HetArC), 153.5 (C(6)), 
164.7 (C(5)HetArC=N), 167.8 (C(2)O); m/z (NSI+) 372 ([M+Na]+, 100%), 350 ([M+H]+, 
55%); HRMS (NSI+) C21H20O2NS ([M+H]
+) requires 350.1209, found 350.1210 ( 
ppm). 
(11R)-10-Benzoyl-11-(4-methoxyphenyl)-8-thia-1-azatricyclo[7.4.0.02,7]trideca-2,4,6,9-
tetraen-13-one (239a) and (4R)-5-(1,3-benzothiazol-2-yl)-4-(4-methoxyphenyl)-6-
phenyl-3,4-dihydro-2H-pyran-2-one (239b) 
 
The title compounds were prepared according to General Procedure H from (E)-3-(4-
Methoxyphenyl)acrylic 3-(4-methoxyphenyl)propanoic anhydride (314 mg, 1.00 mmol) and 
2-phenacyl benzthiazole (182 mg, 0.72 mmol), EtN(iPr)2 (138 μL, 0.79 mmol) and HBTM 
2.1 (2 mg, 1 mol %) in THF (2 mL) and purified by chromatography on silica gel (10:2 
CH2Cl2/hexane) to afford 40a as a yellow solid and 40b as a yellow solid  
239a (major): (436 mg, 59%); mp 190-191 °C; 
20
D][ 135.6 (c 1.0 in CHCl3); chiral HPLC 
analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR 
minor: 18.4 min, tR major: 31.1 min, 85% ee; max (film)/cm-1 2972 (C-H), 2843 (C-H), 1721 
(C=O), 1603 (C=C), 1510 (C=C), 1474 (C-N), 1358 (C-S), 1298 (C-O); δH (300 MHz, 
CDCl3) 3.00 (1H, dd, J 15.8, 2.3, C(12)H2), 3.24 (1H, dd, J 15.8, 6.6 C(12)H2), 3.77 (3H, s, 
OCH3), 4.29 (1H, dd, J 6.6, 2.2, C(11)H), 6.78-6.84 (2H, m, C(11)ArC(3)H), 6.97-7.05 (2H, 
m, C(11)ArC(2)H), 7.23-7.31 (4H, m, ArH), 7.32-7.43 (3H, m, ArH), 7.56-7.65 (1H, m, 
C(6)H), 8.43-8.49 (1H, m, C(3)H); δC (75 MHz, CDCl3) 38.0 (C(11)H), 41.8 (C(12)H2), 55.4 
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(OCH3), 108.2 (C(10)), 114.8 (2×C(11)ArC(3)H), 117.7 (C(3)H), 122.1 (C(6)H), 126.0 
(C(5)H), 127.2 (2×ArCH and C(4)H), 127.9 (C(7)), 128.0 (2×ArCH), 128.2 (2×ArCH), 
130.4 (C(10)COPhC(4)H), 132.7 (C(11)ArC(1)), 136.2 (C(2)), 139.5 (C(10)COPhC(1)), 
156.1 (C(9)), 159.0 (C(11)ArC(4)), 168.2 (C(13)O), 191.4 (C(10)CO); m/z (NSI+) 436 
([M+Na]+, 100%), 414 ([M+H]+, 60%); HRMS (NSI+) C25H20O3NS ([M+H]
+) requires 
414.1158, found 414.1160 (+0.4 ppm). 
239b (minor): (41 mg, 6%); mp 148-151 °C; 
20
D][   (c 1.0 in CHCl3); chiral HPLC 
analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR 
minor: 9.7 min, tR major: 14.6 min, 89% ee; max (film)/cm-1 2944 (C-H), 1778 (C=O), 1645 
(C=N), 1510 (C=C), 1435 (C=C), 1346 (C-S), 1240 (C-O); δH (500 MHz, CDCl3) 3.06 (1H, 
dd, J 15.7, 1.4, C(3)H2), 3.30 (1H, dd, J 15.7, 7.5, C(3)H2), 3.75 (3H, s, OCH3), 4.97 (1H, d, 
J 6.5, C(4)H), 6.84 (2H, d, J 8.7, C(4)ArC(3)H), 7.28 (3H, dd, J 16.1, 8.3, C(4)ArC(2)H, 
C(5)HetArC(5)H), 7.38-7.46 (3H, m, C(5)HetArC(6)H, C(6)PhC(3)H), 7.50 (1H, m, 
C(6)PhC(4)H), 7.55-7.59 (2H, m, C(6)PhC(2)H), 7.62 (1H, d, J 8.0, C(5)HetArC(4)H), 7.95 
(1H, d, J 8.2, C(5)HetArC(7)H); δC (126 MHz, CDCl3) 37.2 (C(3)H2), 40.6 (C(4)H), 55.3 
(OCH3), 114.6 (2×C(4)ArC(3)H), 115.4 (C(5)), 121.3 (C(5)HetArC(7)), 123.1 
(C(5)HetArC(4)), 125.5 (C(5)HetArC(6)), 126.2 (C(5)HetArC(5)), 128.2 (2×ArCH), 128.9 
(2×ArCH), 130.1 (2×ArCH), 130.8 (C(6)PhC(4)H), 131.6 (C(4)ArC(1)), 131.9 
(C(6)PhC(1)), 138.2 (C(5)HetArC), 152.2 (C(5)HetArC), 154.2 (C(6)), 159.1 (C(4)ArC(4)), 
164.4 (C(5)HetArC=N)), 166.8 (C(2)O); m/z (NSI+) 436 ([M+Na]+, 100%), 414 ([M+H]+, 
90%); HRMS (NSI+) C25H20O3NS ([M+H]
+) requires 414.1158, found 414.1156 (0.6 
ppm). 
(R)-4-benzoyl-3-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-
a]pyridin-1-one (238a) and (R)-5-(benzo[d]thiazol-2-yl)-6-phenyl-4-(4-
(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyran-2-one (239b) 
 
The title compounds were prepared according to General Procedure H from (E)-p-
trifluoromethylcinnamic anhydride (275 mg, 0.66 mmol) and 2-phenacylbenzothiazole (120 
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mg, 0.47 mmol), EtN(iPr)2 (90 μL, 0.52 mmol) and HBTM 2.1 (7.3 mg, 0.024 mmol) in 
THF (1.5 mL) and purified by chromatography on silica gel (CH2Cl2) to give 239a/239b as 
a yellow solid (83:17 mixture of regioisomers, 252 mg, 78%). Analytical samples were 
separated by careful chromatography. 
239a (major): mp 168–170 °C; 
20
D][  -100.0 (c 1.0 in CH2Cl2); chiral HPLC analysis, 
ChiralPak AD-H (5% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 56.3 
min, tR minor: 31.1 min, 79% ee; max (film)/cm-1 2359 (C-H), 1719 (C=O), 1618 (C=O), 
1489 (C=C); δH (500 MHz, CDCl3) 3.02 (1H, dd, J 16.0, 2.4, C(2)HH), 3.33 (1H, dd, J 16.0, 
7.0, C(2)HH), 4.42 (1H, dd, J 7.1, 2.4, C(3)H), 7.17 – 7.25 (4H, m, 2 × C(3)ArC(3)H, 
C(5’)H, C(6’)H), 7.26 – 7.33 (2H, m, 2 × C(3)ArC(2)H), 7.33 – 7.44 (3H, m, 2 × 
C(4)COArC(3)H, C(4)COArC(4)H), 7.52 – 7.58 (2H, m, 2 × C(4)COArC(2)H), 7.59 – 7.65 
(1H, m, C(7’)H), 8.46 (1H, dd, J 7.9, 1.5, C(4’)H); δC (126 MHz, CDCl3) 38.6 (C(3)H), 41.2 
(C(2)H2), 106.9 (C(4)), 117.7 (C(4’)H), 122.2 (C(7’)H), 124.0 (q, 
1JCF 272.2, CF3), 126.3, 
(C(6’)H), 126.5 (q, 3JCF 3.7, 2 × C(3)ArC(3)H), 126.9 (2 × C(4)COPhC(2)H), 127.3 
(C(5’)H), 127.5 (2 × C(4)COPhC(3)H), 127.7 (C(7a’)), 128.5 (2 × C(3)ArC(2)H), 130.0 (q, 
2JCF 32.7, C(3)ArC(4)-CF3), 130.6 (C(4)COPhC(4)H), 136.0 (C(4a’)), 139.5 (C(4)COPhC(1)), 
145.3 (C(3)ArC(1)), 156.8 (C(5)), 167.4 (C(1)O), 191.2 (C(4)COPh); δF (470 MHz, CDCl3) –
62.6; m/z (APCI+) 452 ([M+H]+, 100%); HRMS (APCI+) C25H17NO2S ([M+H]
+) requires 
452.0927, found 452.0923 (–0.8 ppm). 
239b (minor): mp 208–211 °C; 
20
D][  +14.4 (c 0.125 in CH2Cl2); chiral HPLC analysis, 
ChiralPak AD-H (5% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 15.2 
min, tR minor: 11.5 min, 90% ee; max (film)/cm-1 2955 (C-H), 2926 (C-H), 1782 (C=O); δH 
(500 MHz, CDCl3) 3.08 (1H, dd, J 15.8, 1.7, C(3)HH), 3.35 (1H, dd, J 15.9, 7.7, C(3)HH), 
5.14 (1H, dd, J 7.7, 1.7, C(4)H), 7.27 – 7.33 (1H, m, benzothiazoleC(6)H), 7.36 – 7.43 (1H, 
m, benzothiazoleC(5)H), 7.43 – 7.50 (4H, m, ArH), 7.49 – 7.65 (6H, m, ArH), 7.91 (1H, d, 
J 8.3, benzothiazoleC(7)H); δC (126 MHz, CDCl3) 36.6 (C(3)H2), 40.8 (C(4)H), 114.8 (C(5)), 
121.4 (benzothiazoleC(4)H), 123.2 (benzothiazoleC(7)H), 125.7 (benzothiazoleC(6)H), 
126.3 (benzothiazoleC(5)H), 126.3 (q, 3JCF 4.0, 2 × C(4)ArC(3)H), 127.6 (2 × 
C(6)PhC(2)H), 129.2 (2 × C(4)ArC(2)H), 130.2 (2 × C(6)PhC(3)H), 131.2 (C(6)PhC(4)H), 
131.7 (C(6)PhC(1)), 135.7 (benzothiazoleC(7a)), 143.9 (C(4)ArC(1)), 152.4 
(benzothiazoleC(4a)), 155.0 (C(6)), 163.6 (benzothiazoleC(2)), 166.2 (C(2)O) [C(4)ArC(4)-
CF3 and CF3 not seen in 
13C NMR due to low sample quantity, visibility could not be 
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improved]; δF (470 MHz, CDCl3) –62.7; m/z (APCI
+) 452 ([M+H]+, 100%); HRMS 
(APCI+) C25H17NO2S ([M+H]
+) requires 452.0927, found 452.0920 (–1.5 ppm). 
(S)-4-benzoyl-3-(2-bromophenyl)-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-a]pyridin-
1-one (240a) and (S)-5-(benzo[d]thiazol-2-yl)-4-(2-bromophenyl)-6-phenyl-3,4-
dihydro-2H-pyran-2-one (240b) 
 
The title compounds were prepared according to General Procedure H from (E)-2-
bromocinnamic anhydride (436 mg, 1.00 mmol) and 2-phenacyl benzothiazole (182 mg, 
0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF 
(2 mL) and purified by chromatography on silica gel (20% EtOAc/petrol) to give 
240a/240b as a yellow oil (92:8 mixture of regioisomers, 204 mg, 62%); 
20
D][  –137.6 (c 
0.5, CH2Cl2); max (film)/cm-1 3061 (C-H), 3011 (C-H), 2905 (C-H), 1780 (C=O, lactone), 
1720 (C=O, ketone), 1606 (C=O, lactam), 1572 (C=N), 1481 (C=C); m/z (APCI+) 462 
([M+H]+, 100%); HRMS (APCI+) C24H17Br
79NO2S ([M+H]
+) requires 462.0158, found 
462.0156 (–0.4 ppm). 
240a (major): chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 
mL min-1, 211 nm, 30 °C), tR major: 18.7 min, tR minor: 13.0 min, 81% ee; δH (500 MHz, 
CDCl3) 3.12 (1H, dd, J 16.1, 2.3, C(2)HH), 3.23 (1H, dd, J 16.1, 7.3, C(2)HH), 4.73 (1H, dd, 
J 7.3, 2.3, C(3)H), 7.13 – 7.26 (5H, m, ArH), 7.27 – 7.33 (2H, m, ArH), 7.34 – 7.43 (3H, m, 
ArH), 7.61 – 7.66 (2H, m, 2 × C(4)COArC(2)H), 8.40 – 8.56 (1H, m, C(4’)H); δC (126 
MHz, CDCl3) 38.4 (C(3)H), 39.1 (C(2)H2), 107.2 (C(4)), 117.5 (C(4’)H), 122.1 (C(7’)), 123.7 
(C(3)ArC(1)Br), 126.0 (C(6’)H), 126.6 (2 × C(4)COArC(2)H), 127.2 (C(5’)H), 127.8 
(C(7a’)), 128.1 (C(3)ArCH), 128.2 (2 × C(4)COArC(3)H), 128.5 (C(3)ArCH), 129.4 
(C(3)ArCH), 130.3 (C(4)COArC(4)H), 134.0 (C(3)ArC(6)H), 136.0 (C(4a’)), 139.0 
(C(4)COArC(1)), 139.0 (C(3)ArC(2)), 157.0 (C(5)), 167.6 (C(1)O), 191.0 (C(4)COPh). 
240b (minor): chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 
mL min-1, 211 nm, 30 °C), tR major: 8.2 min, tR minor: 7.6 min, 33% ee; δH (500 MHz, 
CDCl3, characteristic peaks) 3.18 (1H, dd, J 16.1, 1.8, C(3)HH), 3.30 (1H, dd, J 15.9, 7.8, 
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C(3)HH), 5.47 (1H, dd, J 7.8, 1.7, C(4)H), 7.93 (1H, d, J 8.4, benzothiazoleC(7)H); δC (126 
MHz, CDCl3) 35.3 (C(3)H2), 41.1 (C(4)H), 114.0 (C(5)), 121.2 (ArCH), 123.3 (ArCH), 125.5 
(ArCH), 126.1 (ArCH), 127.4 (ArCH), 128.9 (2 × C(6)ArC(3)H), 129.5 (ArCH), 129.9 (2 × 
C(6)ArC(2)H), 130.9 (C(6)ArC(4)H), 131.7 (C(6)ArC(1)), 133.9 (ArCH), 135.6 
(benzothiazoleC(7a)), 137.7 (C4)ArC(2)), 152.3 (benzothiazoleC(4a)), 155.3 (C(6)), 163.6 
(benzothiazoleC(2)), 166.1 (C(2)O). 
 (R)-4-benzoyl-3-(3-bromophenyl)-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-a]pyridin-
1-one (241a) and (R)-5-(benzo[d]thiazol-2-yl)-4-(3-bromophenyl)-6-phenyl-3,4-
dihydro-2H-pyran-2-one (241b) 
 
The title compounds were prepared according to General Procedure H from (E)-3-
bromocinnamic anhydride (436 mg, 1.00 mmol) and 2-phenacyl benzothiazole (182 mg, 
0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF 
(2 mL) and purified by chromatography on silica gel (20% EtOAc/petrol) to give 
241a/241b as a yellow solid (86:14 mixture of regioisomers, 287 mg, 86%); mp 163–167 
°C; 
20
D][ –197.8 (c 0.5, CH2Cl2); max (film)/cm
-1 3050 (C-H), 1774 (C=O, lactone), 1717 
(C=O, ketone), 1601 (C=O, lactam), 1571 (C=N), 1474 (C=C); m/z (APCI+) 462 ([M+H]+, 
100%); HRMS (APCI+) C24H17Br
79NO2S ([M+H]
+) requires 462.0158, found 462.0156 (–0.4 
ppm). 
241a (major): chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 
mL min-1, 211 nm, 30 °C), tR major: 21.4 min, tR minor: 15.8 min, 84% ee; δH (500 MHz, 
CDCl3) 3.04 (1H, dd, J 16.0, 2.4, C(2)HH), 3.25 – 3.33 (1H, m, C(2)HH), 4.34 (1H, dd, J 
7.1, 2.4, C(3)H), 7.02 – 7.07 (1H, m, C(3)ArC(6)H)), 7.16 (2H, t, J 7.8, ArH), 7.24 – 7.45 
(9H, m, ArH), 7.62 (1H, dd, J 7.4, 1.7, C(7’)H), 8.48 (1H, dd, J 8.1, 1.4, C(4’)H); δC (126 
MHz, CDCl3) 38.3 (C(3)H), 41.1 (C(2)H2), 106.8 (C(4)), 117.6 (C(4’)H), 122.0 (C(7’)H), 
123.3 (C(3)ArC(1)Br), 125.3 (C(6’)H), 126.1 (C(3)ArC(6)H), 126.8 (2 × C(4)COArC(2)H), 
127.2 (C(3)ArC(2)H), 127.6 (C(7a’)), 128.2 (2 × C(4)COArC(2)H), 130.1 (ArCH), 130.4 
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(ArCH), 130.9 (ArCH), 130.9 (ArCH), 136.0 (C(4a’)), 139.3 (C(4)COArC(1)), 143.4 
(C(3)ArC(3)), 156.5 (C(5)), 167.5 (C(1)O), 191.2 (C(4)COAr). 
241b (minor): chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 
mL min-1, 211 nm, 30 °C), tR major: 11.7 min, tR minor: 8.4 min, 84% ee; δH (500 MHz, 
CDCl3, chatacteristic peaks) 3.08 (1H, dd, J 15.8, 1.7, C(3)HH), 3.34 (1H, dd, J 15.8, 7.6, 
C(3)HH), 5.06 (1H, dd, J 7.7, 1.7, C(4)H), 7.94 (1H, d, J 8.2, benzothiazoleC(7)H); δC (126 
MHz, CDCl3, characteristic peaks) 36.7 (C(3)H2), 40.6 (C(4)H), 114.5 (C(5)), 121.2 
(benzothiazoleC(7)H), 123.0 (benzothiazoleC(4)H), 123.2 (C(4)ArC(1)Br), 125.4 (ArCH), 
125.5 (ArCH), 126.1 (ArCH), 129.0 (2 × C(6)ArC(3)H), 130.0 (2 × C(6)ArC(2)H), 130.8 
(ArCH), 131.0 (ArCH), 131.6 (C(6)ArC(1)), 135.6 (benzothiazoleC(7a)), 142.0 (C(4)ArC(3)), 
152.2 (benzothiazoleC(4a)), 154.9 (C(6)), 163.6 (benzothiazoleC(2)), 166.1 (C(2)O). 
(S)-4-Benzoyl-3-methyl-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-a]pyridin-1-one 
(245a) and (S)-5-(benzo[d]thiazol-2-yl)-4-methyl-6-phenyl-3,4-dihydro-2H-pyran-2-
one (245b) 
 
The title compounds were prepared according to General Procedure H from (E)-crotonic 
anhydride (154 mg, 1.00 mmol) and 2-phenacyl benzothiazole (182 mg, 0.72 mmol), 
EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF (2 mL) and 
purified by chromatography on silica gel (10:2 CH2Cl2/hexane→CH2Cl2) to give 245a as a 
yellow solid (126 mg, 55%) and 245b as a yellow oil (21 mg, 9%). 
245a (major): mp 156–157 °C; 
20
D][  +93.2 (c 0.5 in CH2Cl2); chiral HPLC analysis, 
ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 
14.6 min, tR minor: 11.6 min, 86% ee; max (film)/cm-1 3420 (C-H), 2963 (C-H), 1713 
(C=O), 1602 (C=O); δH (400 MHz, CDCl3) 1.08 (3H, d, J 7.0, CH3), 2.69 (1H, dd, J 16.0, 
2.2, C(2)HH), 3.04 (1H, dd, J 16.0, 6.3, C(2)HH), 3.28 (1H, pd, J 6.9, 2.2, C(3)H), 7.22 – 
7.31 (1H, m, ArH), 7.28 – 7.38 (1H, m, ArH), 7.39 – 7.46 (3H, m, ArH), 7.46 – 7.53 (3H, 
m, ArH), 8.48 – 8.54 (1H, m, C(4’)H); δC (101 MHz, CDCl3) 19.6 (CH3), 27.8 (C(3)H), 40.0 
(C(2)H2), 110.5 (C(4)), 117.5 (C(4’)H), 121.9 (C(7’)H), 125.8 (C(6’)H), 126.8 (2 × 
C(4)COPhC(3)H), 126.9 (C(5’)H), 127.7 (C(7a’)), 128.4 (2 × C(4)COPhC(2)H), 130.0 
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(C(4)COPhC(4)H), 136.1 (C(4a’)), 140.0 (C(4)COPhC(1)), 154.2 (C(5)), 168.9 (C(1)O), 
191.4 (C(4)COPh); m/z (NSI+) 322 ([M+H]+, 100%); HRMS (NSI+) C19H16NO2S ([M+H]
+) 
requires 322.0896, found 322.0901 (+1.5 ppm). 
245b (minor): 
20
D][   (c 0.2 in CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (5% 
i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 18.9 min, tR minor: 9.5 
min, 92% ee; max (film)/cm-1 3057 (C-H), 2963 (C-H), 1775 (C=O); δH (500 MHz, CDCl3) 
1.30 (3H, d, J 7.1, CH3), 2.79 (1H, dd, J 15.7, 2.0, C(3)H2), 3.02 (1H, dd, J 15.7, 6.7, 
C(3)H2), 3.82 (1H, pd, J 7.1, 2.0, C(4)H), 7.28 – 7.35 (1H, m, benzothiazoleC(6)H), 7.37 – 
7.52 (6H, m, ArH), 7.63 – 7.68 (1H, m, benzothiazoleC(4)H), 7.95 – 8.01 (1H, m, 
benzothiazoleC(7)H); δC (126 MHz, CDCl3) 19.0 (CH3), 30.8 (C(4)H), 36.0 (C(3)H2), 117.9 
(C(5)), 121.3 (benzothiazoleC(4)H), 123.0 (benzothiazoleC(7)H), 125.5 
(benzothiazoleC(4)H), 126.2 (benzothiazoleC(5)H), 129.0 (2 × C(6)PhC(3)H), 130.1 (2 × 
C(6)PhC(2)H), 130.7 (C(6)PhC(4)H), 132.1 (C(6)PhC(1)), 135.7 (benzothiazoleC(7a)), 152.6 
(benzothiazoleC(4a)), 153.3 (C(6)), 164.2 (benzothiazoleC(2)), 167.6 (C(2)O); m/z (NSI+) 
322 ([M+H]+, 100%); HRMS (NSI+) C19H16NO2S ([M+H]
+) requires 322.0896, found 
322.0901 (+1.5 ppm). 
 (R)-4-benzoyl-3-(furan-3-yl)-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-a]pyridin-1-one 
(243a)and (R)-5-(benzo[d]thiazol-2-yl)-4-(furan-3-yl)-6-phenyl-3,4-dihydro-2H-
pyran-2-one (243b) 
 
The title compounds were prepared according to General Procedure H from (2E)-3-(furan-3-
yl)prop-2-enoic anhydride (258 mg, 1.00 mmol) and 2-phenacyl benzothiazole (182 mg, 
0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF 
(2 mL) and purified by chromatography on silica gel (10:2 CH2Cl2/hexane) to give 243a as 
a yellow solid (132 mg, 40%) and 243b as a yellow oil (15 mg, 5%). 
243a (major): mp 92–94 ˚C; 
20
D][ +11.2 (c 0.5, CH2Cl2); chiral HPLC analysis, ChiralPak 
AD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 31.0 min, tR 
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minor: 17.0 min, 90% ee; max (film)/cm-1 3063 (C-H), 1721 (C=O), 1607 (C=O), 1574 
(C=N), 1474 (C=C); δH (300 MHz, CDCl3) 3.04 (1H, dd, J 15.9, 2.4, C(2)HH), 3.20 (1H, 
dd, J 16.0, 6.1, C(2)HH), 4.32 (1H, ddd, J 6.2, 2.4, 1.1, C(3)H), 6.21 (1H, dd, J 1.9, 1.0, 
furylC(4)H), 7.16 (1H, q, J 1.2, furylC(2)H), 7.27 – 7.47 (6H, m, ArH), 7.49 – 7.59 (3H, m, 
ArH), 8.39 – 8.59 (1H, m, C(4’3)H); δC (75 MHz, CDCl3) 30.3 (C(3)H), 40.0 (C(2)H2), 107.9 
(C(4)), 109.3 (furylC(4)H), 117.6 (C(4’)H), 122.0 (C(7’)H), 125.6 (furylC(2)H), 125.9 
(C(6’)H), 127.1 (C(5’)H), 127.1 (2 × C(4)COPhC(2)H), 127.7 (C(7a’)), 128.3 (2 × 
C(4)COPhC(3)H), 130.5 (C(4)COPhC(4)H), 136.1 (C(4a’)), 139.4 (C(4)COPhC(1)), 139.7 
(furylC(2)H), 144.2 (furylC(5)H), 156.0 (C(5)), 168.1 (C(1)O), 190.6 (C(4)CO); m/z (APCI+) 
374 ([M+H]+, 100%); HRMS (APCI+) C22H16O3NS ([M+H]
+) requires 374.0845, found 
374.0841 (–1.2 ppm). 
243b (minor): 
20
D][ +65.5 (c 0.2, CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (20% i-
PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 13.9 min, tR minor: 7.9 min, 
94% ee; max (film)/cm-1 3117 (C-H), 3065 (C-H), 2920 (C-H), 1782 (C=O), 1647 (C=N), 
1597 (C=C), 1343 (C=N); δH (300 MHz, CDCl3) 3.11 (1H, dd, J 15.8, 2.2, C(3)HH)), 3.21 
(1H, dd, J 15.8, 6.5, C(3)HH), 4.87 – 5.09 (1H, m, C(4)H), 6.32 (1H, dd, J 1.9, 1.0, 
furylC(4)H), 7.28 – 7.37 (3H, m, ArH), 7.39 – 7.47 (3H, m, ArH), 7.47 – 7.55 (3H, m, 
ArH), 7.64 (1H, dt, J 7.9, 0.9, benzothiazoleC(4)H), 7.97 (1H, dt, J 8.1, 0.9, 
benzothiazoleC(7)H); δC (126 MHz, CDCl3) 32.3 (C(4)H), 35.5 (C(3)H2), 109.5 
(furylC(4)H), 115.8 (C(5)), 121.4 (benzothiazoleC(7)H), 123.2 (benzothiazoleC(4)H), 124.2 
(furylC(3)), 125.6 (benzothiazoleC(6)H), 126.2 (benzothiazoleC(5)H), 129.1 (2 × 
C(6)PhC(2)H), 130.1 (2 × C(6)PhC(3)H), 131.0 (C(6)PhC(4)H), 131.8 (C(6)PhC(1)), 135.8 
(benzothiazoleC(4a)), 139.5 (furylC(2)H), 143.9 (furylC(5)H), 152.5 (benzothiazoleC(7a)), 
154.18 (C(6)), 164.0 (benzothiazoleC(2)), 167.0 (C(2)O); m/z (APCI+) 374 ([M+H]+, 100%); 
HRMS (APCI+) C22H16O3NS ([M+H]
+) requires 374.0845, found 374.0845 (–0.1 ppm). 
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(R)-4-benzoyl-3-(thiophen-3-yl)-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-a]pyridin-1-
one (244a) and (R)-5-(benzo[d]thiazol-2-yl)-6-phenyl-4-(thiophen-3-yl)-3,4-dihydro-
2H-pyran-2-one (244b) 
 
The title compounds were prepared according to General Procedure H from (2E)-3-
(thiophen-3-yl)prop-2-enoic anhydride (290 mg, 1.00 mmol) and 2-phenacyl benzothiazole 
(182 mg, 0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 
mmol) in THF (2 mL) and purified by chromatography on silica gel (6:4→10:2 
CH2Cl2/hexane) to give 244a as a yellow solid (123 mg, 46%) and 244b as a yellow solid 
(16 mg, 6%) 
244a (major): mp 154–157 °C; 
20
D][ –82.4 (c 1.0, CH2Cl2); chiral HPLC analysis, 
ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 
31.3 min, tR minor: 18.2 min, 82% ee; max (film)/cm-1 3090 (C-H), 2924 (C-H), 1726 
(C=O), 1603 (C=O), 1574 (C=C), 1474 (C=C); δH (500 MHz, CDCl3) 3.08 (1H, dd, J 16.1, 
2.4, C(2)HH), 3.22 (1H, dd, J 16.0, 6.4, C(2)HH), 4.44 (1H, dd, J 6.6, 2.4, C(3)H), 6.84 (1H, 
d, J 5.0, thiopheneC(4)H), 6.92 (1H, d, J 3.4, thiopheneC(2)H), 7.24 – 7.46 (8H, m, ArH), 
7.57 (1H, d, J 7.5, C(7’)H), 8.46 (1H, d, J 8.1, C(4’)H); δC (126 MHz, CDCl3) 34.5 (C(3)H), 
40.6 (C(2)H2), 108.5 (C(4)), 117.7 (C(4’)H), 121.7 (thiopheneC(2)H), 122.0 (C(7’)), 126.0 
(C(6’)H), 126.4 (thiopheneC(5)H), 127.1 (C(5’), 127.2 (2 × C(4)COPhC(2)H), 127.5 
(thiopheneC(4)H), 127.8 (C(7a’)), 128.3 (2 × C(4)COPhC(3)H), 130.5 (C(4)COPhC(4)H), 
136.1 (C(4a’), 139.4 (C(4)COPhC(1)), 141.8 (thiopheneC(3)), 156.0 (C(5)), 168.1 (C(1)O), 
191.0 (C(4)COPh); m/z (APCI+) 390 ([M+H]+, 100%); HRMS (APCI+) C22H16O2NS2 
([M+H]+) requires 390.0617, found 390.0617 (+0.0 ppm). 
244b (minor): mp 149–152 °C; 
20
D][ –52.5 (c 0.4, CH2Cl2); chiral HPLC analysis, 
ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 
13.7 min, tR minor: 8.8 min, 85% ee; max (film)/cm-1 3102 (C-H), 2920 (C-H), 1780 (C=O), 
1647 (C=N), 1595 (C=C), 1431 (C=C); δH (500 MHz, CDCl3) 3.18 (1H, dd, J 15.8, 2.0, 
C(3)HH), 3.25 (1H, dd, J 15.8, 6.9, C(3)HH), 5.13 (1H, dd, J 6.7, 2.5 (C(4)H), 7.01 (1H, dd, 
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J 5.0, 1.4, thiopheneC(4)H), 7.16 – 7.18 (1H, m, thiopheneC(2)H), 7.25 – 7.28 (1H, m, 
ArH), 7.28 – 7.34 (1H, m, ArH), 7.39 – 7.45 (3H, m, ArH), 7.48 – 7.54 (3H, m, ArH), 7.62 
– 7.65 (1H, m, benzothiazoleC(7)H), 7.96 (1H, dt, J 8.2, 0.9, benzothiazoleC(4)H); δC (126 
MHz, CDCl3) 36.0 (C(3)H2), 36.6 (C(4)H), 116.0 (C(5)), 121.4 (benzothiazoleC(4)H), 121.7 
(thiopheneC(2)H), 123.2 (benzothiazoleC(7)H), 125.6 (benzothiazoleC(6)H), 126.2 
(benzothiazoleC(5)H), 126.6 (thiopheneC(5)H), 127.0 (thiopheneC(4)H), 129.0 (2 × 
C(6)PhC(2)H), 130.1 (2 × C(6)PhC(3)H), 130.9 (C(6)PhC(4)H), 131.9 (C(6)PhC(1)), 135.9 
(benzothiazoleC(4a)), 140.2 (thiopheneC(3)), 152.5 (benzothiazoleC(7a)), 154.0 (C(6)), 
164.2 (benzothiazoleC(2)), 167.0 (C(2)O); m/z (APCI+) 390 ([M+H]+, 100%); HRMS 
(APCI+) C22H16O2NS2 ([M+H]
+) requires 390.0617, found 390.0616 (–0.2 ppm). 
Ethyl (S)-4-benzoyl-1-oxo-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-a]pyridine-3-
carboxylate (246a) and ethyl (S)-5-(benzo[d]thiazol-2-yl)-2-oxo-6-phenyl-3,4-
dihydro-2H-pyran-4-carboxylate (246b) 
 
The title compounds were prepared according to General Procedure H from (E)-4-ethoxy-4-
oxobut-2-enoic anhydride (297 mg, 1.00 mmol) and 2-phenacyl benzothiazole (182 mg, 
0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF 
(2 mL) and purified by chromatography on silica gel (10:2 CH2Cl2/hexane→CH2Cl2) to 
give 246a as a yellow oil (136 mg, 50%) and 246b as a yellow oil (13 mg, 5%). 
246a (major): 
20
D][ –20.1 (c 1.0, CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (20% i-
PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 27.6 min, tR minor: 23.9 
min, 52% ee; max (film)/cm-1 2982 (C-H), 2249 (C-H), 1724 (C=O), 1609 (C=O); δH (300 
MHz, CDCl3) 1.13 (3H, t, J 7.1, CH2CH3), 3.05 (1H, dd, J 16.4, 6.5, C(2)HH), 3.19 (1H, dd, 
J 16.4, 2.6, C(2)HH), 4.00 – 4.10 (3H, m, CH2CH3, C(3)H), 7.29 – 7.35 (1H, m, C(6’)H), 
7.35 – 7.42 (1H, m, C(6’)H), 7.42 – 7.60 (6H, m, AriH), 8.34 – 8.72 (1H, m, C(4’)H); δC (75 
MHz, CDCl3) 14.0 (CH2CH3), 35.3 (C(2)H2), 39.1 (C(3)H), 61.8 (CH2CH3), 102.8 (C(4)), 
117.8 (C(4’)H), 121.9 (C(7’)H), 126.0 (C(6’)H), 127.0 (2 × C(4)COPhC(2)H), 127.2 
(C(5’)H), 127.4 (C(7a’)), 128.5 (2 × C(4)COPhC(3)H), 130.2 (C(4)COPhC(4)H), 136.1 
(C(4a’)), 139.8 (C(4)COPhC(1)), 157.3 (C(5)), 167.3 (C(1)O), 171.6 (COOEt), 191.1 
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(C(4)COPh); m/z (NSI+) 380 ([M+H]+, 70%), plus unknown degradation peaks; HRMS 
(NSI+) C21H18O4NS ([M+H]
+) requires 380.0951, found 380.0951 (-0.0 ppm). 
246b (minor): 
20
D][ –2.0 (c 0.25, CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (20% i-
PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 22.7 min, tR minor: 11.1 
min, 56% ee; max (film)/cm-1 2982 (C-H), 2361 (C-H), 1782 (C=O), 1728 (C=O), 1651 
(C=O); δH (400 MHz, CDCl3) 1.15 (3H, t, J 7.1, CH2CH3), 3.05 (1H, dd, J 16.3, 7.4, 
C(3)HH), 3.27 (1H, dd, J 16.3, 2.1, C(3)HH), 4.06 – 4.22 (2H, m, CH2CH3), 4.68 (1H, dd, J 
7.4, 2.1, benzothiazoleC(6)H), 7.32 (1H, ddd, J 8.2, 7.2, 1.2, benzothiazoleC(5)H), 7.37 – 
7.54 (6H, m, ArH), 7.65 (1H, ddd, J 8.0, 1.3, 0.7, benzothiazoleC(7)H), 7.97 (1H, ddd, J 8.2, 
1.2, 0.6, benzothiazoleC(4)H); δC (126 MHz, CDCl3) 14.1 (CH2CH3), 31.3 (C(3)H2), 41.5 
(C(4)H), 62.0 (CH2CH3), 110.9 (C(5)), 121.4 (benzothiazoleC(4)H), 123.2 
(benzothiazoleC(7)H), 125.6 (benzothiazoleC(6)H), 126.2 (benzothiazoleC(5)H), 129.0 (2 × 
C(6)PhC(2)H), 130.1 (2 × C(6)PhC(3)H), 131.1 (C(6)PhC(4)H), 131.7 (C(6)PhC(1)), 135.8 
(benzothiazoleC(7a), 152.5 (benzothiazoleC(4a), 155.4 (C(6)), 163.9 (benzothiazoleC(2)), 
165.6 (C(2)O), 170.7 (COOEt); m/z (NSI+) 380 ([M+H]+, 15%), plus unknown degradation 
peaks; HRMS (NSI+) C21H18O4NS ([M+H]
+) requires 380.0951, found 380.0950 (-0.3 ppm). 
(R)-N,N-dimethyl-1-oxo-3-phenyl-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-
a]pyridine-4-carboxamide (260) 
 
The title compound was prepared according to General Procedure H from (E)-cinnamic 
anhydride (70 mg, 0.25 mmol), and 2-(1,3-benzothiazol-2-yl)-N,N-dimethylacetamide (40 
mg, 0.18 mmol), EtN(iPr)2 (35 μL, 0.20 mmol) and HBTM 2.1 (2.8 mg, 0.05 mmol) in 
THF (0.5 mL) and purified by chromatography on silica gel (10% EtOAc/CH2Cl2) to give 
260 as an off-white foamy solid (44 mg, 70%); mp 71–74 °C; 
20
D][  –96.4 (c 0.5 in CH2Cl2); 
chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 211 
nm, 30 °C), tR major: 17.1 min, tR minor: 27.3 min, 96% ee; max (film)/cm-1 3061 (C-H), 
2924 (C-H), 1703 (C=O), 1614 (C=C), 1584 (C=C), 1489 (C-N), 1385 (C-S), 1306 (C-O); 
δH (300 MHz, CDCl3) 2.85 (6H, s, N(CH3)2), 2.98 (1H, dd, J 16.2, 5.9, C(2)HH), 3.19 (1H, 
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dd, J 16.2, 7.1, C(2)HH), 4.21 (1H, t, J 6.5, C(3)H), 7.14 – 7.18 (1H, m, ArH), 7.20 – 7.26 
(4H, m, ArH), 7.28 – 7.32 (3H, m, ArH), 8.36 (1H, dd, J 8.1, 1.0, C(4’)H); δC (126 MHz, 
CDCl3) 37.0 (2 × N(CH3)2), 40.2 (C(2)H2), 40.9 (C(3)H), 106.4 (C(4)), 117.6 (C(4’)H), 121.4 
(C(7’)H), 125.5 (C(6’)H), 126.1 (C(7a’)), 126.4 (C(5’)H), 126.9 (2 × C(3)PhC(2)H), 127.6 
(C(3)PhC(4)H), 129.2 (2 × C(3)PhC(3)H), 137.3 (C(4a’)), 140.9 (C(3)PhC(1)), 142.3 (C(5)), 
167.8 (C(1)O), 169.4 (CONMe2); m/z (NSI
+) 373 ([M+Na]+, 100%), 389 ([M+K]+, 70%); 
HRMS (NSI+) C20H18O2N2NaS ([M+Na]
+) requires 373.0981, found 373.0974 (–1.9 ppm). 
(R)-N,N-dimethyl-1-oxo-3-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-
benzo[4,5]thiazolo[3,2-a]pyridine-4-carboxamide (269) 
 
The title compound was prepared according to General Procedure H from (E)-p-
trifluoromethylcinnamic anhydride (414 mg, 1.00 mmol), and 2-(1,3-benzothiazol-2-yl)-
N,N-dimethylacetamide (158 mg, 0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 
2.1 (11.1 mg, 0.036 mmol) in THF (2 mL) and purified by chromatography on silica gel 
(10% EtOAc/CH2Cl2) to give 269 as a yellow foamy solid (179 mg, 60%); mp 192–193 °C; 
20
D][  –104.1 (c 1 in CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, 
flow rate 1.0 mL min-1, 211 nm, 30 °C), tR major: 14.3 min, tR minor: 21.2 min, 95% ee; max 
(film)/cm-1 2974 (C-H), 2938 (C-H), 1705 (C=O), 1692 (C=O), 1626 (C=C); δH (500 MHz, 
CDCl3) 2.89 (6H, s, N(CH3)2), 2.96 (1H, dd, J 16.2, 6.2, C(2)H2), 3.19 (1H, dd, J 16.3, 7.1, 
C(2)H2), 4.27 (1H, t, J 6.7, C(3)H), 7.12 – 7.19 (1H, m, ArH), 7.18 – 7.25 (1H, m, ArH), 
7.26 – 7.31 (1H, m, ArH), 7.37 (2H, d, J 8.1, 2 × C(3)ArC(2)H), 7.53 – 7.60 (2H, m, 2 × 
C(3)ArC(3)H), 8.31 – 8.36 (1H, m, C(4’)H); δC (126 MHz, CDCl3) 36.9 (2 × N(CH3)2), 40.0 
(C(3)H), 40.5 (C(2)H2), 105.0 (C(4)), 117.5 (C(4’)H), 121.3 (C(7’)H), 124.0 (q, J 272.1, CF3), 
125.5 (C(6’)H), 125.6 (C(7a’)), 126.1 (q, J 3.8, 2 × C(3)ArC(3)H), 126.4 (C(5’)H), 127.3 (2 × 
C(3)ArC(2)H), 129.7 (q, J 32.5 C(3)ArC(4)CF3), 137.0 (C(4a’)), 142.9 (C(3)ArC(1)), 145.1 
(C(5)), 167.0 (C(1)O), 169.0 (CONMe2); δF (470 MHz, CDCl3) –62.53; m/z (APCI
+) 419 
([M+H]+, 100%); HRMS (NSI+) C21H18F3N2O2S ([M+H]
+) requires 419.1036, found 
419.1040 (+1.1 ppm). 
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(R)-3-(4-methoxyphenyl)-N,N-dimethyl-1-oxo-2,3-dihydro-1H-
benzo[4,5]thiazolo[3,2-a]pyridine-4-carboxamide (270) 
 
The title compound was prepared according to General Procedure H from (E)-4-
methoxycinnamic anhydride (338 mg, 1.00 mmol), and 2-(1,3-benzothiazol-2-yl)-N,N-
dimethylacetamide (158 mg, 0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 
(11.1 mg, 0.036 mmol) in THF (2 mL) and purified by chromatography on silica gel (10% 
EtOAc/CH2Cl2) to give 270 as a yellow solid (145 mg, 53%); mp 157–159 °C; 
20
D][  –
120.3 (c 1 in CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow 
rate 1.0 mL min-1, 211 nm, 30 °C), tR major: 19.9 min, tR minor: 27.8 min, 93% ee; max 
(film)/cm-1 2929 (C-H), 1711 (C=O), 1688 (C=O), 1609 (C=C); δH (500 MHz, CDCl3) 
2.87 (6H, s, N(CH3)2), 2.95 (1H, dd, J 16.1, 5.9, C(2)H2), 3.15 (1H, dd, J 16.1, 7.0, C(2)H2), 
3.77 (3H, s, OCH3), 4.15 (1H, t, J 6.4, C(3)H), 6.80 – 6.86 (2H, m, C(3)ArC(3)H), 7.12 – 
7.19 (3H, m, ArH), 7.22 (1H, ddd, J 8.3, 7.5, 1.4, ArH), 7.26 – 7.31 (1H, m, ArH), 8.35 (1H, 
dd, J 8.2, 1.2, C(4’)H); δC (126 MHz, CDCl3) 36.9 (2 × N(CH3)2), 39.3 (C(3)H), 41.0 
(C(2)H2), 55.3 (OCH3), 106.6 (C(4)), 114.4 (2 × C(3)ArC(3)H), 117.5 (C(4’)H), 121.2 
(C(7’)H), 125.3 (C(6’)H), 126.0 (C(7a’)), 126.2 (C(5’)H), 127.9 (2 × C(3)ArC(2)H), 132.7 
(C(3)ArC(4)), 137.2 (C(4a’)), 142.1 (C(3)ArC(1)), 158.82 (C(5)), 167.8 (CO), 169.3 (CO); 
m/z (NSI+) 381 ([M+H]+, 100%), 761 ([2M+H]+, 35%); HRMS (NSI+) C21H20N2O3S 
([M+H]+) requires 381.1267, found 381.1267 (–0.1 ppm). 
 (S)-3-(2-bromophenyl)-N,N-dimethyl-1-oxo-2,3-dihydro-1H-
benzo[4,5]thiazolo[3,2-a]pyridine-4-carboxamide (271) 
 
The title compound was prepared according to General Procedure H from (E)-2-
bromocinnamic anhydride (436 mg, 1.00 mmol) and 2-(1,3-benzothiazol-2-yl)-N,N-
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dimethylacetamide (158 mg, 0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 
(11.1 mg, 0.036 mmol) in THF (2 mL) and purified by chromatography on silica gel (10% 
EtOAc/CH2Cl2) to give 271 as a yellow solid (243 mg, 79%); mp 149–152 °C; 
20
D][  –20.0 
(c 1.0, CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 
mL min-1, 211 nm, 30 °C), tR major: 22.8 min, tR minor: 16.2 min, 96% ee; max (film)/cm-1 
2924 (C-H), 1710 (C=O), 1604 (C=O), 1585 (C=N), 1454 (C=C); δH (500 MHz, CDCl3) 
2.87 (6H, s, N(CH3)3), 2.95 (1H, dd, J 16.2, 5.6, C(2)HH), 3.14 (1H, dd, J 16.2, 6.9, 
C(2)HH), 4.64 (1H, dd, J 6.9, 5.6, C(3)H), 7.08 – 7.15 (1H, m, ArH), 7.16 – 7.29 (4H, m, 
ArH), 7.35 (1H, dd, J 7.5, 1.5, C(3)ArC(2)H), 7.59 (1H, dd, J 8.0, 1.3, C(7’)H), 8.31 – 8.36 
(1H, m, C(4’)H); δC (126 MHz, CDCl3) 37.2 (2 × N(CH3)2), 39.2 (C(3)H), 39.5 (C(2)H2), 
104.8 (C(4)), 117.5 (C(4’)H), 121.3 (C(7’)H), 123.7 (C(3)ArC(1)Br), 125.5 (C(6’)H), 126.2 
(ArCH), 126.8 (C(7a’)), 128.1 (ArCH), 128.3 (ArCH), 129.2 (ArCH), 133.7 (C(3)ArC(6)), 
136.8 (C(4a’)), 139.2 (C(3)ArC(2)), 147.3 (C(5)), 167.3 (C(1)O), 169.0 (CONMe2); m/z 
(APCI+) 431 ([M+H]+, 100%); HRMS (APCI+) C20H18Br
81O2N2S ([M+H]
+) requires 
429.0267, found 429.0267 (+0.0 ppm). 
 (R)-3-(3-bromophenyl)-N,N-dimethyl-1-oxo-2,3-dihydro-1H-
benzo[4,5]thiazolo[3,2-a]pyridine-4-carboxamide (272) 
 
The title compound was prepared according to General Procedure H from (E)-3-
bromocinnamic anhydride (436 mg, 1.00 mmol) and 2-(1,3-benzothiazol-2-yl)-N,N-
dimethylacetamide (158 mg, 0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 
(11.1 mg, 0.036 mmol) in THF (2 mL) and purified by chromatography on silica gel 
(CH2Cl2 → 10% EtOAc/CH2Cl2) to give 272 as a yellow solid (283 mg, 92%) ; mp 69–72 
°C; 
20
D][ –103.3 (c 1.0, CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (20% i-
PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 15.4 min, tR minor: 38.8 
min, 96% ee; max (film)/cm-1 2922 (C-H), 1701 (C=O), 1613 (C=O), 1587 (C=N), 1452 
(C=C); δH (500 MHz, CDCl3) 2.89 (6H, s, N(CH3)2), 2.94 (1H, dd, J 16.3, 6.1, C(2)HH), 
3.16 (1H, dd, J 16.3, 7.2, C(2)HH), 4.18 (1H, dd, J 7.2, 6.0, C(3)H), 7.14 – 7.19 (3H, m, 
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ArH), 7.20 – 7.25 (1H, m, ArH), 7.28 – 7.30 (1H, m, ArH), 7.35 – 7.40 (2H, m, ArH), 8.35 
(1H, dd, J 8.3, 0.8, C(4’)H); δC (75 MHz, CDCl3) 37.0 (2 × N(CH3)2), 40.0 (C(3)H), 40.6 
(C(2)H2), 105.4 (C(5)), 117.7 (C(4’)H), 121.4 (C(7’)H), 123.1 (C(3)ArC(1)Br), 125.5, (ArCH), 
125.6 (ArCH), 125.8 (C(7a’)), 126.5 (C(5’)H), 130.1 (ArCH), 130.8 (ArCH), 130.8 (ArCH), 
137.2 (C(4a’), 142.7 (C(3)ArC(3)), 143.4 (C(5)), 167.3 (C(1)O), 169.1 (CONMe2); m/z 
(APCI+) 429 ([M+H]+, 100%); HRMS (APCI+) C20H18Br
79N2O2S ([M+H]
+) requires 
429.0267, found 429.0267 (+0.0 ppm). 
(S)-N,N,3-trimethyl-1-oxo-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-a]pyridine-4-
carboxamide (276) 
 
The title compound was prepared according to General Procedure H from (E)-crotonic 
anhydride (154 mg, 1.00 mmol), and 2-(1,3-benzothiazol-2-yl)-N,N-dimethylacetamide (158 
mg, 0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in 
THF (2 mL) and purified by chromatography on silica gel (10% EtOAc/CH2Cl2→10% 
EtOAc/CH2Cl2) to give 276 as a yellow oil (146 mg, 71%); 
20
D][  +9.7 (c 1.5 in CH2Cl2); 
chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 211 
nm, 30 °C), tR major: 9.6 min, tR minor: 13.6 min, 94% ee; max (film)/cm-1 2963 (C-H), 
2926 (C-H), 1699 (br, 2 × C=O), 1622 (C=C); δH (500 MHz, CDCl3) 1.19 (3H, d, J 6.9, 
C(3)CH3), 2.59 (1H, dd, J 16.1, 6.9, C(2)HH), 2.90 (1H, dd, J 16.1, 6.3, C(2)HH), 3.01 (1H, 
h, J 7.0, C(3)H), 3.07 (6H, s, N(CH3)2), 7.12 (1H, td, J 7.6, 1.2, C(5’)H), 7.18 – 7.21 (1H, m, 
C(6’)H), 7.21 – 7.24 (1H, m, C(7’)H), 8.31 – 8.39 (1H, m, C(4’)H); δc (126 MHz, CDCl3) 
18.7 (C(3)CH3), 29.6 (C(3)H), 36.7 (2 × N(CH3)2), 40.4 (C(2)H2), 108.5 (C(4)), 117.4 
(C(4’)H), 121.2 (C(7’)H), 125.2 (C(6’)H), 125.4 (C(7a’)), 126.2 (C(5’)H), 137.3 (C(4a’)), 138.3 
(C(5)), 168.3 (C(1)O), 169.5 (CONMe2); m/z (NSI
+) 289 ([M+H]+, 20%), 311 
([M+Na]+,40%), 327 ([M+K]+, 90%) plus degradation peaks; HRMS (NSI+) C15H16N2O2S 
([M+H]+) requires 289.1005, found 289.1005 (–0.1 ppm). 
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 (S)-3-(furan-2-yl)-N,N-dimethyl-1-oxo-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-
a]pyridine-4-carboxamide (273) 
 
The title compound was prepared according to General Procedure H from (E)-3-(Furan-2-
yl)acrylic anhydride (258 mg, 1.00 mmol), and 2-(1,3-benzothiazol-2-yl)-N,N-
dimethylacetamide (158 mg, 0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 
(11.1 mg, 0.036 mmol) in THF (2 mL) and purified by chromatography on silica gel 
(CH2Cl2→10% EtOAc/CH2Cl2) to give 273 as a brown oil (193 mg, 79%); 
20
D][  –109.3 (c 
0.5 in CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1.0 
mL min-1, 211 nm, 30 °C), tR major: 14.4 min, tR minor: 20.3 min, 95% ee; max (film)/cm-1 
2974 (C-H), 2928 (C-H), 1705 (br, 2 × C=O), 1616 (C=C), 1583 (furan), 1489 (furan); δH 
(500 MHz, CDCl3) 2.97 (6H, s, N(CH3)2), 3.10 (1H, dd, J 16.2, 3.9, C(2)HH), 3.18 (1H, dd, 
J 16.4, 7.0, C(2)HH), 4.26 (1H, dd, J 7.1, 3.9 C(3)H), 6.15 (1H, d, J 3.2 (C(3)furylC(3)H), 
6.28 (1H, dd, J 3.3, 1.9, C(3)furylC(4)H), 7.14 – 7.19 (1H, m, C(5’)H), 7.21 – 7.27 (1H, m, 
C(6’)H), 7.27 – 7.31 (1H, m C(3)furylC(5)H), 7.32 (1H, dd, J 1.9, 0.9, C(7’)H), 8.38 (1H, dd, 
J 8.2, 1.1, C(4’)H); δC (126 MHz, CDCl3) 33.7 (C(3)H), 37.0 (2 × N(CH3)2), 37.4 (C(2)H2), 
103.6 (C(4)), 106.2 (C(3)furylC(3)H), 110.6 (C(3)furylC(4)H), 117.7 (C(4’)H), 121.3 
(C(7’)H), 125.4 (C(6’)H), 125.6 (C(7a’)), 126.4 (C(5’)H), 137.4 (C(4a’)), 141.6 
(C(3)furylC(2)), 142.4 (C(3)furylC(5)H), 153.4 (C(5)), 167.6 (C(1)O), 169.2 (CONMe2); m/z 
(NSI+) 341 ([M+H]+, 15%), 363 ([M+Na]+, 100%), 379 ([M+K]+, 10%); HRMS (NSI+) 
C18H17N2O3S ([M+H]
+) requires 341.0954, found 341.0949 (–1.6 ppm). 
 (R)-3-(furan-3-yl)-N,N-dimethyl-1-oxo-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-
a]pyridine-4-carboxamide (274) 
 
The title compound was prepared according to General Procedure H from (2E)-3-(furan-3-
yl)prop-2-enoic anhydride (258 mg, 1.00 mmol) and 2-(1,3-benzothiazol-2-yl)-N,N-
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dimethylacetamide (158 mg, 0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 
(11.1 mg, 0.036 mmol) in THF (2 mL) and purified by chromatography on silica gel (10% 
EtOAc/CH2Cl2) to give 274 as a yellow oil (130 mg, 53%); 
20
D][  –53.7 (c 1.0 in CH2Cl2); 
chiral HPLC analysis, ChiralPak OJ-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 
30 °C), tR major: 24.5 min, tR minor: 19.4 min, 96% ee; max (film)/cm-1 2926 (C-H), 1701 
(C=O), 1614 (C=O), 1583 (C=N), 1462 (C=C); δH (300 MHz, CDCl3) 2.85 (1H, dd, J 4.9, 
16.1, C(2)HH), 2.89 (6H, s, N(CH3)2), 3.02 (1H, dd, J 16.1, 6.6, C(2)HH), 3.95 – 4.06 (1H, 
m, C(3)H), 6.22 (1H, dd, J 1.9, 1.0, furylC(4)H), 7.06 (1H, td, J 7.5, 1.4, C(5’)H), 7.09 – 7.16 
(1H, m, C(6’)H), 7.16 – 7.21 (1H, m, C(7’)H), 7.24 (1H, dt, J 1.7, 0.9, furylC(2)H), 7.27 (1H, 
t, J 1.7, furylC(5)H), 8.20 – 8.29 (1H, m, C(4’)H); δC (75 MHz, CDCl3) 31.0 (C(3)H), 37.1 (2 
× N(CH3)2), 39.5 (C(2)H2), 105.7 (C(4)), 109.3 (furylC(4)H), 117.5 (C(4’)H), 121.2 (C(7’)H), 
124.7 (furylC(3)), 125.3 (C(6’)H), 125.8 (C(7a’)), 126.2 (C(5’)H), 137.1 (C(4a’)), 139.3 
(furylC(2)H), 142.0 (C(5)), 143.9 (furylC(5)H), 167.8 (C(1)O), 169.2 (CONMe2); m/z 
(APCI+) 341 ([M+H]+, 100%); HRMS (APCI+) C18H17O3N2S ([M+H]
+) requires 341.0954, 
found 341.0953 (–0.4 ppm). 
 (R)-N,N-dimethyl-1-oxo-3-(thiophen-3-yl)-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-
a]pyridine-4-carboxamide (275) 
 
The title compund was prepared according to General Procedure H from (2E)-3-(thiophen-3-
yl)prop-2-enoic anhydride (290 mg, 1.00 mmol) and 2-(1,3-benzothiazol-2-yl)-N,N-
dimethylacetamide (158 mg, 0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 
(11.1 mg, 0.036 mmol) in THF (2 mL) and purified by chromatography on silica gel 
(CH2Cl2→10% EtOAc/CH2Cl2) to give 275 as a yellow oil (148 mg, 58%); 
20
D][ –85.6 (c 
1.0, CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 mL 
min-1, 211 nm, 30 °C), tR major: 25.6 min, tR minor: 22.8 min, 96% ee; max (film)/cm-1 3069 
(C-H), 2926 (C-H), 1701 (C=O), 1613 (C=O), 1483 (C=N), 1452 (C=C); δH (300 MHz, 
CDCl3) 2.91 (6H, s, N(CH3)2), 3.01 (1H, dd, J 16.2, 4.7, C(2)HH), 3.16 (1H, dd, J 16.2, 6.8, 
C(2)HH), 4.27 (1H, dd, J 6.7, 4.9, C(3)H), 6.95 (1H, dd, J 5.0, 1.4, thiopheneC(4)H), 7.05 – 
7.11 (1H, m, thiopheneC(2)H), 7.12 – 7.18 (1H, m, ArH), 7.19 – 7.25 (1H, m, ArH), 7.25 – 
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7.32 (2H, m, ArH), 8.31 – 8.38 (1H, m, C(4’)H); δC (126 MHz, CDCl3) 35.4 (C(3)H), 37.1 
(2 × N(CH3)2), 39.9, (C(2)H2), 106.2 (C(4)), 117.6 (C(4’)H), 121.3 (thiopheneC(2)H), 121.3 
(C(7’)H), 125.4 (C(6’)H), 126.0 (C(7’)), 126.4 (C(5’)H), 126.4 (thiopheneC(5)H), 127.1 
(thiopheneC(4)H), 137.3 (C(4a’)), 141.2 (C(5)), 142.0 (thiopheneC(3)), 167.9 (C(1)O), 169.4 
(CONMe2); m/z (APCI
+) 357 ([M+H]+, 100%); HRMS (APCI+) C18H17O2N2S2 ([M+H]
+) 
requires 357.0726, found 357.0725 (–0.3ppm). 
Ethyl (S)-4-(dimethylcarbamoyl)-1-oxo-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-
a]pyridine-3-carboxylate (277) 
 
The title compound was prepared according to General Procedure H from (E)-4-ethoxy-4-
oxobut-2-enoic anhydride (270 mg, 1.00 mmol), and 2-(1,3-benzothiazol-2-yl)-N,N-
dimethylacetamide (158 mg, 0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 
(11.1 mg, 0.036 mmol) in THF (2 mL) and purified by chromatography on silica gel (10% 
EtOAc/CH2Cl2) to give 277 as a yellow oil (191 mg, 77%); 
20
D][  –81.6 (c 1.0 in CH2Cl2); 
chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 211 
nm, 30 °C), tR major: 17.5 min, tR minor: 31.2 min, 92% ee; max (film)/cm-1 2928 (C-H), 
1724 (C=O), 1709 (C=O), 1620 (C=O); δH (500 MHz, CDCl3) 1.24 (3H, t, J 7.2, CH2CH3), 
3.02 (1H, dd, J 16.5, 7.3, C(2)HH), 3.08 (6H, s, N(CH3)2), 3.10 (1H, dd, J 11.3, 5.2, 
C(2)HH), 3.91 (1H, dd, J 7.3, 5.1, C(3)H), 4.06 – 4.22 (2H, m, CH2CH3), 7.14 (1H, td, J 7.6, 
1.2, C(5’)H), 7.19 – 7.27 (2H, m, ArH), 8.34 (1H, dd, J 8.3, 1.1, C(4’)H); δC (126 MHz, 
CDCl3) 14.1 (C(3)H), 34.6 (C(2)H2), 37.0 (2 × N(CH3)2, 40.1 (CH2CH3), 61.7, CH2CH3), 
100.5 (C(5)), 117.6 (C(4’)H), 121.1 (C(7’)H), 124.8 (C(7a’)), 125.3 (C(6’)H), 126.4 (C(5’)H), 
137.2 (C(4a’)), 141.4 (C(5)), 166.7 (C(1)O), 169.2 (CONMe2), 171.4 (CO2Et); m/z (NSI
+) 
347 ([M+H]+, 100%), plus unknown degradation peaks; HRMS (NSI+) C17H19O4N2S 
([M+H]+) requires 347.1060, found 347.1062 (+0.6 ppm). 
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 (R)-5-(benzo[d]oxazol-2-yl)-4,6-diphenyl-3,4-dihydro-2H-pyran-2-one (263) 
 
The title compound was prepared according to General Procedure H from (E)-cinnamic 
anhydride (70 mg, 0.25 mmol), and 2-phenacylbenzoxazole (43 mg, 0.18 mmol), EtN(iPr)2 
(35 μL, 0.20 mmol) and HBTM 2.1 (2.8 mg, 0.05 mmol) in THF (0.5 mL) and purified by 
chromatography on silica gel (CH2Cl2) to give 263 as an off-white foamy solid (61 mg, 
95%); mp 125–128 °C; 
20
D][  +28.8 (c 1.0 in CH2Cl2); chiral HPLC analysis, ChiralPak OJ-
H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR major: 13.6 min, tR 
minor: 17.3 min, 98% ee; max (film)/cm-1 3061 (C-H), 1778 (C=O), 1690 (C=O), 1645 
(C=N), 1530 (C=C); δH (500 MHz, CDCl3) 3.12 (1H, dd, J 15.7, 1.4, C(3)HH), 3.31 (1H, 
dd, J 15.7, 7.6, C(3)HH), 4.94 (1H, d, J 6.6, C(4)H), 7.17 – 7.20 (1H, m, ArH), 7.21 – 7.27 
(3H, m, ArH), 7.28 – 7.36 (4H, m, ArH), 7.37 – 7.42 (2H, m, ArH), 7.45 – 7.49 (1H, m, 
ArH), 7.51 – 7.55 (2H, m, ArH), 7.62 – 7.66 (1H, m, benzoxazoleC(4)H); δC (126 MHz, 
CDCl3) 36.6 (C(3)H2), 40.2 (C(4)H), 107.5 (C(5)), 110.4 (benzoxazoleC(7’)H), 119.9 
(benzoxazoleC(4’)H), 124.5 (benzoxazoleC(6’)H), 125.3 (benzoxazoleC(5’)H), 126.9 (2 × 
ArCH), 127.8 (C(4)PhC(4)H), 128.2 (2 × ArCH), 129.0 (2 × ArCH), 129.3 (2 × ArCH), 
130.4 (C(6)PhC(4)H), 132.6 (C(6)PhC(1)), 139.4 (benzoxazoleC(4a’)), 141.5 (C(4)PhC(1)), 
150.2 (benzoxazoleC(7a’)), 156.0 (C(6)), 160.9 (benzoxazoleC(2’)), 166.2 (C(2)O); m/z 
(NSI+) 390 ([M+Na]+, 100%), 368 ([M+H]+, 40%); HRMS (NSI+) C24H17O3NNa 
([M+Na]+) requires 390.1101, found 390.1094 (–1.7 ppm). 
 (R)-5-(benzo[d]oxazol-2-yl)-6-phenyl-4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-
2H-pyran-2-one (278) 
 
The title compound was prepared according to General Procedure H from (E)-p-
trifluoromethylcinnamic anhydride (414 mg, 1.00 mmol), and 2-phenacylbenzoxazole (171 
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mg, 0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in 
THF (2 mL) and purified by chromatography on silica gel (10:2 CH2Cl2/hexane) to give 
278 as a light green solid (112 mg, 36%); mp 193–196 °C; 
20
D][  +30.4 (c 0.5 in CH2Cl2); 
chiral HPLC analysis, ChiralPak AD-H (5% i-PrOH:hexane, flow rate 1.0 mL min-1, 211 
nm, 30 °C), tR major: 14.3 min, tR minor: 15.7 min, 99% ee; max (film)/cm-1 3061 (C-H), 
2974 (C-H), 1770 (C=O), 1655 (C=C), 168 (C=C); δH (500 MHz, CDCl3) 3.10 (1H, dd, J 
15.8, 1.8, C(3)HH), 3.34 (1H, dd, J 15.8, 7.6, C(3)HH), 4.98 (1H, dd, J 7.8, 2.0, C(4)H), 7.20 
– 7.24 (1H, m, benzoxazoleC(7)H), 7.24 – 7.33 (2H, m, ArH), 7.44 (2H, t, J 7.7 ArH), 7.52 
(3H, td, J 7.8, 1.8, ArH), 7.54 – 7.59 (2H, m, ArH), 7.61 (2H, d, J 8.2, 2 × C(6)ArC(2)H), 
7.66 (1H, dd, J 7.3, 1.6, benzoxazoleC(4)H); δC (126 MHz, CDCl3) 36.3 (C(3)H2), 40.1 
(C(4)H), 106.9 (C(5)), 110.6 (benzoxazoleC(7)H), 120.0 (benzoxazoleC(4)H), 124.0 (q, J 
272.2, CF3), 124.7 (benzoxazoleC(6)H), 125.6 (benzoxazoleC(5)H), 126.4 (q, J 3.8, 2 × 
C(4)ArC(3)H), 127.5 (2 × C(4)ArC(2)H), 128.4 (2 × C(6)ArC(3)H), 129.1 (2 × 
C(6)ArC(2)H), 130.28 (q, J 32.6, C(4)ArC(4)), 130.8 (C(6)ArC(4)H), 132.4 (C(6)ArC(1)), 
141.5 (benzoxazoleC(4a)), 143.7 (C(4)ArC(1)), 150.3 (benzoxazoleC(7a)), 156.6 (C(6)), 
160.6 (benzoxazoleC(2)), 165.8 (C(2)O); δF (470 MHz, CDCl3) –62.68; m/z (APCI
+) 435 
([M+H]+, 85%), plus decomposition peaks: 198 (100%), 252 (100%), 331 (90%), 359 
(90%); HRMS (APCI+) C25H17F3NO3 ([M+H]
+) requires 436.1155, found 436.1154 (–0.2 
ppm). 
 (R)-5-(benzo[d]oxazol-2-yl)-4-(4-methoxyphenyl)-6-phenyl-3,4-dihydro-2H-pyran-
2-one (279) 
 
The title compound was prepared according to General Procedure H from (E)-p-
methoxycinnamic anhydride (338 mg, 1.00mmol), and 2-phenacylbenzoxazole (171 mg, 
0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF 
(2 mL) and purified by chromatography on silica gel (CH2Cl2→10% EtOAC/CH2Cl2) to 
give 279 as a yellow foamy solid (211 mg, 74%); mp 98–99 °C; 
20
D][  +47.0 (c 0.5 in 
CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (5% i-PrOH:hexane, flow rate 1.0 mL 
min-1, 211 nm, 30 °C), tR major: 31.6 min, tR minor: 26.7 min, 90% ee; max (film)/cm-1 2974 
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(C-H), 2901 (C-H), 1772 (C=O), 1636 (C=C), 1601 (C=C); δH (500 MHz, CDCl3) 3.07 
(1H, dd, J 15.7, 1.8, C(3)HH), 3.27 (1H, dd, J 15.6, 7.5, C(3)HH), 3.76 (3H, s, OCH3), 4.84 
(1H, dd, J 7.5, 1.7, C(4)H), 6.82 – 6.89 (2H, m, 2 × C(4)ArC(2)H), 7.19 – 7.31 (5H, m, 
ArH), 7.41 (2H, t, J 7.6, 2 × C(6)ArC(3)H), 7.48 (1H, t, J 7.5, C(5)benzoxazoleC(7)H), 7.54 
(2H, dd, J 7.2, 1.7, 2 × C(6)ArC(2)H), 7.66 (1H, dd, J 7.6, 1.5, C(5)benzoxazoleC(4)H); δC 
(126 MHz, CDCl3) 37.0 (C(3)H2), 39.7 (C(4)H), 55.4 (OCH3), 108.0 (C(5)), 110.6 
(C(5)benzoxazoleC(7)H), 114.7 (2 × C(4)ArC(2)H), 120.0 (C(5)benzoxazoleC(4)H), 124.6 
(C(5)benzoxazoleC(6)H), 125.4 (C(5)benzoxazoleC(5)H), 128.1 (2 × ArCH), 128.3 (2 × 
ArCH), 129.1 (2 × ArCH), 130.5 (C(6)ArC(4)H), 131.4 (C(6)ArC(1)), 132.7 (C(4)ArC(4)), 
141.6 (C(5)benzoxazoleC(4a)), 150.3 (C(5)benzoxazoleC(7a)), 155.9 (C(6)), 159.2 
(C(4)ArC(1)OCH3), 161.1 (C(5)benzoxazoleC(2)), 166.5 (C(2)O); m/z (NSI
+) 398 ([M+H]+, 
25%), 420 ([M+Na]+, 100%), 436 ([M+K]+, 10%); HRMS (NSI+) C25H20NO4 ([M+H]
+) 
requires 398.1387, found 398.1381 (–1.5 ppm). 
(R)-5-(benzo[d]oxazol-2-yl)-4-(3-bromophenyl)-6-phenyl-3,4-dihydro-2H-pyran-2-
one (280) 
 
The title compund was prepared according to General Procedure H from (E)-3-
bromocinnamic anhydride (436 mg, 1.00 mmol) and 2-phenacyl benzoxazole (171 mg, 0.72 
mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF (2 
mL) and purified by chromatography on silica gel (20% EtOAc/petrol) to give 280 as a 
colourless solid (251 mg, 78%); mp 148–149 °C; 
20
D][  +17.7 (C 1.0, CH2Cl2); chiral HPLC 
analysis, ChiralPak OD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR 
major: 12.9 min, tR minor: 9.3 min, 99% ee; max (film)/cm-1 3013 (C-H), 1761 (C=O), 1651 
(C=N), 1452 (C=C); δH (500 MHz, CDCl3) 3.06 (1H, dd, J 15.8, 1.8, C(3)HH), 3.28 (1H, 
dd, J 15.8, 7.6, C(3)HH), 4.85 (1H, dd, J 7.6, 1.8, C(4)H), 7.16 – 7.21 (2H, m, ArH), 7.22 – 
7.30 (3H, m, ArH), 7.36 – 7.43 (3H, m, ArH), 7.46 – 7.51 (2H, m, ArH), 7.51 – 7.56 (2H, 
m, ArH), 7.61 – 7.67 (1H, m, benzoxazoleC(4)H); δC (101 MHz, CDCl3) 36.5 (C(3)H2), 
40.0 (C(4)H), 106.9 (C(5)), 110.6 (benzoxazoleC(7), 120.0 (benzoxazoleC(4)H), 123.4 
 6. Experimental  
 
190 
(C(4)ArC(1)Br), 124.7 (C(4)ArC(4)H), 125.4 (benzoxazoleC(5,6)), 125.5 
(benzoxazoleC(5,6)), 128.3 (2 × C(6)PhC(3)H), 129.1 (2 × C(6)PhC(2)H), 130.3 (ArCH), 
130.7 (ArCH), 130.9 (ArCH), 131.2 (ArCH), 132.5 (C(6)PhC(1)), 141.5 (ArC), 141.8 (ArC), 
150.3 (benzoxazoleC(7a)), 156.5 (C(6)), 160.6 (benzoxazoleC(2)), 165.8 (C(2)O); m/z 
(APCI+) 446 ([M+H]+, 100%); HRMS (APCI+) C24H17Br
79NO3 ([M+H]
+) requires 446.0386, 
found 446.0386 (–0.1 ppm). 
 (S)-5-(benzo[d]oxazol-2-yl)-4-methyl-6-phenyl-3,4-dihydro-2H-pyran-2-one (284) 
 
The title compound was prepared according to General Procedure H from (E)-crotonic 
anhydride (154 mg, 1.00 mmol), and 2-phenacylbenzoxazole (171 mg, 0.72 mmol), 
EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF (2 mL) and 
purified by chromatography on silica gel (CH2Cl2→10% EtOAc/CH2Cl2) to give 284 as a 
white solid (169 mg, 77%); mp 107–109 °C; 
20
D][  +82.8 (c 1.0 in CH2Cl2); chiral HPLC 
analysis, ChiralPak AD-H (5% i-PrOH:hexane, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR 
major: 15.3 min, tR minor: 9.1 min, 93% ee; max (film)/cm-1 2974 (C-H), 2914 (C-H), 1761 
(C=O), 1639 (C=C); δH (400 MHz, CDCl3) 1.36 (3H, d, J 7.1 CH3), 2.81 (1H, dd, J 15.8, 
2.1, C(3)H2), 3.01 (1H, dd, J 15.7, 6.6, C(3)H2), 3.68 (1H, pd, J 7.1, 2.1, C(4)H), 7.23 – 7.36 
(3H, m, ArH), 7.36 – 7.42 (2H, m, 2 × C(6)PhC(3)H), 7.43 – 7.50 (3H, m, ArH), 7.70 – 
7.76 (1H, m, benzoxazoleC(7)H); δC (101 MHz, CDCl3) 19.1 (CH3), 29.8 (C(4)H), 35.6 
(C(3)H2), 109.9 (C(5)), 110.5 (benzoxazoleC(7)H), 119.8 (benzoxazoleC(4)H), 124.6 
(benzoxazoleC(6)H), 125.3 (benzoxazoleC(5)H), 128.1 (2 × C(6)PhC(3)H), 129.0 (2 × 
C(6)PhC(2)H), 130.2 (C(6)PhC(4)H), 132.8 (C(6)PhC(1)), 141.5 (benzoxazoleC(4a)), 150.2 
(benzoxazoleC(7a)), 154.9 (C(6)), 161.1 (benzoxazoleC(2)), 167.0 (C(2)O); m/z (NSI+) 346 
([M+MeCN]+, 100%), 603 ([M+H]+, 20%); HRMS (NSI+) C19H16NO3 ([M+H]
+) requires 
306.1125, found 306.1124 (–0.2 ppm). 
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 (S)-5-(benzo[d]oxazol-2-yl)-4-(furan-2-yl)-6-phenyl-3,4-dihydro-2H-pyran-2-one 
(281) 
 
The title compound was prepared according to General Procedure H from (E)-3-(furan-2-
yl)acrylic anhydride (258 mg, 1.00 mmol), and 2-phenacylbenzoxazole (171 mg, 0.72 
mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF (2 
mL) and purified by chromatography on silica gel (CH2Cl2→10% EtOAc/CH2Cl2) to give 
281 as a brown/green solid (214 mg, 83%); mp 114-116 °C; 
20
D][  +85.2 (c 1.0 in CH2Cl2); 
chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1.0 mL min-1, 211 
nm, 30 °C), tR major: 10.9 min, tR minor: 7.7 min, 97% ee; max (film)/cm-1 2972 (C-H), 
2926 (C-H), 1782 (C=O), 1645 (C=C), 1531 (furan), 1452 (furan); δH (400 MHz, CDCl3) 
3.17 (1H, dd, J 15.9, 6.9, C(3)H2), 3.27 (1H, dd, J 15.9, 2.0, C(3)H2), 4.96 (1H, dd, J 6.9, 1.9, 
C(4)H), 6.23 – 6.27 (2H, m, furylC(3)H and furylC(4)H), 7.21 – 7.36 (4H, m, ArH), 7.37 – 
7.42 (2H, m, 2 × C(6)PhC(3)H), 7.44 – 7.50 (1H, m, benzoxazoleC(7)H), 7.50 – 7.54 (2H, 
m, 2 × C(6)PhC(2)H), 7.69 – 7.76 (1H, m, benzoxazoleC(4)H); δC (101 MHz, CDCl3) 33.4 
(C(3)H2), 34.2 (C(4)H), 105.6 (C(5)), 106.8 (furylC(4)H), 110.4 (furylC(3)H), 110.5 
(benzoxazoleC(7)H), 119.9 (benzoxazoleC(4)H), 124.6 (benzoxazoleC(6)H), 125.4 
(benzoxazoleC(5)H), 128.1 (2 × C(6)PhC(3)H), 129.0 (2 × C(6)PhC(2)H), 130.5 
(C(6)PhC(4)H), 132.5 (C(6)PhC(1)), 141.4 (benzoxazoleC(4a)), 142.8 (furylC(5)H), 150.2 
(benzoxazoleC(7a)), 152.1 (furylC(2)), 156.2 (C(6)), 160.8 (benzoxazoleC(2)), 165.9 (C(2)O); 
m/z (NSI+) 358 ([M+H]+, 20%), 375 ([M+NH4]
+, 75%), 390 ([M+CH3OH+H]
+, 100%); 
HRMS (NSI+) C22H16NO4 ([M+H]
+) requires 358.1074, found 358.1079 (+1.4 ppm). 
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 (R)-5-(benzo[d]oxazol-2-yl)-4-(furan-3-yl)-6-phenyl-3,4-dihydro-2H-pyran-2-one 
(282) 
 
The title compund was prepared according to General Procedure H from (2E)-3-(furan-3-
yl)prop-2-enoic anhydride (258 mg, 1.00 mmol) and 2-phenacyl benzoxazole (171 mg, 0.72 
mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF (2 
mL) and purified by chromatography on silica gel (20% EtOAc/petrol) to give 282 as a 
yellow oil (30 mg, 12%); 
20
D][ +89.1 (c 1.5, CH2Cl2); chiral HPLC analysis, ChiralPak AD-
H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 11.2 min, tR minor: 
8.4 min, 95% ee; max (film)/cm-1 2961 (C-H), 2930 (C-H), 1778 (C=O), 1647 (C=N), 1452 
(C=C); δH (300 MHz, CDCl3) 3.10 (1H, dd, J 15.8, 2.5, C(3)HH), 3.18 (1H, dd, J 15.7, 6.3, 
C(3)HH), 4.76 (1H, ddd, J 6.4, 2.5, 0.9, C(4)H), 6.36 (1H, dd, J 1.8, 0.9, furylC(4)H), 7.18 – 
7.32 (3H, m, ArH), 7.32 – 7.42 (4H, m, ArH), 7.42 – 7.50 (3H, m, ArH), 7.66 – 7.72 (1H, 
m, benzoxazoleC(4)H); δC (126 MHz, CDCl3) 31.7 (C(4)H), 35.3 (C(3)H2), 107.9 (C(5)), 
109.3 (furylC(4)H), 110.6 (benzoxazoleC(7)H), 120.0 (benzoxazoleC(4)H), 124.1 
(furylC(3)), 124.7 (benzoxazoleC(6)H), 125.5 (benzoxazoleC(5)H), 128.3 (2 × 
C(6)PhC(2)H), 129.1 (2 × C(6)PhC(3)H), 130.6 (C(6)PhC(4)H), 132.6 (C(6)PhC(1)), 139.5 
(furylC(2)H), 141.6 (benzoxazoleC(4a)), 144.1 (furylC(5)H), 150.3 (benzoxazoleC(7a)), 
155.7 (C(6)), 161.0 (benzoxazoleC(2)), 166.5 (C(2)O); m/z (APCI+) 358 ([M+H]+, 100%); 
HRMS (APCI+) C22H16O4N ([M+H]
+) requires 358.1074, found 358.1071 (–0.8 ppm). 
 (S)-5-(benzo[d]oxazol-2-yl)-6-phenyl-4-(thiophen-3-yl)-3,4-dihydro-2H-pyran-2-
one (283) 
 
The title compund was prepared according to General Procedure H from (2E)-3-(thiophen-3-
yl)prop-2-enoic anhydride (290 mg, 1.00 mmol) and 2-phenacyl benzoxazole (171 mg, 0.72 
mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF (2 
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mL) and purified by chromatography on silica gel (6:4→10:2 CH2Cl2/hexane) to give 283 
as a tan solid (120 mg, 45%) ; mp 105–107 °C; 
20
D][ +80.4 (c 1.0, CH2Cl2); chiral HPLC 
analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR 
major: 10.6 min, tR minor: 8.9 min, 98% ee; max (film)/cm-1 3080 (C-H), 2918 (C-H), 1773 
(C=O), 1653 (C=N), 1451 (C=C), 1352 (C=C); δH (300 MHz, CDCl3) 3.09 – 3.30 (2H, m, 
C(3)H2), 4.95 (1H, ddd, J 6.3, 2.8, 0.9, C(4)H), 7.06 (1H, dd, J 5.0, 1.4, thiopheneC(4)H), 
7.16 – 7.34 (5H, m, ArH), 7.34 – 7.42 (2H, mArH), 7.42 – 7.53 (3H, m, ArH), 7.65 – 7.71 
(1H, m, benzoxazoleC(4)H); δC (126 MHz, CDCl3) 35.8 (C(3)H2), 35.8 (C(4)H), 108.1 
(C(5)), 110.6 (benzoxazoleC(7)H), 120.0 (benzoxazoleC(4)H), 121.7 (thiopheneC(2)H), 
124.7 (benzoxazoleC(6)H), 125.5 (benzoxazoleC(5)H), 126.4 (thiopheneC(5)H), 127.2 
(thiopheneC(4)H), 128.2 (2 × C(6)PhC(2)H), 129.1 (2 × C(6)PhC(3)H), 130.5 
(C(6)PhC(4)H), 132.6 (C(6)PhC(1)), 139.9 (thiopheneC(3)), 141.6 (benzoxazoleC(4a)), 
150.3 (benzoxazoleC(7a)), 155.7 (C(6)), 161.1 (benzoxazoleC(2)), 166.5 (C(2)O); m/z 
(APCI+) 374 ([M+H]+, 100%); HRMS (APCI+) C22H16O3NS ([M+H]
+) requires 374.0845, 
found 374.0846 (+0.2 ppm). 
Ethyl (S)-5-(benzo[d]oxazol-2-yl)-2-oxo-6-phenyl-3,4-dihydro-2H-pyran-4-
carboxylate (285a) and ethyl (S)-4-benzoyl-1-oxo-2,3-dihydro-1H-
benzo[4,5]oxazolo[3,2-a]pyridine-3-carboxylate (285b) 
 
The title compounds were prepared according to General Procedure H from (E)-4-ethoxy-4-
oxobut-2-enoic anhydride (270 mg, 1.0 mmol), and 2-phenacylbenzoxazole (171 mg, 0.72 
mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF (2 
mL) and purified by filtration through a plug of silica gel (CH2Cl2) to give 285a/285b as an 
off-white oily solid (94:6 mixture of regioisomers, 111 mg, 43%); mp 84–93 °C; 
20
D][ –
17.6 (c 1.0, CH2Cl2); max (film)/cm-1 2986 (C-H), 1790 (C=O), 1724 (C=O), 1647 (C=O); 
m/z (NSI+) 386 ([M+Na]+, 30%), plus unknown degradation peaks; HRMS (NSI+) 
C21H17O5NNa ([M+Na]
+) requires 389.0999, found 389.0995 (–1.0 ppm). 
285a (major): chiral HPLC analysis, ChiralPak IA (20% i-PrOH:hexane, flow rate 1.0 mL 
min-1, 211 nm, 30 °C), tR major: 13.9 min, tR minor: 10.8 min, 66% ee; δH (400 MHz, 
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CDCl3) 1.12 (3H, t, J 7.1, CH2CH3), 3.00 (1H, dd, J 16.3, 7.3, C(3)HH), 3.27 (1H, dd, J 16.2, 
2.0, C(3)HH), 4.07 – 4.22 (2H, m, CH2CH3), 4.47 (1H, dd, J 7.3, 2.0, C(4)H), 7.21 – 7.39 
(5H, m, ArH), 7.41 – 7.49 (3H, m, ArH), 7.66 – 7.74 (1H, m, benzoxazoleC(4)H); δC (101 
MHz, CDCl3) 13.9 (CH2CH3), 30.7 (C(3)H2), 40.6 (C(4)H), 62.1 (CH2CH3), 103.0 (C(5)), 
110.5 (benzoxazoleC(7)H), 119.9 (benzoxazoleC(4)H), 124.7 (benzoxazoleC(6)H), 125.5 
(benzoxazoleC(4)H), 128.2 (2 × C(6)PhC(2)H), 129.0 (2 × C(6)PhC(3)H), 130.6 
(C(6)PhC(4)H), 132.3 (C(6)PhC(1)), 141.4 (benzoxazoleC(4a)), 150.2 (benzoxazoleC(7a)), 
156.8 (C(6)), 160.7 (benzoxazoleC(2)), 165.1 (C(2)O), 170.3 (COOEt). 
285b (minor): chiral HPLC analysis, ChiralPak IA (20% i-PrOH:hexane, flow rate 1.0 mL 
min-1, 211 nm, 30 °C), tR major: 12.8 min, tR minor: 15.0 min, 75% ee; δH (400 MHz, 
CDCl3, characteristic peaks) 2.99 (1H, dd, J 17.0, 7.6, C(3)HH), 3.19 ( H, dd, J 17.1, 2.8, 
C(3)HH), 7.95 – 8.01 (1H, m, C(4’)H); δH (400 MHz, CDCl3, characteristic peaks) (1H, dd, 
J 17.1, 7.6, C(2)HH), 3.19 (1H, dd, J 17.1, 2.8, C(2)HH), 7.95 – 7.99 (1H, m, C(4’)H); δC 
(101 MHz, CDCl3, characteristic peaks) 33.4 (C(2)H2), 41.9 (C(3)H), 62.1 (CH2CH3), 133.8 
(C(4)COPhC(4)H), 135.7 (C(4a’)), 140.7 (C(4)COPhC(1)), 150.9 (C(5)), 161.2 (C(1)O), 
193.2 (C(4)COPh). 
tert-butyl (R)-1-oxo-3-phenyl-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-a]pyridine-4-
carboxylate (261) 
 
The title compound was prepared according to modified General Procedure H from (E)-
cinnamic anhydride (278 mg, 1.00 mmol), and tert-butyl 2-(1,3-benzothiazol-2-yl)acetate 
(179 mg, 0.72 mmol), polymer-supported BEMP (2.2 mmol/g loading, 364 mg, 0.80 mmol) 
and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF (2 mL) and purified by chromatography on 
silica gel (10:2 CH2Cl2/hexane) to give 261 as a yellow solid (169 mg, 65%); mp 105–110 
˚C; 
20
D][  –213.6 (c 0.5 in CH2Cl2); chiral HPLC analysis, ChiralPak AD-H (2.5% i-
PrOH:hexane, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR major: 16.3 min, tR minor: 11.0 
min, 75% ee; max (film)/cm-1 2979 (C-H), 2928 (C-H), 1717 (C=O), 1668 (C=O), 1454 
(C=C); δH (500 MHz, CDCl3) 1.45 (9H, s, OC(CH3)3), 3.02 (1H, dd, J 16.3, 2.0, C(2)HH), 
3.26 (1H, dd, J 16.3, 8.1, C(2)HH), 4.28 (1H, dd, J 8.3, 2.0, C(3)H), 7.18 – 7.33 (7H, m, 
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ArH), 7.42 – 7.47 (1H, m, C(7’)H), 8.46 (1H, d, J 8.2, C(4’)H); δC
 (126 MHz, CDCl3) 28.4 (3 
× OC(CH3)3), 37.4 (C(2)H), 40.3 (C(3)H2), 81.3 (OC(CH3)3), 102.2 (C(4)), 117.5 (C(4’)H), 
121.5 (C(7’)H), 125.6 (C(6’)H), 126.5 (C(5’)H), 126.7 (2 × C(3)ArC(2)H), 127.2 (C(7a’)), 
127.3 (C(3)ArC(4)H), 128.9 (2 × C(3)ArC(3)H), 136.9 (C(4a’)), 142.0 (C(3)ArC(1)), 151.1 
(C(5)), 166.1 (C(1)O), 168.5 (C(4)CO; m/z (NSI+) 346 ([M–tBu+Na]+, 100%), 380 
([M+H]+,20%), 402 ([M+Na]+, 25%), 418 ([M+K]+, 70%); HRMS (NSI+) C22H21O3NS 
([M+H]+) requires 380.1315, found 380.1311 (–1.0 ppm). 
 (R)-4-(4-nitrobenzoyl)-3-phenyl-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-a]pyridin-1-
one (262a) and (R)-5-(benzo[d]thiazol-2-yl)-6-(4-nitrophenyl)-4-phenyl-3,4-dihydro-
2H-pyran-2-one (262b) 
 
The title compounds were prepared according to General Procedure H from (E)-cinnamic 
anhydride (278 mg, 1.00 mmol) and 2-(1,3-benzothiazol-2-yl)-1-(4-nitrophenyl)ethanone 
(215 mg, 0.72 mmol), EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 
mmol) in THF (2 mL) and purified by chromatography on silica gel (CH2Cl2) to give 262a 
as a yellow solid (141 mg, 46%) and 262b as a yellow solid (41 mg, 13%). 
262a (major): mp 225–229 °C; 
20
D][   (c 0.5 in CH2Cl2); chiral HPLC analysis, 
ChiralPak AD-H (40% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 
31.8 min, tR minor: 24.5 min, 83% ee; max (film)/cm-1 3111 (C-H), 3065 (C-H), 3030 (C-H), 
2870 (C-H), 1717 (C=O), 1701 (C=O), 1614 (C=C), 1520 (C=C), 1495 (NO2), 1340 (NO2); 
δH (300 MHz, CDCl3) 3.06 (1H, dd, J 15.9, 2.2, C(2)HH), 3.33 (1H, dd, J 15.9, 7.0, 
C(2)HH), 4.20 (1H, dd, J 6.6, 1.8, C(3)H), 7.00 – 7.13 (2H, m, C(3)PhC(2)H), 7.22 – 7.47 
(7H, m, ArH), 7.60 – 7.69 (1H, dd, J 3.8, 1.8, C(7’)H), 8.11 (2H, d, J 8.6 C(4)COArC(4)H), 
8.45 – 8.53 (1H, dd, J 7.5, 1.5, C(4’)H); δC (75 MHz, CDCl3) 38.7 (C(2)H2), 41.5 (C(3)H), 
106.8 (C(4)), 117.7 (C(4’)H), 122.2 (C(7’)H), 123.4 (2 × C(4)COArC(3)H), 126.2 (C(6’)H), 
126.7 (2 × C(3)PhC(2)H), 127.3 (C(7a’)), 127.5 (C(3)PhC(4)H), 128.0 (2 × C(3)PhC(3)H), 
128.0 (C(5’)H), 129.7 (2 × C(4)COArC(2)H), 136.0 (C(4a’)), 140.5 (C(3)PhC(1)), 145.4 
(C(4)COArC(1)), 148.5 (C(4)COArC(4)), 157.8 (C(5)), 167.5 (C(1)O), 188.9 (C(4)CO); m/z 
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(APCI+) 429 ([M+H]+, 100%); HRMS (APCI+) C24H17O4N2S ([M+H]
+) requires 429.0904, 
found 429.0903 (–0.1 ppm). 
262b (minor): mp 89–92 °C; 
20
D][  2.6 (c 0.5 in CH2Cl2); chiral HPLC analysis, ChiralPak 
AD-H (5% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 36.3 min, tR 
minor: 41.4 min, 28% ee; max (film)/cm-1 3105 (C-H), 3028 (C-H), 1780 (C=O), 1520 
(NO2), 1343 (NO2); δH (300 MHz, CDCl3) 3.11 (1H, dd, J 15.9, 1.8, C(3)HH), 3.36 (1H, dd, 
J 15.9, 7.6, C(3)HH), 4.89 (1H, dd, J 7.6, 1.7, C(4)H), 7.24 – 7.37 (6H, m, ArH), 7.44 (1H, 
ddd, J 8.3, 7.3, 1.3, C(5)benzothiazoleC(5)H), 7.64 – 7.69 (1H, m, 
C(5)benzothiazoleC(4)H), 7.70 – 7.76 (2H, m, C(6)ArC(2)H), 7.94 (1H, d, J 7.8, 
C(5)benzothiazoleC(7)H), 8.19 – 8.26 (2H, m, C(6)ArC(3)H); δC (75 MHz, CDCl3) 37.1 
(C(4)H), 42.5 (C(3)H2), 117.1 (C(5)), 121.8 (C(5)benzothiazoleC(7)H), 123.8 
(C(5)benzothiazoleC(4)H), 124.2 (2 × C(6)ArC(3)H), 126.3 (C(5)benzothiazoleC(6)H), 
126.9 (C(5)benzothiazoleC(5)H), 127.3 (C(4)PhC(4)H), 128.5 (2 × C(4)PhC(2)H), 129.8 (2 
× C(4)PhC(3)H), 131.3 (2 × C(6)ArC(2)H), 135.9 (C(5)benzothiazoleC(7a)), 138.5 
(C(6)ArC(1)), 139.2 (C(4)PhC(1)), 149.1 (C(5)benzothiazoleC(4a)), 151.5 (C(6)ArC(4)), 
153.0 (C(6)), 163.2 (C(5)benzothiazoleC(2)), 166.0 (C(2)O); m/z (APCI+) 429 ([M+H]+, 
100%); HRMS (APCI+) C24H17O4N2S ([M+H]
+) requires 429.0904, found 429.0902 (–0.4 
ppm). 
(3S,4R)-4-benzoyl-3-methyl-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-1(2H)-one 
and (S)-5-(1H-benzo[d]imidazol-2-yl)-4-methyl-6-phenyl-3,4-dihydro-2H-pyran-2-
one (266) 
 
The title compounds were prepared according to General Procedure H from (E)-crotonic 
anhydride (154 mg, 1.0 mmol), and 2-phenacylbenzimidazole (170 mg, 0.72 mmol), 
EtN(iPr)2 (140 μL, 0.80 mmol) and HBTM 2.1 (11.1 mg, 0.036 mmol) in THF (2 mL) and 
purified by chromatography on silica gel (5%→30% EtOAc/petroleum ether) to give a 
green oil that was further purified by trituration with Et2O to give 266 as an off-white solid 
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(79 mg, 36%, 87A : 4B : 9C); mp 142–144 °C; 
20
D][  +18.1 (c 1.0, CH2Cl2); chiral HPLC: 
no separation conditions found therefore ee unknown; max (film)/cm-1 3067 (N-H), 2970 
(C-H), 1719 (C=O), 1670 (C=O), 1f597 (C=N); δH (300 MHz, CDCl3) 1.05 – 1.28 (3.6H, 
m, A,B,C-CH3), 2.54 – 2.76 (1.1H, m, A-C(2)HH, C-C(3)HH), 2.76 – 3.04 (1.2H, m, A-
C(3)H, B-C(2)HH, B-C(3)H, C-C(3)HH), 3.12 (1H, dd, J 17.3, 4.6, A-C(2)HH), 3.28 
(0.1H, tdd, J 11.0, 8.1, 5.9, B-C(3)H, C-(3)HH), 4.95 (1H, dd, J 6.2, 2.2, A-C(4)H), 5.36 – 
5.40 (0.05H, m, B-C(4)H), 7.28 – 7.44 (2.H, m, ArH), 7.46 – 7.58 (3H, m, ArH), 7.58 – 
7.70 (2H, m, ArH), 8.02 – 8.15 (2.1H, m, A-PhC(2)H), 8.19 – 8.31 (1.1H, m, A-C(4’)H, B-
C(4’)H); δC (101 MHz, CDCl3) 18.3 (B-CH3), 19.9 (A-CH3), 21.9 (C-CH3), 27.9 (C-C(4)H), 
31.3 (A-C(3)H), 31.6 (B-C(3)H), 37.7 (B-C(2)H2), 38.7 (A-C(2)H2), 40.9 (C-C(3)H2), 45.7 
(B-C(4)H), 50.0 (A-C(4)H), 97.8 (C-C(5)), 115.2 (B-C(4’)H), 115.6 (A-C(4’)H), 115.7 
(ArCH), 116.9 (ArCH), 119.7 (B-C(7’)H), 119.9 (A-C(7’)H), 124.6 (ArCH), 125.4 (A-
C(5’,6’)H), 125.5 (B-C(5’,6’)H), 125.5 (A-C(5’,6’)H), 125.7 (B-C(5’,6’)H), 127.7 (ArCH), 
128.6 (ArCH), 129.1 (2 × A—PhC(2,3)H), 129.1 (2 × A—PhC(2,3)H), 129.7 (ArCH), 
130.3 (ArCH), 131.1 (A-C(4a’)), 131.4 (B-C(4a’)), 134.2 (A-PhC(4)H), 134.3 (ArCH), 136.0 
(A-PhC(1)), 137.1 (ArC), 140.0 (ArC), 142.6 (B-C(4a’)), 142.8 (A-C(4a’)), 151.6 (A-C(5)), 
152.1 (B-C(5)), 153.7 (C-C(6)), 167.7 (A-C(1)), 168.2 (B-C(1)), 168.6 (C-C(2)), 196.7 (A-
COPh), 196.9 (B-COPh); m/z (NSI+) 305 ([M+H]+, 100%), 327 ([M+Na]+, 60%), 343 
([M+K]+, 55%), 631 ([2M+Na]+, 55%), 647 ([2M+K]+, 100%); HRMS (NSI+) C19H17N2O2 
([M+H]+) requires 305.1285, found 305.1284 (–0.2 ppm). 
4-benzoyl-3,3-dimethyl-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-a]pyridin-1-one (305) 
 
The title compound was prepared according to General Procedure H from 3-methylbut-2-
enoic anhydride (91 mg, 0.50 mmol), and 2-phenacylbenzothiazole (91 mg, 0.36 mmol), 
EtN(iPr)2 (70 μL, 0.40 mmol) and HBTM 2.1 (3.4 mg, 0.018 mmol) in THF (1 mL) and 
purified by chromatography on silica gel (10% EtOAc/petroleum ether) to give 305 as a 
yellow solid (75 mg, 62%); mp 110–113 °C; max (film)/cm
-1 2928 (C-H), 2870 (C-H), 1719 
(C=O), 1593 (C=O); δH (300 MHz, CDCl3) 1.26 (6H, s, C(3)(CH3)2), 2.70 (2H, s C(2)H2), 
7.14 – 7.32 (3H, m, ArH), 7.41 – 7.57 (3H, m, ArH), 7.59 – 7.66 (2H, m, 2 × 
C(4)COPhC(2)H), 8.43 – 8.50 (1H, m, C(4’)H); δC (126 MHz, CDCl3) 26.7 (2 × 
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C(3)(CH3)2), 35.1 (C(3)(CH3)2), 49.4 (C(2)H2), 117.3 (C(4)), 117.6 (C(4’)H), 121.3 (C(7’)H), 
125.7 (C(6’)H), 126.7 (C(5’)H), 126.9 (C(7a’)), 128.1 (2 × C(4)COPhC(2)H), 128.9 (2 × 
C(4)COPhC(3)H), 131.6 (C(4)COPhC(4)H), 136.4 (C(4a’)), 140.7 (C(4)COPhC(1)), 150.4 
(C(5)), 168.9 (C1)O), 194.4 (C(4)COPh); m/z (NSI+) 336 ([M+H]+, 30%), 374 ([M+K]+, 
100%); HRMS (NSI+) C20H18O2NS ([M+H]
+) requires 336.1053, found 336.1048 (–1.4 
ppm). 
 (R)-4-benzoyl-3-methyl-3-(trifluoromethyl)-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-
a]pyridin-1-one (310) and (E)-2-(benzo[d]thiazol-2-yl)-6,6,6-trifluoro-5-methyl-1-
phenylhex-4-ene-1,3-dione (311) 
 
The title compounds were prepared according to General Procedure H from (2Z)4,4,4-
trifluoro-3-methylbut-2-enoic anhydride (406 mg, 1.40 mmol) and 2-phenacyl 
benzothiazole (253 mg, 1.00 mmol), EtN(iPr)2 (190 μL, 1.10 mmol) and HBTM 2.1 (15.4 
mg, 0.05 mmol) in THF (2.5 mL) and purified by chromatography on silica gel (10:2 
CH2Cl2/hexane) to give 74a/b as a yellow solid (75:25 mixture of isomers, 163 mg, 42%). 
The mixture was separated by Et2O trituration to give 310 as a yellow solid (50 mg, 13%) 
and 311 as a yellow oil which was solidified by hexane trituration (110 mg, 28%). 
310 (1,4-addition): mp 145–150 °C; 
20
D][   (c 0.5 in CH2Cl2); chiral HPLC analysis, 
ChiralPak AD-H (10% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 
18.1 min, tR minor: 16.4 min, 96% ee; max (film)/cm-1 3019 (C-H), 1721 (C=O), 1638 
(C=O); δH (500 MHz, CDCl3) 1.35 (3H, s, CH3), 2.96 (1H, d, J 16.8, C(2)HH), 3.12 (1H, d, 
J 16.8, C(2)HH), 7.20 – 7.25 (1H, m, C(5’)H), 7.29 – 7.35 (2H, m, ArH), 7.43 – 7.49 (2H, 
m, 2 × C(4)COPhC(3)H), 7.49 – 7.55 (1H, m, C(7’)H), 7.57 – 7.63 (2H, m, 2 × 
C(4)COPhC(2)H), 8.42 – 8.49 (1H, m, C(4’)H); δC (126 MHz, CDCl3) 21.1 (CH3), 41.8 
(C(2)H2), 43.8 (q, 
2JCF 26.9, C(3)CF3), 105.3 (C(4)), 117.8 (C(4’)H), 121.4 (C(7’)H), 126.1 
(C(6’)H), 126.4 (C(7a’’)), 127.2 (C(5’)H), 127.6 (q, 1JCF 286.1, CF3), 128.1 (2 × 
C(4)COPhC(2)H), 128.8 (2 × C(4)COPhC(3)H), 131.4 (C(4)COPhC(4)H), 136.0 (C(4a’)), 
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140.0 (C(4)COPhC(1)), 156.0 (C(5)), 166.1 (C(1)O), 193.0 (C(4)COPh); δF (470 MHz, 
CDCl3) –75.64; m/z (NSI
+) 390 ([M+H]+, 100%); HRMS (NSI+) C20H15F3O2NS ([M+H]
+) 
requires 390.0770, found 390.0766 (–1.1 ppm). 
311 (1,2-addition): mp 196–198 °C; max (film)/cm-1 3023 (C-H), 1537 (C=O?), 1499 
(C=O?), 1450 (C=N?) highly conjugated system, carbonyl peaks very low?; δH (500 MHz, CDCl3) 
1.98 (6H, s, br, CH3), 6.08 (1H, dt, J 3.0, 1.6, 1-keto-C(4)H), 6.18 (1H, dt, J 3.1, 1.7, 1-enol-
C(4)H), 7.37 – 7.44 (6H, m, ArH), 7.47 – 7.56 (8H, m, ArH), 7.63 (2H, t, J 8.0, 
benzothiazoleC(7)H), 7.85 (2H, d, J 7.9, benzothiazoleC(4)H), 14.72 (1H, s, 1-keto-OH), 
14.98 (1H, s, 1-enol-OH); δC (126 MHz, CDCl3) 12.4 (CH3), 12.4 (CH3), 108.9 (C(2)), 109.1 
(C(2)), 114.2 (benzothiazoleC(7)H), 114.4 (benzothiazoleC(7)H), 122.5 
(benzothiazoleC(4)H), 123.4 (q, 1JCF 274.0, CF3), 123.5 (q, 
1JCF 274.0, CF3), 125.2 
(benzothiazoleC(5)H), 125.2 (benzothiazoleC(5)H), 127.7 (benzothiazoleC(6)H), 127.8 
(benzothiazoleC(6)H), 128.2 (2 × C(1)PhC(2)H), 128.2 (2 × C(1)PhC(2)H), 128.5 (2 × 
C(1)PhC(3)H), 128.5 (2 × C(1)PhC(3)H), 128.9 (q, 2JCF 21.5, C(5)CF3), 130.4 (q, 
3JCF 5.7, 1-
keto-C(4)H), 130.9 (q, 3JCF 5.7, 1-enol-C(4)H), 131.6 (C(1)PhC(4)H), 131.7 (C(1)PhC(4)H), 
132.0 (C(1)PhC(1)), 132.1 (C(1)PhC(1)), 137.9 (benzothiazoleC(4a)), 138.1 
(benzothiazoleC(4a)), 141.7 (benzothiazoleC(7a)), 142.0 (benzothiazoleC(7a)), 168.8 
(benzothiazoleC(2)), 169.2 (benzothiazoleC(2)), 187.3 (1-keto-C(3)OH), 187.6 (1-enol-
C(3)O), 193.2 (1-enol-C(1)OH), 194.1 (1-keto-C(1)O); δF (470 MHz, CDCl3) –70.96, –70.95; 
m/z (NSI+) 390 ([M+H]+, 100%); HRMS (NSI+) C20H15F3O2NS ([M+H]
+) requires 
390.0770, found 390.0763 (–1.8 ppm). 
6.6 Cascade Substrates 
General Procedure I: Enone-Malonate Synthesis 
 
Allylation procedure from Han and Widenhoefer.158 NaH (60% in mineral oil, 1 equiv) was 
suspended in DMF (0.35 M) at 0 ˚C. A solution of dicarbonyl (1 equiv) in DMF (1 M) was 
added and the flask stirred at 0 ˚C for 2 h. A solution of allylbromide (1 equiv) in DMF (1 
M) was added dropwise and the flask stirred at 0 ˚C to rt for 16 h. Water (xx mL) was 
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added and the mixture extracted with ether (xx mL × 2). The combined organic layers were 
washed with brine (xx mL × 3), dried over MgSO4, filtered and concentrated in vacuo to 
give the crude allyl ester (used without further purification) 
The allyl ester was dissolved in a solution of methyl vinyl ketone (3 equiv) in CH2Cl2 (0.5 
M) in a sealable tube and the solution degassed by sparging with argon for 10 minutes. 
Metathesis catalyst M2 (2 mol%) was added, the tube sealed and heated at 50 ˚C for 48 h. 
After cooling to rt the solution was concentrated in vacuo and purified by silica 
chromatography (passed through silica twice to remove Ru residues) to afford 
enonemalonates. 
Diethyl (E)-2-(4-oxopent-2-en-1-yl)malonate (370) 
 
The title compound was prepared according to general procedure I from diethylmalonate 
(2.30 mL, 15.0 mmol in DMF, 15 mL), allylbromide (1.30 mL, 15.0 mmol in DMF, 15 mL) 
and NaH (60% in mineral oil, 0.60 g, 15.0 mmol) in DMF (40 mL). Aqueous work-up 
afforded crude allylmalonate which was dissolved in CH2Cl2 (40 mL) and methyl vinyl 
ketone (3.65 mL, 45.0 mmol) and M2 (285 mg, 0.3 mmol) added. The residue was purified 
by silica chromatography (20% EtOAc/hexane, twice) to afford 370 as a pale yellow oil 
(820 mg, 23%) {Lit. 159 oil}; max (film)/cm-1 2982 (C-H), 2940 (C-H), 1728 (C=O), 1674 
(C=O), 1630 (C=C); δH (400 MHz, CDCl3) 1.26 (6H, t, J 7.1, 2 × CO2CH2CH3), 2.22 (3H, 
s, COCH3), 2.79 (2H, td, J 7.2, 1.5, CH2CH=CH), 3.49 (1H, t, J 7.3, CHCO2Et), 4.20 (4H, 
qd, J 7.1, 2.2, 2 × CO2CH2CH3), 6.11 (1H, dt, J 15.9, 1.5, CH2CH=CH), 6.73 (1H, dt, J 
16.0, 7.0, CH2CH=CH). Data in agreement with the literature.
159 
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Dimethyl (E)-2-(4-oxopent-2-en-1-yl)malonate (391) 
 
The title compound was prepared according to general procedure I from dimethylmalonate 
(1.14 mL, 10.0 mmol in DMF, 10 mL), allylbromide (0.87 mL, 10.0 mmol in DMF, 10 mL) 
and NaH (60% in mineral oil, 0.40 g, 10.0 mmol) in DMF (40 mL). Aqueous work-up 
afforded crude allylmalonate which was dissolved in CH2Cl2 (20 mL) and methyl vinyl 
ketone (2.43 mL, 30.0 mmol) and M2 (190 mg, 0.2 mmol) added. The residue was purified 
by silica chromatography (10-30% EtOAc/hexane) to afford 391 as an orange oil (522 mg, 
23%); max (film)/cm-1 3005 (C-H), 2957 (C-H), 1732 (C=O), 1674 (C=O), 1630 (C=C); δH 
(300 MHz, CDCl3) 2.20 (3H, s, COCH3), 2.78 (2H, td, J 7.1, 1.5, CH2), 3.52 (1H, t, J 7.3, 
CHCO2CH3), 3.72 (6H, s, 2 × OCH3), 6.09 (1H, dt, J 16.0, 1.5, CH=CHCOCH3), 6.69 (1H, 
dt, J 16.0, 7.0, CH=CHCOCH3); δC (75 MHz, CDCl3) 27.2 (COCH3), 31.4 (CH2), 50.4 
(CHCO2CH3), 52.9 (2 × OCH3), 133.2 (CH=CHCOCH3), 142.6 (CH=CHCOCH3), 168.8 
(2 × CO2CH3), 198.1 (COCH3); m/z (NSI
+) 237 ([M+Na]+, 100%), 215 ([M+H]+, 70%); 
HRMS (NSI+) C10H15O5 ([M+H]
+) requires 215.0914, found 215.0914 (+0.0 ppm). 
Diisopropyl (E)-2-(4-oxopent-2-en-1-yl)malonate (389) 
 
The title compound was prepared according to general procedure I from 
diisopropylmalonate (1.90 mL, 10.0 mmol in DMF, 10 mL), allylbromide (0.87 mL, 10.0 
mmol in DMF, 10 mL) and NaH (60% in mineral oil, 0.40 g, 10.0 mmol) in DMF (40 mL). 
Aqueous work-up afforded crude allylmalonate which was dissolved in CH2Cl2 (20 mL) and 
methyl vinyl ketone (2.43 mL, 30.0 mmol) and M2 (190 mg, 0.2 mmol) added. The residue 
was purified by silica chromatography (10→20% EtOAc/hexane) to afford 389 as a pale 
yellow oil (526 mg, 19%); max (film)/cm-1 2982 (C-H), 2938 (C-H), 1724 (C=O), 1676 
(C=O), 1632 (C=C); δH (300 MHz, CDCl3) 1.24 (12H, dd, J 6.2, 1.5, 2 × CH(CH3)2), 2.23 
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(3H, s, COCH3), 2.78 (2H, td, J 7.2, 1.6, CH2), 3.43 (1H, t, J 7.3, CHCO2
iPr), 5.06 (2H, 
hept, J 6.3, CH(CH3)2), 6.12 (1H, dt, J 16.0, 1.5, CH=CHCOCH3), 6.75 (1H, dt, J 16.0, 7.0 
CH=CHCOCH3); δC (75 MHz, CDCl3) 21.7 (2 × CH(CH3)2), 27.1 (COCH3), 31.3 (CH2), 
51.1 (CHCO2
iPr), 69.5 (2 × CH(CH3)2), 133.2 (CH=CHCOCH3), 143.2 (CH=CHCOCH3), 
168.0 (2 × CO2
iPr), 198.2 (COCH3); m/z (NSI
+) 288 ([M+NH4]
+, 100%), 271 ([M+H]+, 
55%); HRMS (NSI+) C14H23O5 ([M+H]
+) requires 271.1540, found 271.1543 (+1.1 ppm). 
Dibenzyl (E)-2-(4-oxopent-2-en-1-yl)malonate (390) 
 
The title compound was prepared according to general procedure I from dibenzylmalonate 
(2.50 mL, 10.0 mmol in DMF, 10 mL), allylbromide (0.87 mL, 10.0 mmol in DMF, 10 mL) 
and NaH (60% in mineral oil, 0.40 g, 10.0 mmol) in DMF (40 mL). Aqueous work-up 
afforded crude allylmalonate which was dissolved in CH2Cl2 (20 mL) and methyl vinyl 
ketone (2.43 mL, 30.0 mmol) and M2 (190 mg, 0.2 mmol) added. The residue was purified 
by silica chromatography (10→20% EtOAc/hexane) to afford 390 as a pale orange oil (683 
mg, 19%); max (film)/cm-1 2982 (C-H), 2938 (C-H), 1724 (C=O), 1676 (C=O), 1632 
(C=C); δH (300 MHz, CDCl3) 2.07 (3H, s, COCH3), 2.77 (2H, td, J 7.2, 1.5, CH2), 3.55 (1H, 
t, J 7.3, CHCO2Bn), 5.09 (4H, s, 2 × CO2CH2Ph), 5.99 (1H, dt, J 16.0, 1.5, 
CH=CHCOCH3), 6.60 (1H, dt, J 16.0, 7.0, CH=CHCOCH3), 7.14 – 7.35 (10H, m, ArH); 
δC (75 MHz, CDCl3) 27.1 (COCH3), 31.4 (CH2), 50.7 (CHCO2Bn), 67.6 (CH2Ph), 128.4 
(ArCH), 128.6 (ArCH), 128.7 (ArCH), 133.4 (CH=CHCOCH3), 135.1 (PhC(1)), 142.4 
(CH=CHCOCH3), 168.1 (2 × CO2Bn), 198.1 (COCH3); m/z (NSI
+) 384 ([M+ NH4]
+, 
100%), 367 ([M+H]+, 10%); HRMS (NSI+) C22H23O5 ([M+H]
+) requires 367.1540, found 
367.1542 (+0.5 ppm). 
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6.7 Cascade Products 
 General Produre J: Michael-Michael-Lactonisation 
 
LiHMDS (1 M in THF, 1.1 equiv) was added to a solution of enonemalonate (1 equiv) in 
dry THF (0.05 M) at 0 ˚C. After 5 minutes NEt(iPr)2 (1.4 equiv) and HBTM 2.1 (20 mol%) 
were added then a reflux condenser added to the setup and the flask warmed to 70 ˚C. A 
solution of acid chloride (1.4 equiv) in THF (1 M) was added and the flask heated at 70 ˚C 
for 2 h. The solution was cooled to room temperature, diluted with EtOAc and washed 
sequentially with 0.1 M HCl and saturated NaHCO3 solution, dried over anhydrous MgSO4, 
filtered and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel to afford the product(s). 
Diethyl (4aS,7R,7aR)-3-methyl-1-oxo-7-phenyl-4a,5,7,7a-
tetrahydrocyclopenta[c]pyran-6,6(1H)-dicarboxylate (371a) and diethyl 2-
cinnamoyl-2-((E)-4-oxopent-2-en-1-yl)malonate (371b) 
 
The title compounds were prepared according to General Procedure J from diethyl (E)-2-(4-
oxopent-2-en-1-yl)malonate (121 mg, 0.5 mmol), LiHMDS (1 M in THF, 0.55 mL, 0.55 
mmol), HBTM 2.1 (30.8 mg, 0.10 mmol), EtN(iPr)2 (0.12 mL, 0.7 mmol) in THF (9.4 mL) 
and cinnamoyl chloride (117 mg, 0.7 mmol) added as a solution in THF (0.6 mL) to give 
371a/371b in 68:32 crude rr The mixture was purified by chromatography on silica gel 
(20% EtOAc/hexane) to afford 371a as a pale yellow oil (76 mg, 41%) and 371b as a pale 
yellow oil (40 mg, 22%). 
371a (1,4-addition): 
20
D][   (c 1.07 in CH2Cl2); chiral HPLC analysis, ChiralPak AD-
H (5% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 14.8 min, tR minor: 
16.5 min, 82% ee; max (film)/cm-1 3032 (C-H), 2982 (C-H), 1717 (C=O); δH (500 MHz, 
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CDCl3) 0.75 (3H, t, J 7.1, CO2CH2CH3), 1.25 (3H, t, J 7.0, CO2CH2CH3), 1.88 (3H, dd, J 
2.2, 1.1, C(3)CH3), 2.16 (1H, dd, J 13.9, 4.0, C(5)HH), 3.03 (1H, dd, J 13.9, 7.3, C(5)HH), 
3.29 – 3.46 (3H, m, CO2CHHCH3, C(4a)H, C(7a)H), 3.73 (1H, dq, J 10.7, 7.1, 
CO2CHHCH3), 4.15 – 4.29 (2H, m, CO2CH2CH3), 4.63 (1H, d, J 9.4, C(7)H), 4.77 (1H, dt, 
J 3.1, 1.2, C(4)H), 7.20 – 7.25 (1H, m, PhC(4)H), 7.25 – 7.30 (2H, m, 2 × PhC(3)H), 7.31 – 
7.36 (2H, m, 2 × PhC(2)H); δC (126 MHz, CDCl3) 13.4 (CO2CH2CH3), 14.1 (CO2CH2CH3), 
18.9 (C(3)CH3), 36.3 (C(4a)H), 41.3 (C(5)H2), 47.7 (C(7a)H), 53.4 (C(7)H), 61.6 
(CO2CH2CH3), 61.9 (CO2CH2CH3), 65.0 (C(6)), 102.4 (C(4)H), 127.7 (PhC(4)H), 128.2 (2 × 
ArCH), 129.0 (2 × ArCH), 137.6 (PhC(1)), 148.5 (C(3)CH3), 169.1 (C(1)O), 170.0 (CO2Et), 
171.4 (CO2Et); m/z (NSI
+) 390 ([M+NH4]
+, 100%), 373 ([M+H]+, 50%); HRMS (NSI+) 
C21H24O6 ([M+H]
+) requires 373.1646, found 373.1650 (+1.2 ppm). 
371b (1,2-addition): max (film)/cm-1 2982 (C-H), 2934 (C-H), 1728 (C=O), 1676 (C=O), 
1609 (C=C); δH (400 MHz, CDCl3) 1.27 (6H, t, J 7.1, 2 × CO2CH2CH3), 2.22 (3H, s, 
COCH3), 3.08 (2H, dd, J 7.3, 1.4, CH2CH=CH), 4.27 (4H, q, J 7.1, 2 × CO2CH2CH3), 6.09 
(1H, dt, J 15.9, 1.4, CH2CH=CH), 6.83 (1H, dt, J 16.0, 7.3, CH2CH=CH), 7.05 (1H, d, J 
15.6, CH=CHPh), 7.33 – 7.45 (3H, m, ArH), 7.51 – 7.59 (2H, m, ArH), 7.72 (1H, d, J 15.6, 
CH=CHPh); δC (101 MHz, CDCl3) 14.2 (2 × CO2CH2CH3), 26.7 (COCH3), 35.2 
(CH2CH=CH), 62.7 (2 × CO2CH2CH3), 70.0 (C(CO2Et)2), 122.5 (CH=CHPh), 128.8 (2 × 
CArH), 129.1 (2 × CArH), 131.1 (CArH), 134.3 (PhC(1)), 134.7 (CH2CH=CH), 142.5 
(CH2CH=CH), 144.5 (CH=CHPh), 167.1 (2 × CO2Et), 189.3 (COCH=CHPh), 198.5 
(COMe); m/z (NSI+) 390 ([M+NH4]
+, 40%), 373 ([M+H]+, 100%); HRMS (NSI+) C21H24O6 
([M+H]+) requires 373.1646, found 373.1652 (+1.7 ppm). 
Dimethyl (4aS,7R,7aR)-3-methyl-1-oxo-7-phenyl-4a,5,7,7a-
tetrahydrocyclopenta[c]pyran-6,6(1H)-dicarboxylate (394a) and dimethyl 2-
cinnamoyl-2-((E)-4-oxopent-2-en-1-yl)malonate (394b) 
 
The title compounds were prepared according to General Procedure J from dimethyl (E)-2-(4-
oxopent-2-en-1-yl)malonate (107 mg, 0.5 mmol), LiHMDS (1 M in THF, 0.55 mL, 0.55 
mmol), HBTM 2.1 (30.8 mg, 0.10 mmol), EtN(iPr)2 (0.12 mL, 0.7 mmol) in THF (9.4 mL) 
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and cinnamoyl chloride (117 mg, 0.7 mmol) added as a solution in THF (0.6 mL) to give 
394a/394b in 75:25 crude rr The mixture was purified by chromatography on silica gel 
(20%→30% EtOAc/hexane) to afford 394a as a pale yellow oil (108 mg, 63%) and 394b 
as a pale yellow oil (40 mg, 23%).  
394a (1,4-addition): 
20
D][   (c 1.50 in CH2Cl2); chiral HPLC analysis, ChiralPak AS-
H (5% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 13.2 min, tR minor: 
23.6 min, 71% ee; max (film)/cm-1 2953 (C-H), 1749 (C=O), 1727 (C=O), 1699 (C=O); δH 
(300 MHz, CDCl3) 1.89 (3H, dd, J 2.0, 1.1, C(3)CH3), 2.14 (1H, dd, J 13.9, 4.0 C(5)HH), 
3.02 (1H, dd, J 14.1, 7.0, C(5)HH), 3.12 (3H, s, CO2CH3), 3.29 – 3.50 (2H, m, C(4a)H, 
C(7a)H), 3.75 (3H, s, CO2CH3), 4.63 (1H, d, J 9.0, C(7)H), 4.75 – 4.80 (1H, m, C(4)H), 7.00 
– 7.48 (5H, m, ArH); δ C (75 MHz, CDCl3) 18.8 (C(3)CH3), 36.2 (C(4a)H), 41.2 (C(5)H2), 
47.4(C(7a)H), 52.3 (CO2CH3), 53.0 (CO2CH3), 53.6 (C(7)H), 65.1 (C(6)), 102.3 (C(4)H), 
127.7 (PhC(4)H), 128.2 (2 × ArCH), 128.8 (2 × ArCH), 137.4 (PhC(1)), 148.5 (C(3)), 168.9 
(C(1)O), 170.3 (CO2CH3), 171.8 (CO2CH3); m/z (NSI
+) 367 ([M+Na]+, 100%), 345 
([M+H]+, 65%); HRMS (NSI+) C19H21O6 ([M+H]
+) requires 345.1333, found 345.1329 (–
1.1 ppm). 
394b (1,2-addition): max (film)/cm-1 2955 (C-H), 1732 (C=O), 1674 (C=O), 1607 (C=C); 
δH (300 MHz, CDCl3) 2.22 (3H, s, COCH3), 3.08 (2H, dd, J 7.3, 1.4, CH2), 3.80 (6H, s, 2 × 
CO2CH3), 6.09 (1H, dt, J 16.0, 1.4, CH=CHCOCH3), 6.81 (1H, dt, J 16.0, 7.3, 
CH=CHCOCH3), 7.00 (1H, d, J 15.6, CH=CHPh), 7.41 (3H, qd, J 2.9, 1.1, ArH), 7.50 – 
7.61 (2H, m, ArH), 7.73 (1H, d, J 15.6, CH=CHPh); δC (75 MHz, CDCl3) 26.8 (COCH3), 
35.3 (CH2), 53.5 (2 × CO2CH3), 70.1 (C(CO2CH3), 122.1 (CH=CHPh), 128.9 (2 × ArCH), 
129.1 (2 × ArCH), 131.2 (PhC(4)H), 134.2 (PhC(1)), 134.7 (CH=CHCOCH3), 142.1 
(CH=CHCOCH3), 145.0 (CH=CHPh), 167.5 (2 × CO2CH3), 189.0 (COCH=CHPh), 198.4 
(COCH3); m/z (NSI
+) 367 ([M+Na]+, 100%), 345 ([M+H]+, 20%); HRMS (NSI+) C19H21O6 
([M+H]+) requires 345.1333, found 345.1330 (–0.8 ppm). 
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Dibenzyl (4aS,7R,7aR)-3-methyl-1-oxo-7-phenyl-4a,5,7,7a-
tetrahydrocyclopenta[c]pyran-6,6(1H)-dicarboxylate (395a) and dibenzyl 2-
cinnamoyl-2-((E)-4-oxopent-2-en-1-yl)malonate (395b) 
 
The title compounds were prepared according to General Procedure J from dibenzyl (E)-2-(4-
oxopent-2-en-1-yl)malonate (183 mg, 0.5 mmol), LiHMDS (1 M in THF, 0.55 mL, 0.55 
mmol), HBTM 2.1 (30.8 mg, 0.10 mmol), EtN(iPr)2 (0.12 mL, 0.7 mmol) in THF (9.4 mL) 
and cinnamoyl chloride (117 mg, 0.7 mmol) added as a solution in THF (0.6 mL) to give 
395a/395b in 77:23 crude rr The mixture was purified by chromatography on silica gel 
(20% EtOAc/hexane) to afford 395a as a pale yellow oil (135 mg, 54%) and 395b as a pale 
yellow oil (41 mg, 16%).  
395a (1,4-addition): 
20
D][   (c 3.42 in CH2Cl2); chiral HPLC analysis, ChiralPak AD-
H (5% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 35.6 min, tR minor: 
38.4 min, 72% ee; max (film)/cm-1 3034 (C-H), 1749 (C=O), 1724 (C=O); δH (300 MHz, 
CDCl3) 1.84 (3H, dd, J 2.1, 1.1, CH3), 2.21 (1H, dd, J 13.9, 3.9, C(5)HH), 3.07 (1H, dd, J 
13.9, 7.2, C(5)HH), 3.29 – 3.42 (1H, m, C(4a)H), 3.43 – 3.48 (1H, m, C(7a)H), 4.20 (1H, d, 
J 12.3, CO2CHH), 4.64 – 4.71 (2H, m, C(4)H, C(7)H), 4.75 (1H, d, J 12.3, CO2CHH), 5.06 
(1H, d, J 12.1, CO2CHH), 5.17 (1H, d, J 12.1, CO2CHH), 6.85 – 6.91 (2H, m), 7.16 – 7.39 
(13H, m, ArH); δC (75 MHz, CDCl3) 18.8 (C(3)CH3), 36.3 (C(4a)H), 41.3 (C(5)H2), 47.7 
(C(7a)H), 53.7 (C(7)H), 65.2 (C(6)), 67.4 (CO2CH2), 67.8 (CO2CH2), 102.3 (C(4)H), 127.8 
(ArCH), 128.0 (2 × ArCH), 128.2 (ArCH), 128.4 (2 × ArCH), 128.4 (2 × ArCH), 128.4 (2 
× ArCH), 128.5 (ArCH), 128.6 (2 × ArCH), 129.0 (2 × ArCH), 134.7 (ArC), 135.2 (ArC), 
137.3 (ArC), 148.6 (C(3)), 168.9 (C(1)O), 169.7 (CO2Bn), 171.0 (CO2Bn); m/z (NSI
+) 497 
([M+H]+, 100%); HRMS (NSI+) C31H29O6 ([M+H]
+) requires 497.1959, found 497.1944 (–
2.9 ppm). 
395b (1,2-addition): max (film)/cm-1 3032 (C-H), 1730 (C=O), 1676 (C=O), 1608 (C=O); 
δH (300 MHz, CDCl3) 2.11 (3H, s, CH3), 3.12 (2H, dd, J 7.4, 1.3, CH2), 5.23 (4H, d, J 2.0, 2 
× CO2CH2), 6.02 (1H, dt, J 16.0, 1.3, CH=CHCOCH3), 6.76 (1H, dt, J 15.9, 7.3 
CH=CHCOCH3), 6.90 (1H, d, J 15.6, CH=CHPh), 7.23 – 7.33 (10H, m, ArH), 7.33 – 7.40 
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(5H, m, ArH), 7.69 (1H, d, J 15.6, CH=CHPh); δC (75 MHz, CDCl3) 26.6 (CH3), 35.2 
(CH2), 68.3 (4 × CO2CH2), 122.6 (CH=CHPh), 128.5 (ArCH), 128.7 (ArCH), 128.7 
(ArCH), 128.8 (ArCH), 128.9 (ArCH), 129.0 (ArCH), 131.1 (ArCH), 134.1 (ArC), 134.6 (2 
× ArC), 134.8 (CH=CHCOCH3), 142.1 (CH=CHCOCH3), 144.8 (|CH=CHPh), 166.8 (2 
× CO2Bn), 188.7 (COCH=CHPh), 198.4 (COCH3); m/z (NSI
+) 497 ([M+H]+, 100%); 
HRMS (NSI+) C31H29O6 ([M+H]
+) requires 497.1959, found 497.1946 (–2.5 ppm). 
Diisopropyl (4aS,7R,7aR)-3-methyl-1-oxo-7-phenyl-4a,5,7,7a-
tetrahydrocyclopenta[c]pyran-6,6(1H)-dicarboxylate (396a) and diisopropyl 2-
cinnamoyl-2-((E)-4-oxopent-2-en-1-yl)malonate (396b) 
 
The title compounds were prepared according to General Procedure J from diisopropyl (E)-2-
(4-oxopent-2-en-1-yl)malonate (135 mg, 0.5 mmol), LiHMDS (1 M in THF, 0.55 mL, 0.55 
mmol), HBTM 2.1 (30.8 mg, 0.10 mmol), EtN(iPr)2 (0.12 mL, 0.7 mmol) in THF (9.4 mL) 
and cinnamoyl chloride (117 mg, 0.7 mmol) added as a solution in THF (0.6 mL) to give 
396a/396b in 61:39 crude rr The mixture was purified by chromatography on silica gel 
(10%→20% EtOAc/hexane) to afford 396a as a pale yellow oil (87 mg, 44%) and 396b as 
a pale yellow oil (isolated as a 7:3 mixture of 396b to enone-malonate 389, 71 mg, , 36%). 
396a (1,4-addition): 
20
D][   (c 0.58 in CH2Cl2); chiral HPLC analysis, ChiralPak AD-
H (5% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 10.2 min, tR minor: 
12.0 min, 70% ee; max (film)/cm-1 2980 (C-H), 2924 (C-H), 1763 (C=O), 1719 (C=O); δH 
(300 MHz, CDCl3) 0.48 (3H, d, J 6.3, CH(CH3)(CH)3), 1.01 (3H, d, J 6.2, CH(CH3)(CH)3), 
1.24 (3H, d, J 6.3, CH(CH3)(CH)3), 1.28 (3H, d, J 6.2, CH(CH3)(CH)3), 1.89 (3H, dd, J 2.1, 
1.1 C(3)CH3), 2.19 (1H, dd, J 13.9, 3.5, C(5)HH), 3.03 (1H, dd, J 13.9, 7.1, C(5)HH), 3.26 – 
3.48 (2H, m, C(4a)H, C(7a)H), 4.46 (1H, p, J 6.3, CH(CH3)2), 4.62 (1H, d, J 9.0, C(4)H), 
4.75 (1H, dq, J 2.9, 1.1, C(7)H), 5.09 (1H, p, J 6.2, CH(CH3)2), 7.19 – 7.38 (5H, m, ArH); δC 
(75 MHz, CDCl3) 18.9 (C(3)CH3), 20.7 (CH(CH3)(CH3)), 21.4, (CH(CH3)(CH3)) 21.6 
(CH(CH3)(CH3)), 21.8 (CH(CH3)(CH3)), 36.3 (C(4a)H), 41.6 (C(5)H2), 48.4 (C(7a)H), 53.4 
(C(7)H), 65.0 (C(6)), 69.4 (CH(CH3)2), 69.5 (CH(CH3)2), 102.4 (C(4)H), 127.7 (PhC(4)H), 
128.3 (2 × ArCH), 129.2 (2 × ArCH), 137.9 (PhC(1)), 148.6 (C(3)), 169.1 (C(1)O), 169.5 
 6. Experimental  
 
208 
(CO2
iPr), 171.0 (CO2
iPr); m/z (NSI+) 401 ([M+H]+, 100%), 423 ([M+Na]+, 65%); HRMS 
(NSI+) C23H29O6 ([M+H]
+) requires 401.1959, found 401.1949 (–2.4 ppm). 
396b (1,2-addition): max (film)/cm-1 2982 (C-H), 1724 (C=O), 1676 (C=O), 1609 (C=O); 
δH (300 MHz, CDCl3) 1.25 (12H, d, J 6.3, 2 × CH(CH3)2), 2.21 (3H, s, COCH3), 3.05 (2H, 
dd, J 7.3, 1.4, CH2), 5.12 (2H, p, J 6.3, 2 × CHCH3)2), 6.09 (1H, dt, J 16.1, 1.4, 
CH=CHCOCH3), 6.83 (1H, dt, J 16.0, 7.3, CH=CHCOCH3), 7.06 (1H, d, J 15.7, 
CH=CHPh), 7.39 (3H, dd, J 5.1, 1.9, ArH), 7.48 – 7.59 (2H, m, ArH), 7.70 (1H, d, J 15.7, 
CH=CHPh); δC (75 MHz, CDCl3) 21.7 (CH(CH3)2), 21.7 (CH(CH3)2), 26.6 (COCH3), 35.1 
(CH2), 70.6 (2 × CH(CH3)2), 122.8 (CH=CHPh), 128.7 (2 × ArCH), 129.1 (2 × ArCH), 
131.0 (PhC(4)H), 134.4 (PhC(1)), 134.7 (CH=CHCOCH3), 142.7 (CH=CHCOCH3), 144.0 
(CH=CHPh), 166.6 (2 × CO2
iPr), 189.6 (COCH=CHPh), 198.5 (COCH3); m/z (NSI
+) 401 
([M+H]+, 30%), 423 ([M+Na]+, 100%); HRMS (NSI+) C23H29O6 ([M+H]
+) requires 
401.1959, found 401.1949 (–2.4 ppm). 
Dimethyl (4aS,7S,7aR)-3,7-dimethyl-1-oxo-4a,5,7,7a-tetrahydrocyclopenta[c]pyran-
6,6(1H)-dicarboxylate (397a) and dimethyl 2-((E)-but-2-enoyl)-2-((E)-4-oxopent-2-
en-1-yl)malonate (397b) 
 
The title compounds were prepared according to General Procedure J from dimethyl (E)-2-(4-
oxopent-2-en-1-yl)malonate (107 mg, 0.5 mmol), LiHMDS (1 M in THF, 0.55 mL, 0.55 
mmol), HBTM 2.1 (30.8 mg, 0.10 mmol), EtN(iPr)2 (0.12 mL, 0.7 mmol) in THF (9.4 mL) 
and crotonoyl chloride (67 μL, 0.7 mmol) added as a solution in THF (0.6 mL) to give 
397a/397b in 73:27 crude rr The mixture was purified by chromatography on silica gel 
(20%→30% EtOAc/hexane) to afford 397a as a pale yellow oil (79 mg, 56%) and 397b as 
a pale yellow oil (28 mg, 20%).  
397a (1,4-addition): 
20
D][   (c 0.98 in CH2Cl2); chiral HPLC analysis, ChiralPak AS-
H (2.5% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 11.9 min, tR 
minor: 27.3 min, 90% ee; max (film)/cm-1 2955 (C-H), 1726 (C=O); δH (300 MHz, CDCl3) 
1.14 (3H, d, J 6.9, C(7)CH3), 1.81 (3H, dd, J 2.3, 1.1, C(3)CH3), 2.00 (1H, dd, J 14.0, 4.3, 
C(5)CHH), 2.71 (1H, ddd, J 11.2, 8.7, 0.8, C(7)H), 2.77 (1H, dd, J 14.0, 8.2, C(5)HH), 2.90 
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– 3.08 (1H, m, C(7a)H), 3.06 – 3.17 (1H, m, C(4a)H), 3.71 (6H, d, J 3.0, 2 × CO2CH3), 4.65 
(1H, dp, J 2.3, 1.2, C(4)H); δC (75 MHz, CDCl3) 15.2 (C(7)CH3), 18.8 (C(3)CH3), 34.8 
(C(4a)H), 41.1 (C(5)H2), 44.1 (C(7)H), 48.2 (C(7a)H), 52.6 (OCH3), 52.8 (OCH3), 62.2 
(C(6)), 103.2 (C(4)H), 147.0 (C(3)), 169.6 (C(1)O), 171.2 (CO2CH3), 171.7 (CO2CH3); m/z 
submitted; HRMS submitted. 
397b (1,2-addition): max (film)/cm-1 2957 (C-H), 1732 (C=O), 1676 (C=O); δH (300 MHz, 
CDCl3) 1.92 (3H, dd, J 7.0, 1.7, CH=CHCH3), 2.21 (3H, s, COCH3), 3.00 (2H, dd, J 7.4, 
1.4, CH2), 3.78 (6H, s, 2 × CO2CH3), 6.05 (1H, dt, J 16.0, 1.4, CH=CHCOCH3), 6.39 (1H, 
dq, J 15.1, 1.6, CH=CHCH3), 6.77 (1H, dt, J 16.0, 7.3, CH=CHCOCH3), 7.05 (1H, dq, J 
15.2, 7.0, CH=CHCH3); δC (75 MHz, CDCl3) 18.6 (CH=CHCH3), 26.7 (COCH3), 35.2 
(CH2), 53.4 (2 × CO2CH3), 69.7 (C(CO2CH3)2), 127.4 (CH=CHCH3), 134.7 
(CH=CHCOCH3), 142.2 (CH=CHCOCH3), 145.9 (CH=CHCH3), 167.5 (2 × CO2CH3), 
188.7 (COCH=CH), 198.5 (COCH3); m/z submitted; HRMS submitted. 
Dibenzyl (4aS,7S,7aR)-3,7-dimethyl-1-oxo-4a,5,7,7a-tetrahydrocyclopenta[c]pyran-
6,6(1H)-dicarboxylate (398a) and dibenzyl 2-((E)-but-2-enoyl)-2-((E)-4-oxopent-2-
en-1-yl)malonate (398b) 
 
The title compounds were prepared according to General Procedure J from dibenzyl (E)-2-(4-
oxopent-2-en-1-yl)malonate (183 mg, 0.5 mmol), LiHMDS (1 M in THF, 0.55 mL, 0.55 
mmol), HBTM 2.1 (30.8 mg, 0.10 mmol), EtN(iPr)2 (0.12 mL, 0.7 mmol) in THF (9.4 mL) 
and crotonoyl chloride (67 μL, 0.7 mmol) added as a solution in THF (0.6 mL) to give 
398a/398b in 77:23 crude rr The mixture was purified by chromatography on silica gel 
(20% EtOAc/hexane) to afford 398a as a pale yellow oil (118 mg, 54%) and 398b as a pale 
yellow oil (30 mg, 14%).  
398a (1,4-addition): 
20
D][   (c 1.55 in CH2Cl2); chiral HPLC analysis, ChiralPak AD-
H (5% i-PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 21.4 min, tR minor: 
23.2 min, 90% ee; max (film)/cm-1 2955 (C-H), 1748 (C=O), 1722 (C=O); δH (400 MHz, 
CDCl3) 1.15 (3H, d, J 6.9, C(7)CH3), 1.79 (3H, dd, J 2.3, 1.1, C(3)CH3), 2.06 (1H, dd, J 14.0, 
4.3, C(5)HH), 2.73 (1H, ddd, J 11.1, 8.8, 0.9, C(7)H), 2.81 (1H, dd, J 13.9, 8.2, C(5)HH), 
 6. Experimental  
 
210 
2.99 – 3.08 (1H, m, C(7a)H), 3.08 – 3.16 (1H, m, C(4a)H), 4.59 (1H, dp, J 2.1, 1.1, C(4)H), 
4.98 – 5.19 (4H, m, 2 × CO2CH2Ph), 7.19 – 7.27 (4H, m, ArCH), 7.29 – 7.37 (6H, m, 
ArCH); δC (101 MHz, CDCl3) 15.3 (C(7)CH3), 18.8 (C(3)CH3), 34.9 (C(4a)H), 41.2 
(C(5)H2), 44.2 (C(7)H), 48.4 (C(7a)H), 62.4 (C(6)), 67.5 (CO2CH2Ph), 67.5 (CO2CH2Ph), 
103.1 (C(4)H), 128.3 (2 × ArCH), 128.4 (2 × ArCH), 128.5 (ArCH), 128.6 (ArCH), 128.6 (2 
× ArCH), 128.7 (2 × ArCH), 135.0 (PhC(1)), 135.4 (PhC(1)), 147.1 (C(3)), 169.6 (C(1)O), 
170.5 (CO2Bn), 170.9 (CO2Bn); m/z submitted; HRMS submitted. 
398b (1,2-addition): max (film)/cm-1 2967 (C-H), 1728 (C=O), 1694 (C=O), 1676 (C=O); 
δH (400 MHz, CDCl3) 1.79 (3H, dd, J 7.0, 1.7, CH=CHCH3), 2.06 (3H, s, COCH3), 3.01 
(2H, dd, J 7.3, 1.4, CH2), 5.18 (4 H, d, J 1.4, 2 × CO2CH2Ph), 5.95 (1H, dt, J 16.0, 1.4, 
CH=CHCOCH3), 6.29 (1H, dq, J 15.2, 1.7, CH=CHCH3), 6.67 (1H, dt, J 16.0, 7.3, 
CH=CHCOCH3), 6.98 (1H, dq, J 15.2, 7.0, CH=CHCH3), 7.19 – 7.30 (4H, m, ArH), 7.30 
– 7.35 (6H, m, ArH); δC (101 MHz, CDCl3) 18.4 (CH=CHCH3), 26.5 (CICH3), 35.1 (CH2), 
68.2 (2 × CO2CH2Ph), 69.6 (C(CO2Bn)2), 127.7 (CH=CHCH3), 128.6 (4 × ArCH), 128.8 (4 
× ArCH), 128.8 (2 × ArCH), 134.7 (2 × PhC(1)), 134.8 (CH=CHCOCH3), 142.1 
(CH=CHCOCH3), 145.6 (CH=CHCH3), 166.8 (2 × CO2Bn), 188.5 (COCH=CH), 198.4 
(COCH3); m/z submitted; HRMS submitted. 
 
6.8 Misc 
Methyl (3S)-4-(1,3-benzothiazol-2-yl)-5-(4-nitrophenyl)-5-oxo-3-phenylpentanoate 
(293) 
 
To a solution of (E)-cinnamic anhydride (556 mg, 2.0 mmol) in THF (4 ml), was added 2-
(1,3-benzothiazol-2-yl)-1-(4-nitrophenyl)ethanone (417 mg, 1.4 mmol), HBTM 2.1 (22 mg, 
0.07 mmol) and NEt(iPr)2 (260 μL, 1.5 mmol) at 0 °C. The reaction mixture was stirred and 
gradually warmed to room temperature over 18 h. DMAP (171 mg, 1.4 mmol) and MeOH 
(4 ml) were then added and the flask stirred at room temperature for 24h. The solution was 
diluted with EtOAc and washed sequentially with 0.1 M HCl and saturated NaHCO3 
 6. Experimental  
 
211 
solution, dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification by 
chromatography on silica gel (10:2 DCM/hexane → 5% EtOAc/DCM) followed by 
trituration with Et2O to remove a bright yellow contaminant gave 293 as a pale yellow solid 
(580 mg, 90%, 5:1 dr); mp 109-112 C; 
22
D][  +7.8 (c 0.5 in CHCl3); max (film) /cm
-1 3028 
(C-H), 2951 (C-H), 1724 (C=O, ester), 1695 (C=O, ketone), 1522 (NO2); m/z (NSI
+) 461 
([M+H]+, 100%), 483 ([M+Na]+, 55%), 943 ([2M+Na]+, 30%); HRMS (NSI+) C25H21N2O5S 
([M+H]+) requires 461.1166, found 461.1166 (+0.1 ppm). 
Major diastereomer: chiral HPLC analysis; Chiralcel IB (8% i-PrOH:hexane, flow rate 1.5 
mL min-1, 254 nm, 30 °C) tR major: 10.5 min, tR minor: 11.5 min, 66% ee; δH (400 MHz, 
CDCl3) 2.82 – 2.98 (2H, m, 2 × C(2)HH), 3.55 (3H, s, CO2CH3), 4.29 (1H, ddt, J 8.9, 6.3, 
4.4, C(3)H), 5.87 (1H, d, J 9.9, C(4)H), 7.03 – 7.24 (5H, m, C(3)Ph-ArH), 7.29 (1H, ddd, J 
8.2, 7.3, 1.2, benzothiazoleC(6)H), 7.37 (1H, ddd, J 8.3, 7.2, 1.3, benzothiazoleC(5)H), 7.72 
(1H, ddd, J 8.0, 1.3, 0.6, benzothiazoleC(7)H), 7.85 – 7.91 (1H, m, benzothiazoleC(4)H), 
8.26 – 8.31 (2H, m, 2 × C(5)PhNO2-C(2)H), 8.31 – 8.36 (2H, m, 2 × C(5)PhNO2-C(3)H); 
δC (101 MHz, CDCl3) 38.8 (C(2)H2), 45.0 (C(3)H), 51.9 (CO2CH3), 57.1 (C(3)H), 121.7 
(benzothiazoleC(7)H), 123.3 (benzothiazoleC(4)H), 124.1 (2 × C(5)ArC(3)H), 125.5 
(benzothiazoleC(6)H), 126.2 (benzothiazoleC(5)H), 127.6 (C(3)PhC(4)H), 128.4 (2 × 
C(3)PhC(2)H), 128.7 (2 × C(3)PhC(3)H), 130.3 (2 × C(5)ArC(2)H), 135.6 
(benzothiazoleC(7a)), 139.2 (C(3)PhC(1)), 140.8 (C(5)ArC(1)), 150.7 (C(5)ArC(4)), 152.4 
(benzothiazoleC(4a)), 165.67 (benzothiazoleC(2)), 172.0 (CO2CH3), 195.3 (C(5)O). 
Minor diastereomer: chiral HPLC analysis; Chiralcel IB (8% i-PrOH:hexane, flow rate 1.5 
mL min-1, 254 nm, 30 °C) tR major: 16.1 min, tR minor: 12.4 min, 68% ee; δH (400 MHz, 
CDCl3, characteristic peaks) 2.64 (1H, dd, J 15.9, 4.2, C(2)HH), 2.78 (1H, dd, J 15.9, 10.4, 
C(2)HH), 3.41 (3H, s, CO2CH3), 5.71 (1H, d, J 11.2, C(4)H), 7.51 (1H, ddd, J 8.3, 7.2, 1.3, 
benzothiazoleC(6)H), 7.93 – 7.98 2H, m, 2 × C(5)PhNO2-C(2)H), 8.05 (1H, dt, J 8.3, 0.8, 
benzothiazoleC(4)H), 8.11 – 8.17 (2H, m, 2 × C(5)PhNO2-C(3)H); δC (101 MHz, CDCl3, 
characteristic peaks) 38.6 (C(2)H2), 51.7 (CO2CH3), 58.7 (C(4)H), 122.0 
(benzothiazoleC(7)H), 123.4 (benzothiazoleC(4)H), 123.9 (2 × C(5)ArC(3)H), 125.9 
(benzothiazoleC(6)H), 126.6 (benzothiazoleC(5)H), 129.6 (2 × C(5)ArC(2)H), 166.1 
(benzothiazoleC(2)), 171.5 (CO2CH3), 196.0 (C(5)O). 
The corresponding racemic reaction was carried out on a gram scale from (E)-cinnamic 
anhydride (1.39 g, 5.0 mmol) and 2-(1,3-benzothiazol-2-yl)-1-(4-nitrophenyl)ethanone (1.07 
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g, 3.6 mmol), NEt(iPr)2 (700 μL, 4.0 mmol) and racemic HBTM 2.1 (55mg, 0.18 mmol) in 
THF (10 mL) followed by addition of DMAP (0.44 g, 3.6 mmol) and MeOH (10 mL). 
Purification by chromatography on silica gel (10:2 DCM/hexane → 5% EtOAc/DCM) to 
give 293 as a yellow solid (1.57 g, 95%, 3:1 dr); mp 148-150 C. 
Methyl (3S)-4-(1,3-benzothiazol-2-yl)-5-(4-nitrophenyl)-5-oxo-3-phenylpentanoic 
acid (292) 
 
Methyl (3S)-4-(1,3-benzothiazol-2-yl)-5-(4-nitrophenyl)-5-oxo-3-phenylpentanoate (575 
mg, 1.25 mmol) was added to concentrated HCl (20 ml) and heated at 60 ˚C for 72h. After 
cooling to room temperature the solution was washed with DCM × 4. The combined 
organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo. 
Purification by chromatography on silica gel (DCM → 10% MeOH/DCM) gave 292 as a 
yellow solid (516 mg, 92%); mp 204-207 C; 
22
D][  +1.2 (c 0.5 in CH2Cl2); chiral HPLC 
analysis no separation conditions found therefore ee unknown; .max (film) /cm-1 2906 
(OH), 1709 (C=O, acid), 1689 (C=O, ketone), 1523 (NO2); NMR analysis of major 
diasteromer A and minor B (configuration of the stereocentres unknown): δH (400 MHz, 
DMSO) 2.61 – 2.90 (4H, m, C(2)CH2 A+B), 4.04 – 4.19 (2H, m, C(3)H A+B), 6.10 (1H, d, 
J 10.5, C(4)H B), 6.24 (1 H, d, J 10.7, C(4)H A), 6.98 – 7.40 (10H, m, ArH), 7.40 – 7.55 
(4H, m, ArH), 7.78 – 7.84 (1H, m, benzothiazoleC(7)H B), 7.87 – 7.91 (1H, m, 
benzothiazoleC(4)H B), 7.99 – 8.05 (1H, m, benzothiazoleC(7)H A), 8.07 – 8.13 (1H, m, 
benzothiazoleC(4)H A), 8.14 – 8.20 (2H, m, 2 × PhNO2C(2) A), 8.21 – 8.27 (2H, m, 2 × 
PhNO2C(3) A), 8.30 – 8.35 (2H, m, 2 × PhNO2C(2) B), 8.35 – 8.42 (2H, m, 2 × 
PhNO2C(3) B), 12.07 (2H, s, COOH A+B); δC (101 MHz, DMSO) 39.2 (C(2)H2, A+B), 
44.5 (C(3)H, B), 45.1 (C(3)H, A), 56.0 (C(4)H, A+B), 122.1 (ArCH), 122.4 (ArCH), 122.6 
(ArCH), 122.9 (ArCH), 124.0 (4 × ArCH), 125.2 (ArCH), 125.6 (ArCH), 126.1 (ArCH), 
126.5 (ArCH), 126.8 (ArCH), 126.9 (ArCH), 128.0 (2 × ArCH), 128.2 (2 × ArCH), 128.4 (2 
× ArCH), 128.7 (2 × ArCH), 129.8 (2 × ArCH), 130.3 (2 × ArCH), 135.0 (C(3)PhC(1)), 
135.1 (C(3)PhC(1)), 140.1 (benzothiazoleC(7a), A+B), 140.5 (PhNO2C(1), A), 141.1 
(PhNO2C(1), B), 150.2 (PhNO2C(4), A+B), 151.9 (benzothiazoleC(4a), B), 152.3 
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(benzothiazoleC(4a), A), 166.1 (benzothiazoleC(2), B), 166.3 (benzothiazoleC(2), B), 172.1 
(COOH, A), 172.3 (COOH, B), 195.2 (C(5)O, A+B); m/z (NSI-) 445 ([M-H]-, 100%); 
HRMS (NSI-) C24H17N2O5S ([M-H]
-) requires 445.0864, found 445.0861 (-0.6 ppm). 
The corresponding racemic reaction was carried out on a gram scale from Methyl (3S)-4-
(1,3-benzothiazol-2-yl)-5-(4-nitrophenyl)-5-oxo-3-phenylpentanoate (1.57 g, 3.4 mmol) and 
concentrated HCl (50 ml). Purification by chromatography on silica gel (10:2 DCM/hexane 
→ 5% EtOAc/DCM) to give 292 as a yellow solid (1.13 g, 74%); mp 200-202 C. 
Recyclisation experiments: 
 
To a solution of methyl (3S)-4-(1,3-benzothiazol-2-yl)-5-(4-nitrophenyl)-5-oxo-3-
phenylpentanoic acid (85 mg, 0.19 mmol) in THF (0.5 mL) was added NEt(iPr)2 (0.045 mL, 
0.25 mmol) and pivaloyl chloride (0.03 mL, 0.23 mmol). After 30 minutes HBTM 2.1 (5.9 
mg, 0.019 mmol) and NEt(iPr)2 (0.04 mL, 0.23 mmol) were added and the reaction stirred 
for 2 h. The reaction mixture was diluted with EtOAc (5 mL) and washed with 0.1 M HCl, 
saturated aqueous NaHCO3 and brine, dried over MgSO4, filtered and concentrated in 
vacuo. The regioisomeric ratio of 262a/262b was analysed by 1H NMR of the crude 
reaction mixture. Major N-cyclised regioisomer 262a was isolated on an analytical scale by 
silica chromatography (CH2Cl2) and analysed by chiral HPLC (ChiralPak AD-H (40% i-
PrOH:hexane, flow rate 1 mL min-1, 211 nm, 30 °C), tR major: 31.8 min, tR minor: 24.5 
min), results as specified in the appropriate tables in Section 3.4.1. 
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Crossover experiment: 
 
To a solution of methyl (3S)-4-(1,3-benzothiazol-2-yl)-5-(4-nitrophenyl)-5-oxo-3-
phenylpentanoic acid (112 mg, 0.25 mmol) in THF (1 mL) was added NEt(iPr)2 (0.04 mL, 
0.25 mmol) followed by pivaloyl chloride (0.04 mL, 0.30 mmol). After 30 minutes HBTM 
2.1 (7.7 mh, 0.025 mmol) and 2-phenacylbenzothiazole (63 mg, 0.25 mmol) were added 
and the reaction stirred for 2 h. The reaction mixture was diluted with EtOAc (5 mL) and 
washed with 0.1 M HCl, saturated aqueous NaHCO3 and brine, dried over MgSO4, filtered 
and concentrated in vacuo. The regioisomeric ratio analysed by 1H NMR of the crude 
reaction mixture (228a 11 : 228b 4 : 262a 100 : 262b 16). Major N-cyclised regioisomers 
were isolated on an analytical scale by silica chromatography (CH2Cl2) and analysed by 
chiral HPLC. 
262a: Chiral HPLC analysis, ChiralPak AD-H (40% i-PrOH:hexane, flow rate 1 mL min-1, 
211 nm, 30 °C), tR major: 31.8 min, tR minor: 24.5 min, 63:37 er. 
228a: chiral HPLC analysis, ChiralPak AD-H (20% i-PrOH:hexane, flow rate 1 mL min-1, 
211 nm, 30 °C), tR minor: 13.2 min, tR major: 22.5 min, 89:11 er. 
(R)-3-(4'-methoxy-[1,1'-biphenyl]-3-yl)-N,N-dimethyl-1-oxo-2,3-dihydro-1H-
benzo[4,5]thiazolo[3,2-a]pyridine-4-carboxamide (313) 
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(R)-3-(3-Bromophenyl)-N,N-dimethyl-1-oxo-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-
a]pyridine-4-carboxamide (128 mg, 0.30 mmol), 4-methoxyboronic acid (68 mg, 0.45 
mmol), sodium carbonate (64 mg, 0.60 mmol), Pd(OAc)2 (3.4 mg, 0.015 mmol) and 
diphenylphosphinoferrocene (dppf, 16.6 mg, 0.03 mmol) were added to degassed 
dioxane/water (9:1, 3 mL) under N2 and heated in a sealed tube at 100 °C for 15 h. The 
reaction was then cooled to room temperature and flushed through a plug of silica with 
EtOAc, the collected solution was concentrated in vacuo and then purified by 
chromatography on silica gel (CH2Cl2→10% EtOAC/CH2Cl2) to give 313 as a pale yellow 
oil (103 mg, 70%); 
20
D][ –78.7 (c 1.0, CH2Cl2); chiral HPLC analysis, ChiralPak AS-H (20% 
i-PrOH:hexane, flow rate 1 mL min-1, 220 nm, 30 °C), tR major: 13.0 min, tR minor: 26.8 
min, >99% ee; max (film)/cm-1 2930 (C-H), 2836 (C-H), 1701 (C=O), 1608 (C=O), 1585 
(C=N), 1481 (C=C); δH (400 MHz, CDCl3) 2.86 (6H, s, N(CH3)2), 3.02 (1H, dd, J 16.2, 6.4, 
C(2)HH), 3.20 (1H, dd, J 16.2, 7.1, C(2)HH), 3.83 (3H, s, OCH3), 4.26 (1H, at, J 6.7, 
C(3)H), 6.90 – 7.00 (2H, m, 2 × biphenylC(3’’’)H), 7.12 – 7.36 (5H, m, ArH), 7.39 – 7.45 
(2H, m, ArH), 7.45 – 7.50 (2H, m, 2 × biphenylC(2’’’)H), 8.34 – 8.39 (1H, m, C(4’)H); δC 
(101 MHz, CDCl3) 37.0 (2 × N(CH3)2), 40.4 (C(3)H), 40.9 (C(4)H2), 55.4 (OCH3), 106.4 
(C(4)), 114.3 (2 × biphenylC(3’’’)H), 117.5 (C(4’)H), 121.3 (C(7’)H), 125.0 (ArCH), 125.3 
(ArCH), 125.4 (ArCH), 125.9 (ArCH), 126.0 (C(7a’)), 126.3 (ArCH), 128.2 (2 × 
biphenylC(2’’’)H), 129.5 (ArCH), 133.2 (biphenylC(1’’’)), 137.2, (C(4a’)), 141.4 (ArC), 141.6 
(ArC), 142.3 (ArC), 159.4 (C(5)), 167.7 (C(1)O), 169.3 (CONMe2); m/z (NSI
+) 457 
([M+H]+, 100%), 479 ([M+Na]+, 55%), 495 ([M+K]+, 50%), 935 (2M+Na]+, 55%), 951 
(2M+K]+, 50%); HRMS (NSI+) C27H25O3N2S ([M+H]
+) requires 457.1580, found 457.1577 
(–0.7 ppm). 
Methyl (R,E)-3-(3-(4-(dimethylcarbamoyl)-1-oxo-2,3-dihydro-1H-
benzo[4,5]thiazolo[3,2-a]pyridin-3-yl)phenyl)acrylate (316) 
 
(R)-3-(3-Bromophenyl)-N,N-dimethyl-1-oxo-2,3-dihydro-1H-benzo[4,5]thiazolo[3,2-
a]pyridine-4-carboxamide (128 mg, 0.30 mmol), methyl acrylate (34 μL, 0.38 mmol), 
 6. Experimental  
 
216 
triethylamine (52 μL, 0.38 mmol), Pd(OAc)2 (3.4 mg, 0.015 mmol) and P(o-tolyl)3 (9.1 mg, 
0.03 mmol) were added to degassed DMF (2 mL) under N2 and heated in a sealed tube at 
125 °C for 15 h. The reaction was then cooled to room temperature and flushed through a 
plug of silica with EtOAc, the collected solution was concentrated in vacuo and redissolved 
in Et2O (20 mL). This solution was washed with brine (4 × 20 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The crude oil obtained was then purified by 
chromatography on silica gel (10% EtOAc/CH2Cl2→20% EtOAc/CH2Cl2) to give 316 as a 
pale yellow oil (115 mg, 89%) plus recovered starting material (14 mg, 11%); 
20
D][ –81.6 (c 
1.0, CH2Cl2); chiral HPLC analysis: no separation conditions found therefore ee unknown; 
max (film)/cm-1 3007 (C-H), 2947 (C-H), 1701 (C=O), 1616 (br, 2 × C=O), 1581 (C=N), 
1487, (C=C); δH (400 MHz, CDCl3) 2.86 (6H, s, N(CH3)2), 2.96 (1H, dd, J 16.3, 6.1, 
C(2)HH), 3.18 (1H, dd, J 16.3, 7.1, C(2)HH), 3.78 (3H, s, OCH3), 4.22 (1H, at, J 6.6, 
C(3)H), 6.39 (1H, d, J 16.0, ArCH=CHCO2Me), 7.09 – 7.36 (5H, m, ArH), 7.40 – 7.44 (1H, 
m, C(7’)H), 7.62 (1H, d, J 16.0, ArCH=CHCO2Me), 8.33 – 8.36 (1H, m, C(4’)H); δC (126 
MHz, CDCl3) 36.9, 40.1, 40.7, 51.8, 105.6, 117.6, 118.4, 121.3, 125.5, 125.8, 126.4, 126.8, 
126.9, 128.7, 129.8, 135.2, 137.1, 141.8, 142.5, 144.4, 167.3, 167.4, 169.1; m/z (NSI+) 435 
([M+H]+, 100%), 457 ([M+Na]+, 60%), 891 (2M+Na]+, 30%); HRMS (NSI+) C24H23O4N2S 
([M+H]+) requires 435.1373, found 4355.1369 (–0.9 ppm). 
Methyl (R,E)-3-(3-(5-(benzo[d]oxazol-2-yl)-2-oxo-6-phenyl-3,4-dihydro-2H-pyran-
4-yl)phenyl)acrylate (317a) and methyl (R,E)-3-(3-(4-benzoyl-1-oxo-2,3-dihydro-1H-
benzo[4,5]oxazolo[3,2-a]pyridin-3-yl)phenyl)acrylate (317b) 
 
(R)-5-(benzo[d]oxazol-2-yl)-4-(3-bromophenyl)-6-phenyl-3,4-dihydro-2H-pyran-2-one (134 
mg, 0.3 mmol), methyl acrylate (34 μL, 0.375 mmol), triethylamine (52 μL, 0.375 mmol), 
Pd(OAc)2 (3.4 mg, 0.015 mmol) and P(o-tolyl)3 (9.1 mh, 0.03 mmol) were added to 
degassed DMF (2 mL) under N2 and heated in a sealed tube at 125 °C for 15 h. The 
reaction was then cooled to room temperature and flushed through a plug of silica with 
EtOAc, the collected solution was concentrated in vacuo and redissolved in Et2O (20 mL). 
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This solution was washed with brine (4 × 20 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude oil obtained was then purified by chromatography on silica 
gel (CH2Cl2→2% EtOAc/CH2Cl2) to give 317a as a pale yellow oil (56 mg, 41%), 317b as 
an off-white solid (15 mg, 11%) and recovered starting material (8 mg, 6%). 
317a (major): 
20
D][ +0.9 (c 1.0, CH2Cl2); no separation conditions found therefore ee 
unknown; max (film)/cm-1 2949 (C-H), 1778 (C=O), 1707 (C=O), 1637 (C=N), 1450 
(C=C); δH (400 MHz, CDCl3) 3.07 (1H, dd, J 15.8, 1.8, C(3)HH), 3.30 (1H, dd, J 15.8, 7.6, 
C(3)HH), 3.80 (3H, s, OCH3), 4.90 (1H, dd, J 7.6, 1.8, C(4)H), 6.40 (1H, d, J 16.0, 
ArCH=CHCO2Me), 7.16 – 7.29 (3H, m, ArH), 7.31 – 7.43 (5H, m, ArH), 7.45 – 7.56 (4H, 
m, ArH), 7.62 – 7.65 (1H, m, benzoxazoleC(4)H), 7.64 (1H, d, J 16.1, ArCH=CHCO2Me); 
δC (101 MHz, CDCl3) 36.6 (C(3)H2), 40.2 (C(4)H), 51.9 (OCH3), 107.2 (C(5)), 110.6 
(benzoxazoleC(7)H), 118.6 (ArCH=CHCO2Me), 120.0 (benzoxazoleC(4)H), 124.7 (ArCH), 
125.5 (ArCH), 127.1 (ArCH), 127.4 (ArCH), 128.3 (2 × C(6)PhC(2)H), 128.7 (ArCH), 
129.1 (2 × C(6)PhC(3)H), 130.0 (ArCH), 130.7 (ArCH), 132.5 (C(6)PhC(1)), 135.5 
(C(3)ArC(1)CH=), 140.4 (ArC), 141.5 (ArC), 144.4 (ArCH=CHCO2Me), 150.3 
(benzoxazoleC((7a)), 156.4 (C(6)), 160.8 (benzoxazoleC(2)), 166.0 (C(2)O), 167.3 (CO2Me); 
m/z (NSI+) 452 ([M+H]+, 100%), 474 ([M+Na]+, 50%), 925 (2M+Na]+, 30%); HRMS 
(NSI+) C28H22O5N ([M+H]
+) requires 452.1492, found 452.1484 (–1.9 ppm). 
317b (minor): mp 120-123 °C; 
20
D][ –179.4 (c 0.35, CH2Cl2); no separation conditions 
found therefore ee unknown; max (film)/cm-1 2949 (C-H), 1715 (C=O), 1660 (C=O), 1637 
(C=O), 1595 (C=N), 1476 (C=C); δH (400 MHz, CDCl3) 3.08 (1H, dd, J 16.9, 2.6, 
C(2)HH), 3.24 (1H, dd, J 16.9, 7.6, C(2)HH), 3.79 (3H, s, OCH3), 4.70 (1H, dd, J 7.6, 2.6, 
C(3)H), 6.38 (1H, d, J 16.0, ArCH=CHCO2Me), 6.92 – 6.97 (1H, m, C(5’)H), 7.14 – 7.24 
(2H, m, ArH), 7.29 – 7.35 (2H, m, ArH), 7.38 – 7.45 (4H, m, ArH), 7.48 – 7.55 (1H, m, 
ArH), 7.58 – 7.68 (3H, m, C(7’)H, ArCH=CHCO2Me, ArH), 7.95 – 8.01 (1H, m, C(4’)H); 
δC (101 MHz, CDCl3) 36.5 (C(3)H), 39.4 (C(2)H2), 51.9 (OCH3), 93.7 (C(4)), 110.1 (C(7’)H), 
115.2 (C(4’)H), 118.2 (ArCH=CHCO2Me), 125.0 (ArCH), 125.7 (ArCH), 126.7 (ArCH), 
126.9 (ArCH), 126.9 (C(4a’)), 128.1 (4 × C(4)COPhC(2,3)H), 128.5 (ArCH), 129.7 (ArCH), 
131.3 (C(4)COPhC(4)H), 135.2 (C(3)ArC(1)-CH=), 140.8 (C(4)COPhC(1)), 142.8 
(C(3)ArC(3)-CH), 144.8 (ArCH=CHCO2Me), 146.7 (C(7a’)), 155.9 (C(5)), 166.9 (CO2Me), 
167.5 (C(1)O), 191.5 (COPh); m/z (NSI+) 452 ([M+H]+, 100%), 474 ([M+Na]+, 70%), 925 
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(2M+Na]+, 45%); HRMS (NSI+) C28H22O5N ([M+H]
+) requires 452.1492, found 452.1486 
(–1.4 ppm). 
 (Z)-3-oxo-1,3-diphenylprop-1-en-1-yl cinnamate (203) 
 
EtN(iPr)2 (5.4 mL, 31.2 mmol) was added to a solution of 1,3-diphenylpropane-1,3-dione 
(5.6 g, 25.0 mmol) in THF (25 mL). After 30 min stirring at room temperature, trans-
cinnamoyl chloride (5.0 g, 30.0 mmol) was added and the flask heated at 50 ˚C for 16 h. 
After cooling to room temperature, the mixture was diluted with EtOAc (30 mL) and 
washed with 2M HCl (50 mL) followed by saturated aqueous NaHCO3 (50 mL), dried over 
MgSO4 and concentrated in vacuo. The residue was purified by column chromatography 
(5%→10% Et2O/Petrol) to afford a 3:1 mixture of unreacted cinnamoyl chloride to 
product (3.5 g, 40%) plus cinnamate 203 as an off-white fluffy solid (665 mg, 8%); mp 109-
111 ˚C {Lit.62  111-112 °C}; δH (300 MHz, CDCl3) 6.69 (1H, d, J 16.0, PhCH=CHCO), 
7.30 (1H, s, C(2)H), 7.38 – 7.64 (11H, m, ArH), 7.74 (2H, d, J 7.7, ArH), 7.87 (1H, d, J 
16.0, PhCH=CHCO), 7.98 (2H, d, J 7.6, ArH). Data in agreement with the literature.62  
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